id	sid	tid	token	lemma	pos
eurjchem-2641	1	1	exploring	explore	VERB
eurjchem-2641	1	2	the	the	DET
eurjchem-2641	1	3	mirna-148b	mirna-148b	PROPN
eurjchem-2641	1	4	and	and	CCONJ
eurjchem-2641	1	5	the	the	DET
eurjchem-2641	1	6	caspase-3	caspase-3	NUM
eurjchem-2641	1	7	/	/	SYM
eurjchem-2641	1	8	bcl-2	bcl-2	VERB
eurjchem-2641	1	9	/	/	SYM
eurjchem-2641	1	10	bax	bax	NOUN
eurjchem-2641	1	11	axis	axis	NOUN
eurjchem-2641	1	12	as	as	ADP
eurjchem-2641	1	13	a	a	DET
eurjchem-2641	1	14	potential	potential	ADJ
eurjchem-2641	1	15	predictive	predictive	ADJ
eurjchem-2641	1	16	marker	marker	NOUN
eurjchem-2641	1	17	in	in	ADP
eurjchem-2641	1	18	breast	breast	NOUN
eurjchem-2641	1	19	cancer	cancer	NOUN
eurjchem-2641	1	20	european	european	PROPN
eurjchem-2641	1	21	journal	journal	PROPN
eurjchem-2641	1	22	of	of	ADP
eurjchem-2641	1	23	chemistry	chemistry	NOUN
eurjchem-2641	1	24	16	16	NUM
eurjchem-2641	1	25	(	(	PUNCT
eurjchem-2641	1	26	2	2	NUM
eurjchem-2641	1	27	)	)	PUNCT
eurjchem-2641	1	28	(	(	PUNCT
eurjchem-2641	1	29	2025	2025	NUM
eurjchem-2641	1	30	)	)	PUNCT
eurjchem-2641	1	31	222	222	NUM
eurjchem-2641	1	32	-	-	SYM
eurjchem-2641	1	33	232	232	NUM
eurjchem-2641	1	34	european	european	ADJ
eurjchem-2641	1	35	journal	journal	PROPN
eurjchem-2641	1	36	of	of	ADP
eurjchem-2641	1	37	chemistry	chemistry	NOUN
eurjchem-2641	1	38	issn	issn	VERB
eurjchem-2641	1	39	2153	2153	NUM
eurjchem-2641	1	40	-	-	SYM
eurjchem-2641	1	41	2249	2249	NUM
eurjchem-2641	1	42	(	(	PUNCT
eurjchem-2641	1	43	print	print	NOUN
eurjchem-2641	1	44	)	)	PUNCT
eurjchem-2641	1	45	/	/	PUNCT
eurjchem-2641	1	46	issn	issn	PROPN
eurjchem-2641	1	47	2153	2153	NUM
eurjchem-2641	1	48	-	-	SYM
eurjchem-2641	1	49	2257	2257	NUM
eurjchem-2641	1	50	(	(	PUNCT
eurjchem-2641	1	51	online	online	ADJ
eurjchem-2641	1	52	)	)	PUNCT
eurjchem-2641	1	53	–	–	PUNCT
eurjchem-2641	2	1	copyright	copyright	NOUN
eurjchem-2641	2	2	©	©	PROPN
eurjchem-2641	2	3	2025	2025	NUM
eurjchem-2641	2	4	the	the	DET
eurjchem-2641	2	5	authors	author	NOUN
eurjchem-2641	2	6	–	–	PUNCT
eurjchem-2641	2	7	atlanta	atlanta	PROPN
eurjchem-2641	2	8	publishing	publishing	PROPN
eurjchem-2641	2	9	house	house	PROPN
eurjchem-2641	2	10	llc	llc	PROPN
eurjchem-2641	2	11	–	–	PUNCT
eurjchem-2641	2	12	printed	print	VERB
eurjchem-2641	2	13	in	in	ADP
eurjchem-2641	2	14	the	the	DET
eurjchem-2641	2	15	usa	usa	PROPN
eurjchem-2641	2	16	.	.	PUNCT
eurjchem-2641	3	1	this	this	DET
eurjchem-2641	3	2	work	work	NOUN
eurjchem-2641	3	3	is	be	AUX
eurjchem-2641	3	4	published	publish	VERB
eurjchem-2641	3	5	and	and	CCONJ
eurjchem-2641	3	6	licensed	license	VERB
eurjchem-2641	3	7	by	by	ADP
eurjchem-2641	3	8	atlanta	atlanta	PROPN
eurjchem-2641	3	9	publishing	publishing	PROPN
eurjchem-2641	3	10	house	house	PROPN
eurjchem-2641	3	11	llc	llc	PROPN
eurjchem-2641	3	12	–	–	PUNCT
eurjchem-2641	3	13	cc	cc	PROPN
eurjchem-2641	3	14	by	by	ADP
eurjchem-2641	3	15	nc	nc	PROPN
eurjchem-2641	3	16	–	–	PUNCT
eurjchem-2641	3	17	some	some	DET
eurjchem-2641	3	18	rights	right	NOUN
eurjchem-2641	3	19	reserved	reserve	VERB
eurjchem-2641	3	20	.	.	PUNCT
eurjchem-2641	4	1	https://dx.doi.org/10.5155/eurjchem.16.2.222-232.2641	https://dx.doi.org/10.5155/eurjchem.16.2.222-232.2641	PROPN
eurjchem-2641	4	2	european	european	PROPN
eurjchem-2641	4	3	journal	journal	PROPN
eurjchem-2641	4	4	of	of	ADP
eurjchem-2641	4	5	chemistry	chemistry	NOUN
eurjchem-2641	4	6	view	view	NOUN
eurjchem-2641	4	7	journal	journal	PROPN
eurjchem-2641	4	8	online	online	PROPN
eurjchem-2641	4	9	view	view	NOUN
eurjchem-2641	4	10	article	article	NOUN
eurjchem-2641	4	11	online	online	ADV
eurjchem-2641	4	12	exploring	explore	VERB
eurjchem-2641	4	13	the	the	DET
eurjchem-2641	4	14	mirna-148b	mirna-148b	PROPN
eurjchem-2641	4	15	and	and	CCONJ
eurjchem-2641	4	16	the	the	DET
eurjchem-2641	4	17	caspase-3	caspase-3	NUM
eurjchem-2641	4	18	/	/	SYM
eurjchem-2641	4	19	bcl-2	bcl-2	VERB
eurjchem-2641	4	20	/	/	SYM
eurjchem-2641	4	21	bax	bax	NOUN
eurjchem-2641	4	22	axis	axis	NOUN
eurjchem-2641	4	23	as	as	ADP
eurjchem-2641	4	24	a	a	DET
eurjchem-2641	4	25	potential	potential	ADJ
eurjchem-2641	4	26	predictive	predictive	ADJ
eurjchem-2641	4	27	marker	marker	NOUN
eurjchem-2641	4	28	in	in	ADP
eurjchem-2641	4	29	breast	breast	NOUN
eurjchem-2641	4	30	cancer	cancer	NOUN
eurjchem-2641	4	31	gamaleldin	gamaleldin	VERB
eurjchem-2641	4	32	ibrahim	ibrahim	PROPN
eurjchem-2641	4	33	harisa	harisa	NOUN
eurjchem-2641	4	34	1	1	NUM
eurjchem-2641	4	35	,	,	PUNCT
eurjchem-2641	4	36	*	*	PROPN
eurjchem-2641	4	37	,	,	PUNCT
eurjchem-2641	4	38	gamal	gamal	PROPN
eurjchem-2641	4	39	abd	abd	PROPN
eurjchem-2641	4	40	el	el	PROPN
eurjchem-2641	4	41	-	-	PROPN
eurjchem-2641	4	42	hay	hay	PROPN
eurjchem-2641	4	43	omran	omran	NOUN
eurjchem-2641	4	44	2	2	NUM
eurjchem-2641	4	45	,	,	PUNCT
eurjchem-2641	4	46	mohamed	mohame	VERB
eurjchem-2641	4	47	noureldin	noureldin	PROPN
eurjchem-2641	4	48	3	3	NUM
eurjchem-2641	4	49	,	,	PUNCT
eurjchem-2641	4	50	ahmed	ahme	VERB
eurjchem-2641	4	51	noreldin	noreldin	VERB
eurjchem-2641	4	52	4	4	NUM
eurjchem-2641	4	53	,	,	PUNCT
eurjchem-2641	4	54	samiyah	samiyah	NOUN
eurjchem-2641	4	55	alshehri	alshehri	VERB
eurjchem-2641	4	56	5	5	NUM
eurjchem-2641	4	57	,	,	PUNCT
eurjchem-2641	4	58	sulthan	sulthan	SCONJ
eurjchem-2641	4	59	al	al	PROPN
eurjchem-2641	4	60	rashid	rashid	PROPN
eurjchem-2641	4	61	6	6	NUM
eurjchem-2641	4	62	and	and	CCONJ
eurjchem-2641	4	63	tarek	tarek	PROPN
eurjchem-2641	4	64	mahmoud	mahmoud	PROPN
eurjchem-2641	4	65	okda	okda	PROPN
eurjchem-2641	4	66	2	2	NUM
eurjchem-2641	4	67	1	1	NUM
eurjchem-2641	4	68	kayyali	kayyali	NOUN
eurjchem-2641	4	69	chair	chair	NOUN
eurjchem-2641	4	70	for	for	ADP
eurjchem-2641	4	71	pharmaceutical	pharmaceutical	NOUN
eurjchem-2641	4	72	industry	industry	NOUN
eurjchem-2641	4	73	,	,	PUNCT
eurjchem-2641	4	74	department	department	NOUN
eurjchem-2641	4	75	of	of	ADP
eurjchem-2641	4	76	pharmaceutics	pharmaceutic	NOUN
eurjchem-2641	4	77	,	,	PUNCT
eurjchem-2641	4	78	college	college	NOUN
eurjchem-2641	4	79	of	of	ADP
eurjchem-2641	4	80	pharmacy	pharmacy	NOUN
eurjchem-2641	4	81	,	,	PUNCT
eurjchem-2641	4	82	king	king	PROPN
eurjchem-2641	4	83	saud	saud	PROPN
eurjchem-2641	4	84	university	university	PROPN
eurjchem-2641	4	85	,	,	PUNCT
eurjchem-2641	4	86	riyadh	riyadh	PROPN
eurjchem-2641	4	87	11451	11451	NUM
eurjchem-2641	4	88	,	,	PUNCT
eurjchem-2641	4	89	saudi	saudi	PROPN
eurjchem-2641	4	90	arabia	arabia	PROPN
eurjchem-2641	4	91	2	2	NUM
eurjchem-2641	4	92	department	department	NOUN
eurjchem-2641	4	93	of	of	ADP
eurjchem-2641	4	94	biochemistry	biochemistry	NOUN
eurjchem-2641	4	95	,	,	PUNCT
eurjchem-2641	4	96	faculty	faculty	NOUN
eurjchem-2641	4	97	of	of	ADP
eurjchem-2641	4	98	pharmacy	pharmacy	NOUN
eurjchem-2641	4	99	,	,	PUNCT
eurjchem-2641	4	100	damanhour	damanhour	NOUN
eurjchem-2641	4	101	university	university	NOUN
eurjchem-2641	4	102	,	,	PUNCT
eurjchem-2641	4	103	damanhour	damanhour	NOUN
eurjchem-2641	4	104	22511	22511	NUM
eurjchem-2641	4	105	,	,	PUNCT
eurjchem-2641	4	106	egypt	egypt	PROPN
eurjchem-2641	4	107	3	3	NUM
eurjchem-2641	4	108	department	department	PROPN
eurjchem-2641	4	109	of	of	ADP
eurjchem-2641	4	110	biochemistry	biochemistry	NOUN
eurjchem-2641	4	111	,	,	PUNCT
eurjchem-2641	4	112	division	division	NOUN
eurjchem-2641	4	113	of	of	ADP
eurjchem-2641	4	114	clinical	clinical	ADJ
eurjchem-2641	4	115	and	and	CCONJ
eurjchem-2641	4	116	biological	biological	ADJ
eurjchem-2641	4	117	sciences	science	NOUN
eurjchem-2641	4	118	,	,	PUNCT
eurjchem-2641	4	119	college	college	NOUN
eurjchem-2641	4	120	of	of	ADP
eurjchem-2641	4	121	pharmacy	pharmacy	NOUN
eurjchem-2641	4	122	,	,	PUNCT
eurjchem-2641	4	123	arab	arab	PROPN
eurjchem-2641	4	124	academy	academy	PROPN
eurjchem-2641	4	125	for	for	ADP
eurjchem-2641	4	126	science	science	NOUN
eurjchem-2641	4	127	,	,	PUNCT
eurjchem-2641	4	128	technology	technology	NOUN
eurjchem-2641	4	129	and	and	CCONJ
eurjchem-2641	4	130	maritime	maritime	ADJ
eurjchem-2641	4	131	transport	transport	NOUN
eurjchem-2641	4	132	,	,	PUNCT
eurjchem-2641	4	133	alexandria	alexandria	PROPN
eurjchem-2641	4	134	1029	1029	NUM
eurjchem-2641	4	135	,	,	PUNCT
eurjchem-2641	4	136	egypt	egypt	PROPN
eurjchem-2641	4	137	4	4	NUM
eurjchem-2641	4	138	department	department	NOUN
eurjchem-2641	4	139	of	of	ADP
eurjchem-2641	4	140	histology	histology	NOUN
eurjchem-2641	4	141	and	and	CCONJ
eurjchem-2641	4	142	cytology	cytology	NOUN
eurjchem-2641	4	143	,	,	PUNCT
eurjchem-2641	4	144	faculty	faculty	NOUN
eurjchem-2641	4	145	of	of	ADP
eurjchem-2641	4	146	veterinary	veterinary	ADJ
eurjchem-2641	4	147	medicine	medicine	NOUN
eurjchem-2641	4	148	,	,	PUNCT
eurjchem-2641	4	149	damanhur	damanhur	VERB
eurjchem-2641	4	150	university	university	PROPN
eurjchem-2641	4	151	,	,	PUNCT
eurjchem-2641	4	152	damanhur	damanhur	VERB
eurjchem-2641	4	153	22516	22516	NUM
eurjchem-2641	4	154	,	,	PUNCT
eurjchem-2641	4	155	egypt	egypt	PROPN
eurjchem-2641	4	156	5	5	NUM
eurjchem-2641	4	157	department	department	PROPN
eurjchem-2641	4	158	of	of	ADP
eurjchem-2641	4	159	pharmacology	pharmacology	NOUN
eurjchem-2641	4	160	and	and	CCONJ
eurjchem-2641	4	161	toxicology	toxicology	NOUN
eurjchem-2641	4	162	,	,	PUNCT
eurjchem-2641	4	163	college	college	NOUN
eurjchem-2641	4	164	of	of	ADP
eurjchem-2641	4	165	pharmacy	pharmacy	NOUN
eurjchem-2641	4	166	,	,	PUNCT
eurjchem-2641	4	167	king	king	PROPN
eurjchem-2641	4	168	saud	saud	PROPN
eurjchem-2641	4	169	university	university	PROPN
eurjchem-2641	4	170	,	,	PUNCT
eurjchem-2641	4	171	riyadh	riyadh	PROPN
eurjchem-2641	4	172	11451	11451	NUM
eurjchem-2641	4	173	,	,	PUNCT
eurjchem-2641	4	174	saudi	saudi	PROPN
eurjchem-2641	4	175	arabia	arabia	PROPN
eurjchem-2641	4	176	6	6	NUM
eurjchem-2641	4	177	department	department	NOUN
eurjchem-2641	4	178	of	of	ADP
eurjchem-2641	4	179	pharmacology	pharmacology	NOUN
eurjchem-2641	4	180	,	,	PUNCT
eurjchem-2641	4	181	saveetha	saveetha	PROPN
eurjchem-2641	4	182	medical	medical	PROPN
eurjchem-2641	4	183	college	college	PROPN
eurjchem-2641	4	184	and	and	CCONJ
eurjchem-2641	4	185	hospital	hospital	NOUN
eurjchem-2641	4	186	,	,	PUNCT
eurjchem-2641	4	187	saveetha	saveetha	PROPN
eurjchem-2641	4	188	institute	institute	PROPN
eurjchem-2641	4	189	of	of	ADP
eurjchem-2641	4	190	medical	medical	ADJ
eurjchem-2641	4	191	and	and	CCONJ
eurjchem-2641	4	192	technical	technical	ADJ
eurjchem-2641	4	193	sciences	science	NOUN
eurjchem-2641	4	194	(	(	PUNCT
eurjchem-2641	4	195	simats	simat	NOUN
eurjchem-2641	4	196	)	)	PUNCT
eurjchem-2641	4	197	,	,	PUNCT
eurjchem-2641	4	198	saveetha	saveetha	PROPN
eurjchem-2641	4	199	university	university	PROPN
eurjchem-2641	4	200	,	,	PUNCT
eurjchem-2641	4	201	chennai	chennai	NOUN
eurjchem-2641	4	202	602105	602105	NUM
eurjchem-2641	4	203	,	,	PUNCT
eurjchem-2641	4	204	tamil	tamil	PROPN
eurjchem-2641	4	205	nadu	nadu	PROPN
eurjchem-2641	4	206	,	,	PUNCT
eurjchem-2641	4	207	india	india	PROPN
eurjchem-2641	4	208	*	*	PUNCT
eurjchem-2641	4	209	corresponding	correspond	VERB
eurjchem-2641	4	210	author	author	NOUN
eurjchem-2641	4	211	at	at	ADP
eurjchem-2641	4	212	:	:	PUNCT
eurjchem-2641	4	213	kayyali	kayyali	ADJ
eurjchem-2641	4	214	chair	chair	NOUN
eurjchem-2641	4	215	for	for	ADP
eurjchem-2641	4	216	pharmaceutical	pharmaceutical	NOUN
eurjchem-2641	4	217	industry	industry	NOUN
eurjchem-2641	4	218	,	,	PUNCT
eurjchem-2641	4	219	department	department	NOUN
eurjchem-2641	4	220	of	of	ADP
eurjchem-2641	4	221	pharmaceutics	pharmaceutic	NOUN
eurjchem-2641	4	222	,	,	PUNCT
eurjchem-2641	4	223	college	college	NOUN
eurjchem-2641	4	224	of	of	ADP
eurjchem-2641	4	225	pharmacy	pharmacy	NOUN
eurjchem-2641	4	226	,	,	PUNCT
eurjchem-2641	4	227	king	king	PROPN
eurjchem-2641	4	228	saud	saud	PROPN
eurjchem-2641	4	229	university	university	PROPN
eurjchem-2641	4	230	,	,	PUNCT
eurjchem-2641	4	231	riyadh	riyadh	PROPN
eurjchem-2641	4	232	11451	11451	NUM
eurjchem-2641	4	233	,	,	PUNCT
eurjchem-2641	4	234	saudi	saudi	PROPN
eurjchem-2641	4	235	arabia	arabia	PROPN
eurjchem-2641	4	236	.	.	PUNCT
eurjchem-2641	5	1	e	e	X
eurjchem-2641	5	2	-	-	NOUN
eurjchem-2641	5	3	mail	mail	NOUN
eurjchem-2641	5	4	:	:	PUNCT
eurjchem-2641	5	5	harisa@ksu.edu.sa	harisa@ksu.edu.sa	PROPN
eurjchem-2641	5	6	(	(	PUNCT
eurjchem-2641	5	7	g.i	g.i	PROPN
eurjchem-2641	5	8	.	.	PUNCT
eurjchem-2641	5	9	harisa	harisa	PROPN
eurjchem-2641	5	10	)	)	PUNCT
eurjchem-2641	5	11	.	.	PUNCT
eurjchem-2641	6	1	10.5155	10.5155	NUM
eurjchem-2641	6	2	/	/	SYM
eurjchem-2641	6	3	eurjchem.16.2.222	eurjchem.16.2.222	NOUN
eurjchem-2641	6	4	-	-	SYM
eurjchem-2641	6	5	232.2641	232.2641	NUM
eurjchem-2641	6	6	received	receive	VERB
eurjchem-2641	6	7	:	:	PUNCT
eurjchem-2641	6	8	10	10	NUM
eurjchem-2641	6	9	january	january	PROPN
eurjchem-2641	6	10	2025	2025	NUM
eurjchem-2641	6	11	received	receive	VERB
eurjchem-2641	6	12	in	in	ADP
eurjchem-2641	6	13	revised	revise	VERB
eurjchem-2641	6	14	form	form	NOUN
eurjchem-2641	6	15	:	:	PUNCT
eurjchem-2641	6	16	10	10	NUM
eurjchem-2641	6	17	april	april	PROPN
eurjchem-2641	6	18	2025	2025	NUM
eurjchem-2641	6	19	accepted	accept	VERB
eurjchem-2641	6	20	:	:	PUNCT
eurjchem-2641	6	21	1	1	NUM
eurjchem-2641	6	22	may	may	AUX
eurjchem-2641	6	23	2025	2025	NUM
eurjchem-2641	6	24	published	publish	VERB
eurjchem-2641	6	25	online	online	ADV
eurjchem-2641	6	26	:	:	PUNCT
eurjchem-2641	6	27	30	30	NUM
eurjchem-2641	6	28	june	june	PROPN
eurjchem-2641	6	29	2025	2025	NUM
eurjchem-2641	6	30	printed	print	VERB
eurjchem-2641	6	31	:	:	PUNCT
eurjchem-2641	6	32	30	30	NUM
eurjchem-2641	6	33	june	june	PROPN
eurjchem-2641	6	34	2025	2025	NUM
eurjchem-2641	6	35	breast	breast	NOUN
eurjchem-2641	6	36	cancers	cancer	NOUN
eurjchem-2641	6	37	(	(	PUNCT
eurjchem-2641	6	38	bcs	bc	NOUN
eurjchem-2641	6	39	)	)	PUNCT
eurjchem-2641	6	40	are	be	AUX
eurjchem-2641	6	41	the	the	DET
eurjchem-2641	6	42	second	second	ADJ
eurjchem-2641	6	43	leading	leading	ADJ
eurjchem-2641	6	44	cause	cause	NOUN
eurjchem-2641	6	45	of	of	ADP
eurjchem-2641	6	46	cancer	cancer	NOUN
eurjchem-2641	6	47	-	-	PUNCT
eurjchem-2641	6	48	related	relate	VERB
eurjchem-2641	6	49	deaths	death	NOUN
eurjchem-2641	6	50	among	among	ADP
eurjchem-2641	6	51	women	woman	NOUN
eurjchem-2641	6	52	due	due	ADP
eurjchem-2641	6	53	to	to	ADP
eurjchem-2641	6	54	a	a	DET
eurjchem-2641	6	55	lack	lack	NOUN
eurjchem-2641	6	56	of	of	ADP
eurjchem-2641	6	57	prediction	prediction	NOUN
eurjchem-2641	6	58	,	,	PUNCT
eurjchem-2641	6	59	diagnosis	diagnosis	NOUN
eurjchem-2641	6	60	,	,	PUNCT
eurjchem-2641	6	61	and	and	CCONJ
eurjchem-2641	6	62	follow	follow	VERB
eurjchem-2641	6	63	-	-	PUNCT
eurjchem-2641	6	64	up	up	NOUN
eurjchem-2641	6	65	.	.	PUNCT
eurjchem-2641	7	1	micrornas	microrna	NOUN
eurjchem-2641	7	2	(	(	PUNCT
eurjchem-2641	7	3	mirnas	mirna	NOUN
eurjchem-2641	7	4	)	)	PUNCT
eurjchem-2641	7	5	in	in	ADP
eurjchem-2641	7	6	liquid	liquid	ADJ
eurjchem-2641	7	7	biopsies	biopsy	NOUN
eurjchem-2641	7	8	(	(	PUNCT
eurjchem-2641	7	9	lbs	lbs	PROPN
eurjchem-2641	7	10	)	)	PUNCT
eurjchem-2641	7	11	are	be	AUX
eurjchem-2641	7	12	promising	promise	VERB
eurjchem-2641	7	13	tools	tool	NOUN
eurjchem-2641	7	14	for	for	ADP
eurjchem-2641	7	15	the	the	DET
eurjchem-2641	7	16	prediction	prediction	NOUN
eurjchem-2641	7	17	and	and	CCONJ
eurjchem-2641	7	18	follow	follow	VERB
eurjchem-2641	7	19	-	-	PUNCT
eurjchem-2641	7	20	up	up	NOUN
eurjchem-2641	7	21	of	of	ADP
eurjchem-2641	7	22	cancer	cancer	NOUN
eurjchem-2641	7	23	.	.	PUNCT
eurjchem-2641	8	1	this	this	DET
eurjchem-2641	8	2	study	study	NOUN
eurjchem-2641	8	3	aims	aim	VERB
eurjchem-2641	8	4	to	to	PART
eurjchem-2641	8	5	investigate	investigate	VERB
eurjchem-2641	8	6	and	and	CCONJ
eurjchem-2641	8	7	compare	compare	VERB
eurjchem-2641	8	8	serum	serum	PROPN
eurjchem-2641	8	9	mirna-148b	mirna-148b	PROPN
eurjchem-2641	8	10	,	,	PUNCT
eurjchem-2641	8	11	caspase-3	caspase-3	NUM
eurjchem-2641	8	12	,	,	PUNCT
eurjchem-2641	8	13	bax	bax	NOUN
eurjchem-2641	8	14	,	,	PUNCT
eurjchem-2641	8	15	bcl-2	bcl-2	NOUN
eurjchem-2641	8	16	,	,	PUNCT
eurjchem-2641	8	17	and	and	CCONJ
eurjchem-2641	8	18	total	total	ADJ
eurjchem-2641	8	19	antioxidant	antioxidant	ADJ
eurjchem-2641	8	20	capacity	capacity	NOUN
eurjchem-2641	8	21	(	(	PUNCT
eurjchem-2641	8	22	tac	tac	NOUN
eurjchem-2641	8	23	)	)	PUNCT
eurjchem-2641	8	24	of	of	ADP
eurjchem-2641	8	25	bc	bc	PROPN
eurjchem-2641	8	26	patients	patient	NOUN
eurjchem-2641	8	27	with	with	ADP
eurjchem-2641	8	28	healthy	healthy	ADJ
eurjchem-2641	8	29	controls	control	NOUN
eurjchem-2641	8	30	.	.	PUNCT
eurjchem-2641	9	1	in	in	ADP
eurjchem-2641	9	2	this	this	DET
eurjchem-2641	9	3	study	study	NOUN
eurjchem-2641	9	4	,	,	PUNCT
eurjchem-2641	9	5	300	300	NUM
eurjchem-2641	9	6	women	woman	NOUN
eurjchem-2641	9	7	were	be	AUX
eurjchem-2641	9	8	included	include	VERB
eurjchem-2641	9	9	and	and	CCONJ
eurjchem-2641	9	10	divided	divide	VERB
eurjchem-2641	9	11	into	into	ADP
eurjchem-2641	9	12	four	four	NUM
eurjchem-2641	9	13	groups	group	NOUN
eurjchem-2641	9	14	of	of	ADP
eurjchem-2641	9	15	75	75	NUM
eurjchem-2641	9	16	each	each	PRON
eurjchem-2641	9	17	:	:	PUNCT
eurjchem-2641	9	18	group	group	NOUN
eurjchem-2641	9	19	1	1	NUM
eurjchem-2641	9	20	consisted	consist	VERB
eurjchem-2641	9	21	of	of	ADP
eurjchem-2641	9	22	healthy	healthy	ADJ
eurjchem-2641	9	23	controls	control	NOUN
eurjchem-2641	9	24	,	,	PUNCT
eurjchem-2641	9	25	group	group	NOUN
eurjchem-2641	9	26	2	2	NUM
eurjchem-2641	9	27	of	of	ADP
eurjchem-2641	9	28	early	early	ADJ
eurjchem-2641	9	29	-	-	PUNCT
eurjchem-2641	9	30	stage	stage	NOUN
eurjchem-2641	9	31	bc	bc	PROPN
eurjchem-2641	9	32	patients	patient	NOUN
eurjchem-2641	9	33	,	,	PUNCT
eurjchem-2641	9	34	group	group	NOUN
eurjchem-2641	9	35	3	3	NUM
eurjchem-2641	9	36	of	of	ADP
eurjchem-2641	9	37	chemotherapy	chemotherapy	NOUN
eurjchem-2641	9	38	-	-	PUNCT
eurjchem-2641	9	39	treated	treat	VERB
eurjchem-2641	9	40	bc	bc	PROPN
eurjchem-2641	9	41	patients	patient	NOUN
eurjchem-2641	9	42	,	,	PUNCT
eurjchem-2641	9	43	and	and	CCONJ
eurjchem-2641	9	44	group	group	NOUN
eurjchem-2641	9	45	4	4	NUM
eurjchem-2641	9	46	of	of	ADP
eurjchem-2641	9	47	mastectomy	mastectomy	NOUN
eurjchem-2641	9	48	-	-	PUNCT
eurjchem-2641	9	49	treated	treat	VERB
eurjchem-2641	9	50	bc	bc	PROPN
eurjchem-2641	9	51	patients	patient	NOUN
eurjchem-2641	9	52	.	.	PUNCT
eurjchem-2641	10	1	blood	blood	NOUN
eurjchem-2641	10	2	samples	sample	NOUN
eurjchem-2641	10	3	were	be	AUX
eurjchem-2641	10	4	collected	collect	VERB
eurjchem-2641	10	5	for	for	ADP
eurjchem-2641	10	6	a	a	DET
eurjchem-2641	10	7	complete	complete	ADJ
eurjchem-2641	10	8	blood	blood	NOUN
eurjchem-2641	10	9	count	count	NOUN
eurjchem-2641	10	10	and	and	CCONJ
eurjchem-2641	10	11	serum	serum	NOUN
eurjchem-2641	10	12	samples	sample	NOUN
eurjchem-2641	10	13	were	be	AUX
eurjchem-2641	10	14	tested	test	VERB
eurjchem-2641	10	15	for	for	ADP
eurjchem-2641	10	16	mirna-148b	mirna-148b	PROPN
eurjchem-2641	10	17	bax	bax	PROPN
eurjchem-2641	10	18	,	,	PUNCT
eurjchem-2641	10	19	caspase-3	caspase-3	NUM
eurjchem-2641	10	20	,	,	PUNCT
eurjchem-2641	10	21	bcl-2	bcl-2	NOUN
eurjchem-2641	10	22	,	,	PUNCT
eurjchem-2641	10	23	and	and	CCONJ
eurjchem-2641	10	24	tac	tac	PROPN
eurjchem-2641	10	25	.	.	PUNCT
eurjchem-2641	11	1	rt	rt	PROPN
eurjchem-2641	11	2	/	/	SYM
eurjchem-2641	11	3	pcr	pcr	PROPN
eurjchem-2641	11	4	,	,	PUNCT
eurjchem-2641	11	5	elisa	elisa	NOUN
eurjchem-2641	11	6	and	and	CCONJ
eurjchem-2641	11	7	spectrophotometric	spectrophotometric	ADJ
eurjchem-2641	11	8	methods	method	NOUN
eurjchem-2641	11	9	were	be	AUX
eurjchem-2641	11	10	used	use	VERB
eurjchem-2641	11	11	to	to	PART
eurjchem-2641	11	12	determine	determine	VERB
eurjchem-2641	11	13	these	these	DET
eurjchem-2641	11	14	parameters	parameter	NOUN
eurjchem-2641	11	15	.	.	PUNCT
eurjchem-2641	12	1	in	in	ADP
eurjchem-2641	12	2	addition	addition	NOUN
eurjchem-2641	12	3	,	,	PUNCT
eurjchem-2641	12	4	histopathological	histopathological	ADJ
eurjchem-2641	12	5	examinations	examination	NOUN
eurjchem-2641	12	6	were	be	AUX
eurjchem-2641	12	7	performed	perform	VERB
eurjchem-2641	12	8	on	on	ADP
eurjchem-2641	12	9	breast	breast	NOUN
eurjchem-2641	12	10	tissue	tissue	NOUN
eurjchem-2641	12	11	samples	sample	NOUN
eurjchem-2641	12	12	.	.	PUNCT
eurjchem-2641	13	1	the	the	DET
eurjchem-2641	13	2	present	present	ADJ
eurjchem-2641	13	3	results	result	NOUN
eurjchem-2641	13	4	indicated	indicate	VERB
eurjchem-2641	13	5	that	that	SCONJ
eurjchem-2641	13	6	bc	bc	PROPN
eurjchem-2641	13	7	patients	patient	NOUN
eurjchem-2641	13	8	exhibited	exhibit	VERB
eurjchem-2641	13	9	elevated	elevated	ADJ
eurjchem-2641	13	10	mirna-148b	mirna-148b	PROPN
eurjchem-2641	13	11	,	,	PUNCT
eurjchem-2641	13	12	bax	bax	PROPN
eurjchem-2641	13	13	,	,	PUNCT
eurjchem-2641	13	14	and	and	CCONJ
eurjchem-2641	13	15	bcl-2	bcl-2	ADJ
eurjchem-2641	13	16	expressions	expression	NOUN
eurjchem-2641	13	17	compared	compare	VERB
eurjchem-2641	13	18	to	to	ADP
eurjchem-2641	13	19	healthy	healthy	ADJ
eurjchem-2641	13	20	controls	control	NOUN
eurjchem-2641	13	21	.	.	PUNCT
eurjchem-2641	14	1	importantly	importantly	ADV
eurjchem-2641	14	2	,	,	PUNCT
eurjchem-2641	14	3	advanced	advanced	ADJ
eurjchem-2641	14	4	bc	bc	PROPN
eurjchem-2641	14	5	stages	stage	NOUN
eurjchem-2641	14	6	showed	show	VERB
eurjchem-2641	14	7	significantly	significantly	ADV
eurjchem-2641	14	8	higher	high	ADJ
eurjchem-2641	14	9	mirna-148b	mirna-148b	PROPN
eurjchem-2641	14	10	levels	level	NOUN
eurjchem-2641	14	11	than	than	ADP
eurjchem-2641	14	12	early	early	ADJ
eurjchem-2641	14	13	stages	stage	NOUN
eurjchem-2641	14	14	.	.	PUNCT
eurjchem-2641	15	1	however	however	ADV
eurjchem-2641	15	2	,	,	PUNCT
eurjchem-2641	15	3	levels	level	NOUN
eurjchem-2641	15	4	of	of	ADP
eurjchem-2641	15	5	caspase-3	caspase-3	NUM
eurjchem-2641	15	6	and	and	CCONJ
eurjchem-2641	15	7	tac	tac	PROPN
eurjchem-2641	15	8	were	be	AUX
eurjchem-2641	15	9	reduced	reduce	VERB
eurjchem-2641	15	10	in	in	ADP
eurjchem-2641	15	11	bc	bc	PROPN
eurjchem-2641	15	12	patients	patient	NOUN
eurjchem-2641	15	13	compared	compare	VERB
eurjchem-2641	15	14	to	to	ADP
eurjchem-2641	15	15	healthy	healthy	ADJ
eurjchem-2641	15	16	controls	control	NOUN
eurjchem-2641	15	17	.	.	PUNCT
eurjchem-2641	16	1	histopathological	histopathological	ADJ
eurjchem-2641	16	2	analysis	analysis	NOUN
eurjchem-2641	16	3	revealed	reveal	VERB
eurjchem-2641	16	4	various	various	ADJ
eurjchem-2641	16	5	alterations	alteration	NOUN
eurjchem-2641	16	6	in	in	ADP
eurjchem-2641	16	7	breast	breast	NOUN
eurjchem-2641	16	8	tissues	tissue	NOUN
eurjchem-2641	16	9	,	,	PUNCT
eurjchem-2641	16	10	including	include	VERB
eurjchem-2641	16	11	nuclear	nuclear	ADJ
eurjchem-2641	16	12	changes	change	NOUN
eurjchem-2641	16	13	,	,	PUNCT
eurjchem-2641	16	14	the	the	DET
eurjchem-2641	16	15	presence	presence	NOUN
eurjchem-2641	16	16	of	of	ADP
eurjchem-2641	16	17	giant	giant	ADJ
eurjchem-2641	16	18	cells	cell	NOUN
eurjchem-2641	16	19	,	,	PUNCT
eurjchem-2641	16	20	and	and	CCONJ
eurjchem-2641	16	21	inflammation	inflammation	NOUN
eurjchem-2641	16	22	.	.	PUNCT
eurjchem-2641	17	1	the	the	DET
eurjchem-2641	17	2	present	present	ADJ
eurjchem-2641	17	3	study	study	NOUN
eurjchem-2641	17	4	concluded	conclude	VERB
eurjchem-2641	17	5	that	that	SCONJ
eurjchem-2641	17	6	mirna-148b	mirna-148b	PROPN
eurjchem-2641	17	7	and	and	CCONJ
eurjchem-2641	17	8	bcl-2	bcl-2	NOUN
eurjchem-2641	17	9	are	be	AUX
eurjchem-2641	17	10	markedly	markedly	ADV
eurjchem-2641	17	11	elevated	elevate	VERB
eurjchem-2641	17	12	in	in	ADP
eurjchem-2641	17	13	the	the	DET
eurjchem-2641	17	14	serum	serum	NOUN
eurjchem-2641	17	15	of	of	ADP
eurjchem-2641	17	16	bc	bc	PROPN
eurjchem-2641	17	17	patients	patient	NOUN
eurjchem-2641	17	18	compared	compare	VERB
eurjchem-2641	17	19	to	to	ADP
eurjchem-2641	17	20	healthy	healthy	ADJ
eurjchem-2641	17	21	subjects	subject	NOUN
eurjchem-2641	17	22	;	;	PUNCT
eurjchem-2641	17	23	however	however	ADV
eurjchem-2641	17	24	,	,	PUNCT
eurjchem-2641	17	25	bax	bax	PROPN
eurjchem-2641	17	26	and	and	CCONJ
eurjchem-2641	17	27	caspase-3	caspase-3	NUM
eurjchem-2641	17	28	levels	level	NOUN
eurjchem-2641	17	29	were	be	AUX
eurjchem-2641	17	30	reduced	reduce	VERB
eurjchem-2641	17	31	.	.	PUNCT
eurjchem-2641	18	1	these	these	DET
eurjchem-2641	18	2	findings	finding	NOUN
eurjchem-2641	18	3	underscore	underscore	VERB
eurjchem-2641	18	4	that	that	DET
eurjchem-2641	18	5	blood	blood	NOUN
eurjchem-2641	18	6	mirna-148b	mirna-148b	PROPN
eurjchem-2641	18	7	and	and	CCONJ
eurjchem-2641	18	8	caspase-3	caspase-3	NUM
eurjchem-2641	18	9	are	be	AUX
eurjchem-2641	18	10	promising	promise	VERB
eurjchem-2641	18	11	avenues	avenue	NOUN
eurjchem-2641	18	12	for	for	ADP
eurjchem-2641	18	13	the	the	DET
eurjchem-2641	18	14	prediction	prediction	NOUN
eurjchem-2641	18	15	and	and	CCONJ
eurjchem-2641	18	16	follow	follow	VERB
eurjchem-2641	18	17	-	-	PUNCT
eurjchem-2641	18	18	up	up	NOUN
eurjchem-2641	18	19	of	of	ADP
eurjchem-2641	18	20	bc	bc	PROPN
eurjchem-2641	18	21	patients	patient	NOUN
eurjchem-2641	18	22	.	.	PUNCT
eurjchem-2641	19	1	apoptosis	apoptosis	NOUN
eurjchem-2641	19	2	oncogenesis	oncogenesis	NOUN
eurjchem-2641	19	3	liquid	liquid	ADJ
eurjchem-2641	19	4	biopsy	biopsy	NOUN
eurjchem-2641	19	5	gene	gene	NOUN
eurjchem-2641	19	6	expression	expression	NOUN
eurjchem-2641	19	7	cancer	cancer	NOUN
eurjchem-2641	19	8	prognosis	prognosis	NOUN
eurjchem-2641	19	9	therapeutic	therapeutic	ADJ
eurjchem-2641	19	10	target	target	NOUN
eurjchem-2641	19	11	cite	cite	VERB
eurjchem-2641	19	12	this	this	PRON
eurjchem-2641	19	13	:	:	PUNCT
eurjchem-2641	19	14	eur	eur	PROPN
eurjchem-2641	19	15	.	.	PUNCT
eurjchem-2641	20	1	j.	j.	PROPN
eurjchem-2641	20	2	chem	chem	PROPN
eurjchem-2641	20	3	.	.	PUNCT
eurjchem-2641	21	1	2025	2025	NUM
eurjchem-2641	21	2	,	,	PUNCT
eurjchem-2641	21	3	16(2	16(2	NUM
eurjchem-2641	21	4	)	)	PUNCT
eurjchem-2641	21	5	,	,	PUNCT
eurjchem-2641	21	6	222	222	NUM
eurjchem-2641	21	7	-	-	SYM
eurjchem-2641	21	8	232	232	NUM
eurjchem-2641	21	9	journal	journal	NOUN
eurjchem-2641	21	10	website	website	NOUN
eurjchem-2641	21	11	:	:	PUNCT
eurjchem-2641	21	12	www.eurjchem.com	www.eurjchem.com	X
eurjchem-2641	21	13	1	1	X
eurjchem-2641	21	14	.	.	PUNCT
eurjchem-2641	21	15	introduction	introduction	NOUN
eurjchem-2641	21	16	breast	breast	NOUN
eurjchem-2641	21	17	cancer	cancer	NOUN
eurjchem-2641	21	18	(	(	PUNCT
eurjchem-2641	21	19	bc	bc	PROPN
eurjchem-2641	21	20	)	)	PUNCT
eurjchem-2641	21	21	is	be	AUX
eurjchem-2641	21	22	the	the	DET
eurjchem-2641	21	23	most	most	ADV
eurjchem-2641	21	24	common	common	ADJ
eurjchem-2641	21	25	form	form	NOUN
eurjchem-2641	21	26	of	of	ADP
eurjchem-2641	21	27	cancer	cancer	NOUN
eurjchem-2641	21	28	in	in	ADP
eurjchem-2641	21	29	women	woman	NOUN
eurjchem-2641	21	30	worldwide	worldwide	ADV
eurjchem-2641	21	31	and	and	CCONJ
eurjchem-2641	21	32	the	the	DET
eurjchem-2641	21	33	leading	lead	VERB
eurjchem-2641	21	34	cause	cause	NOUN
eurjchem-2641	21	35	of	of	ADP
eurjchem-2641	21	36	cancer	cancer	NOUN
eurjchem-2641	21	37	-	-	PUNCT
eurjchem-2641	21	38	related	relate	VERB
eurjchem-2641	21	39	death	death	NOUN
eurjchem-2641	21	40	[	[	X
eurjchem-2641	21	41	1,2	1,2	NUM
eurjchem-2641	21	42	]	]	PUNCT
eurjchem-2641	21	43	.	.	PUNCT
eurjchem-2641	22	1	bc	bc	PROPN
eurjchem-2641	22	2	risk	risk	NOUN
eurjchem-2641	22	3	factors	factor	NOUN
eurjchem-2641	22	4	include	include	VERB
eurjchem-2641	22	5	genetic	genetic	ADJ
eurjchem-2641	22	6	,	,	PUNCT
eurjchem-2641	22	7	biological	biological	ADJ
eurjchem-2641	22	8	,	,	PUNCT
eurjchem-2641	22	9	and	and	CCONJ
eurjchem-2641	22	10	environmental	environmental	ADJ
eurjchem-2641	22	11	factors	factor	NOUN
eurjchem-2641	22	12	[	[	X
eurjchem-2641	22	13	2,3	2,3	NUM
eurjchem-2641	22	14	]	]	PUNCT
eurjchem-2641	22	15	.	.	PUNCT
eurjchem-2641	23	1	bc	bc	PROPN
eurjchem-2641	23	2	genetic	genetic	ADJ
eurjchem-2641	23	3	risk	risk	NOUN
eurjchem-2641	23	4	factors	factor	NOUN
eurjchem-2641	23	5	are	be	AUX
eurjchem-2641	23	6	members	member	NOUN
eurjchem-2641	23	7	of	of	ADP
eurjchem-2641	23	8	biological	biological	ADJ
eurjchem-2641	23	9	factors	factor	NOUN
eurjchem-2641	23	10	,	,	PUNCT
eurjchem-2641	23	11	including	include	VERB
eurjchem-2641	23	12	mutations	mutation	NOUN
eurjchem-2641	23	13	in	in	ADP
eurjchem-2641	23	14	the	the	DET
eurjchem-2641	23	15	breast	breast	NOUN
eurjchem-2641	23	16	cancer	cancer	NOUN
eurjchem-2641	23	17	gene	gene	NOUN
eurjchem-2641	23	18	,	,	PUNCT
eurjchem-2641	23	19	the	the	DET
eurjchem-2641	23	20	breast	breast	NOUN
eurjchem-2641	23	21	cancer	cancer	NOUN
eurjchem-2641	23	22	gene	gene	NOUN
eurjchem-2641	23	23	2	2	NUM
eurjchem-2641	23	24	,	,	PUNCT
eurjchem-2641	23	25	and	and	CCONJ
eurjchem-2641	23	26	checkpoint	checkpoint	NOUN
eurjchem-2641	23	27	kinase	kinase	NOUN
eurjchem-2641	23	28	2	2	NUM
eurjchem-2641	24	1	[	[	X
eurjchem-2641	24	2	4	4	NUM
eurjchem-2641	24	3	]	]	PUNCT
eurjchem-2641	24	4	.	.	PUNCT
eurjchem-2641	25	1	moreover	moreover	ADV
eurjchem-2641	25	2	,	,	PUNCT
eurjchem-2641	25	3	bc	bc	PROPN
eurjchem-2641	25	4	's	's	PART
eurjchem-2641	25	5	risk	risk	NOUN
eurjchem-2641	25	6	factors	factor	NOUN
eurjchem-2641	25	7	include	include	VERB
eurjchem-2641	25	8	obesity	obesity	NOUN
eurjchem-2641	25	9	,	,	PUNCT
eurjchem-2641	25	10	alcohol	alcohol	NOUN
eurjchem-2641	25	11	consumption	consumption	NOUN
eurjchem-2641	25	12	,	,	PUNCT
eurjchem-2641	25	13	smoking	smoking	NOUN
eurjchem-2641	25	14	,	,	PUNCT
eurjchem-2641	25	15	hormone	hormone	NOUN
eurjchem-2641	25	16	,	,	PUNCT
eurjchem-2641	25	17	and	and	CCONJ
eurjchem-2641	25	18	radiation	radiation	NOUN
eurjchem-2641	25	19	exposure	exposure	NOUN
eurjchem-2641	25	20	[	[	X
eurjchem-2641	25	21	5	5	NUM
eurjchem-2641	25	22	]	]	PUNCT
eurjchem-2641	25	23	.	.	PUNCT
eurjchem-2641	26	1	bcs	bc	NOUN
eurjchem-2641	26	2	are	be	AUX
eurjchem-2641	26	3	classified	classify	VERB
eurjchem-2641	26	4	into	into	ADP
eurjchem-2641	26	5	carcinomas	carcinoma	NOUN
eurjchem-2641	26	6	and	and	CCONJ
eurjchem-2641	26	7	sarcomas	sarcoma	NOUN
eurjchem-2641	26	8	;	;	PUNCT
eurjchem-2641	26	9	breast	breast	NOUN
eurjchem-2641	26	10	carcinomas	carcinoma	NOUN
eurjchem-2641	26	11	are	be	AUX
eurjchem-2641	26	12	further	far	ADV
eurjchem-2641	26	13	subcategorized	subcategorize	VERB
eurjchem-2641	26	14	into	into	ADP
eurjchem-2641	26	15	in	in	ADP
eurjchem-2641	26	16	situ	situ	ADJ
eurjchem-2641	26	17	and	and	CCONJ
eurjchem-2641	26	18	invasive	invasive	ADJ
eurjchem-2641	26	19	carcinomas	carcinoma	NOUN
eurjchem-2641	27	1	[	[	X
eurjchem-2641	27	2	6,7	6,7	NUM
eurjchem-2641	27	3	]	]	PUNCT
eurjchem-2641	27	4	.	.	PUNCT
eurjchem-2641	28	1	understanding	understand	VERB
eurjchem-2641	28	2	the	the	DET
eurjchem-2641	28	3	bc	bc	PROPN
eurjchem-2641	28	4	subtypes	subtype	NOUN
eurjchem-2641	28	5	can	can	AUX
eurjchem-2641	28	6	potentially	potentially	ADV
eurjchem-2641	28	7	treat	treat	VERB
eurjchem-2641	28	8	patients	patient	NOUN
eurjchem-2641	28	9	with	with	ADP
eurjchem-2641	28	10	bc	bc	PROPN
eurjchem-2641	29	1	[	[	X
eurjchem-2641	29	2	6,7	6,7	NUM
eurjchem-2641	29	3	]	]	PUNCT
eurjchem-2641	29	4	.	.	PUNCT
eurjchem-2641	30	1	bc	bc	PROPN
eurjchem-2641	30	2	is	be	AUX
eurjchem-2641	30	3	a	a	DET
eurjchem-2641	30	4	life	life	NOUN
eurjchem-2641	30	5	-	-	PUNCT
eurjchem-2641	30	6	threatening	threaten	VERB
eurjchem-2641	30	7	disease	disease	NOUN
eurjchem-2641	30	8	due	due	ADP
eurjchem-2641	30	9	to	to	ADP
eurjchem-2641	30	10	the	the	DET
eurjchem-2641	30	11	lack	lack	NOUN
eurjchem-2641	30	12	of	of	ADP
eurjchem-2641	30	13	prediction	prediction	NOUN
eurjchem-2641	30	14	,	,	PUNCT
eurjchem-2641	30	15	diagnosis	diagnosis	NOUN
eurjchem-2641	30	16	,	,	PUNCT
eurjchem-2641	30	17	and	and	CCONJ
eurjchem-2641	30	18	targeted	target	VERB
eurjchem-2641	30	19	therapy	therapy	NOUN
eurjchem-2641	30	20	,	,	PUNCT
eurjchem-2641	30	21	in	in	ADP
eurjchem-2641	30	22	addition	addition	NOUN
eurjchem-2641	30	23	to	to	ADP
eurjchem-2641	30	24	bc	bc	PROPN
eurjchem-2641	30	25	metastasis	metastasis	NOUN
eurjchem-2641	30	26	and	and	CCONJ
eurjchem-2641	30	27	multidrug	multidrug	VERB
eurjchem-2641	30	28	resistance	resistance	NOUN
eurjchem-2641	31	1	[	[	X
eurjchem-2641	31	2	6,7	6,7	NUM
eurjchem-2641	31	3	]	]	PUNCT
eurjchem-2641	31	4	.	.	PUNCT
eurjchem-2641	32	1	despite	despite	SCONJ
eurjchem-2641	32	2	the	the	DET
eurjchem-2641	32	3	applicability	applicability	NOUN
eurjchem-2641	32	4	of	of	ADP
eurjchem-2641	32	5	ultrasound	ultrasound	NOUN
eurjchem-2641	32	6	diagnostics	diagnostic	NOUN
eurjchem-2641	32	7	,	,	PUNCT
eurjchem-2641	32	8	magnetic	magnetic	ADJ
eurjchem-2641	32	9	resonance	resonance	NOUN
eurjchem-2641	32	10	imaging	imaging	NOUN
eurjchem-2641	32	11	,	,	PUNCT
eurjchem-2641	32	12	and	and	CCONJ
eurjchem-2641	32	13	other	other	ADJ
eurjchem-2641	32	14	techniques	technique	NOUN
eurjchem-2641	32	15	for	for	ADP
eurjchem-2641	32	16	bc	bc	PROPN
eurjchem-2641	32	17	diagnosis	diagnosis	NOUN
eurjchem-2641	32	18	,	,	PUNCT
eurjchem-2641	32	19	these	these	DET
eurjchem-2641	32	20	methods	method	NOUN
eurjchem-2641	32	21	are	be	AUX
eurjchem-2641	32	22	invasive	invasive	ADJ
eurjchem-2641	32	23	and	and	CCONJ
eurjchem-2641	32	24	unsuitable	unsuitable	ADJ
eurjchem-2641	32	25	for	for	ADP
eurjchem-2641	32	26	bc	bc	PROPN
eurjchem-2641	32	27	cancer	cancer	NOUN
eurjchem-2641	32	28	prediction	prediction	NOUN
eurjchem-2641	32	29	and	and	CCONJ
eurjchem-2641	32	30	monitoring	monitor	VERB
eurjchem-2641	32	31	[	[	X
eurjchem-2641	32	32	8	8	NUM
eurjchem-2641	32	33	]	]	PUNCT
eurjchem-2641	32	34	.	.	PUNCT
eurjchem-2641	33	1	therefore	therefore	ADV
eurjchem-2641	33	2	,	,	PUNCT
eurjchem-2641	33	3	discovering	discover	VERB
eurjchem-2641	33	4	noninvasive	noninvasive	ADJ
eurjchem-2641	33	5	and	and	CCONJ
eurjchem-2641	33	6	better	well	ADJ
eurjchem-2641	33	7	prediction	prediction	NOUN
eurjchem-2641	33	8	methods	method	NOUN
eurjchem-2641	33	9	,	,	PUNCT
eurjchem-2641	33	10	diagnosis	diagnosis	NOUN
eurjchem-2641	33	11	,	,	PUNCT
eurjchem-2641	33	12	followup	followup	NOUN
eurjchem-2641	33	13	,	,	PUNCT
eurjchem-2641	33	14	and	and	CCONJ
eurjchem-2641	33	15	tumor	tumor	NOUN
eurjchem-2641	33	16	characterization	characterization	NOUN
eurjchem-2641	33	17	is	be	AUX
eurjchem-2641	33	18	a	a	DET
eurjchem-2641	33	19	critical	critical	ADJ
eurjchem-2641	33	20	issue	issue	NOUN
eurjchem-2641	33	21	[	[	X
eurjchem-2641	33	22	8	8	NUM
eurjchem-2641	33	23	]	]	PUNCT
eurjchem-2641	33	24	.	.	PUNCT
eurjchem-2641	34	1	interestingly	interestingly	ADV
eurjchem-2641	34	2	,	,	PUNCT
eurjchem-2641	34	3	liquid	liquid	ADJ
eurjchem-2641	34	4	biopsies	biopsy	NOUN
eurjchem-2641	34	5	(	(	PUNCT
eurjchem-2641	34	6	lb	lb	X
eurjchem-2641	34	7	)	)	PUNCT
eurjchem-2641	34	8	pinpoint	pinpoint	NOUN
eurjchem-2641	34	9	the	the	DET
eurjchem-2641	34	10	primary	primary	ADJ
eurjchem-2641	34	11	origin	origin	NOUN
eurjchem-2641	34	12	of	of	ADP
eurjchem-2641	34	13	cancer	cancer	NOUN
eurjchem-2641	34	14	and	and	CCONJ
eurjchem-2641	34	15	are	be	AUX
eurjchem-2641	34	16	promising	promise	VERB
eurjchem-2641	34	17	tools	tool	NOUN
eurjchem-2641	34	18	for	for	ADP
eurjchem-2641	34	19	predicting	predict	VERB
eurjchem-2641	34	20	and	and	CCONJ
eurjchem-2641	34	21	monitoring	monitor	VERB
eurjchem-2641	34	22	cancer	cancer	NOUN
eurjchem-2641	34	23	patients	patient	NOUN
eurjchem-2641	34	24	[	[	X
eurjchem-2641	34	25	9,10	9,10	NUM
eurjchem-2641	34	26	]	]	X
eurjchem-2641	34	27	.	.	PUNCT
eurjchem-2641	35	1	lbs	lbs	PROPN
eurjchem-2641	35	2	are	be	AUX
eurjchem-2641	35	3	samples	sample	NOUN
eurjchem-2641	35	4	from	from	ADP
eurjchem-2641	35	5	biofluids	biofluid	NOUN
eurjchem-2641	35	6	such	such	ADJ
eurjchem-2641	35	7	as	as	ADP
eurjchem-2641	35	8	blood	blood	NOUN
eurjchem-2641	35	9	,	,	PUNCT
eurjchem-2641	35	10	urine	urine	NOUN
eurjchem-2641	35	11	,	,	PUNCT
eurjchem-2641	35	12	saliva	saliva	NOUN
eurjchem-2641	35	13	,	,	PUNCT
eurjchem-2641	35	14	pleural	pleural	ADJ
eurjchem-2641	35	15	effusions	effusion	NOUN
eurjchem-2641	35	16	,	,	PUNCT
eurjchem-2641	35	17	and	and	CCONJ
eurjchem-2641	35	18	cerebrospinal	cerebrospinal	ADJ
eurjchem-2641	35	19	fluids	fluid	NOUN
eurjchem-2641	35	20	[	[	X
eurjchem-2641	35	21	9	9	NUM
eurjchem-2641	35	22	]	]	PUNCT
eurjchem-2641	35	23	.	.	PUNCT
eurjchem-2641	36	1	lbs	lbs	PROPN
eurjchem-2641	36	2	have	have	AUX
eurjchem-2641	36	3	been	be	AUX
eurjchem-2641	36	4	designated	designate	VERB
eurjchem-2641	36	5	to	to	PART
eurjchem-2641	36	6	predict	predict	VERB
eurjchem-2641	36	7	,	,	PUNCT
eurjchem-2641	36	8	diagnose	diagnose	NOUN
eurjchem-2641	36	9	,	,	PUNCT
eurjchem-2641	36	10	and	and	CCONJ
eurjchem-2641	36	11	monitor	monitor	VERB
eurjchem-2641	36	12	therapy	therapy	NOUN
eurjchem-2641	36	13	responses	response	NOUN
eurjchem-2641	36	14	in	in	ADP
eurjchem-2641	36	15	patients	patient	NOUN
eurjchem-2641	36	16	with	with	ADP
eurjchem-2641	36	17	bc	bc	PROPN
eurjchem-2641	36	18	instead	instead	ADV
eurjchem-2641	36	19	of	of	ADP
eurjchem-2641	36	20	tissue	tissue	NOUN
eurjchem-2641	36	21	biopsies	biopsy	NOUN
eurjchem-2641	36	22	(	(	PUNCT
eurjchem-2641	36	23	tbs	tbs	NOUN
eurjchem-2641	36	24	)	)	PUNCT
eurjchem-2641	37	1	[	[	X
eurjchem-2641	37	2	10	10	NUM
eurjchem-2641	37	3	]	]	PUNCT
eurjchem-2641	37	4	.	.	PUNCT
eurjchem-2641	37	5	lbs	lbs	PROPN
eurjchem-2641	37	6	offer	offer	VERB
eurjchem-2641	37	7	several	several	ADJ
eurjchem-2641	37	8	advantages	advantage	NOUN
eurjchem-2641	37	9	over	over	ADP
eurjchem-2641	37	10	tbs	tbs	NOUN
eurjchem-2641	37	11	,	,	PUNCT
eurjchem-2641	37	12	including	include	VERB
eurjchem-2641	37	13	being	be	AUX
eurjchem-2641	37	14	easy	easy	ADJ
eurjchem-2641	37	15	to	to	PART
eurjchem-2641	37	16	obtain	obtain	VERB
eurjchem-2641	37	17	,	,	PUNCT
eurjchem-2641	37	18	painless	painless	ADJ
eurjchem-2641	37	19	,	,	PUNCT
eurjchem-2641	37	20	and	and	CCONJ
eurjchem-2641	37	21	allowing	allow	VERB
eurjchem-2641	37	22	the	the	DET
eurjchem-2641	37	23	measurement	measurement	NOUN
eurjchem-2641	37	24	of	of	ADP
eurjchem-2641	37	25	various	various	ADJ
eurjchem-2641	37	26	tumor	tumor	NOUN
eurjchem-2641	37	27	biomarkers	biomarker	NOUN
eurjchem-2641	37	28	[	[	X
eurjchem-2641	37	29	11	11	NUM
eurjchem-2641	37	30	]	]	PUNCT
eurjchem-2641	37	31	.	.	PUNCT
eurjchem-2641	38	1	thus	thus	ADV
eurjchem-2641	38	2	,	,	PUNCT
eurjchem-2641	38	3	biomarkers	biomarker	NOUN
eurjchem-2641	38	4	in	in	ADP
eurjchem-2641	38	5	lbs	lbs	NOUN
eurjchem-2641	38	6	apply	apply	VERB
eurjchem-2641	38	7	to	to	ADP
eurjchem-2641	38	8	the	the	DET
eurjchem-2641	38	9	predicting	predicting	NOUN
eurjchem-2641	38	10	,	,	PUNCT
eurjchem-2641	38	11	diagnosing	diagnosing	NOUN
eurjchem-2641	38	12	and	and	CCONJ
eurjchem-2641	38	13	abstract	abstract	ADJ
eurjchem-2641	38	14	research	research	NOUN
eurjchem-2641	38	15	article	article	NOUN
eurjchem-2641	38	16	keywords	keyword	VERB
eurjchem-2641	38	17	https://dx.doi.org/10.5155/eurjchem.16.2.222-232.2641	https://dx.doi.org/10.5155/eurjchem.16.2.222-232.2641	PROPN
eurjchem-2641	38	18	https://www.eurjchem.com/	https://www.eurjchem.com/	PROPN
eurjchem-2641	38	19	https://dx.doi.org/10.5155/eurjchem.16.2.222-232.2641	https://dx.doi.org/10.5155/eurjchem.16.2.222-232.2641	PROPN
eurjchem-2641	38	20	mailto:harisa@ksu.edu.sa	mailto:harisa@ksu.edu.sa	PROPN
eurjchem-2641	38	21	http://www.eurjchem.com/	http://www.eurjchem.com/	PROPN
eurjchem-2641	38	22	https://crossmark.crossref.org/dialog/?doi=10.5155/eurjchem.16.2.222-232.2641&domain=pdf&date_stamp=2025-06-30	https://crossmark.crossref.org/dialog/?doi=10.5155/eurjchem.16.2.222-232.2641&domain=pdf&date_stamp=2025-06-30	PROPN
eurjchem-2641	38	23	harisa	harisa	PROPN
eurjchem-2641	38	24	et	et	PROPN
eurjchem-2641	38	25	al	al	PROPN
eurjchem-2641	38	26	.	.	PUNCT
eurjchem-2641	38	27	/	/	SYM
eurjchem-2641	38	28	european	european	PROPN
eurjchem-2641	38	29	journal	journal	PROPN
eurjchem-2641	38	30	of	of	ADP
eurjchem-2641	38	31	chemistry	chemistry	NOUN
eurjchem-2641	38	32	16	16	NUM
eurjchem-2641	38	33	(	(	PUNCT
eurjchem-2641	38	34	2	2	NUM
eurjchem-2641	38	35	)	)	PUNCT
eurjchem-2641	38	36	(	(	PUNCT
eurjchem-2641	38	37	2025	2025	NUM
eurjchem-2641	38	38	)	)	PUNCT
eurjchem-2641	38	39	222	222	NUM
eurjchem-2641	38	40	-	-	SYM
eurjchem-2641	38	41	232	232	NUM
eurjchem-2641	38	42	223	223	NUM
eurjchem-2641	38	43	2025	2025	NUM
eurjchem-2641	38	44	–	–	PUNCT
eurjchem-2641	38	45	european	european	ADJ
eurjchem-2641	38	46	journal	journal	NOUN
eurjchem-2641	38	47	of	of	ADP
eurjchem-2641	38	48	chemistry	chemistry	NOUN
eurjchem-2641	38	49	–	–	PUNCT
eurjchem-2641	38	50	cc	cc	NOUN
eurjchem-2641	38	51	by	by	ADP
eurjchem-2641	38	52	nc	nc	PROPN
eurjchem-2641	38	53	–	–	PUNCT
eurjchem-2641	38	54	doi	doi	NOUN
eurjchem-2641	38	55	:	:	PUNCT
eurjchem-2641	38	56	10.5155	10.5155	NUM
eurjchem-2641	38	57	/	/	SYM
eurjchem-2641	38	58	eurjchem.16.2.222	eurjchem.16.2.222	NOUN
eurjchem-2641	38	59	-	-	SYM
eurjchem-2641	38	60	232.2641	232.2641	NUM
eurjchem-2641	38	61	following	follow	VERB
eurjchem-2641	38	62	malignant	malignant	ADJ
eurjchem-2641	38	63	conditions	condition	NOUN
eurjchem-2641	38	64	in	in	ADP
eurjchem-2641	38	65	bc	bc	PROPN
eurjchem-2641	38	66	patients	patient	NOUN
eurjchem-2641	38	67	[	[	X
eurjchem-2641	38	68	10	10	NUM
eurjchem-2641	38	69	]	]	PUNCT
eurjchem-2641	38	70	.	.	PUNCT
eurjchem-2641	39	1	therefore	therefore	ADV
eurjchem-2641	39	2	,	,	PUNCT
eurjchem-2641	39	3	lbs	lbs	PROPN
eurjchem-2641	39	4	are	be	AUX
eurjchem-2641	39	5	suggested	suggest	VERB
eurjchem-2641	39	6	as	as	ADP
eurjchem-2641	39	7	alternative	alternative	ADJ
eurjchem-2641	39	8	noninvasive	noninvasive	ADJ
eurjchem-2641	39	9	tools	tool	NOUN
eurjchem-2641	39	10	instead	instead	ADV
eurjchem-2641	39	11	of	of	ADP
eurjchem-2641	39	12	tbs	tbs	VERB
eurjchem-2641	39	13	in	in	ADP
eurjchem-2641	39	14	cancer	cancer	NOUN
eurjchem-2641	39	15	management	management	NOUN
eurjchem-2641	40	1	[	[	X
eurjchem-2641	40	2	9	9	NUM
eurjchem-2641	40	3	]	]	PUNCT
eurjchem-2641	40	4	.	.	PUNCT
eurjchem-2641	41	1	however	however	ADV
eurjchem-2641	41	2	,	,	PUNCT
eurjchem-2641	41	3	tbs	tbs	ADJ
eurjchem-2641	41	4	and	and	CCONJ
eurjchem-2641	41	5	other	other	ADJ
eurjchem-2641	41	6	technologies	technology	NOUN
eurjchem-2641	41	7	for	for	ADP
eurjchem-2641	41	8	bc	bc	PROPN
eurjchem-2641	41	9	detection	detection	NOUN
eurjchem-2641	41	10	are	be	AUX
eurjchem-2641	41	11	invasive	invasive	ADJ
eurjchem-2641	41	12	and	and	CCONJ
eurjchem-2641	41	13	have	have	VERB
eurjchem-2641	41	14	many	many	ADJ
eurjchem-2641	41	15	limitations	limitation	NOUN
eurjchem-2641	41	16	[	[	X
eurjchem-2641	41	17	12	12	NUM
eurjchem-2641	41	18	]	]	PUNCT
eurjchem-2641	41	19	.	.	PUNCT
eurjchem-2641	42	1	in	in	ADP
eurjchem-2641	42	2	practice	practice	NOUN
eurjchem-2641	42	3	,	,	PUNCT
eurjchem-2641	42	4	lbs	lbs	PROPN
eurjchem-2641	42	5	are	be	AUX
eurjchem-2641	42	6	noninvasive	noninvasive	ADJ
eurjchem-2641	42	7	and	and	CCONJ
eurjchem-2641	42	8	obtained	obtain	VERB
eurjchem-2641	42	9	from	from	ADP
eurjchem-2641	42	10	tumor	tumor	NOUN
eurjchem-2641	42	11	tissues	tissue	NOUN
eurjchem-2641	42	12	in	in	ADP
eurjchem-2641	42	13	an	an	DET
eurjchem-2641	42	14	efficient	efficient	ADJ
eurjchem-2641	42	15	quantity	quantity	NOUN
eurjchem-2641	42	16	and	and	CCONJ
eurjchem-2641	42	17	quality	quality	NOUN
eurjchem-2641	42	18	of	of	ADP
eurjchem-2641	42	19	biomarkers	biomarker	NOUN
eurjchem-2641	42	20	[	[	X
eurjchem-2641	42	21	9	9	NUM
eurjchem-2641	42	22	]	]	PUNCT
eurjchem-2641	42	23	.	.	PUNCT
eurjchem-2641	43	1	consequently	consequently	ADV
eurjchem-2641	43	2	,	,	PUNCT
eurjchem-2641	43	3	lbs	lbs	PROPN
eurjchem-2641	43	4	could	could	AUX
eurjchem-2641	43	5	resolve	resolve	VERB
eurjchem-2641	43	6	the	the	DET
eurjchem-2641	43	7	problems	problem	NOUN
eurjchem-2641	43	8	of	of	ADP
eurjchem-2641	43	9	tbs	tbs	NOUN
eurjchem-2641	43	10	by	by	ADP
eurjchem-2641	43	11	enabling	enable	VERB
eurjchem-2641	43	12	first	first	ADJ
eurjchem-2641	43	13	tumor	tumor	NOUN
eurjchem-2641	43	14	detection	detection	NOUN
eurjchem-2641	43	15	,	,	PUNCT
eurjchem-2641	43	16	prognosis	prognosis	NOUN
eurjchem-2641	43	17	,	,	PUNCT
eurjchem-2641	43	18	and	and	CCONJ
eurjchem-2641	43	19	recurrence	recurrence	NOUN
eurjchem-2641	43	20	potential	potential	NOUN
eurjchem-2641	43	21	[	[	X
eurjchem-2641	43	22	9	9	NUM
eurjchem-2641	43	23	]	]	PUNCT
eurjchem-2641	43	24	.	.	PUNCT
eurjchem-2641	44	1	in	in	ADP
eurjchem-2641	44	2	particular	particular	ADJ
eurjchem-2641	44	3	,	,	PUNCT
eurjchem-2641	44	4	cancer	cancer	NOUN
eurjchem-2641	44	5	cells	cell	NOUN
eurjchem-2641	44	6	release	release	VERB
eurjchem-2641	44	7	their	their	PRON
eurjchem-2641	44	8	signature	signature	NOUN
eurjchem-2641	44	9	into	into	ADP
eurjchem-2641	44	10	body	body	NOUN
eurjchem-2641	44	11	fluids	fluid	NOUN
eurjchem-2641	44	12	[	[	X
eurjchem-2641	44	13	9	9	NUM
eurjchem-2641	44	14	]	]	PUNCT
eurjchem-2641	44	15	.	.	PUNCT
eurjchem-2641	45	1	the	the	DET
eurjchem-2641	45	2	cancer	cancer	NOUN
eurjchem-2641	45	3	signature	signature	NOUN
eurjchem-2641	45	4	includes	include	VERB
eurjchem-2641	45	5	intact	intact	ADJ
eurjchem-2641	45	6	cancer	cancer	NOUN
eurjchem-2641	45	7	cells	cell	NOUN
eurjchem-2641	45	8	,	,	PUNCT
eurjchem-2641	45	9	extracellular	extracellular	ADJ
eurjchem-2641	45	10	vesicles	vesicle	NOUN
eurjchem-2641	45	11	(	(	PUNCT
eurjchem-2641	45	12	evs	evs	PROPN
eurjchem-2641	45	13	)	)	PUNCT
eurjchem-2641	45	14	,	,	PUNCT
eurjchem-2641	45	15	deoxynucleic	deoxynucleic	VERB
eurjchem-2641	45	16	acids	acid	NOUN
eurjchem-2641	45	17	(	(	PUNCT
eurjchem-2641	45	18	dna	dna	PROPN
eurjchem-2641	45	19	)	)	PUNCT
eurjchem-2641	45	20	,	,	PUNCT
eurjchem-2641	45	21	ribonucleic	ribonucleic	ADJ
eurjchem-2641	45	22	acids	acid	NOUN
eurjchem-2641	45	23	(	(	PUNCT
eurjchem-2641	45	24	rnas	rna	NOUN
eurjchem-2641	45	25	)	)	PUNCT
eurjchem-2641	45	26	,	,	PUNCT
eurjchem-2641	45	27	proteins	protein	NOUN
eurjchem-2641	45	28	,	,	PUNCT
eurjchem-2641	45	29	lipids	lipid	NOUN
eurjchem-2641	45	30	,	,	PUNCT
eurjchem-2641	45	31	or	or	CCONJ
eurjchem-2641	45	32	metabolites	metabolite	NOUN
eurjchem-2641	45	33	[	[	X
eurjchem-2641	45	34	9,10	9,10	NUM
eurjchem-2641	45	35	]	]	PUNCT
eurjchem-2641	45	36	.	.	PUNCT
eurjchem-2641	46	1	these	these	DET
eurjchem-2641	46	2	cellular	cellular	ADJ
eurjchem-2641	46	3	,	,	PUNCT
eurjchem-2641	46	4	vesicular	vesicular	ADJ
eurjchem-2641	46	5	,	,	PUNCT
eurjchem-2641	46	6	and	and	CCONJ
eurjchem-2641	46	7	molecular	molecular	ADJ
eurjchem-2641	46	8	structures	structure	NOUN
eurjchem-2641	46	9	in	in	ADP
eurjchem-2641	46	10	lbs	lbs	NOUN
eurjchem-2641	46	11	could	could	AUX
eurjchem-2641	46	12	provide	provide	VERB
eurjchem-2641	46	13	information	information	NOUN
eurjchem-2641	46	14	on	on	ADP
eurjchem-2641	46	15	cancer	cancer	NOUN
eurjchem-2641	46	16	status	status	NOUN
eurjchem-2641	46	17	[	[	X
eurjchem-2641	46	18	9,10	9,10	NUM
eurjchem-2641	46	19	]	]	X
eurjchem-2641	46	20	.	.	PUNCT
eurjchem-2641	47	1	ample	ample	ADJ
eurjchem-2641	47	2	cancer	cancer	NOUN
eurjchem-2641	47	3	biomarkers	biomarker	NOUN
eurjchem-2641	47	4	such	such	ADJ
eurjchem-2641	47	5	as	as	ADP
eurjchem-2641	47	6	tumor	tumor	NOUN
eurjchem-2641	47	7	cells	cell	NOUN
eurjchem-2641	47	8	,	,	PUNCT
eurjchem-2641	47	9	tumor	tumor	NOUN
eurjchem-2641	47	10	-	-	PUNCT
eurjchem-2641	47	11	educated	educate	VERB
eurjchem-2641	47	12	platelets	platelet	NOUN
eurjchem-2641	47	13	,	,	PUNCT
eurjchem-2641	47	14	and	and	CCONJ
eurjchem-2641	47	15	evs	evs	NOUN
eurjchem-2641	47	16	encapsulated	encapsulate	VERB
eurjchem-2641	47	17	tumor	tumor	NOUN
eurjchem-2641	47	18	dna	dna	PROPN
eurjchem-2641	47	19	,	,	PUNCT
eurjchem-2641	47	20	messenger	messenger	NOUN
eurjchem-2641	47	21	(	(	PUNCT
eurjchem-2641	47	22	mrnas	mrnas	PROPN
eurjchem-2641	47	23	)	)	PUNCT
eurjchem-2641	47	24	or	or	CCONJ
eurjchem-2641	47	25	micrornas	microrna	NOUN
eurjchem-2641	47	26	(	(	PUNCT
eurjchem-2641	47	27	mirnas	mirna	NOUN
eurjchem-2641	47	28	)	)	PUNCT
eurjchem-2641	47	29	can	can	AUX
eurjchem-2641	47	30	be	be	AUX
eurjchem-2641	47	31	measured	measure	VERB
eurjchem-2641	47	32	in	in	ADP
eurjchem-2641	47	33	lbs	lbs	NOUN
eurjchem-2641	47	34	,	,	PUNCT
eurjchem-2641	47	35	in	in	ADP
eurjchem-2641	47	36	addition	addition	NOUN
eurjchem-2641	47	37	to	to	ADP
eurjchem-2641	47	38	free	free	ADJ
eurjchem-2641	47	39	cancer	cancer	NOUN
eurjchem-2641	47	40	dna	dna	PROPN
eurjchem-2641	47	41	,	,	PUNCT
eurjchem-2641	47	42	rna	rna	PROPN
eurjchem-2641	47	43	,	,	PUNCT
eurjchem-2641	47	44	mirnas	mirna	NOUN
eurjchem-2641	47	45	,	,	PUNCT
eurjchem-2641	47	46	proteins	protein	NOUN
eurjchem-2641	47	47	,	,	PUNCT
eurjchem-2641	47	48	or	or	CCONJ
eurjchem-2641	47	49	metabolites	metabolite	NOUN
eurjchem-2641	47	50	[	[	PUNCT
eurjchem-2641	47	51	9	9	NUM
eurjchem-2641	47	52	,	,	PUNCT
eurjchem-2641	47	53	10	10	NUM
eurjchem-2641	47	54	]	]	PUNCT
eurjchem-2641	47	55	.	.	PUNCT
eurjchem-2641	48	1	therefore	therefore	ADV
eurjchem-2641	48	2	,	,	PUNCT
eurjchem-2641	48	3	lbs	lbs	PROPN
eurjchem-2641	48	4	are	be	AUX
eurjchem-2641	48	5	applied	apply	VERB
eurjchem-2641	48	6	as	as	ADP
eurjchem-2641	48	7	noninvasive	noninvasive	ADJ
eurjchem-2641	48	8	biomarkers	biomarker	NOUN
eurjchem-2641	48	9	in	in	ADP
eurjchem-2641	48	10	prediction	prediction	NOUN
eurjchem-2641	48	11	,	,	PUNCT
eurjchem-2641	48	12	diagnosis	diagnosis	NOUN
eurjchem-2641	48	13	,	,	PUNCT
eurjchem-2641	48	14	screening	screening	NOUN
eurjchem-2641	48	15	,	,	PUNCT
eurjchem-2641	48	16	prognosis	prognosis	NOUN
eurjchem-2641	48	17	,	,	PUNCT
eurjchem-2641	48	18	and	and	CCONJ
eurjchem-2641	48	19	patient	patient	ADJ
eurjchem-2641	48	20	response	response	NOUN
eurjchem-2641	48	21	to	to	ADP
eurjchem-2641	48	22	therapy	therapy	NOUN
eurjchem-2641	48	23	[	[	X
eurjchem-2641	48	24	13,14	13,14	NUM
eurjchem-2641	48	25	]	]	PUNCT
eurjchem-2641	48	26	.	.	PUNCT
eurjchem-2641	49	1	biomarkers	biomarker	NOUN
eurjchem-2641	49	2	in	in	ADP
eurjchem-2641	49	3	lbs	lbs	NOUN
eurjchem-2641	49	4	are	be	AUX
eurjchem-2641	49	5	suggested	suggest	VERB
eurjchem-2641	49	6	to	to	PART
eurjchem-2641	49	7	monitor	monitor	VERB
eurjchem-2641	49	8	patients	patient	NOUN
eurjchem-2641	49	9	with	with	ADP
eurjchem-2641	49	10	bc	bc	PROPN
eurjchem-2641	50	1	[	[	X
eurjchem-2641	50	2	13,14	13,14	NUM
eurjchem-2641	50	3	]	]	PUNCT
eurjchem-2641	50	4	.	.	PUNCT
eurjchem-2641	51	1	however	however	ADV
eurjchem-2641	51	2	,	,	PUNCT
eurjchem-2641	51	3	lbs	lbs	PROPN
eurjchem-2641	51	4	from	from	ADP
eurjchem-2641	51	5	bc	bc	PROPN
eurjchem-2641	51	6	patients	patient	NOUN
eurjchem-2641	51	7	contain	contain	VERB
eurjchem-2641	51	8	tumor	tumor	NOUN
eurjchem-2641	51	9	cells	cell	NOUN
eurjchem-2641	51	10	,	,	PUNCT
eurjchem-2641	51	11	oncosomes	oncosome	NOUN
eurjchem-2641	51	12	,	,	PUNCT
eurjchem-2641	51	13	proteins	protein	NOUN
eurjchem-2641	51	14	,	,	PUNCT
eurjchem-2641	51	15	dna	dna	NOUN
eurjchem-2641	51	16	,	,	PUNCT
eurjchem-2641	51	17	mrnas	mrna	NOUN
eurjchem-2641	51	18	,	,	PUNCT
eurjchem-2641	51	19	and	and	CCONJ
eurjchem-2641	51	20	mirnas	mirna	NOUN
eurjchem-2641	51	21	[	[	X
eurjchem-2641	51	22	13,14	13,14	NUM
eurjchem-2641	51	23	]	]	PUNCT
eurjchem-2641	51	24	.	.	PUNCT
eurjchem-2641	52	1	mirnas	mirna	NOUN
eurjchem-2641	52	2	are	be	AUX
eurjchem-2641	52	3	members	member	NOUN
eurjchem-2641	52	4	of	of	ADP
eurjchem-2641	52	5	molecular	molecular	ADJ
eurjchem-2641	52	6	cancer	cancer	NOUN
eurjchem-2641	52	7	signatures	signature	NOUN
eurjchem-2641	52	8	in	in	ADP
eurjchem-2641	52	9	lbs	lbs	NOUN
eurjchem-2641	52	10	;	;	PUNCT
eurjchem-2641	52	11	architecturally	architecturally	ADV
eurjchem-2641	52	12	,	,	PUNCT
eurjchem-2641	52	13	mirnas	mirna	NOUN
eurjchem-2641	52	14	contain	contain	VERB
eurjchem-2641	52	15	about	about	ADV
eurjchem-2641	52	16	22	22	NUM
eurjchem-2641	52	17	-	-	SYM
eurjchem-2641	52	18	25	25	NUM
eurjchem-2641	52	19	nucleotides	nucleotide	NOUN
eurjchem-2641	52	20	decoding	decode	VERB
eurjchem-2641	52	21	rnas	rna	NOUN
eurjchem-2641	52	22	.	.	PUNCT
eurjchem-2641	53	1	mirnas	mirna	NOUN
eurjchem-2641	53	2	are	be	AUX
eurjchem-2641	53	3	modulators	modulator	NOUN
eurjchem-2641	53	4	of	of	ADP
eurjchem-2641	53	5	gene	gene	NOUN
eurjchem-2641	53	6	expression	expression	NOUN
eurjchem-2641	53	7	at	at	ADP
eurjchem-2641	53	8	the	the	DET
eurjchem-2641	53	9	genome	genome	NOUN
eurjchem-2641	53	10	,	,	PUNCT
eurjchem-2641	53	11	transcriptome	transcriptome	NOUN
eurjchem-2641	53	12	,	,	PUNCT
eurjchem-2641	53	13	and	and	CCONJ
eurjchem-2641	53	14	proteome	proteome	ADJ
eurjchem-2641	53	15	levels	level	NOUN
eurjchem-2641	53	16	[	[	X
eurjchem-2641	53	17	15	15	NUM
eurjchem-2641	53	18	]	]	PUNCT
eurjchem-2641	53	19	.	.	PUNCT
eurjchem-2641	54	1	thus	thus	ADV
eurjchem-2641	54	2	,	,	PUNCT
eurjchem-2641	54	3	mirnas	mirna	NOUN
eurjchem-2641	54	4	are	be	AUX
eurjchem-2641	54	5	essential	essential	ADJ
eurjchem-2641	54	6	for	for	ADP
eurjchem-2641	54	7	health	health	NOUN
eurjchem-2641	54	8	and	and	CCONJ
eurjchem-2641	54	9	disease	disease	NOUN
eurjchem-2641	54	10	progression	progression	NOUN
eurjchem-2641	54	11	[	[	X
eurjchem-2641	54	12	15	15	NUM
eurjchem-2641	54	13	]	]	PUNCT
eurjchem-2641	54	14	.	.	PUNCT
eurjchem-2641	55	1	in	in	ADP
eurjchem-2641	55	2	this	this	DET
eurjchem-2641	55	3	context	context	NOUN
eurjchem-2641	55	4	,	,	PUNCT
eurjchem-2641	55	5	mirnas	mirna	NOUN
eurjchem-2641	55	6	can	can	AUX
eurjchem-2641	55	7	affect	affect	VERB
eurjchem-2641	55	8	gene	gene	NOUN
eurjchem-2641	55	9	expression	expression	NOUN
eurjchem-2641	55	10	by	by	ADP
eurjchem-2641	55	11	influencing	influence	VERB
eurjchem-2641	55	12	mrna	mrna	NOUN
eurjchem-2641	55	13	transcription	transcription	NOUN
eurjchem-2641	55	14	and	and	CCONJ
eurjchem-2641	55	15	translation	translation	NOUN
eurjchem-2641	56	1	[	[	X
eurjchem-2641	56	2	16,17	16,17	NUM
eurjchem-2641	56	3	]	]	PUNCT
eurjchem-2641	56	4	.	.	PUNCT
eurjchem-2641	57	1	however	however	ADV
eurjchem-2641	57	2	,	,	PUNCT
eurjchem-2641	57	3	mirnas	mirna	NOUN
eurjchem-2641	57	4	could	could	AUX
eurjchem-2641	57	5	interact	interact	VERB
eurjchem-2641	57	6	with	with	ADP
eurjchem-2641	57	7	target	target	NOUN
eurjchem-2641	57	8	mrnas	mrna	NOUN
eurjchem-2641	57	9	or	or	CCONJ
eurjchem-2641	57	10	dna	dna	NOUN
eurjchem-2641	57	11	to	to	PART
eurjchem-2641	57	12	influence	influence	VERB
eurjchem-2641	57	13	gene	gene	NOUN
eurjchem-2641	57	14	expression	expression	NOUN
eurjchem-2641	57	15	[	[	X
eurjchem-2641	57	16	16,17	16,17	NUM
eurjchem-2641	57	17	]	]	PUNCT
eurjchem-2641	57	18	.	.	PUNCT
eurjchem-2641	58	1	therefore	therefore	ADV
eurjchem-2641	58	2	,	,	PUNCT
eurjchem-2641	58	3	mirnas	mirna	NOUN
eurjchem-2641	58	4	are	be	AUX
eurjchem-2641	58	5	involved	involve	VERB
eurjchem-2641	58	6	in	in	ADP
eurjchem-2641	58	7	cell	cell	NOUN
eurjchem-2641	58	8	metabolism	metabolism	NOUN
eurjchem-2641	58	9	,	,	PUNCT
eurjchem-2641	58	10	growth	growth	NOUN
eurjchem-2641	58	11	,	,	PUNCT
eurjchem-2641	58	12	proliferation	proliferation	NOUN
eurjchem-2641	58	13	,	,	PUNCT
eurjchem-2641	58	14	differentiation	differentiation	NOUN
eurjchem-2641	58	15	,	,	PUNCT
eurjchem-2641	58	16	development	development	NOUN
eurjchem-2641	58	17	,	,	PUNCT
eurjchem-2641	58	18	and	and	CCONJ
eurjchem-2641	58	19	death	death	NOUN
eurjchem-2641	59	1	[	[	X
eurjchem-2641	59	2	16,17	16,17	NUM
eurjchem-2641	59	3	]	]	PUNCT
eurjchem-2641	59	4	.	.	PUNCT
eurjchem-2641	60	1	in	in	ADP
eurjchem-2641	60	2	this	this	DET
eurjchem-2641	60	3	context	context	NOUN
eurjchem-2641	60	4	,	,	PUNCT
eurjchem-2641	60	5	mirna	mirna	NOUN
eurjchem-2641	60	6	expression	expression	NOUN
eurjchem-2641	60	7	is	be	AUX
eurjchem-2641	60	8	dysregulated	dysregulate	VERB
eurjchem-2641	60	9	in	in	ADP
eurjchem-2641	60	10	malignant	malignant	ADJ
eurjchem-2641	60	11	cells	cell	NOUN
eurjchem-2641	60	12	.	.	PUNCT
eurjchem-2641	61	1	thus	thus	ADV
eurjchem-2641	61	2	,	,	PUNCT
eurjchem-2641	61	3	mirnas	mirna	NOUN
eurjchem-2641	61	4	might	might	AUX
eurjchem-2641	61	5	act	act	VERB
eurjchem-2641	61	6	as	as	ADP
eurjchem-2641	61	7	oncogenes	oncogene	NOUN
eurjchem-2641	61	8	or	or	CCONJ
eurjchem-2641	61	9	tumor	tumor	NOUN
eurjchem-2641	61	10	suppressor	suppressor	NOUN
eurjchem-2641	61	11	agents	agent	NOUN
eurjchem-2641	61	12	[	[	X
eurjchem-2641	61	13	15	15	NUM
eurjchem-2641	61	14	]	]	PUNCT
eurjchem-2641	61	15	.	.	PUNCT
eurjchem-2641	62	1	consequently	consequently	ADV
eurjchem-2641	62	2	,	,	PUNCT
eurjchem-2641	62	3	mirnas	mirna	NOUN
eurjchem-2641	62	4	play	play	VERB
eurjchem-2641	62	5	crucial	crucial	ADJ
eurjchem-2641	62	6	roles	role	NOUN
eurjchem-2641	62	7	in	in	ADP
eurjchem-2641	62	8	tumorigenesis	tumorigenesis	NOUN
eurjchem-2641	62	9	,	,	PUNCT
eurjchem-2641	62	10	metastasis	metastasis	NOUN
eurjchem-2641	62	11	,	,	PUNCT
eurjchem-2641	62	12	and	and	CCONJ
eurjchem-2641	62	13	apoptosis	apoptosis	NOUN
eurjchem-2641	62	14	[	[	X
eurjchem-2641	62	15	17	17	NUM
eurjchem-2641	62	16	]	]	PUNCT
eurjchem-2641	62	17	.	.	PUNCT
eurjchem-2641	63	1	at	at	ADP
eurjchem-2641	63	2	the	the	DET
eurjchem-2641	63	3	functional	functional	ADJ
eurjchem-2641	63	4	level	level	NOUN
eurjchem-2641	63	5	,	,	PUNCT
eurjchem-2641	63	6	some	some	DET
eurjchem-2641	63	7	mirnas	mirna	NOUN
eurjchem-2641	63	8	are	be	AUX
eurjchem-2641	63	9	oncogenes	oncogene	NOUN
eurjchem-2641	63	10	and	and	CCONJ
eurjchem-2641	63	11	mediate	mediate	ADJ
eurjchem-2641	63	12	cancer	cancer	NOUN
eurjchem-2641	63	13	proliferation	proliferation	NOUN
eurjchem-2641	63	14	,	,	PUNCT
eurjchem-2641	63	15	metastasis	metastasis	NOUN
eurjchem-2641	63	16	,	,	PUNCT
eurjchem-2641	63	17	and	and	CCONJ
eurjchem-2641	63	18	multidrug	multidrug	VERB
eurjchem-2641	63	19	resistance	resistance	NOUN
eurjchem-2641	63	20	[	[	X
eurjchem-2641	63	21	18	18	NUM
eurjchem-2641	63	22	]	]	PUNCT
eurjchem-2641	63	23	.	.	PUNCT
eurjchem-2641	64	1	on	on	ADP
eurjchem-2641	64	2	the	the	DET
eurjchem-2641	64	3	contrary	contrary	NOUN
eurjchem-2641	64	4	,	,	PUNCT
eurjchem-2641	64	5	other	other	ADJ
eurjchem-2641	64	6	mirnas	mirna	NOUN
eurjchem-2641	64	7	are	be	AUX
eurjchem-2641	64	8	tumor	tumor	NOUN
eurjchem-2641	64	9	suppressors	suppressor	NOUN
eurjchem-2641	64	10	that	that	PRON
eurjchem-2641	64	11	mediate	mediate	VERB
eurjchem-2641	64	12	apoptosis	apoptosis	NOUN
eurjchem-2641	64	13	to	to	PART
eurjchem-2641	64	14	inhibit	inhibit	VERB
eurjchem-2641	64	15	the	the	DET
eurjchem-2641	64	16	growth	growth	NOUN
eurjchem-2641	64	17	and	and	CCONJ
eurjchem-2641	64	18	development	development	NOUN
eurjchem-2641	64	19	of	of	ADP
eurjchem-2641	64	20	cancer	cancer	NOUN
eurjchem-2641	64	21	cells	cell	NOUN
eurjchem-2641	64	22	[	[	X
eurjchem-2641	64	23	18	18	NUM
eurjchem-2641	64	24	]	]	PUNCT
eurjchem-2641	64	25	.	.	PUNCT
eurjchem-2641	65	1	furthermore	furthermore	ADV
eurjchem-2641	65	2	,	,	PUNCT
eurjchem-2641	65	3	mirnas	mirna	VERB
eurjchem-2641	65	4	influence	influence	NOUN
eurjchem-2641	65	5	autophagy	autophagy	NOUN
eurjchem-2641	65	6	and	and	CCONJ
eurjchem-2641	65	7	the	the	DET
eurjchem-2641	65	8	epithelial	epithelial	ADJ
eurjchem-2641	65	9	-	-	PUNCT
eurjchem-2641	65	10	mesenchymal	mesenchymal	NOUN
eurjchem-2641	65	11	transition	transition	NOUN
eurjchem-2641	65	12	[	[	X
eurjchem-2641	65	13	19	19	NUM
eurjchem-2641	65	14	]	]	PUNCT
eurjchem-2641	65	15	.	.	PUNCT
eurjchem-2641	66	1	furthermore	furthermore	ADV
eurjchem-2641	66	2	,	,	PUNCT
eurjchem-2641	66	3	mirnas	mirna	NOUN
eurjchem-2641	66	4	regulate	regulate	VERB
eurjchem-2641	66	5	cancer	cancer	NOUN
eurjchem-2641	66	6	cells	cell	NOUN
eurjchem-2641	66	7	angiogenesis	angiogenesis	NOUN
eurjchem-2641	66	8	,	,	PUNCT
eurjchem-2641	66	9	migration	migration	NOUN
eurjchem-2641	66	10	,	,	PUNCT
eurjchem-2641	66	11	invasion	invasion	NOUN
eurjchem-2641	66	12	,	,	PUNCT
eurjchem-2641	66	13	and	and	CCONJ
eurjchem-2641	66	14	metastasis	metastasis	NOUN
eurjchem-2641	66	15	[	[	X
eurjchem-2641	66	16	17,20	17,20	NUM
eurjchem-2641	66	17	]	]	PUNCT
eurjchem-2641	66	18	.	.	PUNCT
eurjchem-2641	67	1	in	in	ADP
eurjchem-2641	67	2	this	this	DET
eurjchem-2641	67	3	regard	regard	NOUN
eurjchem-2641	67	4	,	,	PUNCT
eurjchem-2641	67	5	mirnas	mirna	NOUN
eurjchem-2641	67	6	induce	induce	VERB
eurjchem-2641	67	7	contradictive	contradictive	ADJ
eurjchem-2641	67	8	effects	effect	NOUN
eurjchem-2641	67	9	in	in	ADP
eurjchem-2641	67	10	breast	breast	NOUN
eurjchem-2641	67	11	cancer	cancer	NOUN
eurjchem-2641	67	12	cell	cell	NOUN
eurjchem-2641	67	13	lines	line	NOUN
eurjchem-2641	67	14	[	[	X
eurjchem-2641	67	15	19	19	NUM
eurjchem-2641	67	16	]	]	PUNCT
eurjchem-2641	67	17	.	.	PUNCT
eurjchem-2641	68	1	therefore	therefore	ADV
eurjchem-2641	68	2	,	,	PUNCT
eurjchem-2641	68	3	expression	expression	NOUN
eurjchem-2641	68	4	mirnas	mirna	NOUN
eurjchem-2641	68	5	display	display	VERB
eurjchem-2641	68	6	specific	specific	ADJ
eurjchem-2641	68	7	patterns	pattern	NOUN
eurjchem-2641	68	8	in	in	ADP
eurjchem-2641	68	9	bc	bc	PROPN
eurjchem-2641	68	10	subtypes	subtype	NOUN
eurjchem-2641	68	11	[	[	X
eurjchem-2641	68	12	18	18	NUM
eurjchem-2641	68	13	]	]	PUNCT
eurjchem-2641	68	14	.	.	PUNCT
eurjchem-2641	69	1	consequently	consequently	ADV
eurjchem-2641	69	2	,	,	PUNCT
eurjchem-2641	69	3	mirnas	mirna	NOUN
eurjchem-2641	69	4	could	could	AUX
eurjchem-2641	69	5	be	be	AUX
eurjchem-2641	69	6	used	use	VERB
eurjchem-2641	69	7	as	as	ADP
eurjchem-2641	69	8	biomarkers	biomarker	NOUN
eurjchem-2641	69	9	for	for	ADP
eurjchem-2641	69	10	bc	bc	PROPN
eurjchem-2641	69	11	prediction	prediction	NOUN
eurjchem-2641	69	12	,	,	PUNCT
eurjchem-2641	69	13	diagnosis	diagnosis	NOUN
eurjchem-2641	69	14	,	,	PUNCT
eurjchem-2641	69	15	and	and	CCONJ
eurjchem-2641	69	16	typing	typing	NOUN
eurjchem-2641	69	17	of	of	ADP
eurjchem-2641	69	18	bc	bc	PROPN
eurjchem-2641	70	1	[	[	X
eurjchem-2641	70	2	18	18	NUM
eurjchem-2641	70	3	]	]	PUNCT
eurjchem-2641	70	4	.	.	PUNCT
eurjchem-2641	71	1	frequently	frequently	ADV
eurjchem-2641	71	2	,	,	PUNCT
eurjchem-2641	71	3	mirnas	mirna	NOUN
eurjchem-2641	71	4	are	be	AUX
eurjchem-2641	71	5	liberated	liberate	VERB
eurjchem-2641	71	6	in	in	ADP
eurjchem-2641	71	7	free	free	ADJ
eurjchem-2641	71	8	form	form	NOUN
eurjchem-2641	71	9	or	or	CCONJ
eurjchem-2641	71	10	packaged	package	VERB
eurjchem-2641	71	11	into	into	ADP
eurjchem-2641	71	12	evs	evs	NOUN
eurjchem-2641	71	13	in	in	ADP
eurjchem-2641	71	14	biofluids	biofluid	NOUN
eurjchem-2641	71	15	.	.	PUNCT
eurjchem-2641	72	1	in	in	ADP
eurjchem-2641	72	2	this	this	DET
eurjchem-2641	72	3	regard	regard	NOUN
eurjchem-2641	72	4	,	,	PUNCT
eurjchem-2641	72	5	abundant	abundant	ADJ
eurjchem-2641	72	6	studies	study	NOUN
eurjchem-2641	72	7	have	have	AUX
eurjchem-2641	72	8	demonstrated	demonstrate	VERB
eurjchem-2641	72	9	the	the	DET
eurjchem-2641	72	10	presence	presence	NOUN
eurjchem-2641	72	11	of	of	ADP
eurjchem-2641	72	12	mirnas	mirna	NOUN
eurjchem-2641	72	13	in	in	ADP
eurjchem-2641	72	14	biofluids	biofluid	NOUN
eurjchem-2641	72	15	at	at	ADP
eurjchem-2641	72	16	easily	easily	ADV
eurjchem-2641	72	17	measurable	measurable	ADJ
eurjchem-2641	72	18	levels	level	NOUN
eurjchem-2641	72	19	[	[	X
eurjchem-2641	72	20	21,22	21,22	X
eurjchem-2641	72	21	]	]	X
eurjchem-2641	72	22	.	.	PUNCT
eurjchem-2641	73	1	for	for	ADP
eurjchem-2641	73	2	example	example	NOUN
eurjchem-2641	73	3	,	,	PUNCT
eurjchem-2641	73	4	blood	blood	NOUN
eurjchem-2641	73	5	mirnas	mirna	NOUN
eurjchem-2641	73	6	can	can	AUX
eurjchem-2641	73	7	be	be	AUX
eurjchem-2641	73	8	easily	easily	ADV
eurjchem-2641	73	9	collected	collect	VERB
eurjchem-2641	73	10	and	and	CCONJ
eurjchem-2641	73	11	measured	measure	VERB
eurjchem-2641	73	12	as	as	ADP
eurjchem-2641	73	13	non	non	ADJ
eurjchem-2641	73	14	-	-	ADJ
eurjchem-2641	73	15	invasive	invasive	ADJ
eurjchem-2641	73	16	diagnostic	diagnostic	ADJ
eurjchem-2641	73	17	biomarkers	biomarker	NOUN
eurjchem-2641	73	18	.	.	PUNCT
eurjchem-2641	74	1	several	several	ADJ
eurjchem-2641	74	2	studies	study	NOUN
eurjchem-2641	74	3	have	have	AUX
eurjchem-2641	74	4	suggested	suggest	VERB
eurjchem-2641	74	5	mirnas	mirna	NOUN
eurjchem-2641	74	6	as	as	ADP
eurjchem-2641	74	7	innovative	innovative	ADJ
eurjchem-2641	74	8	biomarkers	biomarker	NOUN
eurjchem-2641	74	9	for	for	ADP
eurjchem-2641	74	10	predicting	predict	VERB
eurjchem-2641	74	11	and	and	CCONJ
eurjchem-2641	74	12	detecting	detect	VERB
eurjchem-2641	74	13	bcs	bc	NOUN
eurjchem-2641	74	14	[	[	X
eurjchem-2641	74	15	23	23	NUM
eurjchem-2641	74	16	]	]	PUNCT
eurjchem-2641	74	17	.	.	PUNCT
eurjchem-2641	75	1	specifically	specifically	ADV
eurjchem-2641	75	2	,	,	PUNCT
eurjchem-2641	75	3	mirna-148	mirna-148	PROPN
eurjchem-2641	75	4	is	be	AUX
eurjchem-2641	75	5	overexpressed	overexpresse	VERB
eurjchem-2641	75	6	in	in	ADP
eurjchem-2641	75	7	many	many	ADJ
eurjchem-2641	75	8	cancers	cancer	NOUN
eurjchem-2641	75	9	,	,	PUNCT
eurjchem-2641	75	10	including	include	VERB
eurjchem-2641	75	11	bcs	bc	NOUN
eurjchem-2641	75	12	[	[	X
eurjchem-2641	75	13	15	15	NUM
eurjchem-2641	75	14	]	]	PUNCT
eurjchem-2641	75	15	.	.	PUNCT
eurjchem-2641	76	1	more	more	ADJ
eurjchem-2641	76	2	studies	study	NOUN
eurjchem-2641	76	3	are	be	AUX
eurjchem-2641	76	4	needed	need	VERB
eurjchem-2641	76	5	to	to	PART
eurjchem-2641	76	6	address	address	VERB
eurjchem-2641	76	7	this	this	DET
eurjchem-2641	76	8	issue	issue	NOUN
eurjchem-2641	76	9	.	.	PUNCT
eurjchem-2641	77	1	certainly	certainly	ADV
eurjchem-2641	77	2	,	,	PUNCT
eurjchem-2641	77	3	bcs	bc	NOUN
eurjchem-2641	77	4	are	be	AUX
eurjchem-2641	77	5	associated	associate	VERB
eurjchem-2641	77	6	with	with	ADP
eurjchem-2641	77	7	altering	alter	VERB
eurjchem-2641	77	8	apoptosis	apoptosis	NOUN
eurjchem-2641	77	9	mechanisms	mechanism	NOUN
eurjchem-2641	77	10	;	;	PUNCT
eurjchem-2641	77	11	thus	thus	ADV
eurjchem-2641	77	12	,	,	PUNCT
eurjchem-2641	77	13	malignant	malignant	NOUN
eurjchem-2641	77	14	transformed	transform	VERB
eurjchem-2641	77	15	breast	breast	NOUN
eurjchem-2641	77	16	cells	cell	NOUN
eurjchem-2641	77	17	overexpressed	overexpresse	VERB
eurjchem-2641	77	18	pro	pro	ADJ
eurjchem-2641	77	19	-	-	ADJ
eurjchem-2641	77	20	survival	survival	ADJ
eurjchem-2641	77	21	proteins	protein	NOUN
eurjchem-2641	77	22	with	with	ADP
eurjchem-2641	77	23	down	down	ADJ
eurjchem-2641	77	24	expression	expression	NOUN
eurjchem-2641	77	25	of	of	ADP
eurjchem-2641	77	26	pro	pro	ADJ
eurjchem-2641	77	27	-	-	ADJ
eurjchem-2641	77	28	apoptotic	apoptotic	ADJ
eurjchem-2641	77	29	proteins	protein	NOUN
eurjchem-2641	77	30	[	[	X
eurjchem-2641	77	31	24	24	NUM
eurjchem-2641	77	32	]	]	PUNCT
eurjchem-2641	77	33	.	.	PUNCT
eurjchem-2641	78	1	hence	hence	ADV
eurjchem-2641	78	2	,	,	PUNCT
eurjchem-2641	78	3	bcl2	bcl2	PROPN
eurjchem-2641	78	4	/	/	SYM
eurjchem-2641	78	5	bax	bax	PROPN
eurjchem-2641	78	6	equilibrium	equilibrium	PROPN
eurjchem-2641	78	7	disruption	disruption	NOUN
eurjchem-2641	78	8	is	be	AUX
eurjchem-2641	78	9	connected	connect	VERB
eurjchem-2641	78	10	with	with	ADP
eurjchem-2641	78	11	breast	breast	NOUN
eurjchem-2641	78	12	cell	cell	NOUN
eurjchem-2641	78	13	tumorigenesis	tumorigenesis	NOUN
eurjchem-2641	78	14	[	[	X
eurjchem-2641	78	15	25	25	NUM
eurjchem-2641	78	16	]	]	PUNCT
eurjchem-2641	78	17	.	.	PUNCT
eurjchem-2641	79	1	bax	bax	PROPN
eurjchem-2641	79	2	is	be	AUX
eurjchem-2641	79	3	a	a	DET
eurjchem-2641	79	4	pro	pro	ADJ
eurjchem-2641	79	5	-	-	ADJ
eurjchem-2641	79	6	apoptotic	apoptotic	ADJ
eurjchem-2641	79	7	protein	protein	NOUN
eurjchem-2641	79	8	that	that	PRON
eurjchem-2641	79	9	plays	play	VERB
eurjchem-2641	79	10	a	a	DET
eurjchem-2641	79	11	vital	vital	ADJ
eurjchem-2641	79	12	role	role	NOUN
eurjchem-2641	79	13	in	in	ADP
eurjchem-2641	79	14	cell	cell	NOUN
eurjchem-2641	79	15	apoptosis	apoptosis	NOUN
eurjchem-2641	79	16	[	[	X
eurjchem-2641	79	17	25	25	NUM
eurjchem-2641	79	18	]	]	PUNCT
eurjchem-2641	79	19	.	.	PUNCT
eurjchem-2641	80	1	bax	bax	NOUN
eurjchem-2641	80	2	increases	increase	VERB
eurjchem-2641	80	3	the	the	DET
eurjchem-2641	80	4	permeability	permeability	NOUN
eurjchem-2641	80	5	of	of	ADP
eurjchem-2641	80	6	the	the	DET
eurjchem-2641	80	7	mitochondrial	mitochondrial	ADJ
eurjchem-2641	80	8	membrane	membrane	NOUN
eurjchem-2641	80	9	to	to	PART
eurjchem-2641	80	10	release	release	VERB
eurjchem-2641	80	11	cytochrome	cytochrome	NOUN
eurjchem-2641	80	12	c	c	NOUN
eurjchem-2641	81	1	[	[	X
eurjchem-2641	81	2	25	25	NUM
eurjchem-2641	81	3	]	]	PUNCT
eurjchem-2641	81	4	.	.	PUNCT
eurjchem-2641	82	1	the	the	DET
eurjchem-2641	82	2	release	release	NOUN
eurjchem-2641	82	3	of	of	ADP
eurjchem-2641	82	4	mitochondrial	mitochondrial	ADJ
eurjchem-2641	82	5	cytochrome	cytochrome	NOUN
eurjchem-2641	82	6	c	c	PROPN
eurjchem-2641	82	7	provokes	provoke	VERB
eurjchem-2641	82	8	redox	redox	ADJ
eurjchem-2641	82	9	imbalance	imbalance	NOUN
eurjchem-2641	82	10	and	and	CCONJ
eurjchem-2641	82	11	oxidative	oxidative	ADJ
eurjchem-2641	82	12	stress	stress	NOUN
eurjchem-2641	82	13	that	that	PRON
eurjchem-2641	82	14	mediate	mediate	VERB
eurjchem-2641	82	15	dna	dna	ADJ
eurjchem-2641	82	16	damage	damage	NOUN
eurjchem-2641	82	17	and	and	CCONJ
eurjchem-2641	82	18	apoptotic	apoptotic	ADJ
eurjchem-2641	82	19	cell	cell	NOUN
eurjchem-2641	82	20	death	death	NOUN
eurjchem-2641	82	21	.	.	PUNCT
eurjchem-2641	83	1	caspases	caspase	NOUN
eurjchem-2641	83	2	are	be	AUX
eurjchem-2641	83	3	also	also	ADV
eurjchem-2641	83	4	activated	activate	VERB
eurjchem-2641	83	5	in	in	ADP
eurjchem-2641	83	6	response	response	NOUN
eurjchem-2641	83	7	to	to	ADP
eurjchem-2641	83	8	apoptotic	apoptotic	ADJ
eurjchem-2641	83	9	signals	signal	NOUN
eurjchem-2641	83	10	[	[	X
eurjchem-2641	83	11	25	25	NUM
eurjchem-2641	83	12	]	]	PUNCT
eurjchem-2641	83	13	.	.	PUNCT
eurjchem-2641	84	1	on	on	ADP
eurjchem-2641	84	2	the	the	DET
eurjchem-2641	84	3	contrary	contrary	NOUN
eurjchem-2641	84	4	,	,	PUNCT
eurjchem-2641	84	5	the	the	DET
eurjchem-2641	84	6	b	b	NOUN
eurjchem-2641	84	7	-	-	PUNCT
eurjchem-2641	84	8	cell	cell	NOUN
eurjchem-2641	84	9	lymphoma	lymphoma	NOUN
eurjchem-2641	84	10	two	two	NUM
eurjchem-2641	84	11	gene	gene	NOUN
eurjchem-2641	84	12	(	(	PUNCT
eurjchem-2641	84	13	bcl2	bcl2	PROPN
eurjchem-2641	84	14	)	)	PUNCT
eurjchem-2641	84	15	antagonizes	antagonize	VERB
eurjchem-2641	84	16	the	the	DET
eurjchem-2641	84	17	bax	bax	PROPN
eurjchem-2641	84	18	action	action	NOUN
eurjchem-2641	84	19	and	and	CCONJ
eurjchem-2641	84	20	induces	induce	VERB
eurjchem-2641	84	21	an	an	DET
eurjchem-2641	84	22	antiapoptotic	antiapoptotic	ADJ
eurjchem-2641	84	23	effect	effect	NOUN
eurjchem-2641	84	24	to	to	PART
eurjchem-2641	84	25	provoke	provoke	VERB
eurjchem-2641	84	26	oncogenesis	oncogenesis	NOUN
eurjchem-2641	84	27	[	[	X
eurjchem-2641	84	28	25	25	NUM
eurjchem-2641	84	29	]	]	PUNCT
eurjchem-2641	84	30	.	.	PUNCT
eurjchem-2641	85	1	thus	thus	ADV
eurjchem-2641	85	2	,	,	PUNCT
eurjchem-2641	85	3	bcl2	bcl2	PROPN
eurjchem-2641	85	4	is	be	AUX
eurjchem-2641	85	5	commonly	commonly	ADV
eurjchem-2641	85	6	upregulated	upregulate	VERB
eurjchem-2641	85	7	in	in	ADP
eurjchem-2641	85	8	several	several	ADJ
eurjchem-2641	85	9	types	type	NOUN
eurjchem-2641	85	10	of	of	ADP
eurjchem-2641	85	11	tumors	tumor	NOUN
eurjchem-2641	85	12	to	to	PART
eurjchem-2641	85	13	encourage	encourage	VERB
eurjchem-2641	85	14	cancer	cancer	NOUN
eurjchem-2641	85	15	development	development	NOUN
eurjchem-2641	85	16	[	[	X
eurjchem-2641	85	17	24	24	NUM
eurjchem-2641	85	18	]	]	PUNCT
eurjchem-2641	85	19	.	.	PUNCT
eurjchem-2641	86	1	furthermore	furthermore	ADV
eurjchem-2641	86	2	,	,	PUNCT
eurjchem-2641	86	3	the	the	DET
eurjchem-2641	86	4	overexpression	overexpression	NOUN
eurjchem-2641	86	5	of	of	ADP
eurjchem-2641	86	6	bcl2	bcl2	NOUN
eurjchem-2641	86	7	is	be	AUX
eurjchem-2641	86	8	mediated	mediate	VERB
eurjchem-2641	86	9	by	by	ADP
eurjchem-2641	86	10	oxidative	oxidative	ADJ
eurjchem-2641	86	11	stress	stress	NOUN
eurjchem-2641	86	12	,	,	PUNCT
eurjchem-2641	86	13	microbial	microbial	ADJ
eurjchem-2641	86	14	infection	infection	NOUN
eurjchem-2641	86	15	,	,	PUNCT
eurjchem-2641	86	16	exposure	exposure	NOUN
eurjchem-2641	86	17	to	to	ADP
eurjchem-2641	86	18	xenobiotics	xenobiotic	NOUN
eurjchem-2641	86	19	,	,	PUNCT
eurjchem-2641	86	20	and	and	CCONJ
eurjchem-2641	86	21	nutrient	nutrient	ADJ
eurjchem-2641	86	22	deprivation	deprivation	NOUN
eurjchem-2641	86	23	[	[	X
eurjchem-2641	86	24	24	24	NUM
eurjchem-2641	86	25	]	]	PUNCT
eurjchem-2641	86	26	.	.	PUNCT
eurjchem-2641	87	1	these	these	DET
eurjchem-2641	87	2	factors	factor	NOUN
eurjchem-2641	87	3	act	act	VERB
eurjchem-2641	87	4	together	together	ADV
eurjchem-2641	87	5	to	to	PART
eurjchem-2641	87	6	induce	induce	VERB
eurjchem-2641	87	7	the	the	DET
eurjchem-2641	87	8	alteration	alteration	NOUN
eurjchem-2641	87	9	of	of	ADP
eurjchem-2641	87	10	the	the	DET
eurjchem-2641	87	11	bcl2	bcl2	PROPN
eurjchem-2641	87	12	/	/	SYM
eurjchem-2641	87	13	bax	bax	PROPN
eurjchem-2641	87	14	balance	balance	NOUN
eurjchem-2641	87	15	[	[	X
eurjchem-2641	87	16	24	24	NUM
eurjchem-2641	87	17	]	]	PUNCT
eurjchem-2641	87	18	.	.	PUNCT
eurjchem-2641	88	1	furthermore	furthermore	ADV
eurjchem-2641	88	2	,	,	PUNCT
eurjchem-2641	88	3	bcl2	bcl2	NOUN
eurjchem-2641	88	4	expression	expression	NOUN
eurjchem-2641	88	5	is	be	AUX
eurjchem-2641	88	6	triggered	trigger	VERB
eurjchem-2641	88	7	by	by	ADP
eurjchem-2641	88	8	the	the	DET
eurjchem-2641	88	9	nuclear	nuclear	ADJ
eurjchem-2641	88	10	factor	factor	NOUN
eurjchem-2641	88	11	kappa	kappa	PROPN
eurjchem-2641	88	12	b	b	PROPN
eurjchem-2641	88	13	family	family	PROPN
eurjchem-2641	88	14	,	,	PUNCT
eurjchem-2641	88	15	janus	janus	PROPN
eurjchem-2641	88	16	kinase	kinase	PROPN
eurjchem-2641	88	17	,	,	PUNCT
eurjchem-2641	88	18	and	and	CCONJ
eurjchem-2641	88	19	signal	signal	VERB
eurjchem-2641	88	20	transduction	transduction	NOUN
eurjchem-2641	88	21	activators	activator	NOUN
eurjchem-2641	88	22	of	of	ADP
eurjchem-2641	88	23	transcription	transcription	NOUN
eurjchem-2641	88	24	and	and	CCONJ
eurjchem-2641	88	25	various	various	ADJ
eurjchem-2641	88	26	cytokines	cytokine	NOUN
eurjchem-2641	89	1	[	[	X
eurjchem-2641	89	2	24	24	NUM
eurjchem-2641	89	3	]	]	PUNCT
eurjchem-2641	89	4	.	.	PUNCT
eurjchem-2641	90	1	higher	high	ADJ
eurjchem-2641	90	2	or	or	CCONJ
eurjchem-2641	90	3	lower	low	ADJ
eurjchem-2641	90	4	levels	level	NOUN
eurjchem-2641	90	5	of	of	ADP
eurjchem-2641	90	6	apoptotic	apoptotic	ADJ
eurjchem-2641	90	7	parameters	parameter	NOUN
eurjchem-2641	90	8	could	could	AUX
eurjchem-2641	90	9	be	be	AUX
eurjchem-2641	90	10	leveraged	leverage	VERB
eurjchem-2641	90	11	as	as	ADP
eurjchem-2641	90	12	biomarkers	biomarker	NOUN
eurjchem-2641	90	13	for	for	ADP
eurjchem-2641	90	14	the	the	DET
eurjchem-2641	90	15	predicting	predicting	NOUN
eurjchem-2641	90	16	,	,	PUNCT
eurjchem-2641	90	17	diagnosing	diagnosing	NOUN
eurjchem-2641	90	18	,	,	PUNCT
eurjchem-2641	90	19	or	or	CCONJ
eurjchem-2641	90	20	monitoring	monitoring	NOUN
eurjchem-2641	90	21	of	of	ADP
eurjchem-2641	90	22	bc	bc	PROPN
eurjchem-2641	91	1	[	[	X
eurjchem-2641	91	2	26	26	NUM
eurjchem-2641	91	3	]	]	PUNCT
eurjchem-2641	91	4	.	.	PUNCT
eurjchem-2641	92	1	furthermore	furthermore	ADV
eurjchem-2641	92	2	,	,	PUNCT
eurjchem-2641	92	3	variations	variation	NOUN
eurjchem-2641	92	4	in	in	ADP
eurjchem-2641	92	5	the	the	DET
eurjchem-2641	92	6	activity	activity	NOUN
eurjchem-2641	92	7	of	of	ADP
eurjchem-2641	92	8	apoptotic	apoptotic	ADJ
eurjchem-2641	92	9	parameters	parameter	NOUN
eurjchem-2641	92	10	were	be	AUX
eurjchem-2641	92	11	demonstrated	demonstrate	VERB
eurjchem-2641	92	12	in	in	ADP
eurjchem-2641	92	13	response	response	NOUN
eurjchem-2641	92	14	to	to	ADP
eurjchem-2641	92	15	cancer	cancer	NOUN
eurjchem-2641	92	16	therapy	therapy	NOUN
eurjchem-2641	92	17	.	.	PUNCT
eurjchem-2641	93	1	this	this	PRON
eurjchem-2641	93	2	may	may	AUX
eurjchem-2641	93	3	provide	provide	VERB
eurjchem-2641	93	4	insights	insight	NOUN
eurjchem-2641	93	5	into	into	ADP
eurjchem-2641	93	6	treatment	treatment	NOUN
eurjchem-2641	93	7	effectiveness	effectiveness	NOUN
eurjchem-2641	93	8	[	[	X
eurjchem-2641	93	9	26	26	NUM
eurjchem-2641	93	10	]	]	PUNCT
eurjchem-2641	93	11	.	.	PUNCT
eurjchem-2641	94	1	consequently	consequently	ADV
eurjchem-2641	94	2	,	,	PUNCT
eurjchem-2641	94	3	posttreatment	posttreatment	NOUN
eurjchem-2641	94	4	elevation	elevation	NOUN
eurjchem-2641	94	5	of	of	ADP
eurjchem-2641	94	6	caspases	caspase	NOUN
eurjchem-2641	94	7	indicates	indicate	VERB
eurjchem-2641	94	8	induction	induction	NOUN
eurjchem-2641	94	9	of	of	ADP
eurjchem-2641	94	10	apoptosis	apoptosis	NOUN
eurjchem-2641	94	11	in	in	ADP
eurjchem-2641	94	12	malignant	malignant	ADJ
eurjchem-2641	94	13	cells	cell	NOUN
eurjchem-2641	94	14	with	with	ADP
eurjchem-2641	94	15	better	well	ADJ
eurjchem-2641	94	16	survival	survival	NOUN
eurjchem-2641	94	17	rates	rate	NOUN
eurjchem-2641	94	18	in	in	ADP
eurjchem-2641	94	19	cancer	cancer	NOUN
eurjchem-2641	94	20	patients	patient	NOUN
eurjchem-2641	94	21	[	[	X
eurjchem-2641	94	22	26	26	NUM
eurjchem-2641	94	23	]	]	PUNCT
eurjchem-2641	94	24	.	.	PUNCT
eurjchem-2641	95	1	despite	despite	SCONJ
eurjchem-2641	95	2	the	the	DET
eurjchem-2641	95	3	success	success	NOUN
eurjchem-2641	95	4	of	of	ADP
eurjchem-2641	95	5	conventional	conventional	ADJ
eurjchem-2641	95	6	technologies	technology	NOUN
eurjchem-2641	95	7	,	,	PUNCT
eurjchem-2641	95	8	and	and	CCONJ
eurjchem-2641	95	9	tbs	tbs	VERB
eurjchem-2641	95	10	for	for	ADP
eurjchem-2641	95	11	the	the	DET
eurjchem-2641	95	12	predicting	predicting	NOUN
eurjchem-2641	95	13	and	and	CCONJ
eurjchem-2641	95	14	detecting	detect	VERB
eurjchem-2641	95	15	bc	bc	PROPN
eurjchem-2641	95	16	,	,	PUNCT
eurjchem-2641	95	17	they	they	PRON
eurjchem-2641	95	18	are	be	AUX
eurjchem-2641	95	19	invasive	invasive	ADJ
eurjchem-2641	95	20	methods	method	NOUN
eurjchem-2641	95	21	and	and	CCONJ
eurjchem-2641	95	22	have	have	VERB
eurjchem-2641	95	23	several	several	ADJ
eurjchem-2641	95	24	limitations	limitation	NOUN
eurjchem-2641	95	25	[	[	X
eurjchem-2641	95	26	12	12	NUM
eurjchem-2641	95	27	]	]	PUNCT
eurjchem-2641	95	28	.	.	PUNCT
eurjchem-2641	96	1	therefore	therefore	ADV
eurjchem-2641	96	2	,	,	PUNCT
eurjchem-2641	96	3	discovering	discover	VERB
eurjchem-2641	96	4	noninvasive	noninvasive	ADJ
eurjchem-2641	96	5	and	and	CCONJ
eurjchem-2641	96	6	novel	novel	ADJ
eurjchem-2641	96	7	biomarkers	biomarker	NOUN
eurjchem-2641	96	8	is	be	AUX
eurjchem-2641	96	9	critical	critical	ADJ
eurjchem-2641	96	10	for	for	ADP
eurjchem-2641	96	11	the	the	DET
eurjchem-2641	96	12	early	early	ADJ
eurjchem-2641	96	13	detection	detection	NOUN
eurjchem-2641	96	14	and	and	CCONJ
eurjchem-2641	96	15	control	control	NOUN
eurjchem-2641	96	16	of	of	ADP
eurjchem-2641	96	17	bc	bc	PROPN
eurjchem-2641	97	1	[	[	X
eurjchem-2641	97	2	23	23	NUM
eurjchem-2641	97	3	]	]	PUNCT
eurjchem-2641	97	4	.	.	PUNCT
eurjchem-2641	98	1	in	in	ADP
eurjchem-2641	98	2	this	this	DET
eurjchem-2641	98	3	context	context	NOUN
eurjchem-2641	98	4	,	,	PUNCT
eurjchem-2641	98	5	mirnas	mirna	NOUN
eurjchem-2641	98	6	in	in	ADP
eurjchem-2641	98	7	lbs	lbs	NOUN
eurjchem-2641	98	8	are	be	AUX
eurjchem-2641	98	9	suggested	suggest	VERB
eurjchem-2641	98	10	as	as	ADP
eurjchem-2641	98	11	promising	promise	VERB
eurjchem-2641	98	12	noninvasive	noninvasive	ADJ
eurjchem-2641	98	13	biomarkers	biomarker	NOUN
eurjchem-2641	98	14	for	for	ADP
eurjchem-2641	98	15	bc	bc	PROPN
eurjchem-2641	98	16	management	management	PROPN
eurjchem-2641	98	17	[	[	X
eurjchem-2641	98	18	18,27	18,27	NUM
eurjchem-2641	98	19	]	]	X
eurjchem-2641	98	20	.	.	PUNCT
eurjchem-2641	99	1	consequently	consequently	ADV
eurjchem-2641	99	2	,	,	PUNCT
eurjchem-2641	99	3	this	this	DET
eurjchem-2641	99	4	study	study	NOUN
eurjchem-2641	99	5	aimed	aim	VERB
eurjchem-2641	99	6	to	to	PART
eurjchem-2641	99	7	investigate	investigate	VERB
eurjchem-2641	99	8	mirna-148b	mirna-148b	PROPN
eurjchem-2641	99	9	in	in	ADP
eurjchem-2641	99	10	patients	patient	NOUN
eurjchem-2641	99	11	with	with	ADP
eurjchem-2641	99	12	bc	bc	PROPN
eurjchem-2641	99	13	as	as	ADP
eurjchem-2641	99	14	a	a	DET
eurjchem-2641	99	15	non	non	ADJ
eurjchem-2641	99	16	-	-	ADJ
eurjchem-2641	99	17	invasive	invasive	ADJ
eurjchem-2641	99	18	biomarker	biomarker	NOUN
eurjchem-2641	99	19	for	for	ADP
eurjchem-2641	99	20	the	the	DET
eurjchem-2641	99	21	prediction	prediction	NOUN
eurjchem-2641	99	22	and	and	CCONJ
eurjchem-2641	99	23	follow	follow	VERB
eurjchem-2641	99	24	-	-	PUNCT
eurjchem-2641	99	25	up	up	NOUN
eurjchem-2641	99	26	of	of	ADP
eurjchem-2641	99	27	bc	bc	PROPN
eurjchem-2641	99	28	.	.	PUNCT
eurjchem-2641	100	1	consequently	consequently	ADV
eurjchem-2641	100	2	,	,	PUNCT
eurjchem-2641	100	3	mirna-148b	mirna-148b	PROPN
eurjchem-2641	100	4	,	,	PUNCT
eurjchem-2641	100	5	caspase-3	caspase-3	NUM
eurjchem-2641	100	6	,	,	PUNCT
eurjchem-2641	100	7	bax	bax	NOUN
eurjchem-2641	100	8	,	,	PUNCT
eurjchem-2641	100	9	bcl-2	bcl-2	NOUN
eurjchem-2641	100	10	,	,	PUNCT
eurjchem-2641	100	11	and	and	CCONJ
eurjchem-2641	100	12	total	total	ADJ
eurjchem-2641	100	13	antioxidant	antioxidant	ADJ
eurjchem-2641	100	14	capacity	capacity	NOUN
eurjchem-2641	100	15	(	(	PUNCT
eurjchem-2641	100	16	tac	tac	NOUN
eurjchem-2641	100	17	)	)	PUNCT
eurjchem-2641	100	18	were	be	AUX
eurjchem-2641	100	19	investigated	investigate	VERB
eurjchem-2641	100	20	in	in	ADP
eurjchem-2641	100	21	female	female	ADJ
eurjchem-2641	100	22	bc	bc	PROPN
eurjchem-2641	100	23	patients	patient	NOUN
eurjchem-2641	100	24	.	.	PUNCT
eurjchem-2641	101	1	2	2	X
eurjchem-2641	101	2	.	.	X
eurjchem-2641	101	3	experimental	experimental	ADJ
eurjchem-2641	101	4	2.1	2.1	NUM
eurjchem-2641	101	5	.	.	PUNCT
eurjchem-2641	101	6	study	study	NOUN
eurjchem-2641	101	7	design	design	NOUN
eurjchem-2641	101	8	and	and	CCONJ
eurjchem-2641	101	9	ethical	ethical	ADJ
eurjchem-2641	101	10	approval	approval	NOUN
eurjchem-2641	101	11	this	this	PRON
eurjchem-2641	101	12	is	be	AUX
eurjchem-2641	101	13	a	a	DET
eurjchem-2641	101	14	comparative	comparative	ADJ
eurjchem-2641	101	15	control	control	NOUN
eurjchem-2641	101	16	study	study	NOUN
eurjchem-2641	101	17	that	that	PRON
eurjchem-2641	101	18	enrolled	enrol	VERB
eurjchem-2641	101	19	300	300	NUM
eurjchem-2641	101	20	female	female	ADJ
eurjchem-2641	101	21	patients	patient	NOUN
eurjchem-2641	101	22	.	.	PUNCT
eurjchem-2641	102	1	this	this	DET
eurjchem-2641	102	2	study	study	NOUN
eurjchem-2641	102	3	was	be	AUX
eurjchem-2641	102	4	conducted	conduct	VERB
eurjchem-2641	102	5	in	in	ADP
eurjchem-2641	102	6	the	the	DET
eurjchem-2641	102	7	outpatient	outpatient	NOUN
eurjchem-2641	102	8	clinic	clinic	NOUN
eurjchem-2641	102	9	of	of	ADP
eurjchem-2641	102	10	damanhour	damanhour	NOUN
eurjchem-2641	102	11	oncology	oncology	NOUN
eurjchem-2641	102	12	center	center	NOUN
eurjchem-2641	102	13	from	from	ADP
eurjchem-2641	102	14	december	december	PROPN
eurjchem-2641	102	15	2021	2021	NUM
eurjchem-2641	102	16	to	to	ADP
eurjchem-2641	102	17	february	february	PROPN
eurjchem-2641	102	18	2023	2023	NUM
eurjchem-2641	102	19	.	.	PUNCT
eurjchem-2641	103	1	the	the	DET
eurjchem-2641	103	2	research	research	NOUN
eurjchem-2641	103	3	ethics	ethic	NOUN
eurjchem-2641	103	4	committee	committee	PROPN
eurjchem-2641	103	5	of	of	ADP
eurjchem-2641	103	6	the	the	DET
eurjchem-2641	103	7	faculty	faculty	NOUN
eurjchem-2641	103	8	of	of	ADP
eurjchem-2641	103	9	pharmacy	pharmacy	NOUN
eurjchem-2641	103	10	,	,	PUNCT
eurjchem-2641	103	11	damanhour	damanhour	NOUN
eurjchem-2641	103	12	university	university	PROPN
eurjchem-2641	103	13	,	,	PUNCT
eurjchem-2641	103	14	egypt	egypt	PROPN
eurjchem-2641	103	15	,	,	PUNCT
eurjchem-2641	103	16	approved	approve	VERB
eurjchem-2641	103	17	the	the	DET
eurjchem-2641	103	18	study	study	NOUN
eurjchem-2641	103	19	(	(	PUNCT
eurjchem-2641	103	20	ref	ref	NOUN
eurjchem-2641	103	21	.	.	PUNCT
eurjchem-2641	104	1	no	no	INTJ
eurjchem-2641	104	2	.	.	PUNCT
eurjchem-2641	105	1	620pb20	620pb20	NUM
eurjchem-2641	105	2	)	)	PUNCT
eurjchem-2641	105	3	.	.	PUNCT
eurjchem-2641	106	1	the	the	DET
eurjchem-2641	106	2	study	study	NOUN
eurjchem-2641	106	3	adhered	adhere	VERB
eurjchem-2641	106	4	to	to	ADP
eurjchem-2641	106	5	the	the	DET
eurjchem-2641	106	6	helsinki	helsinki	PROPN
eurjchem-2641	106	7	declaration	declaration	PROPN
eurjchem-2641	106	8	of	of	ADP
eurjchem-2641	106	9	ethical	ethical	ADJ
eurjchem-2641	106	10	principles	principle	NOUN
eurjchem-2641	106	11	for	for	ADP
eurjchem-2641	106	12	research	research	NOUN
eurjchem-2641	106	13	involving	involve	VERB
eurjchem-2641	106	14	human	human	ADJ
eurjchem-2641	106	15	subjects	subject	NOUN
eurjchem-2641	106	16	.	.	PUNCT
eurjchem-2641	107	1	2.2	2.2	NUM
eurjchem-2641	107	2	.	.	PUNCT
eurjchem-2641	107	3	subjects	subject	VERB
eurjchem-2641	107	4	the	the	DET
eurjchem-2641	107	5	goals	goal	NOUN
eurjchem-2641	107	6	and	and	CCONJ
eurjchem-2641	107	7	procedures	procedure	NOUN
eurjchem-2641	107	8	of	of	ADP
eurjchem-2641	107	9	this	this	DET
eurjchem-2641	107	10	study	study	NOUN
eurjchem-2641	107	11	were	be	AUX
eurjchem-2641	107	12	clarified	clarify	VERB
eurjchem-2641	107	13	in	in	ADP
eurjchem-2641	107	14	verbal	verbal	ADJ
eurjchem-2641	107	15	and	and	CCONJ
eurjchem-2641	107	16	written	write	VERB
eurjchem-2641	107	17	consent	consent	NOUN
eurjchem-2641	107	18	for	for	ADP
eurjchem-2641	107	19	each	each	PRON
eurjchem-2641	107	20	of	of	ADP
eurjchem-2641	107	21	the	the	DET
eurjchem-2641	107	22	study	study	NOUN
eurjchem-2641	107	23	participants	participant	NOUN
eurjchem-2641	107	24	.	.	PUNCT
eurjchem-2641	108	1	information	information	NOUN
eurjchem-2641	108	2	including	include	VERB
eurjchem-2641	108	3	age	age	NOUN
eurjchem-2641	108	4	,	,	PUNCT
eurjchem-2641	108	5	family	family	NOUN
eurjchem-2641	108	6	history	history	NOUN
eurjchem-2641	108	7	of	of	ADP
eurjchem-2641	108	8	bc	bc	PROPN
eurjchem-2641	108	9	,	,	PUNCT
eurjchem-2641	108	10	hypertension	hypertension	NOUN
eurjchem-2641	108	11	,	,	PUNCT
eurjchem-2641	108	12	diabetes	diabetes	NOUN
eurjchem-2641	108	13	,	,	PUNCT
eurjchem-2641	108	14	other	other	ADJ
eurjchem-2641	108	15	malignancies	malignancy	NOUN
eurjchem-2641	108	16	,	,	PUNCT
eurjchem-2641	108	17	and	and	CCONJ
eurjchem-2641	108	18	menopausal	menopausal	ADJ
eurjchem-2641	108	19	symptoms	symptom	NOUN
eurjchem-2641	108	20	was	be	AUX
eurjchem-2641	108	21	obtained	obtain	VERB
eurjchem-2641	108	22	from	from	ADP
eurjchem-2641	108	23	the	the	DET
eurjchem-2641	108	24	medical	medical	ADJ
eurjchem-2641	108	25	records	record	NOUN
eurjchem-2641	108	26	of	of	ADP
eurjchem-2641	108	27	the	the	DET
eurjchem-2641	108	28	patients	patient	NOUN
eurjchem-2641	108	29	.	.	PUNCT
eurjchem-2641	109	1	furthermore	furthermore	ADV
eurjchem-2641	109	2	,	,	PUNCT
eurjchem-2641	109	3	the	the	DET
eurjchem-2641	109	4	tumor	tumor	NOUN
eurjchem-2641	109	5	size	size	NOUN
eurjchem-2641	109	6	of	of	ADP
eurjchem-2641	109	7	all	all	DET
eurjchem-2641	109	8	participants	participant	NOUN
eurjchem-2641	109	9	was	be	AUX
eurjchem-2641	109	10	reported	report	VERB
eurjchem-2641	109	11	.	.	PUNCT
eurjchem-2641	110	1	the	the	DET
eurjchem-2641	110	2	female	female	NOUN
eurjchem-2641	110	3	enrolled	enrol	VERB
eurjchem-2641	110	4	in	in	ADP
eurjchem-2641	110	5	this	this	DET
eurjchem-2641	110	6	study	study	NOUN
eurjchem-2641	110	7	does	do	AUX
eurjchem-2641	110	8	not	not	PART
eurjchem-2641	110	9	have	have	VERB
eurjchem-2641	110	10	diabetes	diabetes	NOUN
eurjchem-2641	110	11	,	,	PUNCT
eurjchem-2641	110	12	connective	connective	ADJ
eurjchem-2641	110	13	tissue	tissue	NOUN
eurjchem-2641	110	14	diseases	disease	NOUN
eurjchem-2641	110	15	,	,	PUNCT
eurjchem-2641	110	16	autoimmune	autoimmune	ADJ
eurjchem-2641	110	17	diseases	disease	NOUN
eurjchem-2641	110	18	,	,	PUNCT
eurjchem-2641	110	19	other	other	ADJ
eurjchem-2641	110	20	malignancies	malignancy	NOUN
eurjchem-2641	110	21	,	,	PUNCT
eurjchem-2641	110	22	cardiac	cardiac	ADJ
eurjchem-2641	110	23	,	,	PUNCT
eurjchem-2641	110	24	respiratory	respiratory	ADJ
eurjchem-2641	110	25	,	,	PUNCT
eurjchem-2641	110	26	renal	renal	ADJ
eurjchem-2641	110	27	diseases	disease	NOUN
eurjchem-2641	110	28	,	,	PUNCT
eurjchem-2641	110	29	or	or	CCONJ
eurjchem-2641	110	30	other	other	ADJ
eurjchem-2641	110	31	diseases	disease	NOUN
eurjchem-2641	110	32	.	.	PUNCT
eurjchem-2641	111	1	the	the	DET
eurjchem-2641	111	2	300	300	NUM
eurjchem-2641	111	3	females	female	NOUN
eurjchem-2641	111	4	were	be	AUX
eurjchem-2641	111	5	classified	classify	VERB
eurjchem-2641	111	6	into	into	ADP
eurjchem-2641	111	7	four	four	NUM
eurjchem-2641	111	8	groups	group	NOUN
eurjchem-2641	111	9	:	:	PUNCT
eurjchem-2641	111	10	group	group	NOUN
eurjchem-2641	111	11	i	i	PRON
eurjchem-2641	111	12	(	(	PUNCT
eurjchem-2641	111	13	control	control	PROPN
eurjchem-2641	111	14	):	):	PUNCT
eurjchem-2641	111	15	included	include	VERB
eurjchem-2641	111	16	75	75	NUM
eurjchem-2641	111	17	healthy	healthy	ADJ
eurjchem-2641	111	18	volunteers	volunteer	NOUN
eurjchem-2641	111	19	.	.	PUNCT
eurjchem-2641	112	1	group	group	PROPN
eurjchem-2641	112	2	ii	ii	PROPN
eurjchem-2641	112	3	(	(	PUNCT
eurjchem-2641	112	4	early	early	ADJ
eurjchem-2641	112	5	stage	stage	NOUN
eurjchem-2641	112	6	):	):	PUNCT
eurjchem-2641	112	7	this	this	DET
eurjchem-2641	112	8	group	group	NOUN
eurjchem-2641	112	9	included	include	VERB
eurjchem-2641	112	10	75	75	NUM
eurjchem-2641	112	11	early	early	ADJ
eurjchem-2641	112	12	-	-	PUNCT
eurjchem-2641	112	13	stage	stage	NOUN
eurjchem-2641	112	14	bc	bc	PROPN
eurjchem-2641	112	15	patients	patient	NOUN
eurjchem-2641	112	16	.	.	PUNCT
eurjchem-2641	113	1	group	group	PROPN
eurjchem-2641	113	2	iii	iii	PROPN
eurjchem-2641	113	3	(	(	PUNCT
eurjchem-2641	113	4	chemotherapy	chemotherapy	NOUN
eurjchem-2641	113	5	):	):	PUNCT
eurjchem-2641	113	6	this	this	DET
eurjchem-2641	113	7	group	group	NOUN
eurjchem-2641	113	8	included	include	VERB
eurjchem-2641	113	9	75	75	NUM
eurjchem-2641	113	10	patients	patient	NOUN
eurjchem-2641	113	11	with	with	ADP
eurjchem-2641	113	12	bc	bc	PROPN
eurjchem-2641	113	13	receiving	receive	VERB
eurjchem-2641	113	14	chemotherapy	chemotherapy	NOUN
eurjchem-2641	113	15	(	(	PUNCT
eurjchem-2641	113	16	doxorubicin	doxorubicin	PROPN
eurjchem-2641	113	17	and	and	CCONJ
eurjchem-2641	113	18	cyclophosphamide	cyclophosphamide	PROPN
eurjchem-2641	113	19	(	(	PUNCT
eurjchem-2641	113	20	60	60	NUM
eurjchem-2641	113	21	and	and	CCONJ
eurjchem-2641	113	22	600	600	NUM
eurjchem-2641	113	23	mg	mg	PROPN
eurjchem-2641	113	24	/	/	SYM
eurjchem-2641	113	25	m²	m²	PROPN
eurjchem-2641	113	26	)	)	PUNCT
eurjchem-2641	113	27	iv	iv	NUM
eurjchem-2641	113	28	every	every	DET
eurjchem-2641	113	29	3	3	NUM
eurjchem-2641	113	30	weeks/4	weeks/4	PROPN
eurjchem-2641	113	31	cycles	cycle	NOUN
eurjchem-2641	113	32	,	,	PUNCT
eurjchem-2641	113	33	respectively	respectively	ADV
eurjchem-2641	113	34	[	[	X
eurjchem-2641	113	35	28	28	NUM
eurjchem-2641	113	36	]	]	PUNCT
eurjchem-2641	113	37	.	.	PUNCT
eurjchem-2641	114	1	group	group	PROPN
eurjchem-2641	114	2	iv	iv	PROPN
eurjchem-2641	114	3	(	(	PUNCT
eurjchem-2641	114	4	surgery	surgery	NOUN
eurjchem-2641	114	5	):	):	PUNCT
eurjchem-2641	114	6	included	include	VERB
eurjchem-2641	114	7	75	75	NUM
eurjchem-2641	114	8	patients	patient	NOUN
eurjchem-2641	114	9	with	with	ADP
eurjchem-2641	114	10	bc	bc	PROPN
eurjchem-2641	114	11	who	who	PRON
eurjchem-2641	114	12	were	be	AUX
eurjchem-2641	114	13	treated	treat	VERB
eurjchem-2641	114	14	surgically	surgically	ADV
eurjchem-2641	114	15	(	(	PUNCT
eurjchem-2641	114	16	mastectomy	mastectomy	NOUN
eurjchem-2641	114	17	involves	involve	VERB
eurjchem-2641	114	18	the	the	DET
eurjchem-2641	114	19	removal	removal	NOUN
eurjchem-2641	114	20	of	of	ADP
eurjchem-2641	114	21	the	the	DET
eurjchem-2641	114	22	entire	entire	ADJ
eurjchem-2641	114	23	breast	breast	NOUN
eurjchem-2641	114	24	,	,	PUNCT
eurjchem-2641	114	25	including	include	VERB
eurjchem-2641	114	26	tissue	tissue	NOUN
eurjchem-2641	114	27	and	and	CCONJ
eurjchem-2641	114	28	skin	skin	NOUN
eurjchem-2641	114	29	)	)	PUNCT
eurjchem-2641	114	30	.	.	PUNCT
eurjchem-2641	115	1	figure	figure	NOUN
eurjchem-2641	115	2	1	1	NUM
eurjchem-2641	115	3	shows	show	VERB
eurjchem-2641	115	4	the	the	DET
eurjchem-2641	115	5	studied	study	VERB
eurjchem-2641	115	6	groups	group	NOUN
eurjchem-2641	115	7	.	.	PUNCT
eurjchem-2641	116	1	2.3	2.3	NUM
eurjchem-2641	116	2	.	.	PUNCT
eurjchem-2641	116	3	blood	blood	NOUN
eurjchem-2641	116	4	sample	sample	NOUN
eurjchem-2641	116	5	collection	collection	NOUN
eurjchem-2641	116	6	blood	blood	NOUN
eurjchem-2641	116	7	samples	sample	NOUN
eurjchem-2641	116	8	(	(	PUNCT
eurjchem-2641	116	9	6	6	NUM
eurjchem-2641	116	10	ml	ml	NOUN
eurjchem-2641	116	11	)	)	PUNCT
eurjchem-2641	116	12	were	be	AUX
eurjchem-2641	116	13	collected	collect	VERB
eurjchem-2641	116	14	from	from	ADP
eurjchem-2641	116	15	the	the	DET
eurjchem-2641	116	16	peripheral	peripheral	ADJ
eurjchem-2641	116	17	veins	vein	NOUN
eurjchem-2641	116	18	of	of	ADP
eurjchem-2641	116	19	the	the	DET
eurjchem-2641	116	20	participants	participant	NOUN
eurjchem-2641	116	21	.	.	PUNCT
eurjchem-2641	117	1	224	224	NUM
eurjchem-2641	117	2	harisa	harisa	NOUN
eurjchem-2641	117	3	et	et	PROPN
eurjchem-2641	117	4	al	al	PROPN
eurjchem-2641	117	5	.	.	PUNCT
eurjchem-2641	117	6	/	/	SYM
eurjchem-2641	117	7	european	european	PROPN
eurjchem-2641	117	8	journal	journal	PROPN
eurjchem-2641	117	9	of	of	ADP
eurjchem-2641	117	10	chemistry	chemistry	NOUN
eurjchem-2641	117	11	16	16	NUM
eurjchem-2641	117	12	(	(	PUNCT
eurjchem-2641	117	13	2	2	NUM
eurjchem-2641	117	14	)	)	PUNCT
eurjchem-2641	117	15	(	(	PUNCT
eurjchem-2641	117	16	2025	2025	NUM
eurjchem-2641	117	17	)	)	PUNCT
eurjchem-2641	117	18	222	222	NUM
eurjchem-2641	117	19	-	-	SYM
eurjchem-2641	117	20	232	232	NUM
eurjchem-2641	117	21	2025	2025	NUM
eurjchem-2641	117	22	–	–	PUNCT
eurjchem-2641	117	23	european	european	ADJ
eurjchem-2641	117	24	journal	journal	NOUN
eurjchem-2641	117	25	of	of	ADP
eurjchem-2641	117	26	chemistry	chemistry	NOUN
eurjchem-2641	117	27	–	–	PUNCT
eurjchem-2641	117	28	cc	cc	NOUN
eurjchem-2641	117	29	by	by	ADP
eurjchem-2641	117	30	nc	nc	PROPN
eurjchem-2641	117	31	–	–	PUNCT
eurjchem-2641	117	32	doi	doi	NOUN
eurjchem-2641	117	33	:	:	PUNCT
eurjchem-2641	117	34	10.5155	10.5155	NUM
eurjchem-2641	117	35	/	/	SYM
eurjchem-2641	117	36	eurjchem.16.2.222	eurjchem.16.2.222	NUM
eurjchem-2641	117	37	-	-	SYM
eurjchem-2641	117	38	232.2641	232.2641	NUM
eurjchem-2641	117	39	table	table	NOUN
eurjchem-2641	117	40	1	1	NUM
eurjchem-2641	117	41	.	.	PUNCT
eurjchem-2641	118	1	the	the	DET
eurjchem-2641	118	2	primers	primer	NOUN
eurjchem-2641	118	3	sequence	sequence	NOUN
eurjchem-2641	118	4	of	of	ADP
eurjchem-2641	118	5	mirna-148b	mirna-148b	PROPN
eurjchem-2641	118	6	,	,	PUNCT
eurjchem-2641	118	7	caspase-3	caspase-3	NUM
eurjchem-2641	118	8	,	,	PUNCT
eurjchem-2641	118	9	bcl2	bcl2	PROPN
eurjchem-2641	118	10	bax	bax	PROPN
eurjchem-2641	118	11	,	,	PUNCT
eurjchem-2641	118	12	and	and	CCONJ
eurjchem-2641	118	13	u6	u6	PROPN
eurjchem-2641	118	14	.	.	PUNCT
eurjchem-2641	119	1	primer	primer	NOUN
eurjchem-2641	119	2	name	name	NOUN
eurjchem-2641	119	3	sequences	sequence	NOUN
eurjchem-2641	119	4	primer	primer	NOUN
eurjchem-2641	119	5	of	of	ADP
eurjchem-2641	119	6	mirna-148b	mirna-148b	PROPN
eurjchem-2641	119	7	tm	tm	NOUN
eurjchem-2641	119	8	=	=	PROPN
eurjchem-2641	119	9	59.3	59.3	NUM
eurjchem-2641	119	10	f	f	NOUN
eurjchem-2641	119	11	:	:	PUNCT
eurjchem-2641	119	12	5′catcgccctgtggatgactg3′	5′catcgccctgtggatgactg3′	NUM
eurjchem-2641	119	13	tm	tm	NOUN
eurjchem-2641	119	14	=	=	NOUN
eurjchem-2641	119	15	58.9	58.9	NUM
eurjchem-2641	119	16	r	r	NOUN
eurjchem-2641	119	17	:	:	PUNCT
eurjchem-2641	119	18	5′ggccatatagttccacaaaggc3′	5′ggccatatagttccacaaaggc3′	NUM
eurjchem-2641	119	19	primer	primer	NOUN
eurjchem-2641	119	20	of	of	ADP
eurjchem-2641	119	21	caspase-3	caspase-3	NUM
eurjchem-2641	119	22	tm	tm	NOUN
eurjchem-2641	119	23	=	=	NOUN
eurjchem-2641	119	24	60.6	60.6	NUM
eurjchem-2641	119	25	f	f	NOUN
eurjchem-2641	119	26	:	:	PUNCT
eurjchem-2641	119	27	5′	5′	NUM
eurjchem-2641	119	28	tgtcctgggacaccggttat3′	tgtcctgggacaccggttat3′	NOUN
eurjchem-2641	119	29	tm	tm	NOUN
eurjchem-2641	119	30	=	=	NOUN
eurjchem-2641	119	31	60.1	60.1	NUM
eurjchem-2641	119	32	r	r	NOUN
eurjchem-2641	119	33	:	:	PUNCT
eurjchem-2641	119	34	5′	5′	NUM
eurjchem-2641	119	35	tctgttgccacctttcggtt3′	tctgttgccacctttcggtt3′	PRON
eurjchem-2641	119	36	primer	primer	NOUN
eurjchem-2641	119	37	of	of	ADP
eurjchem-2641	119	38	bcl-2	bcl-2	PUNCT
eurjchem-2641	119	39	tm	tm	NOUN
eurjchem-2641	119	40	=	=	PROPN
eurjchem-2641	119	41	57.1	57.1	NUM
eurjchem-2641	119	42	f	f	NOUN
eurjchem-2641	119	43	:	:	PUNCT
eurjchem-2641	119	44	5′aaatacaacatcacagagaagt3′	5′aaatacaacatcacagagaagt3′	NUM
eurjchem-2641	119	45	tm	tm	NOUN
eurjchem-2641	119	46	=	=	NOUN
eurjchem-2641	119	47	60.1	60.1	NUM
eurjchem-2641	119	48	r	r	NOUN
eurjchem-2641	119	49	:	:	PUNCT
eurjchem-2641	119	50	5′	5′	NUM
eurjchem-2641	119	51	tcccggttatcgtaccctgt3′	tcccggttatcgtaccctgt3′	NOUN
eurjchem-2641	119	52	primer	primer	NOUN
eurjchem-2641	119	53	of	of	ADP
eurjchem-2641	119	54	bax	bax	PROPN
eurjchem-2641	119	55	tm	tm	PROPN
eurjchem-2641	119	56	=	=	PROPN
eurjchem-2641	120	1	60.02	60.02	NUM
eurjchem-2641	120	2	f	f	X
eurjchem-2641	120	3	:	:	PUNCT
eurjchem-2641	120	4	5′gtctccggcgaattggagat3′	5′gtctccggcgaattggagat3′	NUM
eurjchem-2641	120	5	tm	tm	NOUN
eurjchem-2641	120	6	=	=	NOUN
eurjchem-2641	120	7	59.83	59.83	NUM
eurjchem-2641	120	8	r	r	NOUN
eurjchem-2641	120	9	:	:	PUNCT
eurjchem-2641	120	10	5′acccggaagaagacctctcg3′	5′acccggaagaagacctctcg3′	NUM
eurjchem-2641	120	11	primer	primer	NOUN
eurjchem-2641	120	12	of	of	ADP
eurjchem-2641	120	13	u6	u6	ADJ
eurjchem-2641	120	14	tm	tm	NOUN
eurjchem-2641	120	15	=	=	PROPN
eurjchem-2641	120	16	60.5	60.5	NUM
eurjchem-2641	120	17	f	f	NOUN
eurjchem-2641	120	18	:	:	PUNCT
eurjchem-2641	120	19	5′ttgtgggcaaggatgtggtc3′	5′ttgtgggcaaggatgtggtc3′	NUM
eurjchem-2641	120	20	tm	tm	NOUN
eurjchem-2641	120	21	=	=	NOUN
eurjchem-2641	120	22	60.4	60.4	NUM
eurjchem-2641	120	23	r	r	NOUN
eurjchem-2641	120	24	:	:	PUNCT
eurjchem-2641	120	25	5′ccgcatcctgtagcaactgt3′	5′ccgcatcctgtagcaactgt3′	NUM
eurjchem-2641	120	26	figure	figure	NOUN
eurjchem-2641	120	27	1	1	NUM
eurjchem-2641	120	28	.	.	PUNCT
eurjchem-2641	120	29	study	study	NOUN
eurjchem-2641	120	30	design	design	NOUN
eurjchem-2641	120	31	.	.	PUNCT
eurjchem-2641	121	1	a	a	DET
eurjchem-2641	121	2	1	1	NUM
eurjchem-2641	121	3	ml	ml	NOUN
eurjchem-2641	121	4	was	be	AUX
eurjchem-2641	121	5	collected	collect	VERB
eurjchem-2641	121	6	using	use	VERB
eurjchem-2641	121	7	a	a	DET
eurjchem-2641	121	8	complete	complete	ADJ
eurjchem-2641	121	9	aseptic	aseptic	ADJ
eurjchem-2641	121	10	technique	technique	NOUN
eurjchem-2641	121	11	into	into	ADP
eurjchem-2641	121	12	an	an	DET
eurjchem-2641	121	13	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
eurjchem-2641	121	14	acid	acid	NOUN
eurjchem-2641	121	15	(	(	PUNCT
eurjchem-2641	121	16	edta	edta	NOUN
eurjchem-2641	121	17	)	)	PUNCT
eurjchem-2641	121	18	tube	tube	NOUN
eurjchem-2641	121	19	for	for	ADP
eurjchem-2641	121	20	a	a	DET
eurjchem-2641	121	21	complete	complete	ADJ
eurjchem-2641	121	22	blood	blood	NOUN
eurjchem-2641	121	23	count	count	NOUN
eurjchem-2641	121	24	(	(	PUNCT
eurjchem-2641	121	25	cbc	cbc	NOUN
eurjchem-2641	121	26	)	)	PUNCT
eurjchem-2641	121	27	assessment	assessment	NOUN
eurjchem-2641	121	28	.	.	PUNCT
eurjchem-2641	122	1	the	the	DET
eurjchem-2641	122	2	remaining	remain	VERB
eurjchem-2641	122	3	5	5	NUM
eurjchem-2641	122	4	ml	ml	NOUN
eurjchem-2641	122	5	was	be	AUX
eurjchem-2641	122	6	collected	collect	VERB
eurjchem-2641	122	7	in	in	ADP
eurjchem-2641	122	8	a	a	DET
eurjchem-2641	122	9	tube	tube	NOUN
eurjchem-2641	122	10	containing	contain	VERB
eurjchem-2641	122	11	separated	separate	VERB
eurjchem-2641	122	12	gel	gel	NOUN
eurjchem-2641	122	13	,	,	PUNCT
eurjchem-2641	122	14	followed	follow	VERB
eurjchem-2641	122	15	by	by	ADP
eurjchem-2641	122	16	centrifugation	centrifugation	NOUN
eurjchem-2641	122	17	at	at	ADP
eurjchem-2641	122	18	5000	5000	NUM
eurjchem-2641	122	19	rpm	rpm	NOUN
eurjchem-2641	122	20	for	for	ADP
eurjchem-2641	122	21	10	10	NUM
eurjchem-2641	122	22	minutes	minute	NOUN
eurjchem-2641	122	23	to	to	PART
eurjchem-2641	122	24	separate	separate	VERB
eurjchem-2641	122	25	the	the	DET
eurjchem-2641	122	26	serum	serum	NOUN
eurjchem-2641	122	27	.	.	PUNCT
eurjchem-2641	123	1	the	the	DET
eurjchem-2641	123	2	serum	serum	NOUN
eurjchem-2641	123	3	collected	collect	VERB
eurjchem-2641	123	4	was	be	AUX
eurjchem-2641	123	5	stored	store	VERB
eurjchem-2641	123	6	at	at	ADP
eurjchem-2641	123	7	-80	-80	NOUN
eurjchem-2641	123	8	°	°	NOUN
eurjchem-2641	123	9	c	c	NOUN
eurjchem-2641	123	10	to	to	PART
eurjchem-2641	123	11	evaluate	evaluate	VERB
eurjchem-2641	123	12	the	the	DET
eurjchem-2641	123	13	mirna-148b	mirna-148b	PROPN
eurjchem-2641	123	14	and	and	CCONJ
eurjchem-2641	123	15	bax	bax	NOUN
eurjchem-2641	123	16	genes	gene	NOUN
eurjchem-2641	123	17	using	use	VERB
eurjchem-2641	123	18	the	the	DET
eurjchem-2641	123	19	quantitative	quantitative	ADJ
eurjchem-2641	123	20	real	real	ADJ
eurjchem-2641	123	21	-	-	PUNCT
eurjchem-2641	123	22	time	time	NOUN
eurjchem-2641	123	23	pcr	pcr	NOUN
eurjchem-2641	123	24	technique	technique	NOUN
eurjchem-2641	123	25	(	(	PUNCT
eurjchem-2641	123	26	qrt	qrt	NOUN
eurjchem-2641	123	27	-	-	PUNCT
eurjchem-2641	123	28	pcr	pcr	NOUN
eurjchem-2641	123	29	)	)	PUNCT
eurjchem-2641	123	30	.	.	PUNCT
eurjchem-2641	124	1	however	however	ADV
eurjchem-2641	124	2	,	,	PUNCT
eurjchem-2641	124	3	the	the	DET
eurjchem-2641	124	4	caspase-3	caspase-3	NUM
eurjchem-2641	124	5	and	and	CCONJ
eurjchem-2641	124	6	bcl-2	bcl-2	NOUN
eurjchem-2641	124	7	proteins	protein	NOUN
eurjchem-2641	124	8	were	be	AUX
eurjchem-2641	124	9	measured	measure	VERB
eurjchem-2641	124	10	by	by	ADP
eurjchem-2641	124	11	the	the	DET
eurjchem-2641	124	12	elisa	elisa	NOUN
eurjchem-2641	124	13	technique	technique	NOUN
eurjchem-2641	124	14	.	.	PUNCT
eurjchem-2641	125	1	spectrophotometry	spectrophotometry	NOUN
eurjchem-2641	125	2	was	be	AUX
eurjchem-2641	125	3	used	use	VERB
eurjchem-2641	125	4	to	to	PART
eurjchem-2641	125	5	determine	determine	VERB
eurjchem-2641	125	6	the	the	DET
eurjchem-2641	125	7	tac	tac	NOUN
eurjchem-2641	125	8	.	.	PUNCT
eurjchem-2641	126	1	cbc	cbc	PROPN
eurjchem-2641	126	2	was	be	AUX
eurjchem-2641	126	3	evaluated	evaluate	VERB
eurjchem-2641	126	4	with	with	ADP
eurjchem-2641	126	5	the	the	DET
eurjchem-2641	126	6	advia-2120	advia-2120	ADJ
eurjchem-2641	126	7	hematology	hematology	NOUN
eurjchem-2641	126	8	analyzer	analyzer	NOUN
eurjchem-2641	126	9	®	®	NOUN
eurjchem-2641	126	10	(	(	PUNCT
eurjchem-2641	126	11	siemens	siemens	PROPN
eurjchem-2641	126	12	healthcare	healthcare	PROPN
eurjchem-2641	126	13	,	,	PUNCT
eurjchem-2641	126	14	diagnostics	diagnostic	NOUN
eurjchem-2641	126	15	,	,	PUNCT
eurjchem-2641	126	16	usa	usa	PROPN
eurjchem-2641	126	17	)	)	PUNCT
eurjchem-2641	126	18	,	,	PUNCT
eurjchem-2641	126	19	according	accord	VERB
eurjchem-2641	126	20	to	to	ADP
eurjchem-2641	126	21	the	the	DET
eurjchem-2641	126	22	manufacturer	manufacturer	NOUN
eurjchem-2641	126	23	's	's	PART
eurjchem-2641	126	24	protocol	protocol	NOUN
eurjchem-2641	126	25	.	.	PUNCT
eurjchem-2641	127	1	2.4	2.4	NUM
eurjchem-2641	127	2	.	.	PUNCT
eurjchem-2641	127	3	gene	gene	NOUN
eurjchem-2641	127	4	expression	expression	NOUN
eurjchem-2641	127	5	study	study	VERB
eurjchem-2641	127	6	the	the	DET
eurjchem-2641	127	7	mirna-148b	mirna-148b	PROPN
eurjchem-2641	127	8	,	,	PUNCT
eurjchem-2641	127	9	caspase-3	caspase-3	NUM
eurjchem-2641	127	10	,	,	PUNCT
eurjchem-2641	127	11	bcl2	bcl2	NOUN
eurjchem-2641	127	12	and	and	CCONJ
eurjchem-2641	127	13	bax	bax	PROPN
eurjchem-2641	127	14	genes	gene	NOUN
eurjchem-2641	127	15	were	be	AUX
eurjchem-2641	127	16	analyzed	analyze	VERB
eurjchem-2641	127	17	using	use	VERB
eurjchem-2641	127	18	qrt	qrt	NOUN
eurjchem-2641	127	19	-	-	PUNCT
eurjchem-2641	127	20	pcr	pcr	NOUN
eurjchem-2641	127	21	.	.	PUNCT
eurjchem-2641	128	1	firstly	firstly	ADV
eurjchem-2641	128	2	,	,	PUNCT
eurjchem-2641	128	3	the	the	DET
eurjchem-2641	128	4	total	total	ADJ
eurjchem-2641	128	5	rna	rna	NOUN
eurjchem-2641	128	6	was	be	AUX
eurjchem-2641	128	7	extracted	extract	VERB
eurjchem-2641	128	8	from	from	ADP
eurjchem-2641	128	9	the	the	DET
eurjchem-2641	128	10	serum	serum	NOUN
eurjchem-2641	128	11	of	of	ADP
eurjchem-2641	128	12	all	all	DET
eurjchem-2641	128	13	samples	sample	NOUN
eurjchem-2641	128	14	[	[	X
eurjchem-2641	128	15	29	29	NUM
eurjchem-2641	128	16	]	]	PUNCT
eurjchem-2641	128	17	.	.	PUNCT
eurjchem-2641	129	1	the	the	DET
eurjchem-2641	129	2	samples	sample	NOUN
eurjchem-2641	129	3	were	be	AUX
eurjchem-2641	129	4	processed	process	VERB
eurjchem-2641	129	5	using	use	VERB
eurjchem-2641	129	6	mirna	mirna	NOUN
eurjchem-2641	129	7	extraction	extraction	NOUN
eurjchem-2641	129	8	kit	kit	NOUN
eurjchem-2641	129	9	#	#	NOUN
eurjchem-2641	129	10	217004	217004	NUM
eurjchem-2641	129	11	(	(	PUNCT
eurjchem-2641	129	12	qiagen	qiagen	PROPN
eurjchem-2641	129	13	,	,	PUNCT
eurjchem-2641	129	14	germany	germany	PROPN
eurjchem-2641	129	15	)	)	PUNCT
eurjchem-2641	129	16	according	accord	VERB
eurjchem-2641	129	17	to	to	ADP
eurjchem-2641	129	18	the	the	DET
eurjchem-2641	129	19	manufacturer	manufacturer	NOUN
eurjchem-2641	129	20	's	's	PART
eurjchem-2641	129	21	protocol	protocol	NOUN
eurjchem-2641	129	22	.	.	PUNCT
eurjchem-2641	130	1	the	the	DET
eurjchem-2641	130	2	extracted	extract	VERB
eurjchem-2641	130	3	rna	rna	NOUN
eurjchem-2641	130	4	concentration	concentration	NOUN
eurjchem-2641	130	5	and	and	CCONJ
eurjchem-2641	130	6	purity	purity	NOUN
eurjchem-2641	130	7	were	be	AUX
eurjchem-2641	130	8	evaluated	evaluate	VERB
eurjchem-2641	130	9	using	use	VERB
eurjchem-2641	130	10	a	a	DET
eurjchem-2641	130	11	nanodrop	nanodrop	NOUN
eurjchem-2641	130	12	2000	2000	NUM
eurjchem-2641	130	13	spectrophotometer	spectrophotometer	NOUN
eurjchem-2641	130	14	(	(	PUNCT
eurjchem-2641	130	15	thermo	thermo	NOUN
eurjchem-2641	130	16	fisher	fisher	PROPN
eurjchem-2641	130	17	scientific	scientific	PROPN
eurjchem-2641	130	18	,	,	PUNCT
eurjchem-2641	130	19	wilmington	wilmington	PROPN
eurjchem-2641	130	20	,	,	PUNCT
eurjchem-2641	130	21	usa	usa	PROPN
eurjchem-2641	130	22	)	)	PUNCT
eurjchem-2641	130	23	by	by	ADP
eurjchem-2641	130	24	measuring	measure	VERB
eurjchem-2641	130	25	the	the	DET
eurjchem-2641	130	26	absorbent	absorbent	ADJ
eurjchem-2641	130	27	wavelengths	wavelength	NOUN
eurjchem-2641	130	28	from	from	ADP
eurjchem-2641	130	29	260	260	NUM
eurjchem-2641	130	30	to	to	PART
eurjchem-2641	130	31	280	280	NUM
eurjchem-2641	130	32	nm	nm	NOUN
eurjchem-2641	130	33	.	.	PUNCT
eurjchem-2641	131	1	the	the	DET
eurjchem-2641	131	2	concentration	concentration	NOUN
eurjchem-2641	131	3	of	of	ADP
eurjchem-2641	131	4	isolated	isolated	ADJ
eurjchem-2641	131	5	rna	rna	NOUN
eurjchem-2641	131	6	was	be	AUX
eurjchem-2641	131	7	expressed	express	VERB
eurjchem-2641	131	8	as	as	ADP
eurjchem-2641	131	9	µg	µg	NOUN
eurjchem-2641	131	10	/	/	SYM
eurjchem-2641	131	11	m.	m.	NOUN
eurjchem-2641	131	12	an	an	DET
eurjchem-2641	131	13	aliquot	aliquot	NOUN
eurjchem-2641	131	14	of	of	ADP
eurjchem-2641	131	15	extracted	extract	VERB
eurjchem-2641	131	16	total	total	ADJ
eurjchem-2641	131	17	rna	rna	NOUN
eurjchem-2641	131	18	(	(	PUNCT
eurjchem-2641	131	19	1	1	NUM
eurjchem-2641	131	20	µg	µg	NOUN
eurjchem-2641	131	21	of	of	ADP
eurjchem-2641	131	22	rna	rna	NOUN
eurjchem-2641	131	23	)	)	PUNCT
eurjchem-2641	131	24	was	be	AUX
eurjchem-2641	131	25	reverse	reverse	ADJ
eurjchem-2641	131	26	transscribed	transscribe	VERB
eurjchem-2641	131	27	into	into	ADP
eurjchem-2641	131	28	cdna	cdna	PROPN
eurjchem-2641	131	29	using	use	VERB
eurjchem-2641	131	30	the	the	DET
eurjchem-2641	131	31	rt	rt	PROPN
eurjchem-2641	131	32	/	/	SYM
eurjchem-2641	131	33	pcr	pcr	NOUN
eurjchem-2641	131	34	premix	premix	NOUN
eurjchem-2641	131	35	kit	kit	NOUN
eurjchem-2641	131	36	#	#	NOUN
eurjchem-2641	131	37	122020	122020	NUM
eurjchem-2641	131	38	-	-	SYM
eurjchem-2641	131	39	96	96	NUM
eurjchem-2641	131	40	.	.	PUNCT
eurjchem-2641	132	1	the	the	DET
eurjchem-2641	132	2	expression	expression	NOUN
eurjchem-2641	132	3	of	of	ADP
eurjchem-2641	132	4	the	the	DET
eurjchem-2641	132	5	mirna-148b	mirna-148b	PROPN
eurjchem-2641	132	6	,	,	PUNCT
eurjchem-2641	132	7	caspase-3	caspase-3	NUM
eurjchem-2641	132	8	,	,	PUNCT
eurjchem-2641	132	9	bcl2	bcl2	NOUN
eurjchem-2641	132	10	and	and	CCONJ
eurjchem-2641	132	11	bax	bax	PROPN
eurjchem-2641	132	12	genes	gene	NOUN
eurjchem-2641	132	13	was	be	AUX
eurjchem-2641	132	14	analyzed	analyze	VERB
eurjchem-2641	132	15	using	use	VERB
eurjchem-2641	132	16	qrt	qrt	NOUN
eurjchem-2641	132	17	-	-	PUNCT
eurjchem-2641	132	18	pcr	pcr	ADJ
eurjchem-2641	132	19	,	,	PUNCT
eurjchem-2641	132	20	sybr	sybr	ADP
eurjchem-2641	132	21	green	green	ADJ
eurjchem-2641	132	22	and	and	CCONJ
eurjchem-2641	132	23	master	master	NOUN
eurjchem-2641	132	24	mix	mix	NOUN
eurjchem-2641	132	25	(	(	PUNCT
eurjchem-2641	132	26	thermo	thermo	NOUN
eurjchem-2641	132	27	fisher	fisher	PROPN
eurjchem-2641	132	28	,	,	PUNCT
eurjchem-2641	132	29	scientific	scientific	PROPN
eurjchem-2641	132	30	,	,	PUNCT
eurjchem-2641	132	31	inc	inc	PROPN
eurjchem-2641	132	32	.	.	PROPN
eurjchem-2641	132	33	,	,	PUNCT
eurjchem-2641	132	34	waltham	waltham	PROPN
eurjchem-2641	132	35	,	,	PUNCT
eurjchem-2641	132	36	ma	ma	PROPN
eurjchem-2641	132	37	)	)	PUNCT
eurjchem-2641	132	38	.	.	PUNCT
eurjchem-2641	133	1	expression	expression	NOUN
eurjchem-2641	133	2	cycles	cycle	NOUN
eurjchem-2641	133	3	proceed	proceed	VERB
eurjchem-2641	133	4	as	as	SCONJ
eurjchem-2641	133	5	follows	follow	VERB
eurjchem-2641	133	6	:	:	PUNCT
eurjchem-2641	133	7	activation	activation	NOUN
eurjchem-2641	133	8	step	step	NOUN
eurjchem-2641	133	9	at	at	ADP
eurjchem-2641	133	10	95	95	NUM
eurjchem-2641	133	11	°	°	ADP
eurjchem-2641	133	12	c	c	NOUN
eurjchem-2641	133	13	for	for	ADP
eurjchem-2641	133	14	10	10	NUM
eurjchem-2641	133	15	minutes	minute	NOUN
eurjchem-2641	133	16	;	;	PUNCT
eurjchem-2641	133	17	denaturation	denaturation	NOUN
eurjchem-2641	133	18	at	at	ADP
eurjchem-2641	133	19	95	95	NUM
eurjchem-2641	133	20	°	°	ADP
eurjchem-2641	133	21	c	c	NOUN
eurjchem-2641	133	22	for	for	ADP
eurjchem-2641	133	23	15	15	NUM
eurjchem-2641	133	24	seconds	second	NOUN
eurjchem-2641	133	25	repeated	repeat	VERB
eurjchem-2641	133	26	for	for	ADP
eurjchem-2641	133	27	40	40	NUM
eurjchem-2641	133	28	cycles	cycle	NOUN
eurjchem-2641	133	29	;	;	PUNCT
eurjchem-2641	133	30	annealing	anneal	VERB
eurjchem-2641	133	31	at	at	ADP
eurjchem-2641	133	32	56	56	NUM
eurjchem-2641	133	33	°	°	NOUN
eurjchem-2641	133	34	c	c	NOUN
eurjchem-2641	133	35	for	for	ADP
eurjchem-2641	133	36	15	15	NUM
eurjchem-2641	133	37	seconds	second	NOUN
eurjchem-2641	133	38	;	;	PUNCT
eurjchem-2641	133	39	extension	extension	NOUN
eurjchem-2641	133	40	at	at	ADP
eurjchem-2641	133	41	72	72	NUM
eurjchem-2641	133	42	°	°	ADP
eurjchem-2641	133	43	c	c	NOUN
eurjchem-2641	133	44	for	for	ADP
eurjchem-2641	133	45	30	30	NUM
eurjchem-2641	133	46	seconds	second	NOUN
eurjchem-2641	133	47	;	;	PUNCT
eurjchem-2641	133	48	and	and	CCONJ
eurjchem-2641	133	49	final	final	ADJ
eurjchem-2641	133	50	extension	extension	NOUN
eurjchem-2641	133	51	at	at	ADP
eurjchem-2641	133	52	72	72	NUM
eurjchem-2641	133	53	°	°	ADP
eurjchem-2641	133	54	c	c	NOUN
eurjchem-2641	133	55	for	for	ADP
eurjchem-2641	133	56	10	10	NUM
eurjchem-2641	133	57	minutes	minute	NOUN
eurjchem-2641	133	58	.	.	PUNCT
eurjchem-2641	134	1	the	the	DET
eurjchem-2641	134	2	experiments	experiment	NOUN
eurjchem-2641	134	3	were	be	AUX
eurjchem-2641	134	4	repeated	repeat	VERB
eurjchem-2641	134	5	three	three	NUM
eurjchem-2641	134	6	times	time	NOUN
eurjchem-2641	134	7	(	(	PUNCT
eurjchem-2641	134	8	triplet	triplet	NOUN
eurjchem-2641	134	9	)	)	PUNCT
eurjchem-2641	134	10	.	.	PUNCT
eurjchem-2641	135	1	the	the	DET
eurjchem-2641	135	2	relative	relative	ADJ
eurjchem-2641	135	3	expressions	expression	NOUN
eurjchem-2641	135	4	of	of	ADP
eurjchem-2641	135	5	mirna-148b	mirna-148b	PROPN
eurjchem-2641	135	6	,	,	PUNCT
eurjchem-2641	135	7	caspase-3	caspase-3	NUM
eurjchem-2641	135	8	,	,	PUNCT
eurjchem-2641	135	9	bcl2	bcl2	NOUN
eurjchem-2641	135	10	and	and	CCONJ
eurjchem-2641	135	11	bax	bax	PROPN
eurjchem-2641	135	12	were	be	AUX
eurjchem-2641	135	13	presented	present	VERB
eurjchem-2641	135	14	as	as	ADP
eurjchem-2641	135	15	fold	fold	ADJ
eurjchem-2641	135	16	changes	change	NOUN
eurjchem-2641	135	17	relative	relative	ADJ
eurjchem-2641	135	18	to	to	ADP
eurjchem-2641	135	19	u6	u6	NOUN
eurjchem-2641	135	20	,	,	PUNCT
eurjchem-2641	135	21	and	and	CCONJ
eurjchem-2641	135	22	the	the	DET
eurjchem-2641	135	23	results	result	NOUN
eurjchem-2641	135	24	were	be	AUX
eurjchem-2641	135	25	calculated	calculate	VERB
eurjchem-2641	135	26	using	use	VERB
eurjchem-2641	135	27	the	the	DET
eurjchem-2641	135	28	2−δδct	2−δδct	NUM
eurjchem-2641	135	29	method	method	NOUN
eurjchem-2641	136	1	[	[	X
eurjchem-2641	136	2	30,31	30,31	NOUN
eurjchem-2641	136	3	]	]	PUNCT
eurjchem-2641	136	4	.	.	PUNCT
eurjchem-2641	137	1	table	table	NOUN
eurjchem-2641	137	2	1	1	NUM
eurjchem-2641	137	3	displays	display	VERB
eurjchem-2641	137	4	the	the	DET
eurjchem-2641	137	5	primer	primer	NOUN
eurjchem-2641	137	6	sequence	sequence	NOUN
eurjchem-2641	137	7	of	of	ADP
eurjchem-2641	137	8	mirna-148b	mirna-148b	PROPN
eurjchem-2641	137	9	,	,	PUNCT
eurjchem-2641	137	10	casp-3	casp-3	NUM
eurjchem-2641	137	11	,	,	PUNCT
eurjchem-2641	137	12	bcl2	bcl2	PROPN
eurjchem-2641	137	13	,	,	PUNCT
eurjchem-2641	137	14	bax	bax	PROPN
eurjchem-2641	137	15	,	,	PUNCT
eurjchem-2641	137	16	and	and	CCONJ
eurjchem-2641	137	17	u6	u6	NOUN
eurjchem-2641	137	18	.	.	PUNCT
eurjchem-2641	138	1	2.5	2.5	NUM
eurjchem-2641	138	2	.	.	PUNCT
eurjchem-2641	139	1	assessment	assessment	NOUN
eurjchem-2641	139	2	of	of	ADP
eurjchem-2641	139	3	caspase-3	caspase-3	NUM
eurjchem-2641	139	4	caspase-3	caspase-3	NUM
eurjchem-2641	139	5	activity	activity	NOUN
eurjchem-2641	139	6	was	be	AUX
eurjchem-2641	139	7	evaluated	evaluate	VERB
eurjchem-2641	139	8	using	use	VERB
eurjchem-2641	139	9	the	the	DET
eurjchem-2641	139	10	elisa	elisa	NOUN
eurjchem-2641	139	11	kit	kit	NOUN
eurjchem-2641	139	12	#	#	NOUN
eurjchem-2641	139	13	e	e	NOUN
eurjchem-2641	139	14	-	-	NOUN
eurjchem-2641	139	15	elh0017	elh0017	ADJ
eurjchem-2641	139	16	(	(	PUNCT
eurjchem-2641	139	17	elabscience	elabscience	NOUN
eurjchem-2641	139	18	biotechnology	biotechnology	NOUN
eurjchem-2641	139	19	company	company	NOUN
eurjchem-2641	139	20	,	,	PUNCT
eurjchem-2641	139	21	usa	usa	PROPN
eurjchem-2641	139	22	)	)	PUNCT
eurjchem-2641	139	23	.	.	PUNCT
eurjchem-2641	140	1	briefly	briefly	NOUN
eurjchem-2641	140	2	,	,	PUNCT
eurjchem-2641	140	3	100	100	NUM
eurjchem-2641	140	4	μl	μl	ADP
eurjchem-2641	140	5	of	of	ADP
eurjchem-2641	140	6	standard	standard	NOUN
eurjchem-2641	140	7	,	,	PUNCT
eurjchem-2641	140	8	blank	blank	ADJ
eurjchem-2641	140	9	and	and	CCONJ
eurjchem-2641	140	10	sample	sample	NOUN
eurjchem-2641	140	11	was	be	AUX
eurjchem-2641	140	12	added	add	VERB
eurjchem-2641	140	13	and	and	CCONJ
eurjchem-2641	140	14	incubated	incubate	VERB
eurjchem-2641	140	15	for	for	ADP
eurjchem-2641	140	16	90	90	NUM
eurjchem-2641	140	17	minutes	minute	NOUN
eurjchem-2641	140	18	at	at	ADP
eurjchem-2641	140	19	37	37	NUM
eurjchem-2641	140	20	°	°	NOUN
eurjchem-2641	140	21	c	c	NOUN
eurjchem-2641	140	22	.	.	PUNCT
eurjchem-2641	141	1	then	then	ADV
eurjchem-2641	141	2	100	100	NUM
eurjchem-2641	141	3	μl	μl	ADP
eurjchem-2641	141	4	of	of	ADP
eurjchem-2641	141	5	biotinylated	biotinylated	ADJ
eurjchem-2641	141	6	detection	detection	NOUN
eurjchem-2641	141	7	ab	ab	PROPN
eurjchem-2641	141	8	working	working	NOUN
eurjchem-2641	141	9	solution	solution	NOUN
eurjchem-2641	141	10	was	be	AUX
eurjchem-2641	141	11	added	add	VERB
eurjchem-2641	141	12	and	and	CCONJ
eurjchem-2641	141	13	incubated	incubate	VERB
eurjchem-2641	141	14	for	for	ADP
eurjchem-2641	141	15	10	10	NUM
eurjchem-2641	141	16	minutes	minute	NOUN
eurjchem-2641	141	17	at	at	ADP
eurjchem-2641	141	18	37	37	NUM
eurjchem-2641	141	19	°	°	NOUN
eurjchem-2641	141	20	c	c	NOUN
eurjchem-2641	141	21	.	.	PUNCT
eurjchem-2641	142	1	then	then	ADV
eurjchem-2641	142	2	350	350	NUM
eurjchem-2641	142	3	μl	μl	ADP
eurjchem-2641	142	4	of	of	ADP
eurjchem-2641	142	5	wash	wash	NOUN
eurjchem-2641	142	6	buffer	buffer	NOUN
eurjchem-2641	142	7	was	be	AUX
eurjchem-2641	142	8	added	add	VERB
eurjchem-2641	142	9	to	to	ADP
eurjchem-2641	142	10	each	each	PRON
eurjchem-2641	142	11	well	well	ADV
eurjchem-2641	142	12	,	,	PUNCT
eurjchem-2641	142	13	soaked	soak	VERB
eurjchem-2641	142	14	for	for	ADP
eurjchem-2641	142	15	1	1	NUM
eurjchem-2641	142	16	minute	minute	NOUN
eurjchem-2641	142	17	,	,	PUNCT
eurjchem-2641	142	18	and	and	CCONJ
eurjchem-2641	142	19	the	the	DET
eurjchem-2641	142	20	solution	solution	NOUN
eurjchem-2641	142	21	was	be	AUX
eurjchem-2641	142	22	aspirated	aspirate	VERB
eurjchem-2641	142	23	from	from	ADP
eurjchem-2641	142	24	each	each	DET
eurjchem-2641	142	25	well	well	NOUN
eurjchem-2641	142	26	.	.	PUNCT
eurjchem-2641	143	1	after	after	ADP
eurjchem-2641	143	2	that	that	PRON
eurjchem-2641	143	3	,	,	PUNCT
eurjchem-2641	143	4	100	100	NUM
eurjchem-2641	143	5	μl	μl	NUM
eurjchem-2641	143	6	of	of	ADP
eurjchem-2641	143	7	hrp	hrp	PROPN
eurjchem-2641	143	8	conjugate	conjugate	ADJ
eurjchem-2641	143	9	working	working	NOUN
eurjchem-2641	143	10	solution	solution	NOUN
eurjchem-2641	143	11	was	be	AUX
eurjchem-2641	143	12	added	add	VERB
eurjchem-2641	143	13	and	and	CCONJ
eurjchem-2641	143	14	incubated	incubate	VERB
eurjchem-2641	143	15	for	for	ADP
eurjchem-2641	143	16	30	30	NUM
eurjchem-2641	143	17	minutes	minute	NOUN
eurjchem-2641	143	18	at	at	ADP
eurjchem-2641	143	19	37	37	NUM
eurjchem-2641	143	20	°	°	NOUN
eurjchem-2641	143	21	c	c	NOUN
eurjchem-2641	143	22	.	.	PUNCT
eurjchem-2641	144	1	substrate	substrate	NOUN
eurjchem-2641	144	2	reagent	reagent	NOUN
eurjchem-2641	144	3	(	(	PUNCT
eurjchem-2641	144	4	90	90	NUM
eurjchem-2641	144	5	μl	μl	PRON
eurjchem-2641	144	6	)	)	PUNCT
eurjchem-2641	144	7	was	be	AUX
eurjchem-2641	144	8	added	add	VERB
eurjchem-2641	144	9	and	and	CCONJ
eurjchem-2641	144	10	incubated	incubate	VERB
eurjchem-2641	144	11	for	for	ADP
eurjchem-2641	144	12	15	15	NUM
eurjchem-2641	144	13	minutes	minute	NOUN
eurjchem-2641	144	14	at	at	ADP
eurjchem-2641	144	15	37	37	NUM
eurjchem-2641	144	16	°	°	NOUN
eurjchem-2641	144	17	c	c	NOUN
eurjchem-2641	144	18	.	.	PUNCT
eurjchem-2641	145	1	a	a	DET
eurjchem-2641	145	2	50	50	NUM
eurjchem-2641	145	3	μl	μl	PRON
eurjchem-2641	145	4	stop	stop	NOUN
eurjchem-2641	145	5	solution	solution	NOUN
eurjchem-2641	145	6	was	be	AUX
eurjchem-2641	145	7	added	add	VERB
eurjchem-2641	145	8	and	and	CCONJ
eurjchem-2641	145	9	the	the	DET
eurjchem-2641	145	10	optical	optical	ADJ
eurjchem-2641	145	11	density	density	NOUN
eurjchem-2641	145	12	was	be	AUX
eurjchem-2641	145	13	measured	measure	VERB
eurjchem-2641	145	14	using	use	VERB
eurjchem-2641	145	15	a	a	DET
eurjchem-2641	145	16	microplate	microplate	NOUN
eurjchem-2641	145	17	reader	reader	NOUN
eurjchem-2641	145	18	at	at	ADP
eurjchem-2641	145	19	450	450	NUM
eurjchem-2641	145	20	nm	nm	NOUN
eurjchem-2641	145	21	.	.	PUNCT
eurjchem-2641	146	1	caspase-3	caspase-3	NUM
eurjchem-2641	146	2	concentration	concentration	NOUN
eurjchem-2641	146	3	was	be	AUX
eurjchem-2641	146	4	calculated	calculate	VERB
eurjchem-2641	146	5	using	use	VERB
eurjchem-2641	146	6	the	the	DET
eurjchem-2641	146	7	standard	standard	ADJ
eurjchem-2641	146	8	curve	curve	NOUN
eurjchem-2641	146	9	.	.	PUNCT
eurjchem-2641	147	1	2.6	2.6	NUM
eurjchem-2641	147	2	.	.	PUNCT
eurjchem-2641	147	3	assessment	assessment	NOUN
eurjchem-2641	147	4	of	of	ADP
eurjchem-2641	147	5	bcl-2	bcl-2	PUNCT
eurjchem-2641	147	6	the	the	DET
eurjchem-2641	147	7	bcl-2	bcl-2	NUM
eurjchem-2641	147	8	elisa	elisa	NOUN
eurjchem-2641	147	9	kit	kit	NOUN
eurjchem-2641	147	10	#	#	PROPN
eurjchem-2641	147	11	cs0520	cs0520	PROPN
eurjchem-2641	147	12	was	be	AUX
eurjchem-2641	147	13	used	use	VERB
eurjchem-2641	147	14	to	to	PART
eurjchem-2641	147	15	determine	determine	VERB
eurjchem-2641	147	16	serum	serum	NOUN
eurjchem-2641	147	17	bcl-2	bcl-2	NOUN
eurjchem-2641	147	18	levels	level	NOUN
eurjchem-2641	147	19	.	.	PUNCT
eurjchem-2641	148	1	standard	standard	ADJ
eurjchem-2641	148	2	diluent	diluent	NOUN
eurjchem-2641	148	3	standards	standard	NOUN
eurjchem-2641	148	4	samples	sample	NOUN
eurjchem-2641	148	5	(	(	PUNCT
eurjchem-2641	148	6	100	100	NUM
eurjchem-2641	148	7	μl	μl	PRON
eurjchem-2641	148	8	)	)	PUNCT
eurjchem-2641	148	9	were	be	AUX
eurjchem-2641	148	10	added	add	VERB
eurjchem-2641	148	11	to	to	ADP
eurjchem-2641	148	12	the	the	DET
eurjchem-2641	148	13	appropriate	appropriate	ADJ
eurjchem-2641	148	14	wells	well	NOUN
eurjchem-2641	148	15	,	,	PUNCT
eurjchem-2641	148	16	and	and	CCONJ
eurjchem-2641	148	17	100	100	NUM
eurjchem-2641	148	18	μl	μl	ADP
eurjchem-2641	148	19	of	of	ADP
eurjchem-2641	148	20	anti	anti	ADJ
eurjchem-2641	148	21	-	-	ADJ
eurjchem-2641	148	22	bcl-2	bcl-2	ADJ
eurjchem-2641	148	23	detection	detection	NOUN
eurjchem-2641	148	24	antibodies	antibody	NOUN
eurjchem-2641	148	25	were	be	AUX
eurjchem-2641	148	26	added	add	VERB
eurjchem-2641	148	27	and	and	CCONJ
eurjchem-2641	148	28	incubated	incubate	VERB
eurjchem-2641	148	29	for	for	ADP
eurjchem-2641	148	30	1	1	NUM
eurjchem-2641	148	31	hour	hour	NOUN
eurjchem-2641	148	32	at	at	ADP
eurjchem-2641	148	33	room	room	NOUN
eurjchem-2641	148	34	temperature	temperature	NOUN
eurjchem-2641	148	35	.	.	PUNCT
eurjchem-2641	149	1	firstly	firstly	ADV
eurjchem-2641	149	2	,	,	PUNCT
eurjchem-2641	149	3	100	100	NUM
eurjchem-2641	149	4	μl	μl	NUM
eurjchem-2641	149	5	of	of	ADP
eurjchem-2641	149	6	anti	anti	ADJ
eurjchem-2641	149	7	-	-	ADJ
eurjchem-2641	149	8	rabbit	rabbit	ADJ
eurjchem-2641	149	9	igg	igg	PROPN
eurjchem-2641	149	10	-	-	PUNCT
eurjchem-2641	149	11	hrp	hrp	PROPN
eurjchem-2641	149	12	working	working	NOUN
eurjchem-2641	149	13	solution	solution	NOUN
eurjchem-2641	149	14	was	be	AUX
eurjchem-2641	149	15	incubated	incubate	VERB
eurjchem-2641	149	16	for	for	ADP
eurjchem-2641	149	17	30	30	NUM
eurjchem-2641	149	18	minutes	minute	NOUN
eurjchem-2641	149	19	at	at	ADP
eurjchem-2641	149	20	room	room	NOUN
eurjchem-2641	149	21	temperature	temperature	NOUN
eurjchem-2641	149	22	.	.	PUNCT
eurjchem-2641	150	1	100	100	NUM
eurjchem-2641	150	2	μl	μl	ADP
eurjchem-2641	150	3	of	of	ADP
eurjchem-2641	150	4	stabilized	stabilized	ADJ
eurjchem-2641	150	5	coloring	coloring	NOUN
eurjchem-2641	150	6	agents	agent	NOUN
eurjchem-2641	150	7	were	be	AUX
eurjchem-2641	150	8	then	then	ADV
eurjchem-2641	150	9	added	add	VERB
eurjchem-2641	150	10	and	and	CCONJ
eurjchem-2641	150	11	incubated	incubate	VERB
eurjchem-2641	150	12	for	for	ADP
eurjchem-2641	150	13	30	30	NUM
eurjchem-2641	150	14	minutes	minute	NOUN
eurjchem-2641	150	15	at	at	ADP
eurjchem-2641	150	16	room	room	NOUN
eurjchem-2641	150	17	temperature	temperature	NOUN
eurjchem-2641	150	18	.	.	PUNCT
eurjchem-2641	151	1	finally	finally	ADV
eurjchem-2641	151	2	,	,	PUNCT
eurjchem-2641	151	3	100	100	NUM
eurjchem-2641	151	4	μl	μl	ADP
eurjchem-2641	151	5	of	of	ADP
eurjchem-2641	151	6	the	the	DET
eurjchem-2641	151	7	stop	stop	NOUN
eurjchem-2641	151	8	solution	solution	NOUN
eurjchem-2641	151	9	was	be	AUX
eurjchem-2641	151	10	added	add	VERB
eurjchem-2641	151	11	and	and	CCONJ
eurjchem-2641	151	12	mixed	mixed	ADJ
eurjchem-2641	151	13	well	well	ADV
eurjchem-2641	151	14	.	.	PUNCT
eurjchem-2641	152	1	the	the	DET
eurjchem-2641	152	2	optical	optical	ADJ
eurjchem-2641	152	3	density	density	NOUN
eurjchem-2641	152	4	was	be	AUX
eurjchem-2641	152	5	recorded	record	VERB
eurjchem-2641	152	6	at	at	ADP
eurjchem-2641	152	7	450	450	NUM
eurjchem-2641	152	8	nm	nm	NOUN
eurjchem-2641	152	9	.	.	PUNCT
eurjchem-2641	153	1	bcl-2	bcl-2	VERB
eurjchem-2641	153	2	concentrations	concentration	NOUN
eurjchem-2641	153	3	were	be	AUX
eurjchem-2641	153	4	determined	determine	VERB
eurjchem-2641	153	5	by	by	ADP
eurjchem-2641	153	6	interpolation	interpolation	NOUN
eurjchem-2641	153	7	from	from	ADP
eurjchem-2641	153	8	the	the	DET
eurjchem-2641	153	9	standard	standard	ADJ
eurjchem-2641	153	10	curve	curve	NOUN
eurjchem-2641	153	11	.	.	PUNCT
eurjchem-2641	154	1	harisa	harisa	NOUN
eurjchem-2641	154	2	et	et	PROPN
eurjchem-2641	154	3	al	al	PROPN
eurjchem-2641	154	4	.	.	PUNCT
eurjchem-2641	154	5	/	/	SYM
eurjchem-2641	154	6	european	european	PROPN
eurjchem-2641	154	7	journal	journal	PROPN
eurjchem-2641	154	8	of	of	ADP
eurjchem-2641	154	9	chemistry	chemistry	NOUN
eurjchem-2641	154	10	16	16	NUM
eurjchem-2641	154	11	(	(	PUNCT
eurjchem-2641	154	12	2	2	NUM
eurjchem-2641	154	13	)	)	PUNCT
eurjchem-2641	154	14	(	(	PUNCT
eurjchem-2641	154	15	2025	2025	NUM
eurjchem-2641	154	16	)	)	PUNCT
eurjchem-2641	154	17	222	222	NUM
eurjchem-2641	154	18	-	-	SYM
eurjchem-2641	154	19	232	232	NUM
eurjchem-2641	154	20	225	225	NUM
eurjchem-2641	154	21	2025	2025	NUM
eurjchem-2641	154	22	–	–	PUNCT
eurjchem-2641	154	23	european	european	ADJ
eurjchem-2641	154	24	journal	journal	NOUN
eurjchem-2641	154	25	of	of	ADP
eurjchem-2641	154	26	chemistry	chemistry	NOUN
eurjchem-2641	154	27	–	–	PUNCT
eurjchem-2641	154	28	cc	cc	NOUN
eurjchem-2641	154	29	by	by	ADP
eurjchem-2641	154	30	nc	nc	PROPN
eurjchem-2641	154	31	–	–	PUNCT
eurjchem-2641	154	32	doi	doi	NOUN
eurjchem-2641	154	33	:	:	PUNCT
eurjchem-2641	154	34	10.5155	10.5155	NUM
eurjchem-2641	154	35	/	/	SYM
eurjchem-2641	154	36	eurjchem.16.2.222	eurjchem.16.2.222	NUM
eurjchem-2641	154	37	-	-	SYM
eurjchem-2641	154	38	232.2641	232.2641	NUM
eurjchem-2641	154	39	table	table	NOUN
eurjchem-2641	154	40	2	2	NUM
eurjchem-2641	154	41	.	.	PUNCT
eurjchem-2641	155	1	clinical	clinical	ADJ
eurjchem-2641	155	2	data	datum	NOUN
eurjchem-2641	155	3	on	on	ADP
eurjchem-2641	155	4	age	age	NOUN
eurjchem-2641	155	5	,	,	PUNCT
eurjchem-2641	155	6	tumor	tumor	NOUN
eurjchem-2641	155	7	size	size	NOUN
eurjchem-2641	155	8	,	,	PUNCT
eurjchem-2641	155	9	history	history	NOUN
eurjchem-2641	155	10	of	of	ADP
eurjchem-2641	155	11	bc	bc	PROPN
eurjchem-2641	155	12	,	,	PUNCT
eurjchem-2641	155	13	systolic	systolic	ADJ
eurjchem-2641	155	14	blood	blood	NOUN
eurjchem-2641	155	15	pressure	pressure	NOUN
eurjchem-2641	155	16	,	,	PUNCT
eurjchem-2641	155	17	fbg	fbg	NOUN
eurjchem-2641	155	18	,	,	PUNCT
eurjchem-2641	155	19	and	and	CCONJ
eurjchem-2641	155	20	ppg	ppg	NOUN
eurjchem-2641	155	21	of	of	ADP
eurjchem-2641	155	22	the	the	DET
eurjchem-2641	155	23	subjects	subject	NOUN
eurjchem-2641	155	24	studied	study	VERB
eurjchem-2641	155	25	*	*	PUNCT
eurjchem-2641	155	26	.	.	PUNCT
eurjchem-2641	156	1	parameters	parameter	NOUN
eurjchem-2641	156	2	control	control	VERB
eurjchem-2641	156	3	early	early	ADJ
eurjchem-2641	156	4	-	-	PUNCT
eurjchem-2641	156	5	stage	stage	NOUN
eurjchem-2641	156	6	chemotherapy	chemotherapy	NOUN
eurjchem-2641	156	7	surgery	surgery	NOUN
eurjchem-2641	156	8	age	age	NOUN
eurjchem-2641	156	9	47.88±5.42	47.88±5.42	NUM
eurjchem-2641	157	1	48.24±7.46	48.24±7.46	NUM
eurjchem-2641	157	2	48.70±3.72	48.70±3.72	NOUN
eurjchem-2641	157	3	49.40±6.07	49.40±6.07	PROPN
eurjchem-2641	157	4	tumor	tumor	NOUN
eurjchem-2641	157	5	size	size	NOUN
eurjchem-2641	157	6	(	(	PUNCT
eurjchem-2641	157	7	cm2	cm2	NOUN
eurjchem-2641	157	8	)	)	PUNCT
eurjchem-2641	157	9	1.826±0.89	1.826±0.89	NUM
eurjchem-2641	157	10	1.520±0.51	1.520±0.51	NOUN
eurjchem-2641	157	11	15.54±4.01	15.54±4.01	NUM
eurjchem-2641	157	12	history	history	NOUN
eurjchem-2641	157	13	of	of	ADP
eurjchem-2641	157	14	bc	bc	PROPN
eurjchem-2641	158	1	no	no	INTJ
eurjchem-2641	158	2	no	no	INTJ
eurjchem-2641	158	3	no	no	INTJ
eurjchem-2641	158	4	no	no	DET
eurjchem-2641	158	5	hypertension	hypertension	NOUN
eurjchem-2641	158	6	117.30±8.32	117.30±8.32	NUM
eurjchem-2641	158	7	126.90±7.85	126.90±7.85	NUM
eurjchem-2641	158	8	109.50±6.14	109.50±6.14	NUM
eurjchem-2641	158	9	113.70±4.89	113.70±4.89	NUM
eurjchem-2641	158	10	fbg	fbg	PROPN
eurjchem-2641	159	1	91.16±6.74	91.16±6.74	NUM
eurjchem-2641	159	2	87.04±4.15	87.04±4.15	NUM
eurjchem-2641	159	3	93.77±4.41	93.77±4.41	NUM
eurjchem-2641	159	4	83.06±5.18	83.06±5.18	PROPN
eurjchem-2641	159	5	ppg	ppg	NOUN
eurjchem-2641	159	6	134.26±3.02	134.26±3.02	NUM
eurjchem-2641	159	7	137.63±5.19	137.63±5.19	NUM
eurjchem-2641	159	8	125.87±5.74	125.87±5.74	NUM
eurjchem-2641	159	9	114.86±4.19	114.86±4.19	NUM
eurjchem-2641	159	10	a	a	DET
eurjchem-2641	159	11	one	one	NUM
eurjchem-2641	159	12	-	-	PUNCT
eurjchem-2641	159	13	way	way	NOUN
eurjchem-2641	159	14	analysis	analysis	NOUN
eurjchem-2641	159	15	of	of	ADP
eurjchem-2641	159	16	variance	variance	NOUN
eurjchem-2641	159	17	(	(	PUNCT
eurjchem-2641	159	18	anova	anova	PROPN
eurjchem-2641	159	19	)	)	PUNCT
eurjchem-2641	159	20	followed	follow	VERB
eurjchem-2641	159	21	by	by	ADP
eurjchem-2641	159	22	tukey	tukey	PROPN
eurjchem-2641	159	23	post	post	X
eurjchem-2641	159	24	hoc	hoc	X
eurjchem-2641	159	25	test	test	NOUN
eurjchem-2641	159	26	was	be	AUX
eurjchem-2641	159	27	used	use	VERB
eurjchem-2641	159	28	in	in	ADP
eurjchem-2641	159	29	data	datum	NOUN
eurjchem-2641	159	30	analysis	analysis	NOUN
eurjchem-2641	159	31	.	.	PUNCT
eurjchem-2641	160	1	data	datum	NOUN
eurjchem-2641	160	2	were	be	AUX
eurjchem-2641	160	3	expressed	express	VERB
eurjchem-2641	160	4	as	as	ADP
eurjchem-2641	160	5	mean±sd	mean±sd	PROPN
eurjchem-2641	160	6	,	,	PUNCT
eurjchem-2641	160	7	n	n	NOUN
eurjchem-2641	160	8	=	=	SYM
eurjchem-2641	160	9	75	75	NUM
eurjchem-2641	160	10	.	.	PUNCT
eurjchem-2641	161	1	p≤0.05	p≤0.05	NOUN
eurjchem-2641	161	2	was	be	AUX
eurjchem-2641	161	3	used	use	VERB
eurjchem-2641	161	4	to	to	PART
eurjchem-2641	161	5	compare	compare	VERB
eurjchem-2641	161	6	the	the	DET
eurjchem-2641	161	7	significance	significance	NOUN
eurjchem-2641	161	8	between	between	ADP
eurjchem-2641	161	9	the	the	DET
eurjchem-2641	161	10	groups	group	NOUN
eurjchem-2641	161	11	studied	study	VERB
eurjchem-2641	161	12	.	.	PUNCT
eurjchem-2641	162	1	table	table	NOUN
eurjchem-2641	162	2	3	3	NUM
eurjchem-2641	162	3	.	.	PUNCT
eurjchem-2641	162	4	complete	complete	ADJ
eurjchem-2641	162	5	blood	blood	NOUN
eurjchem-2641	162	6	count	count	NOUN
eurjchem-2641	162	7	parameters	parameter	NOUN
eurjchem-2641	162	8	in	in	ADP
eurjchem-2641	162	9	terms	term	NOUN
eurjchem-2641	162	10	of	of	ADP
eurjchem-2641	162	11	hb	hb	NOUN
eurjchem-2641	162	12	level	level	NOUN
eurjchem-2641	162	13	and	and	CCONJ
eurjchem-2641	162	14	lymphocytes	lymphocyte	NOUN
eurjchem-2641	162	15	and	and	CCONJ
eurjchem-2641	162	16	platelet	platelet	NOUN
eurjchem-2641	162	17	numbers	number	NOUN
eurjchem-2641	162	18	of	of	ADP
eurjchem-2641	162	19	the	the	DET
eurjchem-2641	162	20	studied	study	VERB
eurjchem-2641	162	21	subjects	subject	NOUN
eurjchem-2641	162	22	*	*	PUNCT
eurjchem-2641	162	23	.	.	PUNCT
eurjchem-2641	163	1	parameters	parameter	NOUN
eurjchem-2641	163	2	control	control	VERB
eurjchem-2641	163	3	early	early	ADJ
eurjchem-2641	163	4	-	-	PUNCT
eurjchem-2641	163	5	stage	stage	NOUN
eurjchem-2641	163	6	chemotherapy	chemotherapy	NOUN
eurjchem-2641	163	7	surgery	surgery	NOUN
eurjchem-2641	163	8	hb	hb	X
eurjchem-2641	163	9	(	(	PUNCT
eurjchem-2641	163	10	g	g	PROPN
eurjchem-2641	163	11	/	/	SYM
eurjchem-2641	163	12	dl	dl	NOUN
eurjchem-2641	163	13	)	)	PUNCT
eurjchem-2641	163	14	12.67±0.68	12.67±0.68	NUM
eurjchem-2641	163	15	12.42±0.94	12.42±0.94	NUM
eurjchem-2641	163	16	11.07±1.18	11.07±1.18	PROPN
eurjchem-2641	163	17	11.64±1.03	11.64±1.03	NUM
eurjchem-2641	163	18	lymphocytes	lymphocyte	VERB
eurjchem-2641	163	19	29.47±4.35	29.47±4.35	PROPN
eurjchem-2641	163	20	56.30±6.24	56.30±6.24	NUM
eurjchem-2641	163	21	58.40±8.94	58.40±8.94	NUM
eurjchem-2641	163	22	50.48±5.81	50.48±5.81	NUM
eurjchem-2641	163	23	platelets	platelet	NOUN
eurjchem-2641	163	24	(	(	PUNCT
eurjchem-2641	163	25	103	103	NUM
eurjchem-2641	163	26	/	/	SYM
eurjchem-2641	163	27	cm2	cm2	NOUN
eurjchem-2641	163	28	)	)	PUNCT
eurjchem-2641	163	29	183.40±14.8	183.40±14.8	NUM
eurjchem-2641	163	30	130.30±8.69	130.30±8.69	NUM
eurjchem-2641	163	31	96.99±10.06	96.99±10.06	NUM
eurjchem-2641	163	32	118.00±8.10	118.00±8.10	NOUN
eurjchem-2641	163	33	*	*	SYM
eurjchem-2641	163	34	one	one	NUM
eurjchem-2641	163	35	-	-	PUNCT
eurjchem-2641	163	36	way	way	NOUN
eurjchem-2641	163	37	anova	anova	PROPN
eurjchem-2641	163	38	followed	follow	VERB
eurjchem-2641	163	39	by	by	ADP
eurjchem-2641	163	40	tukey	tukey	PROPN
eurjchem-2641	163	41	post	post	ADJ
eurjchem-2641	163	42	-	-	ADJ
eurjchem-2641	163	43	hoc	hoc	ADJ
eurjchem-2641	163	44	test	test	NOUN
eurjchem-2641	163	45	was	be	AUX
eurjchem-2641	163	46	used	use	VERB
eurjchem-2641	163	47	in	in	ADP
eurjchem-2641	163	48	data	datum	NOUN
eurjchem-2641	163	49	analysis	analysis	NOUN
eurjchem-2641	163	50	.	.	PUNCT
eurjchem-2641	164	1	data	datum	NOUN
eurjchem-2641	164	2	were	be	AUX
eurjchem-2641	164	3	expressed	express	VERB
eurjchem-2641	164	4	as	as	ADP
eurjchem-2641	164	5	mean±sd	mean±sd	PROPN
eurjchem-2641	164	6	,	,	PUNCT
eurjchem-2641	164	7	n	n	NOUN
eurjchem-2641	164	8	=	=	SYM
eurjchem-2641	164	9	75	75	NUM
eurjchem-2641	164	10	.	.	PUNCT
eurjchem-2641	165	1	p	p	ADJ
eurjchem-2641	165	2	≤0.05	≤0.05	NOUN
eurjchem-2641	165	3	was	be	AUX
eurjchem-2641	165	4	used	use	VERB
eurjchem-2641	165	5	to	to	PART
eurjchem-2641	165	6	compare	compare	VERB
eurjchem-2641	165	7	the	the	DET
eurjchem-2641	165	8	significance	significance	NOUN
eurjchem-2641	165	9	between	between	ADP
eurjchem-2641	165	10	the	the	DET
eurjchem-2641	165	11	studied	study	VERB
eurjchem-2641	165	12	groups	group	NOUN
eurjchem-2641	165	13	.	.	PUNCT
eurjchem-2641	166	1	table	table	NOUN
eurjchem-2641	166	2	4	4	NUM
eurjchem-2641	166	3	.	.	X
eurjchem-2641	167	1	summary	summary	NOUN
eurjchem-2641	167	2	and	and	CCONJ
eurjchem-2641	167	3	correlation	correlation	NOUN
eurjchem-2641	167	4	of	of	ADP
eurjchem-2641	167	5	the	the	DET
eurjchem-2641	167	6	cbc	cbc	NOUN
eurjchem-2641	167	7	parameters	parameter	NOUN
eurjchem-2641	167	8	,	,	PUNCT
eurjchem-2641	167	9	as	as	ADV
eurjchem-2641	167	10	well	well	ADV
eurjchem-2641	167	11	as	as	ADP
eurjchem-2641	167	12	mirna148b	mirna148b	PROPN
eurjchem-2641	167	13	,	,	PUNCT
eurjchem-2641	167	14	bax	bax	PROPN
eurjchem-2641	167	15	,	,	PUNCT
eurjchem-2641	167	16	caspase-3	caspase-3	PROPN
eurjchem-2641	167	17	,	,	PUNCT
eurjchem-2641	167	18	bcl2	bcl2	NOUN
eurjchem-2641	167	19	,	,	PUNCT
eurjchem-2641	167	20	and	and	CCONJ
eurjchem-2641	167	21	tac	tac	PROPN
eurjchem-2641	167	22	of	of	ADP
eurjchem-2641	167	23	the	the	DET
eurjchem-2641	167	24	studied	study	VERB
eurjchem-2641	167	25	subjects	subject	NOUN
eurjchem-2641	167	26	parameters	parameter	NOUN
eurjchem-2641	167	27	control	control	VERB
eurjchem-2641	167	28	early	early	ADJ
eurjchem-2641	167	29	-	-	PUNCT
eurjchem-2641	167	30	stage	stage	NOUN
eurjchem-2641	167	31	chemotherapy	chemotherapy	NOUN
eurjchem-2641	167	32	surgery	surgery	NOUN
eurjchem-2641	167	33	hb	hb	ADP
eurjchem-2641	167	34	normal	normal	ADJ
eurjchem-2641	167	35	normal	normal	ADJ
eurjchem-2641	167	36	decreased	decrease	VERB
eurjchem-2641	167	37	*	*	PUNCT
eurjchem-2641	167	38	decreased	decrease	VERB
eurjchem-2641	167	39	*	*	PUNCT
eurjchem-2641	167	40	lymphocytes	lymphocyte	NOUN
eurjchem-2641	167	41	normal	normal	ADJ
eurjchem-2641	167	42	increased	increase	VERB
eurjchem-2641	167	43	*	*	PUNCT
eurjchem-2641	167	44	*	*	PUNCT
eurjchem-2641	167	45	increased	increase	VERB
eurjchem-2641	167	46	*	*	PUNCT
eurjchem-2641	167	47	*	*	PUNCT
eurjchem-2641	167	48	increased	increased	ADJ
eurjchem-2641	167	49	*	*	PUNCT
eurjchem-2641	167	50	platelets	platelet	VERB
eurjchem-2641	167	51	normal	normal	ADJ
eurjchem-2641	167	52	decreased	decrease	VERB
eurjchem-2641	167	53	*	*	PUNCT
eurjchem-2641	167	54	decreased	decrease	VERB
eurjchem-2641	167	55	*	*	PROPN
eurjchem-2641	167	56	*	*	PUNCT
eurjchem-2641	167	57	*	*	PUNCT
eurjchem-2641	167	58	decreased	decrease	VERB
eurjchem-2641	167	59	*	*	PUNCT
eurjchem-2641	167	60	*	*	PUNCT
eurjchem-2641	167	61	mirna-148b	mirna-148b	PROPN
eurjchem-2641	167	62	normal	normal	ADJ
eurjchem-2641	167	63	increased	increase	VERB
eurjchem-2641	167	64	*	*	PUNCT
eurjchem-2641	167	65	increased	increase	VERB
eurjchem-2641	167	66	*	*	PUNCT
eurjchem-2641	167	67	*	*	PUNCT
eurjchem-2641	167	68	increased	increase	VERB
eurjchem-2641	167	69	*	*	PUNCT
eurjchem-2641	167	70	*	*	PUNCT
eurjchem-2641	167	71	*	*	PUNCT
eurjchem-2641	167	72	bax	bax	PROPN
eurjchem-2641	167	73	normal	normal	ADJ
eurjchem-2641	167	74	increased	increase	VERB
eurjchem-2641	167	75	*	*	PUNCT
eurjchem-2641	167	76	*	*	PUNCT
eurjchem-2641	167	77	*	*	PUNCT
eurjchem-2641	167	78	increased	increase	VERB
eurjchem-2641	167	79	*	*	PUNCT
eurjchem-2641	167	80	*	*	PUNCT
eurjchem-2641	167	81	increased	increase	VERB
eurjchem-2641	167	82	*	*	PUNCT
eurjchem-2641	168	1	caspase-3	caspase-3	NUM
eurjchem-2641	168	2	normal	normal	ADJ
eurjchem-2641	168	3	decreased	decrease	VERB
eurjchem-2641	168	4	*	*	PUNCT
eurjchem-2641	168	5	decreased	decrease	VERB
eurjchem-2641	168	6	*	*	PROPN
eurjchem-2641	168	7	*	*	PUNCT
eurjchem-2641	168	8	*	*	PUNCT
eurjchem-2641	168	9	decreased	decrease	VERB
eurjchem-2641	168	10	*	*	NOUN
eurjchem-2641	168	11	*	*	PUNCT
eurjchem-2641	168	12	bcl-2	bcl-2	X
eurjchem-2641	168	13	normal	normal	ADJ
eurjchem-2641	168	14	increased	increase	VERB
eurjchem-2641	168	15	*	*	PUNCT
eurjchem-2641	168	16	increased	increase	VERB
eurjchem-2641	168	17	*	*	PUNCT
eurjchem-2641	168	18	*	*	PUNCT
eurjchem-2641	168	19	*	*	PUNCT
eurjchem-2641	168	20	increased	increase	VERB
eurjchem-2641	168	21	*	*	PUNCT
eurjchem-2641	168	22	*	*	PUNCT
eurjchem-2641	168	23	tac	tac	PROPN
eurjchem-2641	168	24	normal	normal	ADJ
eurjchem-2641	168	25	decreased	decrease	VERB
eurjchem-2641	168	26	*	*	PUNCT
eurjchem-2641	168	27	decreased	decrease	VERB
eurjchem-2641	168	28	*	*	PUNCT
eurjchem-2641	168	29	*	*	PUNCT
eurjchem-2641	168	30	decreased	decrease	VERB
eurjchem-2641	168	31	*	*	PUNCT
eurjchem-2641	168	32	*	*	PUNCT
eurjchem-2641	168	33	*	*	PUNCT
eurjchem-2641	168	34	*	*	PUNCT
eurjchem-2641	168	35	there	there	PRON
eurjchem-2641	168	36	is	be	VERB
eurjchem-2641	168	37	a	a	DET
eurjchem-2641	168	38	positive	positive	ADJ
eurjchem-2641	168	39	correlation	correlation	NOUN
eurjchem-2641	168	40	between	between	ADP
eurjchem-2641	168	41	mirna-148b	mirna-148b	PROPN
eurjchem-2641	168	42	,	,	PUNCT
eurjchem-2641	168	43	bcl2	bcl2	NOUN
eurjchem-2641	168	44	,	,	PUNCT
eurjchem-2641	168	45	and	and	CCONJ
eurjchem-2641	168	46	bax	bax	PROPN
eurjchem-2641	168	47	.	.	PROPN
eurjchem-2641	169	1	however	however	ADV
eurjchem-2641	169	2	,	,	PUNCT
eurjchem-2641	169	3	a	a	DET
eurjchem-2641	169	4	negative	negative	ADJ
eurjchem-2641	169	5	correlation	correlation	NOUN
eurjchem-2641	169	6	exists	exist	VERB
eurjchem-2641	169	7	between	between	ADP
eurjchem-2641	169	8	mirna-148b	mirna-148b	PROPN
eurjchem-2641	169	9	,	,	PUNCT
eurjchem-2641	169	10	bcl2	bcl2	NOUN
eurjchem-2641	169	11	,	,	PUNCT
eurjchem-2641	169	12	and	and	CCONJ
eurjchem-2641	169	13	bax	bax	NOUN
eurjchem-2641	169	14	compared	compare	VERB
eurjchem-2641	169	15	to	to	ADP
eurjchem-2641	169	16	caspase-3	caspase-3	NUM
eurjchem-2641	169	17	and	and	CCONJ
eurjchem-2641	169	18	tac	tac	PROPN
eurjchem-2641	169	19	.	.	PUNCT
eurjchem-2641	170	1	on	on	ADP
eurjchem-2641	170	2	the	the	DET
eurjchem-2641	170	3	contrary	contrary	NOUN
eurjchem-2641	170	4	,	,	PUNCT
eurjchem-2641	170	5	there	there	PRON
eurjchem-2641	170	6	is	be	VERB
eurjchem-2641	170	7	a	a	DET
eurjchem-2641	170	8	positive	positive	ADJ
eurjchem-2641	170	9	correlation	correlation	NOUN
eurjchem-2641	170	10	of	of	ADP
eurjchem-2641	170	11	caspase-3	caspase-3	NUM
eurjchem-2641	170	12	and	and	CCONJ
eurjchem-2641	170	13	tac	tac	PROPN
eurjchem-2641	170	14	.	.	PUNCT
eurjchem-2641	171	1	mild	mild	ADJ
eurjchem-2641	171	2	changes	change	NOUN
eurjchem-2641	171	3	*	*	PUNCT
eurjchem-2641	171	4	*	*	PUNCT
eurjchem-2641	171	5	moderate	moderate	ADJ
eurjchem-2641	171	6	changes	change	NOUN
eurjchem-2641	171	7	*	*	PUNCT
eurjchem-2641	171	8	*	*	PUNCT
eurjchem-2641	171	9	*	*	PUNCT
eurjchem-2641	171	10	sever	sever	VERB
eurjchem-2641	171	11	changes	change	NOUN
eurjchem-2641	171	12	.	.	PUNCT
eurjchem-2641	172	1	abbreviations	abbreviation	NOUN
eurjchem-2641	172	2	:	:	PUNCT
eurjchem-2641	172	3	hb	hb	X
eurjchem-2641	172	4	;	;	PUNCT
eurjchem-2641	172	5	hemoglobin	hemoglobin	NOUN
eurjchem-2641	172	6	,	,	PUNCT
eurjchem-2641	172	7	tac	tac	PROPN
eurjchem-2641	172	8	;	;	PUNCT
eurjchem-2641	172	9	total	total	ADJ
eurjchem-2641	172	10	antioxidant	antioxidant	ADJ
eurjchem-2641	172	11	capacity	capacity	NOUN
eurjchem-2641	172	12	.	.	PUNCT
eurjchem-2641	173	1	2.7	2.7	NUM
eurjchem-2641	173	2	.	.	PUNCT
eurjchem-2641	173	3	measurement	measurement	NOUN
eurjchem-2641	173	4	of	of	ADP
eurjchem-2641	173	5	tac	tac	PROPN
eurjchem-2641	173	6	levels	level	NOUN
eurjchem-2641	173	7	serum	serum	VERB
eurjchem-2641	173	8	tac	tac	PROPN
eurjchem-2641	173	9	was	be	AUX
eurjchem-2641	173	10	determined	determine	VERB
eurjchem-2641	173	11	using	use	VERB
eurjchem-2641	173	12	tac	tac	PROPN
eurjchem-2641	173	13	assay	assay	PROPN
eurjchem-2641	173	14	kit	kit	NOUN
eurjchem-2641	173	15	#	#	PROPN
eurjchem-2641	173	16	mak	mak	PROPN
eurjchem-2641	173	17	187	187	NUM
eurjchem-2641	173	18	.	.	PUNCT
eurjchem-2641	174	1	trolox	trolox	PROPN
eurjchem-2641	174	2	standard	standard	ADJ
eurjchem-2641	174	3	solution	solution	NOUN
eurjchem-2641	174	4	(	(	PUNCT
eurjchem-2641	174	5	1	1	NUM
eurjchem-2641	174	6	nmol/µl	nmol/µl	NOUN
eurjchem-2641	174	7	)	)	PUNCT
eurjchem-2641	174	8	(	(	PUNCT
eurjchem-2641	174	9	0	0	NUM
eurjchem-2641	174	10	,	,	PUNCT
eurjchem-2641	174	11	4	4	NUM
eurjchem-2641	174	12	,	,	PUNCT
eurjchem-2641	174	13	8	8	NUM
eurjchem-2641	174	14	,	,	PUNCT
eurjchem-2641	174	15	12	12	NUM
eurjchem-2641	174	16	,	,	PUNCT
eurjchem-2641	174	17	16	16	NUM
eurjchem-2641	174	18	,	,	PUNCT
eurjchem-2641	174	19	and	and	CCONJ
eurjchem-2641	174	20	20	20	NUM
eurjchem-2641	174	21	µl	µl	NOUN
eurjchem-2641	174	22	)	)	PUNCT
eurjchem-2641	174	23	and	and	CCONJ
eurjchem-2641	174	24	50	50	NUM
eurjchem-2641	174	25	µl	µl	NOUN
eurjchem-2641	174	26	samples	sample	NOUN
eurjchem-2641	174	27	were	be	AUX
eurjchem-2641	174	28	added	add	VERB
eurjchem-2641	174	29	to	to	ADP
eurjchem-2641	174	30	water	water	NOUN
eurjchem-2641	174	31	to	to	PART
eurjchem-2641	174	32	bring	bring	VERB
eurjchem-2641	174	33	the	the	DET
eurjchem-2641	174	34	volume	volume	NOUN
eurjchem-2641	174	35	to	to	ADP
eurjchem-2641	174	36	100	100	NUM
eurjchem-2641	174	37	µl	µl	NOUN
eurjchem-2641	174	38	.	.	PROPN
eurjchem-2641	174	39	100	100	NUM
eurjchem-2641	174	40	µl	µl	NOUN
eurjchem-2641	174	41	of	of	ADP
eurjchem-2641	174	42	cupric	cupric	ADJ
eurjchem-2641	174	43	ions	ion	NOUN
eurjchem-2641	174	44	(	(	PUNCT
eurjchem-2641	174	45	cu2	cu2	NOUN
eurjchem-2641	174	46	+	+	NOUN
eurjchem-2641	174	47	)	)	PUNCT
eurjchem-2641	174	48	working	working	NOUN
eurjchem-2641	174	49	solution	solution	NOUN
eurjchem-2641	174	50	was	be	AUX
eurjchem-2641	174	51	then	then	ADV
eurjchem-2641	174	52	added	add	VERB
eurjchem-2641	174	53	to	to	ADP
eurjchem-2641	174	54	all	all	DET
eurjchem-2641	174	55	standards	standard	NOUN
eurjchem-2641	174	56	.	.	PUNCT
eurjchem-2641	175	1	the	the	DET
eurjchem-2641	175	2	samples	sample	NOUN
eurjchem-2641	175	3	were	be	AUX
eurjchem-2641	175	4	mixed	mix	VERB
eurjchem-2641	175	5	well	well	ADV
eurjchem-2641	175	6	and	and	CCONJ
eurjchem-2641	175	7	incubated	incubate	VERB
eurjchem-2641	175	8	for	for	ADP
eurjchem-2641	175	9	90	90	NUM
eurjchem-2641	175	10	minutes	minute	NOUN
eurjchem-2641	175	11	at	at	ADP
eurjchem-2641	175	12	room	room	NOUN
eurjchem-2641	175	13	temperature	temperature	NOUN
eurjchem-2641	175	14	.	.	PUNCT
eurjchem-2641	176	1	the	the	DET
eurjchem-2641	176	2	optical	optical	ADJ
eurjchem-2641	176	3	was	be	AUX
eurjchem-2641	176	4	measured	measure	VERB
eurjchem-2641	176	5	at	at	ADP
eurjchem-2641	176	6	570	570	NUM
eurjchem-2641	176	7	nm	nm	NOUN
eurjchem-2641	176	8	.	.	PUNCT
eurjchem-2641	177	1	the	the	DET
eurjchem-2641	177	2	trolox	trolox	PROPN
eurjchem-2641	177	3	standards	standard	NOUN
eurjchem-2641	177	4	values	value	NOUN
eurjchem-2641	177	5	were	be	AUX
eurjchem-2641	177	6	used	use	VERB
eurjchem-2641	177	7	to	to	PART
eurjchem-2641	177	8	plot	plot	VERB
eurjchem-2641	177	9	a	a	DET
eurjchem-2641	177	10	standard	standard	ADJ
eurjchem-2641	177	11	curve	curve	NOUN
eurjchem-2641	177	12	.	.	PUNCT
eurjchem-2641	178	1	2.8	2.8	NUM
eurjchem-2641	178	2	.	.	PUNCT
eurjchem-2641	179	1	histopathological	histopathological	ADJ
eurjchem-2641	179	2	investigations	investigation	NOUN
eurjchem-2641	179	3	after	after	ADP
eurjchem-2641	179	4	excision	excision	NOUN
eurjchem-2641	179	5	,	,	PUNCT
eurjchem-2641	179	6	human	human	ADJ
eurjchem-2641	179	7	breast	breast	NOUN
eurjchem-2641	179	8	tissue	tissue	NOUN
eurjchem-2641	179	9	was	be	AUX
eurjchem-2641	179	10	washed	wash	VERB
eurjchem-2641	179	11	with	with	ADP
eurjchem-2641	179	12	a	a	DET
eurjchem-2641	179	13	0.9	0.9	NUM
eurjchem-2641	179	14	%	%	NOUN
eurjchem-2641	179	15	sterile	sterile	ADJ
eurjchem-2641	179	16	saline	saline	NOUN
eurjchem-2641	179	17	solution	solution	NOUN
eurjchem-2641	179	18	and	and	CCONJ
eurjchem-2641	179	19	immediately	immediately	ADV
eurjchem-2641	179	20	fixed	fix	VERB
eurjchem-2641	179	21	in	in	ADP
eurjchem-2641	179	22	a	a	DET
eurjchem-2641	179	23	10	10	NUM
eurjchem-2641	179	24	%	%	NOUN
eurjchem-2641	179	25	formalin	formalin	NOUN
eurjchem-2641	179	26	solution	solution	NOUN
eurjchem-2641	179	27	.	.	PUNCT
eurjchem-2641	180	1	formalin	formalin	NOUN
eurjchem-2641	180	2	-	-	PUNCT
eurjchem-2641	180	3	fixed	fix	VERB
eurjchem-2641	180	4	tissue	tissue	NOUN
eurjchem-2641	180	5	specimens	specimen	NOUN
eurjchem-2641	180	6	were	be	AUX
eurjchem-2641	180	7	transferred	transfer	VERB
eurjchem-2641	180	8	to	to	ADP
eurjchem-2641	180	9	70	70	NUM
eurjchem-2641	180	10	%	%	NOUN
eurjchem-2641	180	11	ethanol	ethanol	NOUN
eurjchem-2641	180	12	and	and	CCONJ
eurjchem-2641	180	13	embedded	embed	VERB
eurjchem-2641	180	14	in	in	ADP
eurjchem-2641	180	15	paraffin	paraffin	NOUN
eurjchem-2641	180	16	.	.	PUNCT
eurjchem-2641	181	1	they	they	PRON
eurjchem-2641	181	2	were	be	AUX
eurjchem-2641	181	3	cut	cut	VERB
eurjchem-2641	181	4	into	into	ADP
eurjchem-2641	181	5	5	5	NUM
eurjchem-2641	181	6	µm	µm	ADP
eurjchem-2641	181	7	thick	thick	ADJ
eurjchem-2641	181	8	sections	section	NOUN
eurjchem-2641	181	9	and	and	CCONJ
eurjchem-2641	181	10	mounted	mount	VERB
eurjchem-2641	181	11	on	on	ADP
eurjchem-2641	181	12	positively	positively	ADV
eurjchem-2641	181	13	charged	charge	VERB
eurjchem-2641	181	14	glass	glass	NOUN
eurjchem-2641	181	15	slides	slide	NOUN
eurjchem-2641	181	16	.	.	PUNCT
eurjchem-2641	182	1	the	the	DET
eurjchem-2641	182	2	tissue	tissue	NOUN
eurjchem-2641	182	3	sections	section	NOUN
eurjchem-2641	182	4	were	be	AUX
eurjchem-2641	182	5	stained	stain	VERB
eurjchem-2641	182	6	with	with	ADP
eurjchem-2641	182	7	hematoxylin	hematoxylin	NOUN
eurjchem-2641	182	8	and	and	CCONJ
eurjchem-2641	182	9	eosin	eosin	NOUN
eurjchem-2641	182	10	(	(	PUNCT
eurjchem-2641	182	11	he	he	PRON
eurjchem-2641	182	12	)	)	PUNCT
eurjchem-2641	182	13	and	and	CCONJ
eurjchem-2641	182	14	examined	examine	VERB
eurjchem-2641	182	15	under	under	ADP
eurjchem-2641	182	16	an	an	DET
eurjchem-2641	182	17	optical	optical	ADJ
eurjchem-2641	182	18	microscope	microscope	NOUN
eurjchem-2641	182	19	to	to	PART
eurjchem-2641	182	20	detect	detect	VERB
eurjchem-2641	182	21	pathological	pathological	ADJ
eurjchem-2641	182	22	changes	change	NOUN
eurjchem-2641	182	23	[	[	X
eurjchem-2641	182	24	32	32	NUM
eurjchem-2641	182	25	]	]	PUNCT
eurjchem-2641	182	26	.	.	PUNCT
eurjchem-2641	183	1	2.9	2.9	NUM
eurjchem-2641	183	2	.	.	PUNCT
eurjchem-2641	184	1	statistical	statistical	ADJ
eurjchem-2641	184	2	analysis	analysis	NOUN
eurjchem-2641	184	3	data	datum	NOUN
eurjchem-2641	184	4	were	be	AUX
eurjchem-2641	184	5	investigated	investigate	VERB
eurjchem-2641	184	6	using	use	VERB
eurjchem-2641	184	7	graphpad	graphpad	NOUN
eurjchem-2641	184	8	instat	instat	PROPN
eurjchem-2641	184	9	software	software	PROPN
eurjchem-2641	184	10	,	,	PUNCT
eurjchem-2641	184	11	version	version	NOUN
eurjchem-2641	184	12	4	4	NUM
eurjchem-2641	184	13	(	(	PUNCT
eurjchem-2641	184	14	graphpad	graphpad	NOUN
eurjchem-2641	184	15	,	,	PUNCT
eurjchem-2641	184	16	isi	isi	PROPN
eurjchem-2641	184	17	software	software	PROPN
eurjchem-2641	184	18	inc	inc	PROPN
eurjchem-2641	184	19	.	.	PROPN
eurjchem-2641	184	20	,	,	PUNCT
eurjchem-2641	184	21	la	la	PROPN
eurjchem-2641	184	22	jolla	jolla	PROPN
eurjchem-2641	184	23	,	,	PUNCT
eurjchem-2641	184	24	ca	ca	PROPN
eurjchem-2641	184	25	,	,	PUNCT
eurjchem-2641	184	26	usa	usa	PROPN
eurjchem-2641	184	27	)	)	PUNCT
eurjchem-2641	184	28	.	.	PUNCT
eurjchem-2641	185	1	the	the	DET
eurjchem-2641	185	2	results	result	NOUN
eurjchem-2641	185	3	were	be	AUX
eurjchem-2641	185	4	compared	compare	VERB
eurjchem-2641	185	5	using	use	VERB
eurjchem-2641	185	6	a	a	DET
eurjchem-2641	185	7	one	one	NUM
eurjchem-2641	185	8	-	-	PUNCT
eurjchem-2641	185	9	way	way	NOUN
eurjchem-2641	185	10	analysis	analysis	NOUN
eurjchem-2641	185	11	of	of	ADP
eurjchem-2641	185	12	variance	variance	NOUN
eurjchem-2641	185	13	.	.	PUNCT
eurjchem-2641	186	1	data	datum	NOUN
eurjchem-2641	186	2	were	be	AUX
eurjchem-2641	186	3	expressed	express	VERB
eurjchem-2641	186	4	as	as	ADP
eurjchem-2641	186	5	mean±sd	mean±sd	ADP
eurjchem-2641	186	6	and	and	CCONJ
eurjchem-2641	186	7	p	p	NOUN
eurjchem-2641	186	8	-	-	PUNCT
eurjchem-2641	186	9	value	value	NOUN
eurjchem-2641	186	10	<	<	X
eurjchem-2641	186	11	0.05	0.05	NUM
eurjchem-2641	186	12	was	be	AUX
eurjchem-2641	186	13	used	use	VERB
eurjchem-2641	186	14	as	as	ADP
eurjchem-2641	186	15	a	a	DET
eurjchem-2641	186	16	significance	significance	NOUN
eurjchem-2641	186	17	criterion	criterion	NOUN
eurjchem-2641	186	18	.	.	PUNCT
eurjchem-2641	187	1	3	3	X
eurjchem-2641	187	2	.	.	X
eurjchem-2641	187	3	results	result	VERB
eurjchem-2641	187	4	3.1	3.1	NUM
eurjchem-2641	187	5	.	.	PUNCT
eurjchem-2641	188	1	demographic	demographic	ADJ
eurjchem-2641	188	2	and	and	CCONJ
eurjchem-2641	188	3	clinical	clinical	ADJ
eurjchem-2641	188	4	characteristics	characteristic	NOUN
eurjchem-2641	188	5	table	table	NOUN
eurjchem-2641	188	6	2	2	NUM
eurjchem-2641	188	7	presents	present	VERB
eurjchem-2641	188	8	the	the	DET
eurjchem-2641	188	9	demographic	demographic	ADJ
eurjchem-2641	188	10	data	datum	NOUN
eurjchem-2641	188	11	and	and	CCONJ
eurjchem-2641	188	12	clinical	clinical	ADJ
eurjchem-2641	188	13	characteristics	characteristic	NOUN
eurjchem-2641	188	14	of	of	ADP
eurjchem-2641	188	15	the	the	DET
eurjchem-2641	188	16	participants	participant	NOUN
eurjchem-2641	188	17	.	.	PUNCT
eurjchem-2641	189	1	all	all	DET
eurjchem-2641	189	2	patients	patient	NOUN
eurjchem-2641	189	3	and	and	CCONJ
eurjchem-2641	189	4	controls	control	NOUN
eurjchem-2641	189	5	were	be	AUX
eurjchem-2641	189	6	females	female	NOUN
eurjchem-2641	189	7	.	.	PUNCT
eurjchem-2641	190	1	the	the	DET
eurjchem-2641	190	2	results	result	NOUN
eurjchem-2641	190	3	showed	show	VERB
eurjchem-2641	190	4	that	that	SCONJ
eurjchem-2641	190	5	the	the	DET
eurjchem-2641	190	6	surgery	surgery	NOUN
eurjchem-2641	190	7	-	-	PUNCT
eurjchem-2641	190	8	treated	treat	VERB
eurjchem-2641	190	9	group	group	NOUN
eurjchem-2641	190	10	had	have	VERB
eurjchem-2641	190	11	significantly	significantly	ADV
eurjchem-2641	190	12	larger	large	ADJ
eurjchem-2641	190	13	tumors	tumor	NOUN
eurjchem-2641	190	14	than	than	ADP
eurjchem-2641	190	15	those	those	PRON
eurjchem-2641	190	16	of	of	ADP
eurjchem-2641	190	17	the	the	DET
eurjchem-2641	190	18	other	other	ADJ
eurjchem-2641	190	19	groups	group	NOUN
eurjchem-2641	190	20	(	(	PUNCT
eurjchem-2641	190	21	15.54±4.01	15.54±4.01	NUM
eurjchem-2641	190	22	cm2	cm2	NOUN
eurjchem-2641	190	23	)	)	PUNCT
eurjchem-2641	190	24	.	.	PUNCT
eurjchem-2641	191	1	tumor	tumor	NOUN
eurjchem-2641	191	2	size	size	NOUN
eurjchem-2641	191	3	was	be	AUX
eurjchem-2641	191	4	reported	report	VERB
eurjchem-2641	191	5	to	to	PART
eurjchem-2641	191	6	increase	increase	VERB
eurjchem-2641	191	7	between	between	ADP
eurjchem-2641	191	8	early	early	ADJ
eurjchem-2641	191	9	-	-	PUNCT
eurjchem-2641	191	10	stage	stage	NOUN
eurjchem-2641	191	11	and	and	CCONJ
eurjchem-2641	191	12	chemotherapy	chemotherapy	NOUN
eurjchem-2641	191	13	-	-	PUNCT
eurjchem-2641	191	14	treated	treat	VERB
eurjchem-2641	191	15	groups	group	NOUN
eurjchem-2641	191	16	(	(	PUNCT
eurjchem-2641	191	17	1.826±0.89	1.826±0.89	NUM
eurjchem-2641	191	18	and	and	CCONJ
eurjchem-2641	191	19	1.520±0.51	1.520±0.51	NUM
eurjchem-2641	191	20	cm2	cm2	NOUN
eurjchem-2641	191	21	,	,	PUNCT
eurjchem-2641	191	22	respectively	respectively	ADV
eurjchem-2641	191	23	)	)	PUNCT
eurjchem-2641	191	24	compared	compare	VERB
eurjchem-2641	191	25	to	to	ADP
eurjchem-2641	191	26	the	the	DET
eurjchem-2641	191	27	control	control	NOUN
eurjchem-2641	191	28	.	.	PUNCT
eurjchem-2641	192	1	3.2	3.2	NUM
eurjchem-2641	192	2	.	.	PUNCT
eurjchem-2641	192	3	blood	blood	NOUN
eurjchem-2641	192	4	count	count	NOUN
eurjchem-2641	192	5	table	table	NOUN
eurjchem-2641	192	6	3	3	NUM
eurjchem-2641	192	7	presents	present	VERB
eurjchem-2641	192	8	the	the	DET
eurjchem-2641	192	9	cbc	cbc	PROPN
eurjchem-2641	192	10	parameters	parameter	NOUN
eurjchem-2641	192	11	.	.	PUNCT
eurjchem-2641	193	1	hemoglobin	hemoglobin	NOUN
eurjchem-2641	193	2	levels	level	NOUN
eurjchem-2641	193	3	were	be	AUX
eurjchem-2641	193	4	found	find	VERB
eurjchem-2641	193	5	to	to	PART
eurjchem-2641	193	6	be	be	AUX
eurjchem-2641	193	7	significantly	significantly	ADV
eurjchem-2641	193	8	decreased	decrease	VERB
eurjchem-2641	193	9	in	in	ADP
eurjchem-2641	193	10	both	both	PRON
eurjchem-2641	193	11	chemotherapy	chemotherapy	NOUN
eurjchem-2641	193	12	and	and	CCONJ
eurjchem-2641	193	13	surgery	surgery	NOUN
eurjchem-2641	193	14	groups	group	NOUN
eurjchem-2641	193	15	(	(	PUNCT
eurjchem-2641	193	16	11.07±1.18	11.07±1.18	NOUN
eurjchem-2641	193	17	and	and	CCONJ
eurjchem-2641	193	18	11.64±1.03	11.64±1.03	NUM
eurjchem-2641	193	19	g	g	NOUN
eurjchem-2641	193	20	/	/	SYM
eurjchem-2641	193	21	dl	dl	PROPN
eurjchem-2641	193	22	;	;	PUNCT
eurjchem-2641	193	23	p	p	X
eurjchem-2641	193	24	<	<	X
eurjchem-2641	193	25	0.001	0.001	NUM
eurjchem-2641	193	26	)	)	PUNCT
eurjchem-2641	193	27	,	,	PUNCT
eurjchem-2641	193	28	respectively	respectively	ADV
eurjchem-2641	193	29	,	,	PUNCT
eurjchem-2641	193	30	compared	compare	VERB
eurjchem-2641	193	31	with	with	ADP
eurjchem-2641	193	32	the	the	DET
eurjchem-2641	193	33	control	control	NOUN
eurjchem-2641	193	34	group	group	NOUN
eurjchem-2641	193	35	,	,	PUNCT
eurjchem-2641	193	36	and	and	CCONJ
eurjchem-2641	193	37	no	no	DET
eurjchem-2641	193	38	significant	significant	ADJ
eurjchem-2641	193	39	differences	difference	NOUN
eurjchem-2641	193	40	were	be	AUX
eurjchem-2641	193	41	observed	observe	VERB
eurjchem-2641	193	42	in	in	ADP
eurjchem-2641	193	43	hemoglobin	hemoglobin	NOUN
eurjchem-2641	193	44	levels	level	NOUN
eurjchem-2641	193	45	of	of	ADP
eurjchem-2641	193	46	the	the	DET
eurjchem-2641	193	47	early	early	ADJ
eurjchem-2641	193	48	stage	stage	NOUN
eurjchem-2641	193	49	group	group	NOUN
eurjchem-2641	193	50	compared	compare	VERB
eurjchem-2641	193	51	with	with	ADP
eurjchem-2641	193	52	the	the	DET
eurjchem-2641	193	53	control	control	NOUN
eurjchem-2641	193	54	group	group	NOUN
eurjchem-2641	193	55	(	(	PUNCT
eurjchem-2641	193	56	12.42±0.9	12.42±0.9	NUM
eurjchem-2641	193	57	g	g	PROPN
eurjchem-2641	193	58	/	/	SYM
eurjchem-2641	193	59	dl	dl	PROPN
eurjchem-2641	193	60	;	;	PUNCT
eurjchem-2641	193	61	p	p	X
eurjchem-2641	193	62	>	>	X
eurjchem-2641	193	63	0.05	0.05	NUM
eurjchem-2641	193	64	)	)	PUNCT
eurjchem-2641	193	65	.	.	PUNCT
eurjchem-2641	194	1	the	the	DET
eurjchem-2641	194	2	levels	level	NOUN
eurjchem-2641	194	3	of	of	ADP
eurjchem-2641	194	4	white	white	ADJ
eurjchem-2641	194	5	blood	blood	NOUN
eurjchem-2641	194	6	cells	cell	NOUN
eurjchem-2641	194	7	(	(	PUNCT
eurjchem-2641	194	8	wbcs	wbcs	PROPN
eurjchem-2641	194	9	)	)	PUNCT
eurjchem-2641	194	10	and	and	CCONJ
eurjchem-2641	194	11	lymphocytes	lymphocyte	NOUN
eurjchem-2641	194	12	were	be	AUX
eurjchem-2641	194	13	significantly	significantly	ADV
eurjchem-2641	194	14	increased	increase	VERB
eurjchem-2641	194	15	between	between	ADP
eurjchem-2641	194	16	patients	patient	NOUN
eurjchem-2641	194	17	in	in	ADP
eurjchem-2641	194	18	early	early	ADJ
eurjchem-2641	194	19	-	-	PUNCT
eurjchem-2641	194	20	stage	stage	NOUN
eurjchem-2641	194	21	,	,	PUNCT
eurjchem-2641	194	22	chemotherapy	chemotherapy	NOUN
eurjchem-2641	194	23	,	,	PUNCT
eurjchem-2641	194	24	and	and	CCONJ
eurjchem-2641	194	25	surgery	surgery	NOUN
eurjchem-2641	194	26	groups	group	NOUN
eurjchem-2641	194	27	(	(	PUNCT
eurjchem-2641	194	28	56.30±6.24	56.30±6.24	NUM
eurjchem-2641	194	29	,	,	PUNCT
eurjchem-2641	194	30	58.40±8.94	58.40±8.94	NUM
eurjchem-2641	194	31	,	,	PUNCT
eurjchem-2641	194	32	and	and	CCONJ
eurjchem-2641	194	33	50.48±0.81	50.48±0.81	NUM
eurjchem-2641	194	34	;	;	PUNCT
eurjchem-2641	194	35	p	p	X
eurjchem-2641	194	36	<	<	X
eurjchem-2641	194	37	0.001	0.001	NUM
eurjchem-2641	194	38	)	)	PUNCT
eurjchem-2641	194	39	,	,	PUNCT
eurjchem-2641	194	40	respectively	respectively	ADV
eurjchem-2641	194	41	.	.	PUNCT
eurjchem-2641	195	1	platelet	platelet	NOUN
eurjchem-2641	195	2	count	count	NOUN
eurjchem-2641	195	3	was	be	AUX
eurjchem-2641	195	4	significantly	significantly	ADV
eurjchem-2641	195	5	decreased	decrease	VERB
eurjchem-2641	195	6	in	in	ADP
eurjchem-2641	195	7	patients	patient	NOUN
eurjchem-2641	195	8	in	in	ADP
eurjchem-2641	195	9	the	the	DET
eurjchem-2641	195	10	early	early	ADJ
eurjchem-2641	195	11	stage	stage	NOUN
eurjchem-2641	195	12	,	,	PUNCT
eurjchem-2641	195	13	chemotherapy	chemotherapy	NOUN
eurjchem-2641	195	14	and	and	CCONJ
eurjchem-2641	195	15	surgery	surgery	NOUN
eurjchem-2641	195	16	group	group	NOUN
eurjchem-2641	195	17	patients	patient	NOUN
eurjchem-2641	195	18	(	(	PUNCT
eurjchem-2641	195	19	130.3±8.69	130.3±8.69	NOUN
eurjchem-2641	195	20	,	,	PUNCT
eurjchem-2641	195	21	96.99±10.06	96.99±10.06	NUM
eurjchem-2641	195	22	,	,	PUNCT
eurjchem-2641	195	23	and	and	CCONJ
eurjchem-2641	195	24	118±8.10	118±8.10	NUM
eurjchem-2641	195	25	*	*	SYM
eurjchem-2641	195	26	103	103	NUM
eurjchem-2641	195	27	/	/	SYM
eurjchem-2641	195	28	cm2	cm2	NOUN
eurjchem-2641	195	29	;	;	PUNCT
eurjchem-2641	195	30	p	p	X
eurjchem-2641	195	31	<	<	X
eurjchem-2641	195	32	0.001	0.001	NUM
eurjchem-2641	195	33	)	)	PUNCT
eurjchem-2641	195	34	,	,	PUNCT
eurjchem-2641	195	35	respectively	respectively	ADV
eurjchem-2641	195	36	.	.	PUNCT
eurjchem-2641	196	1	3.3	3.3	NUM
eurjchem-2641	196	2	.	.	PUNCT
eurjchem-2641	197	1	mirna-148b	mirna-148b	PROPN
eurjchem-2641	197	2	,	,	PUNCT
eurjchem-2641	197	3	caspase-3	caspase-3	NUM
eurjchem-2641	197	4	,	,	PUNCT
eurjchem-2641	197	5	bcl-2	bcl-2	NOUN
eurjchem-2641	197	6	and	and	CCONJ
eurjchem-2641	197	7	bax	bax	NOUN
eurjchem-2641	197	8	expression	expression	NOUN
eurjchem-2641	197	9	the	the	DET
eurjchem-2641	197	10	expression	expression	NOUN
eurjchem-2641	197	11	of	of	ADP
eurjchem-2641	197	12	mirna-148b	mirna-148b	PROPN
eurjchem-2641	197	13	was	be	AUX
eurjchem-2641	197	14	significantly	significantly	ADV
eurjchem-2641	197	15	increased	increase	VERB
eurjchem-2641	197	16	in	in	ADP
eurjchem-2641	197	17	the	the	DET
eurjchem-2641	197	18	early	early	ADJ
eurjchem-2641	197	19	stage	stage	NOUN
eurjchem-2641	197	20	,	,	PUNCT
eurjchem-2641	197	21	chemotherapeutic	chemotherapeutic	NOUN
eurjchem-2641	197	22	and	and	CCONJ
eurjchem-2641	197	23	surgery	surgery	NOUN
eurjchem-2641	197	24	-	-	PUNCT
eurjchem-2641	197	25	treated	treat	VERB
eurjchem-2641	197	26	groups	group	NOUN
eurjchem-2641	197	27	(	(	PUNCT
eurjchem-2641	197	28	3.684±1.10	3.684±1.10	NUM
eurjchem-2641	197	29	,	,	PUNCT
eurjchem-2641	197	30	5.260±0.81	5.260±0.81	NUM
eurjchem-2641	197	31	,	,	PUNCT
eurjchem-2641	197	32	and	and	CCONJ
eurjchem-2641	197	33	6.165±	6.165±	NUM
eurjchem-2641	197	34	1.00	1.00	NUM
eurjchem-2641	197	35	)	)	PUNCT
eurjchem-2641	197	36	,	,	PUNCT
eurjchem-2641	197	37	respecttively	respecttively	ADV
eurjchem-2641	197	38	,	,	PUNCT
eurjchem-2641	197	39	compared	compare	VERB
eurjchem-2641	197	40	with	with	ADP
eurjchem-2641	197	41	the	the	DET
eurjchem-2641	197	42	control	control	NOUN
eurjchem-2641	197	43	group	group	NOUN
eurjchem-2641	197	44	.	.	PUNCT
eurjchem-2641	198	1	the	the	DET
eurjchem-2641	198	2	surgery	surgery	NOUN
eurjchem-2641	198	3	-	-	PUNCT
eurjchem-2641	198	4	treated	treat	VERB
eurjchem-2641	198	5	group	group	NOUN
eurjchem-2641	198	6	resulted	result	VERB
eurjchem-2641	198	7	in	in	ADP
eurjchem-2641	198	8	a	a	DET
eurjchem-2641	198	9	more	more	ADV
eurjchem-2641	198	10	significant	significant	ADJ
eurjchem-2641	198	11	up	up	ADJ
eurjchem-2641	198	12	-	-	PUNCT
eurjchem-2641	198	13	regulation	regulation	NOUN
eurjchem-2641	198	14	of	of	ADP
eurjchem-2641	198	15	mirna148b	mirna148b	PROPN
eurjchem-2641	198	16	expression	expression	NOUN
eurjchem-2641	198	17	than	than	ADP
eurjchem-2641	198	18	the	the	DET
eurjchem-2641	198	19	control	control	NOUN
eurjchem-2641	198	20	group	group	NOUN
eurjchem-2641	198	21	(	(	PUNCT
eurjchem-2641	198	22	figure	figure	NOUN
eurjchem-2641	198	23	2a	2a	NUM
eurjchem-2641	198	24	)	)	PUNCT
eurjchem-2641	198	25	.	.	PUNCT
eurjchem-2641	199	1	regarding	regard	VERB
eurjchem-2641	199	2	the	the	DET
eurjchem-2641	199	3	expression	expression	NOUN
eurjchem-2641	199	4	of	of	ADP
eurjchem-2641	199	5	caspase-3	caspase-3	NUM
eurjchem-2641	199	6	,	,	PUNCT
eurjchem-2641	199	7	there	there	PRON
eurjchem-2641	199	8	is	be	VERB
eurjchem-2641	199	9	a	a	DET
eurjchem-2641	199	10	substantial	substantial	ADJ
eurjchem-2641	199	11	decrease	decrease	NOUN
eurjchem-2641	199	12	in	in	ADP
eurjchem-2641	199	13	the	the	DET
eurjchem-2641	199	14	early	early	ADJ
eurjchem-2641	199	15	-	-	PUNCT
eurjchem-2641	199	16	stage	stage	NOUN
eurjchem-2641	199	17	,	,	PUNCT
eurjchem-2641	199	18	chemotherapeutic	chemotherapeutic	NOUN
eurjchem-2641	199	19	,	,	PUNCT
eurjchem-2641	199	20	and	and	CCONJ
eurjchem-2641	199	21	surgery	surgery	NOUN
eurjchem-2641	199	22	treated	treat	VERB
eurjchem-2641	199	23	groups	group	NOUN
eurjchem-2641	199	24	(	(	PUNCT
eurjchem-2641	199	25	0.681±0.039	0.681±0.039	NOUN
eurjchem-2641	199	26	,	,	PUNCT
eurjchem-2641	199	27	0.456±0.026	0.456±0.026	PROPN
eurjchem-2641	199	28	,	,	PUNCT
eurjchem-2641	199	29	and	and	CCONJ
eurjchem-2641	199	30	0.554±0.052	0.554±0.052	NUM
eurjchem-2641	199	31	)	)	PUNCT
eurjchem-2641	199	32	,	,	PUNCT
eurjchem-2641	199	33	respectively	respectively	ADV
eurjchem-2641	199	34	,	,	PUNCT
eurjchem-2641	199	35	compared	compare	VERB
eurjchem-2641	199	36	with	with	ADP
eurjchem-2641	199	37	the	the	DET
eurjchem-2641	199	38	control	control	NOUN
eurjchem-2641	199	39	group	group	NOUN
eurjchem-2641	199	40	(	(	PUNCT
eurjchem-2641	199	41	figure	figure	NOUN
eurjchem-2641	199	42	2b	2b	NOUN
eurjchem-2641	199	43	)	)	PUNCT
eurjchem-2641	199	44	.	.	PUNCT
eurjchem-2641	200	1	similarly	similarly	ADV
eurjchem-2641	200	2	,	,	PUNCT
eurjchem-2641	200	3	there	there	PRON
eurjchem-2641	200	4	was	be	VERB
eurjchem-2641	200	5	a	a	DET
eurjchem-2641	200	6	significant	significant	ADJ
eurjchem-2641	200	7	increase	increase	NOUN
eurjchem-2641	200	8	in	in	ADP
eurjchem-2641	200	9	bcl-2	bcl-2	NOUN
eurjchem-2641	200	10	expression	expression	NOUN
eurjchem-2641	200	11	in	in	ADP
eurjchem-2641	200	12	early	early	ADJ
eurjchem-2641	200	13	-	-	PUNCT
eurjchem-2641	200	14	stage	stage	NOUN
eurjchem-2641	200	15	,	,	PUNCT
eurjchem-2641	200	16	chemotherapeutic	chemotherapeutic	NOUN
eurjchem-2641	200	17	and	and	CCONJ
eurjchem-2641	200	18	surgery	surgery	NOUN
eurjchem-2641	200	19	treated	treat	VERB
eurjchem-2641	200	20	groups	group	NOUN
eurjchem-2641	200	21	(	(	PUNCT
eurjchem-2641	200	22	2.427±0.104	2.427±0.104	NOUN
eurjchem-2641	200	23	,	,	PUNCT
eurjchem-2641	200	24	2.419±0.07	2.419±0.07	NUM
eurjchem-2641	200	25	,	,	PUNCT
eurjchem-2641	200	26	and	and	CCONJ
eurjchem-2641	200	27	2.819±0.09	2.819±0.09	NUM
eurjchem-2641	200	28	)	)	PUNCT
eurjchem-2641	200	29	,	,	PUNCT
eurjchem-2641	200	30	respectively	respectively	ADV
eurjchem-2641	200	31	,	,	PUNCT
eurjchem-2641	200	32	compared	compare	VERB
eurjchem-2641	200	33	to	to	ADP
eurjchem-2641	200	34	the	the	DET
eurjchem-2641	200	35	control	control	NOUN
eurjchem-2641	200	36	group	group	NOUN
eurjchem-2641	200	37	(	(	PUNCT
eurjchem-2641	200	38	figure	figure	NOUN
eurjchem-2641	200	39	2c	2c	NUM
eurjchem-2641	200	40	)	)	PUNCT
eurjchem-2641	200	41	.	.	PUNCT
eurjchem-2641	201	1	furthermore	furthermore	ADV
eurjchem-2641	201	2	,	,	PUNCT
eurjchem-2641	201	3	bax	bax	NOUN
eurjchem-2641	201	4	expression	expression	NOUN
eurjchem-2641	201	5	was	be	AUX
eurjchem-2641	201	6	significantly	significantly	ADV
eurjchem-2641	201	7	decreased	decrease	VERB
eurjchem-2641	201	8	in	in	ADP
eurjchem-2641	201	9	the	the	DET
eurjchem-2641	201	10	early	early	ADJ
eurjchem-2641	201	11	-	-	PUNCT
eurjchem-2641	201	12	stage	stage	NOUN
eurjchem-2641	201	13	,	,	PUNCT
eurjchem-2641	201	14	chemotherapeutic	chemotherapeutic	NOUN
eurjchem-2641	201	15	,	,	PUNCT
eurjchem-2641	201	16	226	226	NUM
eurjchem-2641	201	17	harisa	harisa	NOUN
eurjchem-2641	201	18	et	et	PROPN
eurjchem-2641	201	19	al	al	PROPN
eurjchem-2641	201	20	.	.	PUNCT
eurjchem-2641	201	21	/	/	SYM
eurjchem-2641	201	22	european	european	PROPN
eurjchem-2641	201	23	journal	journal	PROPN
eurjchem-2641	201	24	of	of	ADP
eurjchem-2641	201	25	chemistry	chemistry	NOUN
eurjchem-2641	201	26	16	16	NUM
eurjchem-2641	201	27	(	(	PUNCT
eurjchem-2641	201	28	2	2	NUM
eurjchem-2641	201	29	)	)	PUNCT
eurjchem-2641	201	30	(	(	PUNCT
eurjchem-2641	201	31	2025	2025	NUM
eurjchem-2641	201	32	)	)	PUNCT
eurjchem-2641	201	33	222	222	NUM
eurjchem-2641	201	34	-	-	SYM
eurjchem-2641	201	35	232	232	NUM
eurjchem-2641	201	36	2025	2025	NUM
eurjchem-2641	201	37	–	–	PUNCT
eurjchem-2641	201	38	european	european	ADJ
eurjchem-2641	201	39	journal	journal	NOUN
eurjchem-2641	201	40	of	of	ADP
eurjchem-2641	201	41	chemistry	chemistry	NOUN
eurjchem-2641	201	42	–	–	PUNCT
eurjchem-2641	201	43	cc	cc	NOUN
eurjchem-2641	201	44	by	by	ADP
eurjchem-2641	201	45	nc	nc	PROPN
eurjchem-2641	201	46	–	–	PUNCT
eurjchem-2641	201	47	doi	doi	NOUN
eurjchem-2641	201	48	:	:	PUNCT
eurjchem-2641	201	49	10.5155	10.5155	NUM
eurjchem-2641	201	50	/	/	SYM
eurjchem-2641	201	51	eurjchem.16.2.222	eurjchem.16.2.222	NOUN
eurjchem-2641	201	52	-	-	SYM
eurjchem-2641	201	53	232.2641	232.2641	NUM
eurjchem-2641	201	54	(	(	PUNCT
eurjchem-2641	201	55	a	a	NOUN
eurjchem-2641	201	56	)	)	PUNCT
eurjchem-2641	201	57	(	(	PUNCT
eurjchem-2641	201	58	b	b	X
eurjchem-2641	201	59	)	)	PUNCT
eurjchem-2641	201	60	(	(	PUNCT
eurjchem-2641	201	61	c	c	X
eurjchem-2641	201	62	)	)	PUNCT
eurjchem-2641	201	63	(	(	PUNCT
eurjchem-2641	201	64	d	d	X
eurjchem-2641	201	65	)	)	PUNCT
eurjchem-2641	201	66	figure	figure	NOUN
eurjchem-2641	201	67	2	2	NUM
eurjchem-2641	201	68	.	.	PUNCT
eurjchem-2641	202	1	(	(	PUNCT
eurjchem-2641	202	2	a	a	X
eurjchem-2641	202	3	)	)	PUNCT
eurjchem-2641	202	4	expression	expression	NOUN
eurjchem-2641	202	5	of	of	ADP
eurjchem-2641	202	6	mirna-148b	mirna-148b	PROPN
eurjchem-2641	202	7	,	,	PUNCT
eurjchem-2641	202	8	(	(	PUNCT
eurjchem-2641	202	9	b	b	NOUN
eurjchem-2641	202	10	)	)	PUNCT
eurjchem-2641	202	11	expression	expression	NOUN
eurjchem-2641	202	12	of	of	ADP
eurjchem-2641	202	13	caspase-3	caspase-3	PROPN
eurjchem-2641	202	14	,	,	PUNCT
eurjchem-2641	202	15	(	(	PUNCT
eurjchem-2641	202	16	c	c	NOUN
eurjchem-2641	202	17	)	)	PUNCT
eurjchem-2641	202	18	expression	expression	NOUN
eurjchem-2641	202	19	of	of	ADP
eurjchem-2641	202	20	bcl-2	bcl-2	NOUN
eurjchem-2641	202	21	,	,	PUNCT
eurjchem-2641	202	22	(	(	PUNCT
eurjchem-2641	202	23	d	d	NOUN
eurjchem-2641	202	24	)	)	PUNCT
eurjchem-2641	202	25	expression	expression	NOUN
eurjchem-2641	202	26	of	of	ADP
eurjchem-2641	202	27	bax	bax	PROPN
eurjchem-2641	202	28	in	in	ADP
eurjchem-2641	202	29	all	all	DET
eurjchem-2641	202	30	study	study	NOUN
eurjchem-2641	202	31	groups	group	NOUN
eurjchem-2641	202	32	.	.	PUNCT
eurjchem-2641	203	1	the	the	DET
eurjchem-2641	203	2	expression	expression	NOUN
eurjchem-2641	203	3	of	of	ADP
eurjchem-2641	203	4	mirna148b	mirna148b	PROPN
eurjchem-2641	203	5	,	,	PUNCT
eurjchem-2641	203	6	caspase-3	caspase-3	NUM
eurjchem-2641	203	7	,	,	PUNCT
eurjchem-2641	203	8	bcl-2	bcl-2	NOUN
eurjchem-2641	203	9	,	,	PUNCT
eurjchem-2641	203	10	and	and	CCONJ
eurjchem-2641	203	11	bax	bax	PROPN
eurjchem-2641	203	12	was	be	AUX
eurjchem-2641	203	13	normalized	normalize	VERB
eurjchem-2641	203	14	with	with	ADP
eurjchem-2641	203	15	u6	u6	PROPN
eurjchem-2641	203	16	.	.	PUNCT
eurjchem-2641	204	1	data	datum	NOUN
eurjchem-2641	204	2	were	be	AUX
eurjchem-2641	204	3	expressed	express	VERB
eurjchem-2641	204	4	as	as	ADP
eurjchem-2641	204	5	mean±sd	mean±sd	PROPN
eurjchem-2641	204	6	(	(	PUNCT
eurjchem-2641	204	7	n	n	NOUN
eurjchem-2641	204	8	=	=	NUM
eurjchem-2641	204	9	75	75	NUM
eurjchem-2641	204	10	)	)	PUNCT
eurjchem-2641	204	11	.	.	PUNCT
eurjchem-2641	205	1	in	in	ADP
eurjchem-2641	205	2	data	data	NOUN
eurjchem-2641	205	3	analysis	analysis	NOUN
eurjchem-2641	205	4	,	,	PUNCT
eurjchem-2641	205	5	one	one	NUM
eurjchem-2641	205	6	-	-	PUNCT
eurjchem-2641	205	7	way	way	NOUN
eurjchem-2641	205	8	anova	anova	PROPN
eurjchem-2641	205	9	followed	follow	VERB
eurjchem-2641	205	10	by	by	ADP
eurjchem-2641	205	11	tukey	tukey	PROPN
eurjchem-2641	205	12	post	post	X
eurjchem-2641	205	13	hoc	hoc	X
eurjchem-2641	205	14	test	test	NOUN
eurjchem-2641	205	15	at	at	ADP
eurjchem-2641	205	16	p	p	NOUN
eurjchem-2641	205	17	<	<	X
eurjchem-2641	205	18	0.05	0.05	NUM
eurjchem-2641	205	19	was	be	AUX
eurjchem-2641	205	20	used	use	VERB
eurjchem-2641	205	21	.	.	PUNCT
eurjchem-2641	206	1	*	*	PUNCT
eurjchem-2641	206	2	significant	significant	ADJ
eurjchem-2641	206	3	difference	difference	NOUN
eurjchem-2641	206	4	from	from	ADP
eurjchem-2641	206	5	the	the	DET
eurjchem-2641	206	6	control	control	NOUN
eurjchem-2641	206	7	group	group	NOUN
eurjchem-2641	206	8	.	.	PUNCT
eurjchem-2641	207	1	and	and	CCONJ
eurjchem-2641	207	2	surgery	surgery	NOUN
eurjchem-2641	207	3	-	-	PUNCT
eurjchem-2641	207	4	treated	treat	VERB
eurjchem-2641	207	5	groups	group	NOUN
eurjchem-2641	207	6	(	(	PUNCT
eurjchem-2641	207	7	0.638±0.06	0.638±0.06	NOUN
eurjchem-2641	207	8	,	,	PUNCT
eurjchem-2641	207	9	0.445±0.04	0.445±0.04	NUM
eurjchem-2641	207	10	,	,	PUNCT
eurjchem-2641	207	11	and	and	CCONJ
eurjchem-2641	207	12	0.245±0.02	0.245±0.02	NUM
eurjchem-2641	207	13	)	)	PUNCT
eurjchem-2641	207	14	compared	compare	VERB
eurjchem-2641	207	15	to	to	ADP
eurjchem-2641	207	16	the	the	DET
eurjchem-2641	207	17	control	control	NOUN
eurjchem-2641	207	18	group	group	NOUN
eurjchem-2641	207	19	(	(	PUNCT
eurjchem-2641	207	20	figure	figure	NOUN
eurjchem-2641	207	21	2d	2d	NUM
eurjchem-2641	207	22	)	)	PUNCT
eurjchem-2641	207	23	.	.	PUNCT
eurjchem-2641	208	1	3.4	3.4	NUM
eurjchem-2641	208	2	.	.	PUNCT
eurjchem-2641	209	1	caspase-3	caspase-3	NUM
eurjchem-2641	209	2	and	and	CCONJ
eurjchem-2641	209	3	bcl-2	bcl-2	PUNCT
eurjchem-2641	209	4	serum	serum	NOUN
eurjchem-2641	209	5	levels	level	NOUN
eurjchem-2641	209	6	of	of	ADP
eurjchem-2641	209	7	caspase-3	caspase-3	PROPN
eurjchem-2641	209	8	,	,	PUNCT
eurjchem-2641	209	9	bcl-2	bcl-2	NOUN
eurjchem-2641	209	10	,	,	PUNCT
eurjchem-2641	209	11	and	and	CCONJ
eurjchem-2641	209	12	tac	tac	PROPN
eurjchem-2641	209	13	are	be	AUX
eurjchem-2641	209	14	presented	present	VERB
eurjchem-2641	209	15	in	in	ADP
eurjchem-2641	209	16	figure	figure	NOUN
eurjchem-2641	209	17	3	3	NUM
eurjchem-2641	209	18	.	.	PUNCT
eurjchem-2641	210	1	there	there	PRON
eurjchem-2641	210	2	was	be	VERB
eurjchem-2641	210	3	a	a	DET
eurjchem-2641	210	4	significant	significant	ADJ
eurjchem-2641	210	5	decrease	decrease	NOUN
eurjchem-2641	210	6	in	in	ADP
eurjchem-2641	210	7	caspase-3	caspase-3	NUM
eurjchem-2641	210	8	levels	level	NOUN
eurjchem-2641	210	9	in	in	ADP
eurjchem-2641	210	10	both	both	DET
eurjchem-2641	210	11	chemotherapy	chemotherapy	NOUN
eurjchem-2641	210	12	and	and	CCONJ
eurjchem-2641	210	13	surgery	surgery	NOUN
eurjchem-2641	210	14	-	-	PUNCT
eurjchem-2641	210	15	treated	treat	VERB
eurjchem-2641	210	16	groups	group	NOUN
eurjchem-2641	210	17	(	(	PUNCT
eurjchem-2641	210	18	2.302±0.75	2.302±0.75	NUM
eurjchem-2641	210	19	and	and	CCONJ
eurjchem-2641	210	20	2.773±0.84	2.773±0.84	NUM
eurjchem-2641	210	21	)	)	PUNCT
eurjchem-2641	210	22	compared	compare	VERB
eurjchem-2641	210	23	to	to	ADP
eurjchem-2641	210	24	the	the	DET
eurjchem-2641	210	25	contro	contro	PROPN
eurjchem-2641	210	26	l	l	PROPN
eurjchem-2641	210	27	group	group	NOUN
eurjchem-2641	210	28	(	(	PUNCT
eurjchem-2641	210	29	6.016±0.6672	6.016±0.6672	NOUN
eurjchem-2641	210	30	)	)	PUNCT
eurjchem-2641	210	31	,	,	PUNCT
eurjchem-2641	210	32	harisa	harisa	NOUN
eurjchem-2641	210	33	et	et	PROPN
eurjchem-2641	210	34	al	al	PROPN
eurjchem-2641	210	35	.	.	PUNCT
eurjchem-2641	210	36	/	/	SYM
eurjchem-2641	210	37	european	european	PROPN
eurjchem-2641	210	38	journal	journal	PROPN
eurjchem-2641	210	39	of	of	ADP
eurjchem-2641	210	40	chemistry	chemistry	NOUN
eurjchem-2641	210	41	16	16	NUM
eurjchem-2641	210	42	(	(	PUNCT
eurjchem-2641	210	43	2	2	NUM
eurjchem-2641	210	44	)	)	PUNCT
eurjchem-2641	210	45	(	(	PUNCT
eurjchem-2641	210	46	2025	2025	NUM
eurjchem-2641	210	47	)	)	PUNCT
eurjchem-2641	210	48	222	222	NUM
eurjchem-2641	210	49	-	-	SYM
eurjchem-2641	210	50	232	232	NUM
eurjchem-2641	210	51	227	227	NUM
eurjchem-2641	210	52	2025	2025	NUM
eurjchem-2641	210	53	–	–	PUNCT
eurjchem-2641	210	54	european	european	ADJ
eurjchem-2641	210	55	journal	journal	NOUN
eurjchem-2641	210	56	of	of	ADP
eurjchem-2641	210	57	chemistry	chemistry	NOUN
eurjchem-2641	210	58	–	–	PUNCT
eurjchem-2641	210	59	cc	cc	NOUN
eurjchem-2641	210	60	by	by	ADP
eurjchem-2641	210	61	nc	nc	PROPN
eurjchem-2641	210	62	–	–	PUNCT
eurjchem-2641	210	63	doi	doi	NOUN
eurjchem-2641	210	64	:	:	PUNCT
eurjchem-2641	210	65	10.5155	10.5155	NUM
eurjchem-2641	210	66	/	/	SYM
eurjchem-2641	210	67	eurjchem.16.2.222	eurjchem.16.2.222	NOUN
eurjchem-2641	210	68	-	-	SYM
eurjchem-2641	210	69	232.2641	232.2641	NUM
eurjchem-2641	210	70	(	(	PUNCT
eurjchem-2641	210	71	a	a	NOUN
eurjchem-2641	210	72	)	)	PUNCT
eurjchem-2641	210	73	(	(	PUNCT
eurjchem-2641	210	74	b	b	X
eurjchem-2641	210	75	)	)	PUNCT
eurjchem-2641	210	76	(	(	PUNCT
eurjchem-2641	210	77	c	c	X
eurjchem-2641	210	78	)	)	PUNCT
eurjchem-2641	210	79	figure	figure	NOUN
eurjchem-2641	210	80	3	3	NUM
eurjchem-2641	210	81	.	.	PUNCT
eurjchem-2641	211	1	(	(	PUNCT
eurjchem-2641	211	2	a	a	X
eurjchem-2641	211	3	)	)	PUNCT
eurjchem-2641	211	4	caspase-3	caspase-3	NUM
eurjchem-2641	211	5	levels	level	NOUN
eurjchem-2641	211	6	,	,	PUNCT
eurjchem-2641	211	7	(	(	PUNCT
eurjchem-2641	211	8	b	b	X
eurjchem-2641	211	9	)	)	PUNCT
eurjchem-2641	211	10	bcl-2	bcl-2	NOUN
eurjchem-2641	211	11	levels	level	NOUN
eurjchem-2641	211	12	in	in	ADP
eurjchem-2641	211	13	all	all	DET
eurjchem-2641	211	14	study	study	NOUN
eurjchem-2641	211	15	groups	group	NOUN
eurjchem-2641	211	16	using	use	VERB
eurjchem-2641	211	17	the	the	DET
eurjchem-2641	211	18	elisa	elisa	NOUN
eurjchem-2641	211	19	technique	technique	NOUN
eurjchem-2641	211	20	with	with	ADP
eurjchem-2641	211	21	specific	specific	ADJ
eurjchem-2641	211	22	antibodies	antibody	NOUN
eurjchem-2641	211	23	,	,	PUNCT
eurjchem-2641	211	24	and	and	CCONJ
eurjchem-2641	211	25	(	(	PUNCT
eurjchem-2641	211	26	c	c	NOUN
eurjchem-2641	211	27	)	)	PUNCT
eurjchem-2641	211	28	levels	level	NOUN
eurjchem-2641	211	29	of	of	ADP
eurjchem-2641	211	30	tac	tac	PROPN
eurjchem-2641	211	31	in	in	ADP
eurjchem-2641	211	32	all	all	DET
eurjchem-2641	211	33	study	study	NOUN
eurjchem-2641	211	34	groups	group	NOUN
eurjchem-2641	211	35	using	use	VERB
eurjchem-2641	211	36	a	a	DET
eurjchem-2641	211	37	spectrophotometry	spectrophotometry	NOUN
eurjchem-2641	211	38	assay	assay	NOUN
eurjchem-2641	211	39	.	.	PUNCT
eurjchem-2641	212	1	one	one	NUM
eurjchem-2641	212	2	-	-	PUNCT
eurjchem-2641	212	3	way	way	NOUN
eurjchem-2641	212	4	anova	anova	PROPN
eurjchem-2641	212	5	followed	follow	VERB
eurjchem-2641	212	6	by	by	ADP
eurjchem-2641	212	7	tukey	tukey	PROPN
eurjchem-2641	212	8	posthoc	posthoc	NOUN
eurjchem-2641	212	9	test	test	NOUN
eurjchem-2641	212	10	was	be	AUX
eurjchem-2641	212	11	used	use	VERB
eurjchem-2641	212	12	for	for	ADP
eurjchem-2641	212	13	data	datum	NOUN
eurjchem-2641	212	14	analysis	analysis	NOUN
eurjchem-2641	212	15	;	;	PUNCT
eurjchem-2641	212	16	the	the	DET
eurjchem-2641	212	17	data	datum	NOUN
eurjchem-2641	212	18	were	be	AUX
eurjchem-2641	212	19	expressed	express	VERB
eurjchem-2641	212	20	as	as	ADP
eurjchem-2641	212	21	mean±sd	mean±sd	PROPN
eurjchem-2641	212	22	(	(	PUNCT
eurjchem-2641	212	23	n=	n=	ADJ
eurjchem-2641	212	24	75	75	NUM
eurjchem-2641	212	25	)	)	PUNCT
eurjchem-2641	212	26	.	.	PUNCT
eurjchem-2641	213	1	p	p	X
eurjchem-2641	213	2	<	<	X
eurjchem-2641	213	3	0.05	0.05	NUM
eurjchem-2641	213	4	was	be	AUX
eurjchem-2641	213	5	used	use	VERB
eurjchem-2641	213	6	as	as	ADP
eurjchem-2641	213	7	a	a	DET
eurjchem-2641	213	8	criterion	criterion	NOUN
eurjchem-2641	213	9	of	of	ADP
eurjchem-2641	213	10	significance	significance	NOUN
eurjchem-2641	213	11	.	.	PUNCT
eurjchem-2641	214	1	*	*	PUNCT
eurjchem-2641	214	2	significant	significant	ADJ
eurjchem-2641	214	3	difference	difference	NOUN
eurjchem-2641	214	4	from	from	ADP
eurjchem-2641	214	5	the	the	DET
eurjchem-2641	214	6	control	control	NOUN
eurjchem-2641	214	7	group	group	NOUN
eurjchem-2641	214	8	.	.	PUNCT
eurjchem-2641	215	1	≠	≠	PROPN
eurjchem-2641	215	2	significant	significant	ADJ
eurjchem-2641	215	3	difference	difference	NOUN
eurjchem-2641	215	4	from	from	ADP
eurjchem-2641	215	5	the	the	DET
eurjchem-2641	215	6	early	early	ADJ
eurjchem-2641	215	7	stage	stage	NOUN
eurjchem-2641	215	8	group	group	NOUN
eurjchem-2641	215	9	.	.	PUNCT
eurjchem-2641	216	1	€	€	NUM
eurjchem-2641	216	2	significant	significant	ADJ
eurjchem-2641	216	3	difference	difference	NOUN
eurjchem-2641	216	4	from	from	ADP
eurjchem-2641	216	5	the	the	DET
eurjchem-2641	216	6	chemotherapy	chemotherapy	NOUN
eurjchem-2641	216	7	group	group	NOUN
eurjchem-2641	216	8	.	.	PUNCT
eurjchem-2641	217	1	figure	figure	NOUN
eurjchem-2641	217	2	3a	3a	NUM
eurjchem-2641	217	3	.	.	PUNCT
eurjchem-2641	218	1	in	in	ADP
eurjchem-2641	218	2	addition	addition	NOUN
eurjchem-2641	218	3	,	,	PUNCT
eurjchem-2641	218	4	serum	serum	NOUN
eurjchem-2641	218	5	caspase-3	caspase-3	NUM
eurjchem-2641	218	6	in	in	ADP
eurjchem-2641	218	7	the	the	DET
eurjchem-2641	218	8	early	early	ADJ
eurjchem-2641	218	9	-	-	PUNCT
eurjchem-2641	218	10	stage	stage	NOUN
eurjchem-2641	218	11	group	group	NOUN
eurjchem-2641	218	12	decreased	decrease	VERB
eurjchem-2641	218	13	but	but	CCONJ
eurjchem-2641	218	14	with	with	ADP
eurjchem-2641	218	15	less	less	ADJ
eurjchem-2641	218	16	degree	degree	NOUN
eurjchem-2641	218	17	(	(	PUNCT
eurjchem-2641	218	18	4.933±0.82	4.933±0.82	NUM
eurjchem-2641	218	19	)	)	PUNCT
eurjchem-2641	218	20	compared	compare	VERB
eurjchem-2641	218	21	with	with	ADP
eurjchem-2641	218	22	the	the	DET
eurjchem-2641	218	23	control	control	NOUN
eurjchem-2641	218	24	group	group	NOUN
eurjchem-2641	218	25	;	;	PUNCT
eurjchem-2641	218	26	see	see	VERB
eurjchem-2641	218	27	figure	figure	NOUN
eurjchem-2641	218	28	3a	3a	NUM
eurjchem-2641	218	29	.	.	PUNCT
eurjchem-2641	219	1	on	on	ADP
eurjchem-2641	219	2	the	the	DET
eurjchem-2641	219	3	contrary	contrary	NOUN
eurjchem-2641	219	4	,	,	PUNCT
eurjchem-2641	219	5	the	the	DET
eurjchem-2641	219	6	serum	serum	NOUN
eurjchem-2641	219	7	bcl-2	bcl-2	PUNCT
eurjchem-2641	219	8	level	level	NOUN
eurjchem-2641	219	9	was	be	AUX
eurjchem-2641	219	10	significantly	significantly	ADV
eurjchem-2641	219	11	increased	increase	VERB
eurjchem-2641	219	12	in	in	ADP
eurjchem-2641	219	13	the	the	DET
eurjchem-2641	219	14	chemotherapy	chemotherapy	NOUN
eurjchem-2641	219	15	and	and	CCONJ
eurjchem-2641	219	16	surgery	surgery	NOUN
eurjchem-2641	219	17	treated	treat	VERB
eurjchem-2641	219	18	groups	group	NOUN
eurjchem-2641	219	19	(	(	PUNCT
eurjchem-2641	219	20	1.36±0.05	1.36±0.05	NOUN
eurjchem-2641	219	21	and	and	CCONJ
eurjchem-2641	219	22	0.71±0.11	0.71±0.11	NUM
eurjchem-2641	219	23	)	)	PUNCT
eurjchem-2641	219	24	compared	compare	VERB
eurjchem-2641	219	25	to	to	ADP
eurjchem-2641	219	26	the	the	DET
eurjchem-2641	219	27	control	control	NOUN
eurjchem-2641	219	28	group	group	NOUN
eurjchem-2641	219	29	(	(	PUNCT
eurjchem-2641	219	30	0.43±0.09	0.43±0.09	PROPN
eurjchem-2641	219	31	)	)	PUNCT
eurjchem-2641	219	32	.	.	PUNCT
eurjchem-2641	220	1	similarly	similarly	ADV
eurjchem-2641	220	2	,	,	PUNCT
eurjchem-2641	220	3	in	in	ADP
eurjchem-2641	220	4	the	the	DET
eurjchem-2641	220	5	early	early	ADJ
eurjchem-2641	220	6	-	-	PUNCT
eurjchem-2641	220	7	stage	stage	NOUN
eurjchem-2641	220	8	group	group	NOUN
eurjchem-2641	220	9	,	,	PUNCT
eurjchem-2641	220	10	levels	level	NOUN
eurjchem-2641	220	11	of	of	ADP
eurjchem-2641	220	12	bcl-2	bcl-2	NOUN
eurjchem-2641	220	13	increased	increase	VERB
eurjchem-2641	220	14	in	in	ADP
eurjchem-2641	220	15	serum	serum	NOUN
eurjchem-2641	220	16	(	(	PUNCT
eurjchem-2641	220	17	0.69±0.06	0.69±0.06	NOUN
eurjchem-2641	220	18	)	)	PUNCT
eurjchem-2641	220	19	;	;	PUNCT
eurjchem-2641	220	20	these	these	DET
eurjchem-2641	220	21	findings	finding	NOUN
eurjchem-2641	220	22	were	be	AUX
eurjchem-2641	220	23	displayed	display	VERB
eurjchem-2641	220	24	in	in	ADP
eurjchem-2641	220	25	figure	figure	NOUN
eurjchem-2641	220	26	3b	3b	NUM
eurjchem-2641	220	27	.	.	PUNCT
eurjchem-2641	221	1	3.5	3.5	NUM
eurjchem-2641	221	2	.	.	PUNCT
eurjchem-2641	222	1	tac	tac	NOUN
eurjchem-2641	222	2	the	the	DET
eurjchem-2641	222	3	present	present	ADJ
eurjchem-2641	222	4	results	result	NOUN
eurjchem-2641	222	5	showed	show	VERB
eurjchem-2641	222	6	that	that	SCONJ
eurjchem-2641	222	7	serum	serum	PROPN
eurjchem-2641	222	8	tac	tac	PROPN
eurjchem-2641	222	9	levels	level	NOUN
eurjchem-2641	222	10	decreased	decrease	VERB
eurjchem-2641	222	11	significantly	significantly	ADV
eurjchem-2641	222	12	in	in	ADP
eurjchem-2641	222	13	the	the	DET
eurjchem-2641	222	14	early	early	ADJ
eurjchem-2641	222	15	-	-	PUNCT
eurjchem-2641	222	16	stage	stage	NOUN
eurjchem-2641	222	17	group	group	NOUN
eurjchem-2641	222	18	(	(	PUNCT
eurjchem-2641	222	19	0.22±0.06	0.22±0.06	PROPN
eurjchem-2641	222	20	)	)	PUNCT
eurjchem-2641	222	21	,	,	PUNCT
eurjchem-2641	222	22	chemotherapy	chemotherapy	NOUN
eurjchem-2641	222	23	(	(	PUNCT
eurjchem-2641	222	24	0.18±0.08	0.18±0.08	NOUN
eurjchem-2641	222	25	)	)	PUNCT
eurjchem-2641	222	26	,	,	PUNCT
eurjchem-2641	222	27	and	and	CCONJ
eurjchem-2641	222	28	surgery	surgery	NOUN
eurjchem-2641	222	29	-	-	PUNCT
eurjchem-2641	222	30	treated	treat	VERB
eurjchem-2641	222	31	groups	group	NOUN
eurjchem-2641	222	32	(	(	PUNCT
eurjchem-2641	222	33	0.11±0.05	0.11±0.05	NOUN
eurjchem-2641	222	34	)	)	PUNCT
eurjchem-2641	222	35	compared	compare	VERB
eurjchem-2641	222	36	to	to	ADP
eurjchem-2641	222	37	the	the	DET
eurjchem-2641	222	38	control	control	NOUN
eurjchem-2641	222	39	group	group	NOUN
eurjchem-2641	222	40	(	(	PUNCT
eurjchem-2641	222	41	0.36±0.05	0.36±0.05	NOUN
eurjchem-2641	222	42	)	)	PUNCT
eurjchem-2641	222	43	as	as	SCONJ
eurjchem-2641	222	44	presented	present	VERB
eurjchem-2641	222	45	in	in	ADP
eurjchem-2641	222	46	figure	figure	NOUN
eurjchem-2641	222	47	3c	3c	NUM
eurjchem-2641	222	48	.	.	PUNCT
eurjchem-2641	223	1	the	the	DET
eurjchem-2641	223	2	current	current	ADJ
eurjchem-2641	223	3	investigation	investigation	NOUN
eurjchem-2641	223	4	shows	show	VERB
eurjchem-2641	223	5	a	a	DET
eurjchem-2641	223	6	positive	positive	ADJ
eurjchem-2641	223	7	correlation	correlation	NOUN
eurjchem-2641	223	8	between	between	ADP
eurjchem-2641	223	9	mirna-148b	mirna-148b	PROPN
eurjchem-2641	223	10	,	,	PUNCT
eurjchem-2641	223	11	bcl2	bcl2	NOUN
eurjchem-2641	223	12	,	,	PUNCT
eurjchem-2641	223	13	and	and	CCONJ
eurjchem-2641	223	14	bax	bax	PROPN
eurjchem-2641	223	15	*	*	PROPN
eurjchem-2641	223	16	.	.	PUNCT
eurjchem-2641	224	1	however	however	ADV
eurjchem-2641	224	2	,	,	PUNCT
eurjchem-2641	224	3	a	a	DET
eurjchem-2641	224	4	negative	negative	ADJ
eurjchem-2641	224	5	correlation	correlation	NOUN
eurjchem-2641	224	6	exists	exist	VERB
eurjchem-2641	224	7	between	between	ADP
eurjchem-2641	224	8	mirna-148b	mirna-148b	PROPN
eurjchem-2641	224	9	,	,	PUNCT
eurjchem-2641	224	10	bcl2	bcl2	NOUN
eurjchem-2641	224	11	and	and	CCONJ
eurjchem-2641	224	12	bax	bax	NOUN
eurjchem-2641	224	13	compared	compare	VERB
eurjchem-2641	224	14	to	to	ADP
eurjchem-2641	224	15	caspase-3	caspase-3	NUM
eurjchem-2641	224	16	and	and	CCONJ
eurjchem-2641	224	17	tac	tac	PROPN
eurjchem-2641	224	18	.	.	PUNCT
eurjchem-2641	225	1	on	on	ADP
eurjchem-2641	225	2	the	the	DET
eurjchem-2641	225	3	contrary	contrary	NOUN
eurjchem-2641	225	4	,	,	PUNCT
eurjchem-2641	225	5	there	there	PRON
eurjchem-2641	225	6	is	be	VERB
eurjchem-2641	225	7	a	a	DET
eurjchem-2641	225	8	positive	positive	ADJ
eurjchem-2641	225	9	correlation	correlation	NOUN
eurjchem-2641	225	10	of	of	ADP
eurjchem-2641	225	11	caspase-3	caspase-3	NUM
eurjchem-2641	225	12	and	and	CCONJ
eurjchem-2641	225	13	tac	tac	PROPN
eurjchem-2641	225	14	.	.	PUNCT
eurjchem-2641	225	15	table	table	NOUN
eurjchem-2641	225	16	4	4	NUM
eurjchem-2641	225	17	.	.	X
eurjchem-2641	226	1	summary	summary	NOUN
eurjchem-2641	226	2	and	and	CCONJ
eurjchem-2641	226	3	correlation	correlation	NOUN
eurjchem-2641	226	4	of	of	ADP
eurjchem-2641	226	5	the	the	DET
eurjchem-2641	226	6	cbc	cbc	NOUN
eurjchem-2641	226	7	parameters	parameter	NOUN
eurjchem-2641	226	8	and	and	CCONJ
eurjchem-2641	226	9	mirna148b	mirna148b	PROPN
eurjchem-2641	226	10	,	,	PUNCT
eurjchem-2641	226	11	bax	bax	PROPN
eurjchem-2641	226	12	,	,	PUNCT
eurjchem-2641	226	13	caspase-3	caspase-3	PROPN
eurjchem-2641	226	14	,	,	PUNCT
eurjchem-2641	226	15	bcl2	bcl2	NOUN
eurjchem-2641	226	16	,	,	PUNCT
eurjchem-2641	226	17	and	and	CCONJ
eurjchem-2641	226	18	tac	tac	PROPN
eurjchem-2641	226	19	.	.	PUNCT
eurjchem-2641	227	1	3.6	3.6	NUM
eurjchem-2641	227	2	.	.	PUNCT
eurjchem-2641	228	1	histopathological	histopathological	ADJ
eurjchem-2641	228	2	findings	finding	NOUN
eurjchem-2641	228	3	the	the	DET
eurjchem-2641	228	4	histopathological	histopathological	ADJ
eurjchem-2641	228	5	result	result	NOUN
eurjchem-2641	228	6	showed	show	VERB
eurjchem-2641	228	7	typical	typical	ADJ
eurjchem-2641	228	8	structures	structure	NOUN
eurjchem-2641	228	9	of	of	ADP
eurjchem-2641	228	10	luminal	luminal	ADJ
eurjchem-2641	228	11	and	and	CCONJ
eurjchem-2641	228	12	myoepithelial	myoepithelial	ADJ
eurjchem-2641	228	13	cells	cell	NOUN
eurjchem-2641	228	14	.	.	PUNCT
eurjchem-2641	229	1	moreover	moreover	ADV
eurjchem-2641	229	2	,	,	PUNCT
eurjchem-2641	229	3	regular	regular	ADJ
eurjchem-2641	229	4	,	,	PUNCT
eurjchem-2641	229	5	small	small	ADJ
eurjchem-2641	229	6	,	,	PUNCT
eurjchem-2641	229	7	rounded	rounded	ADJ
eurjchem-2641	229	8	hyperchromatic	hyperchromatic	ADJ
eurjchem-2641	229	9	nuclei	nucleus	NOUN
eurjchem-2641	229	10	in	in	ADP
eurjchem-2641	229	11	the	the	DET
eurjchem-2641	229	12	control	control	NOUN
eurjchem-2641	229	13	group	group	NOUN
eurjchem-2641	229	14	,	,	PUNCT
eurjchem-2641	229	15	see	see	VERB
eurjchem-2641	229	16	figure	figure	NOUN
eurjchem-2641	229	17	4a	4a	NOUN
eurjchem-2641	229	18	.	.	PUNCT
eurjchem-2641	230	1	on	on	ADP
eurjchem-2641	230	2	the	the	DET
eurjchem-2641	230	3	contrary	contrary	NOUN
eurjchem-2641	230	4	,	,	PUNCT
eurjchem-2641	230	5	breast	breast	NOUN
eurjchem-2641	230	6	tissues	tissue	NOUN
eurjchem-2641	230	7	obtained	obtain	VERB
eurjchem-2641	230	8	from	from	ADP
eurjchem-2641	230	9	early	early	ADJ
eurjchem-2641	230	10	-	-	PUNCT
eurjchem-2641	230	11	stage	stage	NOUN
eurjchem-2641	230	12	bc	bc	PROPN
eurjchem-2641	230	13	patients	patient	NOUN
eurjchem-2641	230	14	showed	show	VERB
eurjchem-2641	230	15	histopathological	histopathological	ADJ
eurjchem-2641	230	16	changes	change	NOUN
eurjchem-2641	230	17	regarding	regard	VERB
eurjchem-2641	230	18	heterogeneous	heterogeneous	ADJ
eurjchem-2641	230	19	cells	cell	NOUN
eurjchem-2641	230	20	and	and	CCONJ
eurjchem-2641	230	21	granulomatous	granulomatous	ADJ
eurjchem-2641	230	22	inflammation	inflammation	NOUN
eurjchem-2641	230	23	,	,	PUNCT
eurjchem-2641	230	24	figure	figure	NOUN
eurjchem-2641	230	25	4b	4b	PROPN
eurjchem-2641	230	26	.	.	PUNCT
eurjchem-2641	231	1	furthermore	furthermore	ADV
eurjchem-2641	231	2	,	,	PUNCT
eurjchem-2641	231	3	the	the	DET
eurjchem-2641	231	4	tissue	tissue	NOUN
eurjchem-2641	231	5	from	from	ADP
eurjchem-2641	231	6	the	the	DET
eurjchem-2641	231	7	chemotherapy	chemotherapy	NOUN
eurjchem-2641	231	8	-	-	PUNCT
eurjchem-2641	231	9	treated	treat	VERB
eurjchem-2641	231	10	group	group	NOUN
eurjchem-2641	231	11	showed	show	VERB
eurjchem-2641	231	12	changes	change	NOUN
eurjchem-2641	231	13	in	in	ADP
eurjchem-2641	231	14	nuclear	nuclear	ADJ
eurjchem-2641	231	15	features	feature	NOUN
eurjchem-2641	231	16	,	,	PUNCT
eurjchem-2641	231	17	size	size	NOUN
eurjchem-2641	231	18	,	,	PUNCT
eurjchem-2641	231	19	and	and	CCONJ
eurjchem-2641	231	20	shape	shape	NOUN
eurjchem-2641	231	21	(	(	PUNCT
eurjchem-2641	231	22	figure	figure	NOUN
eurjchem-2641	231	23	4c	4c	NOUN
eurjchem-2641	231	24	)	)	PUNCT
eurjchem-2641	231	25	;	;	PUNCT
eurjchem-2641	231	26	similarly	similarly	ADV
eurjchem-2641	231	27	,	,	PUNCT
eurjchem-2641	231	28	the	the	DET
eurjchem-2641	231	29	tissue	tissue	NOUN
eurjchem-2641	231	30	from	from	ADP
eurjchem-2641	231	31	the	the	DET
eurjchem-2641	231	32	surgery	surgery	NOUN
eurjchem-2641	231	33	group	group	NOUN
eurjchem-2641	231	34	showed	show	VERB
eurjchem-2641	231	35	giant	giant	ADJ
eurjchem-2641	231	36	cells	cell	NOUN
eurjchem-2641	231	37	,	,	PUNCT
eurjchem-2641	231	38	polymorphonuclear	polymorphonuclear	NOUN
eurjchem-2641	231	39	cells	cell	NOUN
eurjchem-2641	231	40	,	,	PUNCT
eurjchem-2641	231	41	and	and	CCONJ
eurjchem-2641	231	42	central	central	ADJ
eurjchem-2641	231	43	inflammation	inflammation	NOUN
eurjchem-2641	231	44	(	(	PUNCT
eurjchem-2641	231	45	figure	figure	NOUN
eurjchem-2641	231	46	4d	4d	NUM
eurjchem-2641	231	47	)	)	PUNCT
eurjchem-2641	231	48	.	.	PUNCT
eurjchem-2641	232	1	3	3	X
eurjchem-2641	232	2	.	.	X
eurjchem-2641	232	3	discussion	discussion	NOUN
eurjchem-2641	232	4	bc	bc	PROPN
eurjchem-2641	232	5	is	be	AUX
eurjchem-2641	232	6	a	a	DET
eurjchem-2641	232	7	complicated	complicated	ADJ
eurjchem-2641	232	8	health	health	NOUN
eurjchem-2641	232	9	problem	problem	NOUN
eurjchem-2641	232	10	due	due	ADP
eurjchem-2641	232	11	to	to	ADP
eurjchem-2641	232	12	a	a	DET
eurjchem-2641	232	13	lack	lack	NOUN
eurjchem-2641	232	14	of	of	ADP
eurjchem-2641	232	15	prediction	prediction	NOUN
eurjchem-2641	232	16	,	,	PUNCT
eurjchem-2641	232	17	relapse	relapse	NOUN
eurjchem-2641	232	18	,	,	PUNCT
eurjchem-2641	232	19	metastasis	metastasis	NOUN
eurjchem-2641	232	20	,	,	PUNCT
eurjchem-2641	232	21	and	and	CCONJ
eurjchem-2641	232	22	drug	drug	NOUN
eurjchem-2641	232	23	resistance	resistance	NOUN
eurjchem-2641	232	24	[	[	X
eurjchem-2641	232	25	33	33	NUM
eurjchem-2641	232	26	]	]	PUNCT
eurjchem-2641	232	27	.	.	PUNCT
eurjchem-2641	233	1	mirnas	mirna	NOUN
eurjchem-2641	233	2	are	be	AUX
eurjchem-2641	233	3	dual	dual	ADV
eurjchem-2641	233	4	-	-	PUNCT
eurjchem-2641	233	5	edged	edge	VERB
eurjchem-2641	233	6	cancer	cancer	NOUN
eurjchem-2641	233	7	inhibition	inhibition	NOUN
eurjchem-2641	233	8	,	,	PUNCT
eurjchem-2641	233	9	oncogenesis	oncogenesis	NOUN
eurjchem-2641	233	10	,	,	PUNCT
eurjchem-2641	233	11	metastasis	metastasis	NOUN
eurjchem-2641	233	12	,	,	PUNCT
eurjchem-2641	233	13	and	and	CCONJ
eurjchem-2641	233	14	drug	drug	NOUN
eurjchem-2641	233	15	resistance	resistance	NOUN
eurjchem-2641	233	16	of	of	ADP
eurjchem-2641	233	17	bc	bc	PROPN
eurjchem-2641	234	1	[	[	X
eurjchem-2641	234	2	34	34	NUM
eurjchem-2641	234	3	]	]	PUNCT
eurjchem-2641	234	4	.	.	PUNCT
eurjchem-2641	235	1	in	in	ADP
eurjchem-2641	235	2	this	this	DET
eurjchem-2641	235	3	regard	regard	NOUN
eurjchem-2641	235	4	,	,	PUNCT
eurjchem-2641	235	5	mirna-26a	mirna-26a	PROPN
eurjchem-2641	235	6	,	,	PUNCT
eurjchem-2641	235	7	-26b	-26b	NOUN
eurjchem-2641	235	8	,	,	PUNCT
eurjchem-2641	235	9	-125a	-125a	PROPN
eurjchem-2641	235	10	,	,	PUNCT
eurjchem-2641	235	11	-125b	-125b	PROPN
eurjchem-2641	235	12	,	,	PUNCT
eurjchem-2641	235	13	-145	-145	PROPN
eurjchem-2641	235	14	,	,	PUNCT
eurjchem-2641	235	15	-486	-486	PROPN
eurjchem-2641	235	16	-	-	PUNCT
eurjchem-2641	235	17	5p	5p	NUM
eurjchem-2641	235	18	,	,	PUNCT
eurjchem-2641	235	19	-497	-497	PROPN
eurjchem-2641	235	20	,	,	PUNCT
eurjchem-2641	235	21	-874	-874	PROPN
eurjchem-2641	235	22	,	,	PUNCT
eurjchem-2641	235	23	and	and	CCONJ
eurjchem-2641	235	24	99a	99a	NOUN
eurjchem-2641	235	25	are	be	AUX
eurjchem-2641	235	26	proposed	propose	VERB
eurjchem-2641	235	27	as	as	ADP
eurjchem-2641	235	28	pro	pro	ADJ
eurjchem-2641	235	29	-	-	ADJ
eurjchem-2641	235	30	apoptotic	apoptotic	ADJ
eurjchem-2641	235	31	mirnas	mirna	NOUN
eurjchem-2641	235	32	and	and	CCONJ
eurjchem-2641	235	33	are	be	AUX
eurjchem-2641	235	34	downregulated	downregulate	VERB
eurjchem-2641	235	35	in	in	ADP
eurjchem-2641	235	36	bc	bc	PROPN
eurjchem-2641	235	37	patients	patient	NOUN
eurjchem-2641	235	38	[	[	X
eurjchem-2641	235	39	35	35	NUM
eurjchem-2641	235	40	]	]	PUNCT
eurjchem-2641	235	41	.	.	PUNCT
eurjchem-2641	236	1	however	however	ADV
eurjchem-2641	236	2	,	,	PUNCT
eurjchem-2641	236	3	mirna-21	mirna-21	PROPN
eurjchem-2641	236	4	,	,	PUNCT
eurjchem-2641	236	5	-155	-155	PROPN
eurjchem-2641	236	6	,	,	PUNCT
eurjchem-2641	236	7	-96	-96	ADV
eurjchem-2641	236	8	,	,	PUNCT
eurjchem-2641	236	9	182	182	NUM
eurjchem-2641	236	10	,	,	PUNCT
eurjchem-2641	236	11	-196a	-196a	ADJ
eurjchem-2641	236	12	,	,	PUNCT
eurjchem-2641	236	13	and	and	CCONJ
eurjchem-2641	236	14	-210	-210	PROPN
eurjchem-2641	236	15	are	be	AUX
eurjchem-2641	236	16	proposed	propose	VERB
eurjchem-2641	236	17	as	as	ADP
eurjchem-2641	236	18	antiapoptotic	antiapoptotic	ADJ
eurjchem-2641	236	19	mirnas	mirna	NOUN
eurjchem-2641	236	20	upregulated	upregulate	VERB
eurjchem-2641	236	21	in	in	ADP
eurjchem-2641	236	22	bc	bc	PROPN
eurjchem-2641	236	23	patients	patient	NOUN
eurjchem-2641	236	24	[	[	X
eurjchem-2641	236	25	35	35	NUM
eurjchem-2641	236	26	]	]	PUNCT
eurjchem-2641	236	27	.	.	PUNCT
eurjchem-2641	237	1	thus	thus	ADV
eurjchem-2641	237	2	,	,	PUNCT
eurjchem-2641	237	3	dysregulation	dysregulation	NOUN
eurjchem-2641	237	4	of	of	ADP
eurjchem-2641	237	5	mirnas	mirna	NOUN
eurjchem-2641	237	6	is	be	AUX
eurjchem-2641	237	7	an	an	DET
eurjchem-2641	237	8	aspect	aspect	NOUN
eurjchem-2641	237	9	of	of	ADP
eurjchem-2641	237	10	the	the	DET
eurjchem-2641	237	11	oncogenesis	oncogenesis	NOUN
eurjchem-2641	237	12	and	and	CCONJ
eurjchem-2641	237	13	development	development	NOUN
eurjchem-2641	237	14	of	of	ADP
eurjchem-2641	237	15	bc	bc	PROPN
eurjchem-2641	237	16	[	[	X
eurjchem-2641	237	17	19	19	NUM
eurjchem-2641	237	18	]	]	PUNCT
eurjchem-2641	237	19	.	.	PUNCT
eurjchem-2641	238	1	despite	despite	SCONJ
eurjchem-2641	238	2	the	the	DET
eurjchem-2641	238	3	success	success	NOUN
eurjchem-2641	238	4	of	of	ADP
eurjchem-2641	238	5	classical	classical	ADJ
eurjchem-2641	238	6	tools	tool	NOUN
eurjchem-2641	238	7	in	in	ADP
eurjchem-2641	238	8	predicting	predict	VERB
eurjchem-2641	238	9	,	,	PUNCT
eurjchem-2641	238	10	diagnosing	diagnosing	NOUN
eurjchem-2641	238	11	,	,	PUNCT
eurjchem-2641	238	12	and	and	CCONJ
eurjchem-2641	238	13	prognostic	prognostic	PROPN
eurjchem-2641	238	14	bc	bc	PROPN
eurjchem-2641	238	15	,	,	PUNCT
eurjchem-2641	238	16	most	most	ADJ
eurjchem-2641	238	17	of	of	ADP
eurjchem-2641	238	18	these	these	DET
eurjchem-2641	238	19	methods	method	NOUN
eurjchem-2641	238	20	are	be	AUX
eurjchem-2641	238	21	invasive	invasive	ADJ
eurjchem-2641	238	22	and	and	CCONJ
eurjchem-2641	238	23	still	still	ADV
eurjchem-2641	238	24	have	have	VERB
eurjchem-2641	238	25	abundant	abundant	ADJ
eurjchem-2641	238	26	limitations	limitation	NOUN
eurjchem-2641	238	27	[	[	X
eurjchem-2641	238	28	36	36	NUM
eurjchem-2641	238	29	]	]	PUNCT
eurjchem-2641	238	30	.	.	PUNCT
eurjchem-2641	239	1	228	228	NUM
eurjchem-2641	239	2	harisa	harisa	NOUN
eurjchem-2641	239	3	et	et	PROPN
eurjchem-2641	239	4	al	al	PROPN
eurjchem-2641	239	5	.	.	PUNCT
eurjchem-2641	239	6	/	/	SYM
eurjchem-2641	239	7	european	european	PROPN
eurjchem-2641	239	8	journal	journal	PROPN
eurjchem-2641	239	9	of	of	ADP
eurjchem-2641	239	10	chemistry	chemistry	NOUN
eurjchem-2641	239	11	16	16	NUM
eurjchem-2641	239	12	(	(	PUNCT
eurjchem-2641	239	13	2	2	NUM
eurjchem-2641	239	14	)	)	PUNCT
eurjchem-2641	239	15	(	(	PUNCT
eurjchem-2641	239	16	2025	2025	NUM
eurjchem-2641	239	17	)	)	PUNCT
eurjchem-2641	239	18	222	222	NUM
eurjchem-2641	239	19	-	-	SYM
eurjchem-2641	239	20	232	232	NUM
eurjchem-2641	239	21	2025	2025	NUM
eurjchem-2641	239	22	–	–	PUNCT
eurjchem-2641	239	23	european	european	ADJ
eurjchem-2641	239	24	journal	journal	NOUN
eurjchem-2641	239	25	of	of	ADP
eurjchem-2641	239	26	chemistry	chemistry	NOUN
eurjchem-2641	239	27	–	–	PUNCT
eurjchem-2641	239	28	cc	cc	NOUN
eurjchem-2641	239	29	by	by	ADP
eurjchem-2641	239	30	nc	nc	PROPN
eurjchem-2641	239	31	–	–	PUNCT
eurjchem-2641	239	32	doi	doi	NOUN
eurjchem-2641	239	33	:	:	PUNCT
eurjchem-2641	239	34	10.5155	10.5155	NUM
eurjchem-2641	239	35	/	/	SYM
eurjchem-2641	239	36	eurjchem.16.2.222	eurjchem.16.2.222	NOUN
eurjchem-2641	239	37	-	-	SYM
eurjchem-2641	239	38	232.2641	232.2641	NUM
eurjchem-2641	239	39	(	(	PUNCT
eurjchem-2641	239	40	a	a	NOUN
eurjchem-2641	239	41	)	)	PUNCT
eurjchem-2641	239	42	(	(	PUNCT
eurjchem-2641	239	43	b	b	X
eurjchem-2641	239	44	)	)	PUNCT
eurjchem-2641	239	45	(	(	PUNCT
eurjchem-2641	239	46	c	c	X
eurjchem-2641	239	47	)	)	PUNCT
eurjchem-2641	239	48	(	(	PUNCT
eurjchem-2641	239	49	d	d	X
eurjchem-2641	239	50	)	)	PUNCT
eurjchem-2641	239	51	figure	figure	NOUN
eurjchem-2641	239	52	4	4	NUM
eurjchem-2641	239	53	.	.	PUNCT
eurjchem-2641	239	54	histopathological	histopathological	ADJ
eurjchem-2641	239	55	changes	change	NOUN
eurjchem-2641	239	56	:	:	PUNCT
eurjchem-2641	239	57	(	(	PUNCT
eurjchem-2641	239	58	a	a	X
eurjchem-2641	239	59	)	)	PUNCT
eurjchem-2641	239	60	the	the	DET
eurjchem-2641	239	61	control	control	NOUN
eurjchem-2641	239	62	group	group	NOUN
eurjchem-2641	239	63	shows	show	VERB
eurjchem-2641	239	64	normal	normal	ADJ
eurjchem-2641	239	65	structures	structure	NOUN
eurjchem-2641	239	66	of	of	ADP
eurjchem-2641	239	67	luminal	luminal	ADJ
eurjchem-2641	239	68	and	and	CCONJ
eurjchem-2641	239	69	myoepithelial	myoepithelial	ADJ
eurjchem-2641	239	70	cells	cell	NOUN
eurjchem-2641	239	71	.	.	PUNCT
eurjchem-2641	240	1	(	(	PUNCT
eurjchem-2641	240	2	b	b	X
eurjchem-2641	240	3	)	)	PUNCT
eurjchem-2641	240	4	early	early	ADJ
eurjchem-2641	240	5	-	-	PUNCT
eurjchem-2641	240	6	stage	stage	NOUN
eurjchem-2641	240	7	bc	bc	PROPN
eurjchem-2641	240	8	group	group	PROPN
eurjchem-2641	240	9	showing	show	VERB
eurjchem-2641	240	10	heterogeneous	heterogeneous	ADJ
eurjchem-2641	240	11	changes	change	NOUN
eurjchem-2641	240	12	in	in	ADP
eurjchem-2641	240	13	breast	breast	NOUN
eurjchem-2641	240	14	tissues	tissue	NOUN
eurjchem-2641	240	15	(	(	PUNCT
eurjchem-2641	240	16	arrow	arrow	NOUN
eurjchem-2641	240	17	)	)	PUNCT
eurjchem-2641	240	18	.	.	PUNCT
eurjchem-2641	241	1	(	(	PUNCT
eurjchem-2641	241	2	c	c	X
eurjchem-2641	241	3	)	)	PUNCT
eurjchem-2641	241	4	the	the	DET
eurjchem-2641	241	5	chemotherapy	chemotherapy	NOUN
eurjchem-2641	241	6	-	-	PUNCT
eurjchem-2641	241	7	treated	treat	VERB
eurjchem-2641	241	8	group	group	NOUN
eurjchem-2641	241	9	showed	show	VERB
eurjchem-2641	241	10	changes	change	NOUN
eurjchem-2641	241	11	in	in	ADP
eurjchem-2641	241	12	nuclear	nuclear	ADJ
eurjchem-2641	241	13	features	feature	NOUN
eurjchem-2641	241	14	(	(	PUNCT
eurjchem-2641	241	15	size	size	NOUN
eurjchem-2641	241	16	and	and	CCONJ
eurjchem-2641	241	17	shape	shape	NOUN
eurjchem-2641	241	18	)	)	PUNCT
eurjchem-2641	241	19	(	(	PUNCT
eurjchem-2641	241	20	arrow	arrow	NOUN
eurjchem-2641	241	21	)	)	PUNCT
eurjchem-2641	241	22	.	.	PUNCT
eurjchem-2641	242	1	(	(	PUNCT
eurjchem-2641	242	2	d	d	X
eurjchem-2641	242	3	)	)	PUNCT
eurjchem-2641	242	4	the	the	DET
eurjchem-2641	242	5	surgery	surgery	NOUN
eurjchem-2641	242	6	group	group	NOUN
eurjchem-2641	242	7	showed	show	VERB
eurjchem-2641	242	8	two	two	NUM
eurjchem-2641	242	9	giant	giant	ADJ
eurjchem-2641	242	10	cells	cell	NOUN
eurjchem-2641	242	11	and	and	CCONJ
eurjchem-2641	242	12	central	central	ADJ
eurjchem-2641	242	13	inflammation	inflammation	NOUN
eurjchem-2641	242	14	(	(	PUNCT
eurjchem-2641	242	15	arrow	arrow	NOUN
eurjchem-2641	242	16	)	)	PUNCT
eurjchem-2641	242	17	.	.	PUNCT
eurjchem-2641	243	1	slides	slide	NOUN
eurjchem-2641	243	2	were	be	AUX
eurjchem-2641	243	3	examined	examine	VERB
eurjchem-2641	243	4	using	use	VERB
eurjchem-2641	243	5	h&e	h&e	PROPN
eurjchem-2641	243	6	stain	stain	NOUN
eurjchem-2641	243	7	with	with	ADP
eurjchem-2641	243	8	magnification	magnification	NOUN
eurjchem-2641	243	9	×40	×40	NUM
eurjchem-2641	243	10	and	and	CCONJ
eurjchem-2641	243	11	scale	scale	NOUN
eurjchem-2641	243	12	bar=	bar=	PROPN
eurjchem-2641	243	13	100	100	NUM
eurjchem-2641	243	14	µm	µm	NOUN
eurjchem-2641	243	15	.	.	PUNCT
eurjchem-2641	244	1	several	several	ADJ
eurjchem-2641	244	2	studies	study	NOUN
eurjchem-2641	244	3	reported	report	VERB
eurjchem-2641	244	4	that	that	SCONJ
eurjchem-2641	244	5	lbs	lbs	PROPN
eurjchem-2641	244	6	mirnas	mirna	NOUN
eurjchem-2641	244	7	act	act	VERB
eurjchem-2641	244	8	as	as	ADP
eurjchem-2641	244	9	novel	novel	ADJ
eurjchem-2641	244	10	noninvasive	noninvasive	ADJ
eurjchem-2641	244	11	biomarkers	biomarker	NOUN
eurjchem-2641	244	12	for	for	ADP
eurjchem-2641	244	13	bc	bc	PROPN
eurjchem-2641	244	14	diagnosis	diagnosis	NOUN
eurjchem-2641	244	15	.	.	PUNCT
eurjchem-2641	245	1	however	however	ADV
eurjchem-2641	245	2	,	,	PUNCT
eurjchem-2641	245	3	mirna	mirna	PROPN
eurjchem-2641	245	4	correlated	correlate	VERB
eurjchem-2641	245	5	with	with	ADP
eurjchem-2641	245	6	positive	positive	ADJ
eurjchem-2641	245	7	estrogen	estrogen	NOUN
eurjchem-2641	245	8	receptors	receptor	NOUN
eurjchem-2641	245	9	(	(	PUNCT
eurjchem-2641	245	10	er	er	INTJ
eurjchem-2641	245	11	)	)	PUNCT
eurjchem-2641	245	12	and	and	CCONJ
eurjchem-2641	245	13	negative	negative	ADJ
eurjchem-2641	245	14	er	er	INTJ
eurjchem-2641	245	15	bc	bc	PROPN
eurjchem-2641	245	16	cells	cell	NOUN
eurjchem-2641	245	17	[	[	X
eurjchem-2641	245	18	37	37	NUM
eurjchem-2641	245	19	]	]	PUNCT
eurjchem-2641	245	20	.	.	PUNCT
eurjchem-2641	246	1	thus	thus	ADV
eurjchem-2641	246	2	,	,	PUNCT
eurjchem-2641	246	3	mirna	mirna	PROPN
eurjchem-2641	246	4	measurement	measurement	PROPN
eurjchem-2641	246	5	in	in	ADP
eurjchem-2641	246	6	lbs	lbs	NOUN
eurjchem-2641	246	7	could	could	AUX
eurjchem-2641	246	8	be	be	AUX
eurjchem-2641	246	9	a	a	DET
eurjchem-2641	246	10	non	non	ADJ
eurjchem-2641	246	11	-	-	ADJ
eurjchem-2641	246	12	invasive	invasive	ADJ
eurjchem-2641	246	13	tool	tool	NOUN
eurjchem-2641	246	14	to	to	PART
eurjchem-2641	246	15	predict	predict	VERB
eurjchem-2641	246	16	bc	bc	PROPN
eurjchem-2641	247	1	[	[	X
eurjchem-2641	247	2	36,37	36,37	X
eurjchem-2641	247	3	]	]	PUNCT
eurjchem-2641	247	4	.	.	PUNCT
eurjchem-2641	248	1	furthermore	furthermore	ADV
eurjchem-2641	248	2	,	,	PUNCT
eurjchem-2641	248	3	a	a	DET
eurjchem-2641	248	4	previous	previous	ADJ
eurjchem-2641	248	5	study	study	NOUN
eurjchem-2641	248	6	indicated	indicate	VERB
eurjchem-2641	248	7	that	that	SCONJ
eurjchem-2641	248	8	mirnas	mirna	NOUN
eurjchem-2641	248	9	are	be	AUX
eurjchem-2641	248	10	overexpressed	overexpresse	VERB
eurjchem-2641	248	11	in	in	ADP
eurjchem-2641	248	12	bc	bc	PROPN
eurjchem-2641	248	13	cells	cell	NOUN
eurjchem-2641	248	14	[	[	X
eurjchem-2641	248	15	36	36	NUM
eurjchem-2641	248	16	]	]	PUNCT
eurjchem-2641	248	17	.	.	PUNCT
eurjchem-2641	249	1	several	several	ADJ
eurjchem-2641	249	2	mirnas	mirna	NOUN
eurjchem-2641	249	3	such	such	ADJ
eurjchem-2641	249	4	as	as	ADP
eurjchem-2641	249	5	mirna-148b-3b	mirna-148b-3b	PROPN
eurjchem-2641	249	6	,	,	PUNCT
eurjchem-2641	249	7	mirma190b	mirma190b	NOUN
eurjchem-2641	249	8	,	,	PUNCT
eurjchem-2641	249	9	mirna-429	mirna-429	ADJ
eurjchem-2641	249	10	,	,	PUNCT
eurjchem-2641	249	11	and	and	CCONJ
eurjchem-2641	249	12	other	other	ADJ
eurjchem-2641	249	13	mirnas	mirna	NOUN
eurjchem-2641	249	14	have	have	AUX
eurjchem-2641	249	15	also	also	ADV
eurjchem-2641	249	16	been	be	AUX
eurjchem-2641	249	17	reported	report	VERB
eurjchem-2641	249	18	as	as	ADP
eurjchem-2641	249	19	a	a	DET
eurjchem-2641	249	20	signature	signature	NOUN
eurjchem-2641	249	21	for	for	ADP
eurjchem-2641	249	22	the	the	DET
eurjchem-2641	249	23	diagnosing	diagnosing	NOUN
eurjchem-2641	249	24	bc	bc	PROPN
eurjchem-2641	250	1	[	[	X
eurjchem-2641	250	2	36	36	NUM
eurjchem-2641	250	3	]	]	PUNCT
eurjchem-2641	250	4	.	.	PUNCT
eurjchem-2641	251	1	specifically	specifically	ADV
eurjchem-2641	251	2	,	,	PUNCT
eurjchem-2641	251	3	mirna148b	mirna148b	PROPN
eurjchem-2641	251	4	shows	show	VERB
eurjchem-2641	251	5	a	a	DET
eurjchem-2641	251	6	significant	significant	ADJ
eurjchem-2641	251	7	relationship	relationship	NOUN
eurjchem-2641	251	8	with	with	ADP
eurjchem-2641	251	9	the	the	DET
eurjchem-2641	251	10	survival	survival	NOUN
eurjchem-2641	251	11	time	time	NOUN
eurjchem-2641	251	12	of	of	ADP
eurjchem-2641	251	13	bc	bc	PROPN
eurjchem-2641	251	14	patients	patient	NOUN
eurjchem-2641	251	15	[	[	X
eurjchem-2641	251	16	36	36	NUM
eurjchem-2641	251	17	]	]	PUNCT
eurjchem-2641	251	18	.	.	PUNCT
eurjchem-2641	252	1	thus	thus	ADV
eurjchem-2641	252	2	,	,	PUNCT
eurjchem-2641	252	3	mirnas	mirna	NOUN
eurjchem-2641	252	4	are	be	AUX
eurjchem-2641	252	5	suggested	suggest	VERB
eurjchem-2641	252	6	as	as	ADP
eurjchem-2641	252	7	a	a	DET
eurjchem-2641	252	8	non	non	ADJ
eurjchem-2641	252	9	-	-	ADJ
eurjchem-2641	252	10	invasive	invasive	ADJ
eurjchem-2641	252	11	biomarker	biomarker	NOUN
eurjchem-2641	252	12	for	for	ADP
eurjchem-2641	252	13	bc	bc	PROPN
eurjchem-2641	252	14	prediction	prediction	NOUN
eurjchem-2641	252	15	,	,	PUNCT
eurjchem-2641	252	16	diagnosis	diagnosis	NOUN
eurjchem-2641	252	17	,	,	PUNCT
eurjchem-2641	252	18	and	and	CCONJ
eurjchem-2641	252	19	improved	improve	VERB
eurjchem-2641	252	20	bc	bc	PROPN
eurjchem-2641	252	21	patient	patient	PROPN
eurjchem-2641	252	22	survival	survival	NOUN
eurjchem-2641	252	23	[	[	X
eurjchem-2641	252	24	38	38	NUM
eurjchem-2641	252	25	]	]	PUNCT
eurjchem-2641	252	26	.	.	PUNCT
eurjchem-2641	253	1	in	in	ADP
eurjchem-2641	253	2	the	the	DET
eurjchem-2641	253	3	present	present	ADJ
eurjchem-2641	253	4	study	study	NOUN
eurjchem-2641	253	5	,	,	PUNCT
eurjchem-2641	253	6	mirna-148b	mirna-148b	PROPN
eurjchem-2641	253	7	transcriptomes	transcriptome	NOUN
eurjchem-2641	253	8	were	be	AUX
eurjchem-2641	253	9	significantly	significantly	ADV
eurjchem-2641	253	10	overexpressed	overexpresse	VERB
eurjchem-2641	253	11	in	in	ADP
eurjchem-2641	253	12	the	the	DET
eurjchem-2641	253	13	surgery	surgery	NOUN
eurjchem-2641	253	14	group	group	NOUN
eurjchem-2641	253	15	compared	compare	VERB
eurjchem-2641	253	16	to	to	ADP
eurjchem-2641	253	17	the	the	DET
eurjchem-2641	253	18	early	early	ADJ
eurjchem-2641	253	19	-	-	PUNCT
eurjchem-2641	253	20	stage	stage	NOUN
eurjchem-2641	253	21	and	and	CCONJ
eurjchem-2641	253	22	chemotherapy	chemotherapy	NOUN
eurjchem-2641	253	23	groups	group	NOUN
eurjchem-2641	253	24	.	.	PUNCT
eurjchem-2641	254	1	furthermore	furthermore	ADV
eurjchem-2641	254	2	,	,	PUNCT
eurjchem-2641	254	3	there	there	PRON
eurjchem-2641	254	4	was	be	VERB
eurjchem-2641	254	5	a	a	DET
eurjchem-2641	254	6	significant	significant	ADJ
eurjchem-2641	254	7	overexpression	overexpression	NOUN
eurjchem-2641	254	8	of	of	ADP
eurjchem-2641	254	9	mirna-148b	mirna-148b	PROPN
eurjchem-2641	254	10	in	in	ADP
eurjchem-2641	254	11	the	the	DET
eurjchem-2641	254	12	chemotherapy	chemotherapy	NOUN
eurjchem-2641	254	13	group	group	NOUN
eurjchem-2641	254	14	compared	compare	VERB
eurjchem-2641	254	15	to	to	ADP
eurjchem-2641	254	16	the	the	DET
eurjchem-2641	254	17	early	early	ADJ
eurjchem-2641	254	18	-	-	PUNCT
eurjchem-2641	254	19	stage	stage	NOUN
eurjchem-2641	254	20	group	group	NOUN
eurjchem-2641	254	21	(	(	PUNCT
eurjchem-2641	254	22	p	p	X
eurjchem-2641	254	23	<	<	X
eurjchem-2641	254	24	0.05	0.05	NUM
eurjchem-2641	254	25	)	)	PUNCT
eurjchem-2641	254	26	.	.	PUNCT
eurjchem-2641	255	1	these	these	DET
eurjchem-2641	255	2	results	result	NOUN
eurjchem-2641	255	3	are	be	AUX
eurjchem-2641	255	4	in	in	ADP
eurjchem-2641	255	5	conjunction	conjunction	NOUN
eurjchem-2641	255	6	with	with	ADP
eurjchem-2641	255	7	several	several	ADJ
eurjchem-2641	255	8	studies	study	NOUN
eurjchem-2641	255	9	that	that	PRON
eurjchem-2641	255	10	proposed	propose	VERB
eurjchem-2641	255	11	mirnas	mirna	NOUN
eurjchem-2641	255	12	as	as	ADP
eurjchem-2641	255	13	noninvasive	noninvasive	ADJ
eurjchem-2641	255	14	biomarkers	biomarker	NOUN
eurjchem-2641	255	15	for	for	ADP
eurjchem-2641	255	16	predicting	predict	VERB
eurjchem-2641	255	17	bc	bc	PROPN
eurjchem-2641	255	18	[	[	X
eurjchem-2641	255	19	37	37	NUM
eurjchem-2641	255	20	]	]	PUNCT
eurjchem-2641	255	21	.	.	PUNCT
eurjchem-2641	256	1	this	this	PRON
eurjchem-2641	256	2	indicated	indicate	VERB
eurjchem-2641	256	3	that	that	SCONJ
eurjchem-2641	256	4	mirna-148b	mirna-148b	PROPN
eurjchem-2641	256	5	expression	expression	NOUN
eurjchem-2641	256	6	was	be	AUX
eurjchem-2641	256	7	higher	high	ADJ
eurjchem-2641	256	8	in	in	ADP
eurjchem-2641	256	9	the	the	DET
eurjchem-2641	256	10	advanced	advance	VERB
eurjchem-2641	256	11	bc	bc	PROPN
eurjchem-2641	256	12	stage	stage	NOUN
eurjchem-2641	256	13	than	than	ADP
eurjchem-2641	256	14	in	in	ADP
eurjchem-2641	256	15	the	the	DET
eurjchem-2641	256	16	early	early	ADJ
eurjchem-2641	256	17	stage	stage	NOUN
eurjchem-2641	256	18	[	[	X
eurjchem-2641	256	19	39,40	39,40	NUM
eurjchem-2641	256	20	]	]	PUNCT
eurjchem-2641	256	21	.	.	PUNCT
eurjchem-2641	257	1	consequently	consequently	ADV
eurjchem-2641	257	2	,	,	PUNCT
eurjchem-2641	257	3	mirna-148b	mirna-148b	PROPN
eurjchem-2641	257	4	could	could	AUX
eurjchem-2641	257	5	be	be	AUX
eurjchem-2641	257	6	considered	consider	VERB
eurjchem-2641	257	7	a	a	DET
eurjchem-2641	257	8	biomarker	biomarker	NOUN
eurjchem-2641	257	9	prediction	prediction	NOUN
eurjchem-2641	257	10	and	and	CCONJ
eurjchem-2641	257	11	prognosis	prognosis	NOUN
eurjchem-2641	257	12	of	of	ADP
eurjchem-2641	257	13	bc	bc	PROPN
eurjchem-2641	258	1	[	[	X
eurjchem-2641	258	2	39	39	NUM
eurjchem-2641	258	3	-	-	SYM
eurjchem-2641	258	4	41	41	NUM
eurjchem-2641	258	5	]	]	PUNCT
eurjchem-2641	258	6	.	.	PUNCT
eurjchem-2641	259	1	the	the	DET
eurjchem-2641	259	2	results	result	NOUN
eurjchem-2641	259	3	of	of	ADP
eurjchem-2641	259	4	the	the	DET
eurjchem-2641	259	5	present	present	ADJ
eurjchem-2641	259	6	work	work	NOUN
eurjchem-2641	259	7	are	be	AUX
eurjchem-2641	259	8	in	in	ADP
eurjchem-2641	259	9	sync	sync	NOUN
eurjchem-2641	259	10	with	with	ADP
eurjchem-2641	259	11	the	the	DET
eurjchem-2641	259	12	results	result	NOUN
eurjchem-2641	259	13	of	of	ADP
eurjchem-2641	259	14	cuk	cuk	PROPN
eurjchem-2641	259	15	et	et	PROPN
eurjchem-2641	259	16	al	al	PROPN
eurjchem-2641	259	17	.	.	PROPN
eurjchem-2641	259	18	,	,	PUNCT
eurjchem-2641	259	19	who	who	PRON
eurjchem-2641	259	20	confirmed	confirm	VERB
eurjchem-2641	259	21	the	the	DET
eurjchem-2641	259	22	overexpression	overexpression	NOUN
eurjchem-2641	259	23	of	of	ADP
eurjchem-2641	259	24	mirna-148b	mirna-148b	PROPN
eurjchem-2641	259	25	in	in	ADP
eurjchem-2641	259	26	the	the	DET
eurjchem-2641	259	27	plasma	plasma	NOUN
eurjchem-2641	259	28	of	of	ADP
eurjchem-2641	259	29	patients	patient	NOUN
eurjchem-2641	259	30	with	with	ADP
eurjchem-2641	259	31	bc	bc	PROPN
eurjchem-2641	260	1	[	[	X
eurjchem-2641	260	2	42	42	NUM
eurjchem-2641	260	3	]	]	PUNCT
eurjchem-2641	260	4	.	.	PUNCT
eurjchem-2641	261	1	in	in	ADP
eurjchem-2641	261	2	the	the	DET
eurjchem-2641	261	3	same	same	ADJ
eurjchem-2641	261	4	context	context	NOUN
eurjchem-2641	261	5	,	,	PUNCT
eurjchem-2641	261	6	the	the	DET
eurjchem-2641	261	7	observation	observation	NOUN
eurjchem-2641	261	8	of	of	ADP
eurjchem-2641	261	9	nassar	nassar	PROPN
eurjchem-2641	261	10	et	et	PROPN
eurjchem-2641	261	11	al	al	PROPN
eurjchem-2641	261	12	.	.	PROPN
eurjchem-2641	261	13	is	be	AUX
eurjchem-2641	261	14	in	in	ADP
eurjchem-2641	261	15	parallel	parallel	NOUN
eurjchem-2641	261	16	with	with	ADP
eurjchem-2641	261	17	the	the	DET
eurjchem-2641	261	18	present	present	ADJ
eurjchem-2641	261	19	study	study	NOUN
eurjchem-2641	261	20	's	's	PART
eurjchem-2641	261	21	finding	finding	NOUN
eurjchem-2641	261	22	regarding	regard	VERB
eurjchem-2641	261	23	the	the	DET
eurjchem-2641	261	24	upregulation	upregulation	NOUN
eurjchem-2641	261	25	of	of	ADP
eurjchem-2641	261	26	mirna-148b	mirna-148b	PROPN
eurjchem-2641	261	27	in	in	ADP
eurjchem-2641	261	28	bc	bc	PROPN
eurjchem-2641	261	29	.	.	PUNCT
eurjchem-2641	262	1	[	[	X
eurjchem-2641	262	2	43	43	NUM
eurjchem-2641	262	3	]	]	PUNCT
eurjchem-2641	262	4	.	.	PUNCT
eurjchem-2641	263	1	the	the	DET
eurjchem-2641	263	2	current	current	ADJ
eurjchem-2641	263	3	results	result	NOUN
eurjchem-2641	263	4	support	support	VERB
eurjchem-2641	263	5	the	the	DET
eurjchem-2641	263	6	suggestion	suggestion	NOUN
eurjchem-2641	263	7	of	of	ADP
eurjchem-2641	263	8	mir-148b	mir-148b	NOUN
eurjchem-2641	263	9	upregulation	upregulation	NOUN
eurjchem-2641	263	10	in	in	ADP
eurjchem-2641	263	11	cancer	cancer	NOUN
eurjchem-2641	263	12	.	.	PUNCT
eurjchem-2641	264	1	a	a	DET
eurjchem-2641	264	2	previous	previous	ADJ
eurjchem-2641	264	3	study	study	NOUN
eurjchem-2641	264	4	demonstrated	demonstrate	VERB
eurjchem-2641	264	5	that	that	SCONJ
eurjchem-2641	264	6	mirna-148b	mirna-148b	PROPN
eurjchem-2641	264	7	is	be	AUX
eurjchem-2641	264	8	overexpressed	overexpresse	VERB
eurjchem-2641	264	9	in	in	ADP
eurjchem-2641	264	10	bc	bc	PROPN
eurjchem-2641	264	11	[	[	X
eurjchem-2641	264	12	36	36	NUM
eurjchem-2641	264	13	]	]	PUNCT
eurjchem-2641	264	14	.	.	PUNCT
eurjchem-2641	265	1	likewise	likewise	ADV
eurjchem-2641	265	2	,	,	PUNCT
eurjchem-2641	265	3	mirna148b	mirna148b	PROPN
eurjchem-2641	265	4	has	have	AUX
eurjchem-2641	265	5	been	be	AUX
eurjchem-2641	265	6	reported	report	VERB
eurjchem-2641	265	7	to	to	PART
eurjchem-2641	265	8	be	be	AUX
eurjchem-2641	265	9	elaborate	elaborate	ADJ
eurjchem-2641	265	10	in	in	ADP
eurjchem-2641	265	11	worsening	worsen	VERB
eurjchem-2641	265	12	some	some	DET
eurjchem-2641	265	13	types	type	NOUN
eurjchem-2641	265	14	of	of	ADP
eurjchem-2641	265	15	cancers	cancer	NOUN
eurjchem-2641	265	16	[	[	X
eurjchem-2641	265	17	44	44	NUM
eurjchem-2641	265	18	]	]	PUNCT
eurjchem-2641	265	19	.	.	PUNCT
eurjchem-2641	266	1	the	the	DET
eurjchem-2641	266	2	present	present	ADJ
eurjchem-2641	266	3	findings	finding	NOUN
eurjchem-2641	266	4	are	be	AUX
eurjchem-2641	266	5	align	align	ADJ
eurjchem-2641	266	6	with	with	ADP
eurjchem-2641	266	7	several	several	ADJ
eurjchem-2641	266	8	mirnas	mirna	NOUN
eurjchem-2641	266	9	investigated	investigate	VERB
eurjchem-2641	266	10	in	in	ADP
eurjchem-2641	266	11	biofluids	biofluid	NOUN
eurjchem-2641	266	12	as	as	ADP
eurjchem-2641	266	13	non	non	ADJ
eurjchem-2641	266	14	-	-	ADJ
eurjchem-2641	266	15	invasive	invasive	ADJ
eurjchem-2641	266	16	biomarkers	biomarker	NOUN
eurjchem-2641	266	17	for	for	ADP
eurjchem-2641	266	18	cancer	cancer	NOUN
eurjchem-2641	266	19	prediction	prediction	NOUN
eurjchem-2641	266	20	[	[	X
eurjchem-2641	266	21	38	38	NUM
eurjchem-2641	266	22	]	]	PUNCT
eurjchem-2641	266	23	.	.	PUNCT
eurjchem-2641	267	1	specifically	specifically	ADV
eurjchem-2641	267	2	,	,	PUNCT
eurjchem-2641	267	3	the	the	DET
eurjchem-2641	267	4	plasma	plasma	NOUN
eurjchem-2641	267	5	level	level	NOUN
eurjchem-2641	267	6	of	of	ADP
eurjchem-2641	267	7	mirnas	mirna	NOUN
eurjchem-2641	267	8	was	be	AUX
eurjchem-2641	267	9	suggested	suggest	VERB
eurjchem-2641	267	10	as	as	ADP
eurjchem-2641	267	11	a	a	DET
eurjchem-2641	267	12	non	non	ADJ
eurjchem-2641	267	13	-	-	ADJ
eurjchem-2641	267	14	invasive	invasive	ADJ
eurjchem-2641	267	15	cancer	cancer	NOUN
eurjchem-2641	267	16	biomarker	biomarker	NOUN
eurjchem-2641	268	1	[	[	X
eurjchem-2641	268	2	38	38	NUM
eurjchem-2641	268	3	]	]	PUNCT
eurjchem-2641	268	4	.	.	PUNCT
eurjchem-2641	269	1	in	in	ADP
eurjchem-2641	269	2	this	this	DET
eurjchem-2641	269	3	regard	regard	NOUN
eurjchem-2641	269	4	,	,	PUNCT
eurjchem-2641	269	5	plasma	plasma	NOUN
eurjchem-2641	269	6	mirna-30b-5p	mirna-30b-5p	PROPN
eurjchem-2641	269	7	was	be	AUX
eurjchem-2641	269	8	indicated	indicate	VERB
eurjchem-2641	269	9	as	as	ADP
eurjchem-2641	269	10	a	a	DET
eurjchem-2641	269	11	biomarker	biomarker	NOUN
eurjchem-2641	269	12	for	for	ADP
eurjchem-2641	269	13	bc	bc	PROPN
eurjchem-2641	269	14	.	.	PROPN
eurjchem-2641	269	15	plasma	plasma	PROPN
eurjchem-2641	269	16	mirna-99a-5p	mirna-99a-5p	PROPN
eurjchem-2641	269	17	was	be	AUX
eurjchem-2641	269	18	also	also	ADV
eurjchem-2641	269	19	measured	measure	VERB
eurjchem-2641	269	20	as	as	ADP
eurjchem-2641	269	21	a	a	DET
eurjchem-2641	269	22	biomarker	biomarker	NOUN
eurjchem-2641	269	23	for	for	ADP
eurjchem-2641	269	24	numerous	numerous	ADJ
eurjchem-2641	269	25	cancers	cancer	NOUN
eurjchem-2641	269	26	[	[	X
eurjchem-2641	269	27	38	38	NUM
eurjchem-2641	269	28	]	]	PUNCT
eurjchem-2641	269	29	.	.	PUNCT
eurjchem-2641	270	1	the	the	DET
eurjchem-2641	270	2	imbalance	imbalance	NOUN
eurjchem-2641	270	3	of	of	ADP
eurjchem-2641	270	4	pro	pro	ADJ
eurjchem-2641	270	5	-	-	ADJ
eurjchem-2641	270	6	survival	survival	ADJ
eurjchem-2641	270	7	,	,	PUNCT
eurjchem-2641	270	8	such	such	ADJ
eurjchem-2641	270	9	as	as	ADP
eurjchem-2641	270	10	bcl-2	bcl-2	NUM
eurjchem-2641	270	11	,	,	PUNCT
eurjchem-2641	270	12	and	and	CCONJ
eurjchem-2641	270	13	proapoptotic	proapoptotic	ADJ
eurjchem-2641	270	14	proteins	protein	NOUN
eurjchem-2641	270	15	,	,	PUNCT
eurjchem-2641	270	16	such	such	ADJ
eurjchem-2641	270	17	as	as	ADP
eurjchem-2641	270	18	bax	bax	PROPN
eurjchem-2641	270	19	,	,	PUNCT
eurjchem-2641	270	20	is	be	AUX
eurjchem-2641	270	21	correlated	correlate	VERB
eurjchem-2641	270	22	with	with	ADP
eurjchem-2641	270	23	the	the	DET
eurjchem-2641	270	24	development	development	NOUN
eurjchem-2641	270	25	of	of	ADP
eurjchem-2641	270	26	various	various	ADJ
eurjchem-2641	270	27	cancers	cancer	NOUN
eurjchem-2641	270	28	and	and	CCONJ
eurjchem-2641	270	29	poor	poor	ADJ
eurjchem-2641	270	30	prognosis	prognosis	NOUN
eurjchem-2641	270	31	[	[	X
eurjchem-2641	270	32	24	24	NUM
eurjchem-2641	270	33	]	]	PUNCT
eurjchem-2641	270	34	.	.	PUNCT
eurjchem-2641	271	1	therefore	therefore	ADV
eurjchem-2641	271	2	,	,	PUNCT
eurjchem-2641	271	3	the	the	DET
eurjchem-2641	271	4	study	study	NOUN
eurjchem-2641	271	5	of	of	ADP
eurjchem-2641	271	6	bcl-2	bcl-2	PROPN
eurjchem-2641	271	7	,	,	PUNCT
eurjchem-2641	271	8	bax	bax	PROPN
eurjchem-2641	271	9	,	,	PUNCT
eurjchem-2641	271	10	and	and	CCONJ
eurjchem-2641	271	11	caspase-3	caspase-3	NUM
eurjchem-2641	271	12	indicates	indicate	VERB
eurjchem-2641	271	13	cell	cell	NOUN
eurjchem-2641	271	14	harisa	harisa	NOUN
eurjchem-2641	271	15	et	et	PROPN
eurjchem-2641	271	16	al	al	PROPN
eurjchem-2641	271	17	.	.	PUNCT
eurjchem-2641	271	18	/	/	SYM
eurjchem-2641	271	19	european	european	PROPN
eurjchem-2641	271	20	journal	journal	PROPN
eurjchem-2641	271	21	of	of	ADP
eurjchem-2641	271	22	chemistry	chemistry	NOUN
eurjchem-2641	271	23	16	16	NUM
eurjchem-2641	271	24	(	(	PUNCT
eurjchem-2641	271	25	2	2	NUM
eurjchem-2641	271	26	)	)	PUNCT
eurjchem-2641	271	27	(	(	PUNCT
eurjchem-2641	271	28	2025	2025	NUM
eurjchem-2641	271	29	)	)	PUNCT
eurjchem-2641	271	30	222	222	NUM
eurjchem-2641	271	31	-	-	SYM
eurjchem-2641	271	32	232	232	NUM
eurjchem-2641	271	33	229	229	NUM
eurjchem-2641	271	34	2025	2025	NUM
eurjchem-2641	271	35	–	–	PUNCT
eurjchem-2641	271	36	european	european	ADJ
eurjchem-2641	271	37	journal	journal	NOUN
eurjchem-2641	271	38	of	of	ADP
eurjchem-2641	271	39	chemistry	chemistry	NOUN
eurjchem-2641	271	40	–	–	PUNCT
eurjchem-2641	271	41	cc	cc	NOUN
eurjchem-2641	271	42	by	by	ADP
eurjchem-2641	271	43	nc	nc	PROPN
eurjchem-2641	271	44	–	–	PUNCT
eurjchem-2641	271	45	doi	doi	NOUN
eurjchem-2641	271	46	:	:	PUNCT
eurjchem-2641	271	47	10.5155	10.5155	NUM
eurjchem-2641	271	48	/	/	SYM
eurjchem-2641	271	49	eurjchem.16.2.222	eurjchem.16.2.222	NOUN
eurjchem-2641	271	50	-	-	PUNCT
eurjchem-2641	271	51	232.2641	232.2641	NUM
eurjchem-2641	271	52	apoptosis	apoptosis	NOUN
eurjchem-2641	271	53	and	and	CCONJ
eurjchem-2641	271	54	the	the	DET
eurjchem-2641	271	55	decreased	decrease	VERB
eurjchem-2641	271	56	bcl-2	bcl-2	VERB
eurjchem-2641	271	57	/	/	SYM
eurjchem-2641	271	58	bax	bax	PROPN
eurjchem-2641	271	59	ratio	ratio	NOUN
eurjchem-2641	271	60	means	mean	VERB
eurjchem-2641	271	61	the	the	DET
eurjchem-2641	271	62	initiation	initiation	NOUN
eurjchem-2641	271	63	of	of	ADP
eurjchem-2641	271	64	apoptosis	apoptosis	NOUN
eurjchem-2641	271	65	[	[	X
eurjchem-2641	271	66	45	45	NUM
eurjchem-2641	271	67	]	]	PUNCT
eurjchem-2641	271	68	.	.	PUNCT
eurjchem-2641	272	1	upregulation	upregulation	NOUN
eurjchem-2641	272	2	of	of	ADP
eurjchem-2641	272	3	the	the	DET
eurjchem-2641	272	4	bcl-2	bcl-2	PUNCT
eurjchem-2641	272	5	gene	gene	NOUN
eurjchem-2641	272	6	renders	render	VERB
eurjchem-2641	272	7	tumor	tumor	NOUN
eurjchem-2641	272	8	cells	cell	NOUN
eurjchem-2641	272	9	grow	grow	VERB
eurjchem-2641	272	10	and	and	CCONJ
eurjchem-2641	272	11	resistant	resistant	ADJ
eurjchem-2641	272	12	to	to	ADP
eurjchem-2641	272	13	anticancer	anticancer	NOUN
eurjchem-2641	272	14	agents	agent	NOUN
eurjchem-2641	272	15	.	.	PUNCT
eurjchem-2641	273	1	therefore	therefore	ADV
eurjchem-2641	273	2	,	,	PUNCT
eurjchem-2641	273	3	bcl-2	bcl-2	PRON
eurjchem-2641	273	4	could	could	AUX
eurjchem-2641	273	5	be	be	AUX
eurjchem-2641	273	6	a	a	DET
eurjchem-2641	273	7	valuable	valuable	ADJ
eurjchem-2641	273	8	indicator	indicator	NOUN
eurjchem-2641	273	9	for	for	ADP
eurjchem-2641	273	10	cancer	cancer	NOUN
eurjchem-2641	273	11	detection	detection	NOUN
eurjchem-2641	273	12	[	[	X
eurjchem-2641	273	13	24	24	NUM
eurjchem-2641	273	14	]	]	PUNCT
eurjchem-2641	273	15	.	.	PUNCT
eurjchem-2641	274	1	in	in	ADP
eurjchem-2641	274	2	the	the	DET
eurjchem-2641	274	3	current	current	ADJ
eurjchem-2641	274	4	study	study	NOUN
eurjchem-2641	274	5	,	,	PUNCT
eurjchem-2641	274	6	bax	bax	PROPN
eurjchem-2641	274	7	was	be	AUX
eurjchem-2641	274	8	significantly	significantly	ADV
eurjchem-2641	274	9	overexpressed	overexpresse	VERB
eurjchem-2641	274	10	in	in	ADP
eurjchem-2641	274	11	the	the	DET
eurjchem-2641	274	12	early	early	ADJ
eurjchem-2641	274	13	-	-	PUNCT
eurjchem-2641	274	14	stage	stage	NOUN
eurjchem-2641	274	15	group	group	NOUN
eurjchem-2641	274	16	compared	compare	VERB
eurjchem-2641	274	17	to	to	ADP
eurjchem-2641	274	18	the	the	DET
eurjchem-2641	274	19	chemotherapy	chemotherapy	NOUN
eurjchem-2641	274	20	and	and	CCONJ
eurjchem-2641	274	21	surgery	surgery	NOUN
eurjchem-2641	274	22	groups	group	NOUN
eurjchem-2641	274	23	.	.	PUNCT
eurjchem-2641	275	1	furthermore	furthermore	ADV
eurjchem-2641	275	2	,	,	PUNCT
eurjchem-2641	275	3	bax	bax	PROPN
eurjchem-2641	275	4	was	be	AUX
eurjchem-2641	275	5	significantly	significantly	ADV
eurjchem-2641	275	6	overexpressed	overexpresse	VERB
eurjchem-2641	275	7	in	in	ADP
eurjchem-2641	275	8	the	the	DET
eurjchem-2641	275	9	chemotherapy	chemotherapy	NOUN
eurjchem-2641	275	10	group	group	NOUN
eurjchem-2641	275	11	compared	compare	VERB
eurjchem-2641	275	12	to	to	ADP
eurjchem-2641	275	13	the	the	DET
eurjchem-2641	275	14	surgery	surgery	NOUN
eurjchem-2641	275	15	group	group	NOUN
eurjchem-2641	275	16	.	.	PUNCT
eurjchem-2641	276	1	the	the	DET
eurjchem-2641	276	2	current	current	ADJ
eurjchem-2641	276	3	results	result	NOUN
eurjchem-2641	276	4	are	be	AUX
eurjchem-2641	276	5	agree	agree	VERB
eurjchem-2641	276	6	with	with	ADP
eurjchem-2641	276	7	the	the	DET
eurjchem-2641	276	8	results	result	NOUN
eurjchem-2641	276	9	published	publish	VERB
eurjchem-2641	276	10	by	by	ADP
eurjchem-2641	276	11	pluta	pluta	PROPN
eurjchem-2641	276	12	et	et	PROPN
eurjchem-2641	276	13	al	al	PROPN
eurjchem-2641	276	14	.	.	PROPN
eurjchem-2641	276	15	,	,	PUNCT
eurjchem-2641	276	16	which	which	PRON
eurjchem-2641	276	17	confirmed	confirm	VERB
eurjchem-2641	276	18	that	that	SCONJ
eurjchem-2641	276	19	bax	bax	PROPN
eurjchem-2641	276	20	is	be	AUX
eurjchem-2641	276	21	one	one	NUM
eurjchem-2641	276	22	of	of	ADP
eurjchem-2641	276	23	the	the	DET
eurjchem-2641	276	24	mechanisms	mechanism	NOUN
eurjchem-2641	276	25	of	of	ADP
eurjchem-2641	276	26	evasion	evasion	NOUN
eurjchem-2641	276	27	of	of	ADP
eurjchem-2641	276	28	apoptosis	apoptosis	NOUN
eurjchem-2641	276	29	by	by	ADP
eurjchem-2641	276	30	tumor	tumor	NOUN
eurjchem-2641	276	31	cells	cell	NOUN
eurjchem-2641	276	32	[	[	X
eurjchem-2641	276	33	45	45	NUM
eurjchem-2641	276	34	]	]	PUNCT
eurjchem-2641	276	35	.	.	PUNCT
eurjchem-2641	277	1	the	the	DET
eurjchem-2641	277	2	increase	increase	NOUN
eurjchem-2641	277	3	of	of	ADP
eurjchem-2641	277	4	the	the	DET
eurjchem-2641	277	5	bax	bax	PROPN
eurjchem-2641	277	6	gene	gene	NOUN
eurjchem-2641	277	7	designated	designate	VERB
eurjchem-2641	277	8	the	the	DET
eurjchem-2641	277	9	initiation	initiation	NOUN
eurjchem-2641	277	10	of	of	ADP
eurjchem-2641	277	11	apoptosis	apoptosis	NOUN
eurjchem-2641	277	12	at	at	ADP
eurjchem-2641	277	13	the	the	DET
eurjchem-2641	277	14	early	early	ADJ
eurjchem-2641	277	15	stages	stage	NOUN
eurjchem-2641	277	16	of	of	ADP
eurjchem-2641	277	17	bc	bc	PROPN
eurjchem-2641	277	18	compared	compare	VERB
eurjchem-2641	277	19	to	to	ADP
eurjchem-2641	277	20	the	the	DET
eurjchem-2641	277	21	surgery	surgery	NOUN
eurjchem-2641	277	22	and	and	CCONJ
eurjchem-2641	277	23	chemotherapy	chemotherapy	NOUN
eurjchem-2641	277	24	groups	group	NOUN
eurjchem-2641	277	25	.	.	PUNCT
eurjchem-2641	278	1	similarly	similarly	ADV
eurjchem-2641	278	2	,	,	PUNCT
eurjchem-2641	278	3	the	the	DET
eurjchem-2641	278	4	present	present	ADJ
eurjchem-2641	278	5	results	result	NOUN
eurjchem-2641	278	6	confirmed	confirm	VERB
eurjchem-2641	278	7	that	that	SCONJ
eurjchem-2641	278	8	bcl-2	bcl-2	NOUN
eurjchem-2641	278	9	increased	increase	VERB
eurjchem-2641	278	10	significantly	significantly	ADV
eurjchem-2641	278	11	in	in	ADP
eurjchem-2641	278	12	chemotherapytreated	chemotherapytreate	VERB
eurjchem-2641	278	13	,	,	PUNCT
eurjchem-2641	278	14	surgery	surgery	NOUN
eurjchem-2641	278	15	-	-	PUNCT
eurjchem-2641	278	16	treated	treat	VERB
eurjchem-2641	278	17	,	,	PUNCT
eurjchem-2641	278	18	and	and	CCONJ
eurjchem-2641	278	19	early	early	ADJ
eurjchem-2641	278	20	stage	stage	NOUN
eurjchem-2641	278	21	groups	group	NOUN
eurjchem-2641	278	22	compared	compare	VERB
eurjchem-2641	278	23	with	with	ADP
eurjchem-2641	278	24	the	the	DET
eurjchem-2641	278	25	control	control	NOUN
eurjchem-2641	278	26	group	group	NOUN
eurjchem-2641	278	27	.	.	PUNCT
eurjchem-2641	279	1	these	these	DET
eurjchem-2641	279	2	findings	finding	NOUN
eurjchem-2641	279	3	are	be	AUX
eurjchem-2641	279	4	consistent	consistent	ADJ
eurjchem-2641	279	5	with	with	ADP
eurjchem-2641	279	6	ample	ample	ADJ
eurjchem-2641	279	7	studies	study	NOUN
eurjchem-2641	279	8	that	that	PRON
eurjchem-2641	279	9	found	find	VERB
eurjchem-2641	279	10	overexpression	overexpression	NOUN
eurjchem-2641	279	11	of	of	ADP
eurjchem-2641	279	12	bcl-2	bcl-2	VERB
eurjchem-2641	279	13	in	in	ADP
eurjchem-2641	279	14	patients	patient	NOUN
eurjchem-2641	279	15	with	with	ADP
eurjchem-2641	279	16	bc	bc	PROPN
eurjchem-2641	279	17	[	[	X
eurjchem-2641	279	18	46,47	46,47	NUM
eurjchem-2641	279	19	]	]	X
eurjchem-2641	279	20	.	.	PUNCT
eurjchem-2641	280	1	in	in	ADP
eurjchem-2641	280	2	this	this	DET
eurjchem-2641	280	3	regard	regard	NOUN
eurjchem-2641	280	4	,	,	PUNCT
eurjchem-2641	280	5	bcl-2	bcl-2	ADJ
eurjchem-2641	280	6	expression	expression	NOUN
eurjchem-2641	280	7	is	be	AUX
eurjchem-2641	280	8	upregulated	upregulate	VERB
eurjchem-2641	280	9	in	in	ADP
eurjchem-2641	280	10	the	the	DET
eurjchem-2641	280	11	early	early	ADJ
eurjchem-2641	280	12	stage	stage	NOUN
eurjchem-2641	280	13	of	of	ADP
eurjchem-2641	280	14	bc	bc	PROPN
eurjchem-2641	280	15	with	with	ADP
eurjchem-2641	280	16	er	er	INTJ
eurjchem-2641	280	17	-	-	PUNCT
eurjchem-2641	280	18	positive	positive	ADJ
eurjchem-2641	280	19	cancer	cancer	NOUN
eurjchem-2641	280	20	[	[	X
eurjchem-2641	280	21	48,49	48,49	X
eurjchem-2641	280	22	]	]	PUNCT
eurjchem-2641	280	23	.	.	PUNCT
eurjchem-2641	281	1	elevation	elevation	NOUN
eurjchem-2641	281	2	of	of	ADP
eurjchem-2641	281	3	bcl-2	bcl-2	NOUN
eurjchem-2641	281	4	mediates	mediate	NOUN
eurjchem-2641	281	5	an	an	DET
eurjchem-2641	281	6	antiapoptotic	antiapoptotic	ADJ
eurjchem-2641	281	7	effect	effect	NOUN
eurjchem-2641	281	8	implicated	implicate	VERB
eurjchem-2641	281	9	in	in	ADP
eurjchem-2641	281	10	carcinogenesis	carcinogenesis	NOUN
eurjchem-2641	281	11	[	[	X
eurjchem-2641	281	12	50	50	NUM
eurjchem-2641	281	13	]	]	PUNCT
eurjchem-2641	281	14	.	.	PUNCT
eurjchem-2641	282	1	in	in	ADP
eurjchem-2641	282	2	addition	addition	NOUN
eurjchem-2641	282	3	,	,	PUNCT
eurjchem-2641	282	4	caspases	caspase	NOUN
eurjchem-2641	282	5	play	play	VERB
eurjchem-2641	282	6	a	a	DET
eurjchem-2641	282	7	crucial	crucial	ADJ
eurjchem-2641	282	8	role	role	NOUN
eurjchem-2641	282	9	in	in	ADP
eurjchem-2641	282	10	apoptosis	apoptosis	NOUN
eurjchem-2641	282	11	;	;	PUNCT
eurjchem-2641	282	12	caspases	caspase	NOUN
eurjchem-2641	282	13	are	be	AUX
eurjchem-2641	282	14	cysteine	cysteine	ADJ
eurjchem-2641	282	15	proteases	protease	NOUN
eurjchem-2641	282	16	that	that	PRON
eurjchem-2641	282	17	have	have	VERB
eurjchem-2641	282	18	critical	critical	ADJ
eurjchem-2641	282	19	functions	function	NOUN
eurjchem-2641	282	20	in	in	ADP
eurjchem-2641	282	21	apoptosis	apoptosis	NOUN
eurjchem-2641	282	22	[	[	X
eurjchem-2641	282	23	51	51	NUM
eurjchem-2641	282	24	]	]	PUNCT
eurjchem-2641	282	25	.	.	PUNCT
eurjchem-2641	283	1	therefore	therefore	ADV
eurjchem-2641	283	2	,	,	PUNCT
eurjchem-2641	283	3	unusual	unusual	ADJ
eurjchem-2641	283	4	caspase	caspase	NOUN
eurjchem-2641	283	5	expression	expression	NOUN
eurjchem-2641	283	6	has	have	AUX
eurjchem-2641	283	7	been	be	AUX
eurjchem-2641	283	8	implicated	implicate	VERB
eurjchem-2641	283	9	in	in	ADP
eurjchem-2641	283	10	various	various	ADJ
eurjchem-2641	283	11	cancers	cancer	NOUN
eurjchem-2641	283	12	.	.	PUNCT
eurjchem-2641	284	1	therefore	therefore	ADV
eurjchem-2641	284	2	,	,	PUNCT
eurjchem-2641	284	3	the	the	DET
eurjchem-2641	284	4	loss	loss	NOUN
eurjchem-2641	284	5	of	of	ADP
eurjchem-2641	284	6	caspases	caspase	NOUN
eurjchem-2641	284	7	encourages	encourage	VERB
eurjchem-2641	284	8	tumorigenesis	tumorigenesis	NOUN
eurjchem-2641	284	9	[	[	X
eurjchem-2641	284	10	51	51	NUM
eurjchem-2641	284	11	]	]	PUNCT
eurjchem-2641	284	12	.	.	PUNCT
eurjchem-2641	285	1	specifically	specifically	ADV
eurjchem-2641	285	2	,	,	PUNCT
eurjchem-2641	285	3	caspase-3	caspase-3	PRON
eurjchem-2641	285	4	is	be	AUX
eurjchem-2641	285	5	an	an	DET
eurjchem-2641	285	6	extensive	extensive	ADJ
eurjchem-2641	285	7	effector	effector	NOUN
eurjchem-2641	285	8	in	in	ADP
eurjchem-2641	285	9	the	the	DET
eurjchem-2641	285	10	process	process	NOUN
eurjchem-2641	285	11	of	of	ADP
eurjchem-2641	285	12	apoptosis	apoptosis	NOUN
eurjchem-2641	285	13	.	.	PUNCT
eurjchem-2641	286	1	caspase-3	caspase-3	NUM
eurjchem-2641	286	2	activation	activation	NOUN
eurjchem-2641	286	3	triggers	trigger	VERB
eurjchem-2641	286	4	the	the	DET
eurjchem-2641	286	5	protease	protease	NOUN
eurjchem-2641	286	6	cascade	cascade	NOUN
eurjchem-2641	286	7	to	to	PART
eurjchem-2641	286	8	induce	induce	VERB
eurjchem-2641	286	9	programmed	programmed	ADJ
eurjchem-2641	286	10	cell	cell	NOUN
eurjchem-2641	286	11	death	death	NOUN
eurjchem-2641	287	1	[	[	X
eurjchem-2641	287	2	51	51	NUM
eurjchem-2641	287	3	]	]	PUNCT
eurjchem-2641	287	4	.	.	PUNCT
eurjchem-2641	288	1	thus	thus	ADV
eurjchem-2641	288	2	,	,	PUNCT
eurjchem-2641	288	3	caspase-3	caspase-3	NUM
eurjchem-2641	288	4	activation	activation	NOUN
eurjchem-2641	288	5	directs	direct	VERB
eurjchem-2641	288	6	the	the	DET
eurjchem-2641	288	7	cells	cell	NOUN
eurjchem-2641	288	8	toward	toward	ADP
eurjchem-2641	288	9	apoptosis	apoptosis	NOUN
eurjchem-2641	288	10	[	[	X
eurjchem-2641	288	11	51	51	NUM
eurjchem-2641	288	12	]	]	PUNCT
eurjchem-2641	288	13	.	.	PUNCT
eurjchem-2641	289	1	in	in	ADP
eurjchem-2641	289	2	bcs	bc	NOUN
eurjchem-2641	289	3	,	,	PUNCT
eurjchem-2641	289	4	low	low	ADJ
eurjchem-2641	289	5	caspase-3	caspase-3	NUM
eurjchem-2641	289	6	expression	expression	NOUN
eurjchem-2641	289	7	is	be	AUX
eurjchem-2641	289	8	closely	closely	ADV
eurjchem-2641	289	9	related	relate	VERB
eurjchem-2641	289	10	to	to	ADP
eurjchem-2641	289	11	the	the	DET
eurjchem-2641	289	12	low	low	ADJ
eurjchem-2641	289	13	expression	expression	NOUN
eurjchem-2641	289	14	of	of	ADP
eurjchem-2641	289	15	apoptosis	apoptosis	NOUN
eurjchem-2641	289	16	-	-	PUNCT
eurjchem-2641	289	17	associated	associate	VERB
eurjchem-2641	289	18	proteins	protein	NOUN
eurjchem-2641	289	19	with	with	ADP
eurjchem-2641	289	20	poor	poor	ADJ
eurjchem-2641	289	21	bc	bc	PROPN
eurjchem-2641	289	22	prognosis	prognosis	NOUN
eurjchem-2641	289	23	[	[	X
eurjchem-2641	289	24	51	51	NUM
eurjchem-2641	289	25	]	]	PUNCT
eurjchem-2641	289	26	.	.	PUNCT
eurjchem-2641	290	1	in	in	ADP
eurjchem-2641	290	2	the	the	DET
eurjchem-2641	290	3	current	current	ADJ
eurjchem-2641	290	4	study	study	NOUN
eurjchem-2641	290	5	,	,	PUNCT
eurjchem-2641	290	6	caspase-3	caspase-3	PRON
eurjchem-2641	290	7	was	be	AUX
eurjchem-2641	290	8	significantly	significantly	ADV
eurjchem-2641	290	9	lower	low	ADJ
eurjchem-2641	290	10	in	in	ADP
eurjchem-2641	290	11	the	the	DET
eurjchem-2641	290	12	early	early	ADJ
eurjchem-2641	290	13	-	-	PUNCT
eurjchem-2641	290	14	stage	stage	NOUN
eurjchem-2641	290	15	,	,	PUNCT
eurjchem-2641	290	16	chemotherapy	chemotherapy	NOUN
eurjchem-2641	290	17	-	-	PUNCT
eurjchem-2641	290	18	treated	treat	VERB
eurjchem-2641	290	19	and	and	CCONJ
eurjchem-2641	290	20	surgery	surgery	NOUN
eurjchem-2641	290	21	-	-	PUNCT
eurjchem-2641	290	22	treated	treat	VERB
eurjchem-2641	290	23	groups	group	NOUN
eurjchem-2641	290	24	than	than	ADP
eurjchem-2641	290	25	the	the	DET
eurjchem-2641	290	26	healthy	healthy	ADJ
eurjchem-2641	290	27	control	control	NOUN
eurjchem-2641	290	28	group	group	NOUN
eurjchem-2641	290	29	.	.	PUNCT
eurjchem-2641	291	1	the	the	DET
eurjchem-2641	291	2	same	same	ADJ
eurjchem-2641	291	3	observations	observation	NOUN
eurjchem-2641	291	4	were	be	AUX
eurjchem-2641	291	5	obtained	obtain	VERB
eurjchem-2641	291	6	by	by	ADP
eurjchem-2641	291	7	devarajan	devarajan	NOUN
eurjchem-2641	291	8	et	et	PROPN
eurjchem-2641	291	9	al	al	PROPN
eurjchem-2641	291	10	.	.	PROPN
eurjchem-2641	291	11	,	,	PUNCT
eurjchem-2641	291	12	who	who	PRON
eurjchem-2641	291	13	found	find	VERB
eurjchem-2641	291	14	that	that	SCONJ
eurjchem-2641	291	15	75	75	NUM
eurjchem-2641	291	16	%	%	NOUN
eurjchem-2641	291	17	of	of	ADP
eurjchem-2641	291	18	bc	bc	PROPN
eurjchem-2641	291	19	cells	cell	NOUN
eurjchem-2641	291	20	lacked	lack	VERB
eurjchem-2641	291	21	the	the	DET
eurjchem-2641	291	22	caspase-3	caspase-3	NUM
eurjchem-2641	291	23	transcriptome	transcriptome	NOUN
eurjchem-2641	291	24	and	and	CCONJ
eurjchem-2641	291	25	proteomes	proteome	NOUN
eurjchem-2641	291	26	as	as	ADP
eurjchem-2641	291	27	mechanisms	mechanism	NOUN
eurjchem-2641	291	28	of	of	ADP
eurjchem-2641	291	29	oncogenesis	oncogenesis	NOUN
eurjchem-2641	291	30	and	and	CCONJ
eurjchem-2641	291	31	drug	drug	NOUN
eurjchem-2641	291	32	resistance	resistance	NOUN
eurjchem-2641	291	33	[	[	X
eurjchem-2641	291	34	52	52	NUM
eurjchem-2641	291	35	]	]	PUNCT
eurjchem-2641	291	36	.	.	PUNCT
eurjchem-2641	292	1	likewise	likewise	ADV
eurjchem-2641	292	2	,	,	PUNCT
eurjchem-2641	292	3	decreased	decrease	VERB
eurjchem-2641	292	4	expression	expression	NOUN
eurjchem-2641	292	5	of	of	ADP
eurjchem-2641	292	6	caspase-3	caspase-3	NUM
eurjchem-2641	292	7	has	have	AUX
eurjchem-2641	292	8	been	be	AUX
eurjchem-2641	292	9	reported	report	VERB
eurjchem-2641	292	10	to	to	PART
eurjchem-2641	292	11	be	be	AUX
eurjchem-2641	292	12	associated	associate	VERB
eurjchem-2641	292	13	with	with	ADP
eurjchem-2641	292	14	malignant	malignant	ADJ
eurjchem-2641	292	15	transformation	transformation	NOUN
eurjchem-2641	292	16	and	and	CCONJ
eurjchem-2641	292	17	tumor	tumor	NOUN
eurjchem-2641	292	18	progression	progression	NOUN
eurjchem-2641	292	19	of	of	ADP
eurjchem-2641	292	20	bc	bc	PROPN
eurjchem-2641	293	1	[	[	X
eurjchem-2641	293	2	53	53	NUM
eurjchem-2641	293	3	]	]	PUNCT
eurjchem-2641	293	4	.	.	PUNCT
eurjchem-2641	294	1	the	the	DET
eurjchem-2641	294	2	imbalances	imbalance	NOUN
eurjchem-2641	294	3	between	between	ADP
eurjchem-2641	294	4	free	free	ADJ
eurjchem-2641	294	5	radicals	radical	NOUN
eurjchem-2641	294	6	production	production	NOUN
eurjchem-2641	294	7	and	and	CCONJ
eurjchem-2641	294	8	antioxidant	antioxidant	ADJ
eurjchem-2641	294	9	defense	defense	NOUN
eurjchem-2641	294	10	disturb	disturb	VERB
eurjchem-2641	294	11	the	the	DET
eurjchem-2641	294	12	ratio	ratio	NOUN
eurjchem-2641	294	13	of	of	ADP
eurjchem-2641	294	14	total	total	ADJ
eurjchem-2641	294	15	oxidant	oxidant	ADJ
eurjchem-2641	294	16	status	status	NOUN
eurjchem-2641	294	17	to	to	ADP
eurjchem-2641	294	18	tac	tac	PROPN
eurjchem-2641	294	19	in	in	ADP
eurjchem-2641	294	20	bc	bc	PROPN
eurjchem-2641	294	21	patients	patient	NOUN
eurjchem-2641	294	22	'	'	PART
eurjchem-2641	294	23	blood	blood	NOUN
eurjchem-2641	294	24	[	[	X
eurjchem-2641	294	25	54	54	NUM
eurjchem-2641	294	26	]	]	PUNCT
eurjchem-2641	294	27	.	.	PUNCT
eurjchem-2641	295	1	this	this	PRON
eurjchem-2641	295	2	resulted	result	VERB
eurjchem-2641	295	3	in	in	ADP
eurjchem-2641	295	4	oxidative	oxidative	ADJ
eurjchem-2641	295	5	stress	stress	NOUN
eurjchem-2641	295	6	that	that	PRON
eurjchem-2641	295	7	alters	alter	VERB
eurjchem-2641	295	8	many	many	ADJ
eurjchem-2641	295	9	cellular	cellular	ADJ
eurjchem-2641	295	10	processes	process	NOUN
eurjchem-2641	295	11	,	,	PUNCT
eurjchem-2641	295	12	such	such	ADJ
eurjchem-2641	295	13	as	as	ADP
eurjchem-2641	295	14	metabolism	metabolism	NOUN
eurjchem-2641	295	15	,	,	PUNCT
eurjchem-2641	295	16	signaling	signal	VERB
eurjchem-2641	295	17	pathways	pathway	NOUN
eurjchem-2641	295	18	,	,	PUNCT
eurjchem-2641	295	19	gene	gene	NOUN
eurjchem-2641	295	20	expression	expression	NOUN
eurjchem-2641	295	21	,	,	PUNCT
eurjchem-2641	295	22	cell	cell	NOUN
eurjchem-2641	295	23	proliferation	proliferation	NOUN
eurjchem-2641	295	24	,	,	PUNCT
eurjchem-2641	295	25	and	and	CCONJ
eurjchem-2641	295	26	apoptosis	apoptosis	NOUN
eurjchem-2641	295	27	[	[	X
eurjchem-2641	295	28	54	54	NUM
eurjchem-2641	295	29	]	]	PUNCT
eurjchem-2641	295	30	.	.	PUNCT
eurjchem-2641	296	1	this	this	PRON
eurjchem-2641	296	2	is	be	AUX
eurjchem-2641	296	3	attributed	attribute	VERB
eurjchem-2641	296	4	to	to	ADP
eurjchem-2641	296	5	altering	alter	VERB
eurjchem-2641	296	6	the	the	DET
eurjchem-2641	296	7	function	function	NOUN
eurjchem-2641	296	8	of	of	ADP
eurjchem-2641	296	9	significant	significant	ADJ
eurjchem-2641	296	10	proteins	protein	NOUN
eurjchem-2641	296	11	,	,	PUNCT
eurjchem-2641	296	12	lipids	lipid	NOUN
eurjchem-2641	296	13	,	,	PUNCT
eurjchem-2641	296	14	and	and	CCONJ
eurjchem-2641	296	15	nucleic	nucleic	ADJ
eurjchem-2641	296	16	acids	acid	NOUN
eurjchem-2641	296	17	as	as	ADP
eurjchem-2641	296	18	the	the	DET
eurjchem-2641	296	19	body	body	NOUN
eurjchem-2641	296	20	's	's	PART
eurjchem-2641	296	21	major	major	ADJ
eurjchem-2641	296	22	biomolecules	biomolecule	NOUN
eurjchem-2641	296	23	.	.	PUNCT
eurjchem-2641	297	1	this	this	PRON
eurjchem-2641	297	2	might	might	AUX
eurjchem-2641	297	3	lead	lead	VERB
eurjchem-2641	297	4	to	to	ADP
eurjchem-2641	297	5	tissue	tissue	NOUN
eurjchem-2641	297	6	damage	damage	NOUN
eurjchem-2641	297	7	and	and	CCONJ
eurjchem-2641	297	8	oncogenesis	oncogenesis	NOUN
eurjchem-2641	297	9	[	[	X
eurjchem-2641	297	10	54	54	NUM
eurjchem-2641	297	11	]	]	PUNCT
eurjchem-2641	297	12	.	.	PUNCT
eurjchem-2641	298	1	in	in	ADP
eurjchem-2641	298	2	the	the	DET
eurjchem-2641	298	3	present	present	ADJ
eurjchem-2641	298	4	work	work	NOUN
eurjchem-2641	298	5	,	,	PUNCT
eurjchem-2641	298	6	serum	serum	PROPN
eurjchem-2641	298	7	tac	tac	PROPN
eurjchem-2641	298	8	levels	level	NOUN
eurjchem-2641	298	9	,	,	PUNCT
eurjchem-2641	298	10	and	and	CCONJ
eurjchem-2641	298	11	current	current	ADJ
eurjchem-2641	298	12	results	result	NOUN
eurjchem-2641	298	13	indicated	indicate	VERB
eurjchem-2641	298	14	that	that	SCONJ
eurjchem-2641	298	15	tac	tac	PROPN
eurjchem-2641	298	16	levels	level	NOUN
eurjchem-2641	298	17	were	be	AUX
eurjchem-2641	298	18	significantly	significantly	ADV
eurjchem-2641	298	19	decreased	decrease	VERB
eurjchem-2641	298	20	in	in	ADP
eurjchem-2641	298	21	the	the	DET
eurjchem-2641	298	22	chemotherapy	chemotherapy	NOUN
eurjchem-2641	298	23	-	-	PUNCT
eurjchem-2641	298	24	treated	treat	VERB
eurjchem-2641	298	25	,	,	PUNCT
eurjchem-2641	298	26	surgery	surgery	NOUN
eurjchem-2641	298	27	-	-	PUNCT
eurjchem-2641	298	28	treated	treat	VERB
eurjchem-2641	298	29	,	,	PUNCT
eurjchem-2641	298	30	and	and	CCONJ
eurjchem-2641	298	31	early	early	ADJ
eurjchem-2641	298	32	-	-	PUNCT
eurjchem-2641	298	33	stage	stage	NOUN
eurjchem-2641	298	34	groups	group	NOUN
eurjchem-2641	298	35	compared	compare	VERB
eurjchem-2641	298	36	to	to	ADP
eurjchem-2641	298	37	healthy	healthy	ADJ
eurjchem-2641	298	38	subjects	subject	NOUN
eurjchem-2641	298	39	.	.	PUNCT
eurjchem-2641	299	1	the	the	DET
eurjchem-2641	299	2	results	result	NOUN
eurjchem-2641	299	3	were	be	AUX
eurjchem-2641	299	4	in	in	ADP
eurjchem-2641	299	5	harmony	harmony	NOUN
eurjchem-2641	299	6	with	with	ADP
eurjchem-2641	299	7	those	those	PRON
eurjchem-2641	299	8	obtained	obtain	VERB
eurjchem-2641	299	9	by	by	ADP
eurjchem-2641	299	10	abbasalizad	abbasalizad	NOUN
eurjchem-2641	299	11	et	et	PROPN
eurjchem-2641	299	12	al	al	PROPN
eurjchem-2641	299	13	.	.	PROPN
eurjchem-2641	299	14	,	,	PUNCT
eurjchem-2641	299	15	who	who	PRON
eurjchem-2641	299	16	reported	report	VERB
eurjchem-2641	299	17	that	that	SCONJ
eurjchem-2641	299	18	the	the	DET
eurjchem-2641	299	19	decrease	decrease	NOUN
eurjchem-2641	299	20	in	in	ADP
eurjchem-2641	299	21	tac	tac	PROPN
eurjchem-2641	299	22	levels	level	NOUN
eurjchem-2641	299	23	was	be	AUX
eurjchem-2641	299	24	correlated	correlate	VERB
eurjchem-2641	299	25	with	with	ADP
eurjchem-2641	299	26	bc	bc	PROPN
eurjchem-2641	299	27	risk	risk	NOUN
eurjchem-2641	299	28	.	.	PUNCT
eurjchem-2641	300	1	however	however	ADV
eurjchem-2641	300	2	,	,	PUNCT
eurjchem-2641	300	3	proper	proper	ADJ
eurjchem-2641	300	4	levels	level	NOUN
eurjchem-2641	300	5	of	of	ADP
eurjchem-2641	300	6	tac	tac	PROPN
eurjchem-2641	300	7	decreased	decrease	VERB
eurjchem-2641	300	8	the	the	DET
eurjchem-2641	300	9	risk	risk	NOUN
eurjchem-2641	300	10	of	of	ADP
eurjchem-2641	300	11	bc	bc	PROPN
eurjchem-2641	301	1	[	[	X
eurjchem-2641	301	2	55	55	NUM
eurjchem-2641	301	3	]	]	PUNCT
eurjchem-2641	301	4	.	.	PUNCT
eurjchem-2641	302	1	similarly	similarly	ADV
eurjchem-2641	302	2	,	,	PUNCT
eurjchem-2641	302	3	rashad	rashad	VERB
eurjchem-2641	302	4	et	et	PROPN
eurjchem-2641	302	5	al	al	PROPN
eurjchem-2641	302	6	.	.	PROPN
eurjchem-2641	303	1	observed	observe	VERB
eurjchem-2641	303	2	significantly	significantly	ADV
eurjchem-2641	303	3	lower	low	ADJ
eurjchem-2641	303	4	tac	tac	PROPN
eurjchem-2641	303	5	levels	level	NOUN
eurjchem-2641	303	6	in	in	ADP
eurjchem-2641	303	7	cancer	cancer	NOUN
eurjchem-2641	303	8	patients	patient	NOUN
eurjchem-2641	303	9	than	than	ADP
eurjchem-2641	303	10	in	in	ADP
eurjchem-2641	303	11	healthy	healthy	ADJ
eurjchem-2641	303	12	subjects	subject	NOUN
eurjchem-2641	303	13	[	[	X
eurjchem-2641	303	14	56	56	NUM
eurjchem-2641	303	15	]	]	PUNCT
eurjchem-2641	303	16	.	.	PUNCT
eurjchem-2641	304	1	conversely	conversely	ADV
eurjchem-2641	304	2	,	,	PUNCT
eurjchem-2641	304	3	ample	ample	ADJ
eurjchem-2641	304	4	studies	study	NOUN
eurjchem-2641	304	5	have	have	AUX
eurjchem-2641	304	6	documented	document	VERB
eurjchem-2641	304	7	increase	increase	NOUN
eurjchem-2641	304	8	serum	serum	PROPN
eurjchem-2641	304	9	tac	tac	PROPN
eurjchem-2641	304	10	levels	level	NOUN
eurjchem-2641	304	11	in	in	ADP
eurjchem-2641	304	12	bc	bc	PROPN
eurjchem-2641	304	13	situations	situation	NOUN
eurjchem-2641	304	14	as	as	ADP
eurjchem-2641	304	15	a	a	DET
eurjchem-2641	304	16	compensatory	compensatory	ADJ
eurjchem-2641	304	17	mechanism	mechanism	NOUN
eurjchem-2641	304	18	for	for	ADP
eurjchem-2641	304	19	maintaining	maintain	VERB
eurjchem-2641	304	20	redox	redox	NOUN
eurjchem-2641	304	21	balance	balance	NOUN
eurjchem-2641	304	22	[	[	X
eurjchem-2641	304	23	54	54	NUM
eurjchem-2641	304	24	]	]	PUNCT
eurjchem-2641	304	25	.	.	PUNCT
eurjchem-2641	305	1	mirna-148b	mirna-148b	PROPN
eurjchem-2641	305	2	inhibition	inhibition	NOUN
eurjchem-2641	305	3	has	have	AUX
eurjchem-2641	305	4	been	be	AUX
eurjchem-2641	305	5	documented	document	VERB
eurjchem-2641	305	6	to	to	PART
eurjchem-2641	305	7	improve	improve	VERB
eurjchem-2641	305	8	antioxidant	antioxidant	ADJ
eurjchem-2641	305	9	power	power	NOUN
eurjchem-2641	305	10	with	with	ADP
eurjchem-2641	305	11	enhanced	enhanced	ADJ
eurjchem-2641	305	12	cell	cell	NOUN
eurjchem-2641	305	13	survival	survival	NOUN
eurjchem-2641	305	14	by	by	ADP
eurjchem-2641	305	15	suppressing	suppress	VERB
eurjchem-2641	305	16	apoptosis	apoptosis	NOUN
eurjchem-2641	305	17	and	and	CCONJ
eurjchem-2641	305	18	activating	activate	VERB
eurjchem-2641	305	19	the	the	DET
eurjchem-2641	305	20	wnt	wnt	NOUN
eurjchem-2641	305	21	/	/	SYM
eurjchem-2641	305	22	β	β	NOUN
eurjchem-2641	305	23	-	-	ADJ
eurjchem-2641	305	24	catenin	catenin	ADJ
eurjchem-2641	305	25	signaling	signal	VERB
eurjchem-2641	305	26	pathway	pathway	NOUN
eurjchem-2641	306	1	[	[	X
eurjchem-2641	306	2	57	57	NUM
eurjchem-2641	306	3	]	]	PUNCT
eurjchem-2641	306	4	.	.	PUNCT
eurjchem-2641	307	1	the	the	DET
eurjchem-2641	307	2	present	present	ADJ
eurjchem-2641	307	3	study	study	NOUN
eurjchem-2641	307	4	reported	report	VERB
eurjchem-2641	307	5	a	a	DET
eurjchem-2641	307	6	negative	negative	ADJ
eurjchem-2641	307	7	correlation	correlation	NOUN
eurjchem-2641	307	8	between	between	ADP
eurjchem-2641	307	9	mirna148b	mirna148b	PROPN
eurjchem-2641	307	10	and	and	CCONJ
eurjchem-2641	307	11	tac	tac	PROPN
eurjchem-2641	307	12	levels	level	NOUN
eurjchem-2641	307	13	.	.	PUNCT
eurjchem-2641	308	1	however	however	ADV
eurjchem-2641	308	2	,	,	PUNCT
eurjchem-2641	308	3	up	up	ADP
eurjchem-2641	308	4	-	-	PUNCT
eurjchem-2641	308	5	regulation	regulation	NOUN
eurjchem-2641	308	6	of	of	ADP
eurjchem-2641	308	7	the	the	DET
eurjchem-2641	308	8	mirna-148b	mirna-148b	PROPN
eurjchem-2641	308	9	transcriptome	transcriptome	NOUN
eurjchem-2641	308	10	is	be	AUX
eurjchem-2641	308	11	associated	associate	VERB
eurjchem-2641	308	12	with	with	ADP
eurjchem-2641	308	13	a	a	DET
eurjchem-2641	308	14	lower	low	ADJ
eurjchem-2641	308	15	tac	tac	NOUN
eurjchem-2641	308	16	ability	ability	NOUN
eurjchem-2641	308	17	[	[	X
eurjchem-2641	308	18	56	56	NUM
eurjchem-2641	308	19	]	]	PUNCT
eurjchem-2641	308	20	.	.	PUNCT
eurjchem-2641	309	1	furthermore	furthermore	ADV
eurjchem-2641	309	2	,	,	PUNCT
eurjchem-2641	309	3	the	the	DET
eurjchem-2641	309	4	present	present	ADJ
eurjchem-2641	309	5	results	result	NOUN
eurjchem-2641	309	6	confirmed	confirm	VERB
eurjchem-2641	309	7	hematological	hematological	ADJ
eurjchem-2641	309	8	and	and	CCONJ
eurjchem-2641	309	9	tac	tac	PROPN
eurjchem-2641	309	10	appears	appear	VERB
eurjchem-2641	309	11	to	to	PART
eurjchem-2641	309	12	be	be	AUX
eurjchem-2641	309	13	positively	positively	ADV
eurjchem-2641	309	14	and	and	CCONJ
eurjchem-2641	309	15	negatively	negatively	ADV
eurjchem-2641	309	16	correlated	correlate	VERB
eurjchem-2641	309	17	with	with	ADP
eurjchem-2641	309	18	mir	mir	NOUN
eurjchem-2641	309	19	-	-	PUNCT
eurjchem-2641	309	20	na-148b	na-148b	NOUN
eurjchem-2641	309	21	,	,	PUNCT
eurjchem-2641	309	22	caspase-3	caspase-3	NUM
eurjchem-2641	309	23	,	,	PUNCT
eurjchem-2641	309	24	bax	bax	PROPN
eurjchem-2641	309	25	,	,	PUNCT
eurjchem-2641	309	26	bcl2	bcl2	PROPN
eurjchem-2641	309	27	and	and	CCONJ
eurjchem-2641	309	28	tac	tac	PROPN
eurjchem-2641	309	29	.	.	PUNCT
eurjchem-2641	310	1	therefore	therefore	ADV
eurjchem-2641	310	2	,	,	PUNCT
eurjchem-2641	310	3	the	the	DET
eurjchem-2641	310	4	present	present	ADJ
eurjchem-2641	310	5	findings	finding	NOUN
eurjchem-2641	310	6	suggest	suggest	VERB
eurjchem-2641	310	7	the	the	DET
eurjchem-2641	310	8	use	use	NOUN
eurjchem-2641	310	9	of	of	ADP
eurjchem-2641	310	10	these	these	DET
eurjchem-2641	310	11	parameters	parameter	NOUN
eurjchem-2641	310	12	to	to	PART
eurjchem-2641	310	13	predict	predict	VERB
eurjchem-2641	310	14	,	,	PUNCT
eurjchem-2641	310	15	detect	detect	VERB
eurjchem-2641	310	16	,	,	PUNCT
eurjchem-2641	310	17	and	and	CCONJ
eurjchem-2641	310	18	monitor	monitor	VERB
eurjchem-2641	310	19	bc	bc	PROPN
eurjchem-2641	310	20	.	.	PROPN
eurjchem-2641	311	1	histopathological	histopathological	ADJ
eurjchem-2641	311	2	examination	examination	NOUN
eurjchem-2641	311	3	is	be	AUX
eurjchem-2641	311	4	an	an	DET
eurjchem-2641	311	5	essential	essential	ADJ
eurjchem-2641	311	6	method	method	NOUN
eurjchem-2641	311	7	for	for	ADP
eurjchem-2641	311	8	the	the	DET
eurjchem-2641	311	9	investigation	investigation	NOUN
eurjchem-2641	311	10	of	of	ADP
eurjchem-2641	311	11	new	new	ADJ
eurjchem-2641	311	12	biomarkers	biomarker	NOUN
eurjchem-2641	311	13	of	of	ADP
eurjchem-2641	311	14	diseases	disease	NOUN
eurjchem-2641	311	15	[	[	X
eurjchem-2641	311	16	58	58	NUM
eurjchem-2641	311	17	]	]	PUNCT
eurjchem-2641	311	18	.	.	PUNCT
eurjchem-2641	312	1	in	in	ADP
eurjchem-2641	312	2	the	the	DET
eurjchem-2641	312	3	present	present	ADJ
eurjchem-2641	312	4	study	study	NOUN
eurjchem-2641	312	5	,	,	PUNCT
eurjchem-2641	312	6	there	there	PRON
eurjchem-2641	312	7	are	be	VERB
eurjchem-2641	312	8	a	a	DET
eurjchem-2641	312	9	series	series	NOUN
eurjchem-2641	312	10	of	of	ADP
eurjchem-2641	312	11	histopathological	histopathological	ADJ
eurjchem-2641	312	12	changes	change	NOUN
eurjchem-2641	312	13	and	and	CCONJ
eurjchem-2641	312	14	heterogeneous	heterogeneous	ADJ
eurjchem-2641	312	15	breast	breast	NOUN
eurjchem-2641	312	16	cells	cell	NOUN
eurjchem-2641	312	17	in	in	ADP
eurjchem-2641	312	18	tissues	tissue	NOUN
eurjchem-2641	312	19	obtained	obtain	VERB
eurjchem-2641	312	20	from	from	ADP
eurjchem-2641	312	21	earlystage	earlystage	NOUN
eurjchem-2641	312	22	bc	bc	PROPN
eurjchem-2641	312	23	,	,	PUNCT
eurjchem-2641	312	24	as	as	ADV
eurjchem-2641	312	25	well	well	ADV
eurjchem-2641	312	26	as	as	ADP
eurjchem-2641	312	27	chemotherapy	chemotherapy	NOUN
eurjchem-2641	312	28	and	and	CCONJ
eurjchem-2641	312	29	surgerytreated	surgerytreate	VERB
eurjchem-2641	312	30	groups	group	NOUN
eurjchem-2641	312	31	.	.	PUNCT
eurjchem-2641	313	1	furthermore	furthermore	ADV
eurjchem-2641	313	2	,	,	PUNCT
eurjchem-2641	313	3	typical	typical	ADJ
eurjchem-2641	313	4	cytological	cytological	ADJ
eurjchem-2641	313	5	characteristics	characteristic	NOUN
eurjchem-2641	313	6	and	and	CCONJ
eurjchem-2641	313	7	changes	change	NOUN
eurjchem-2641	313	8	in	in	ADP
eurjchem-2641	313	9	nuclear	nuclear	ADJ
eurjchem-2641	313	10	characters	character	NOUN
eurjchem-2641	313	11	,	,	PUNCT
eurjchem-2641	313	12	including	include	VERB
eurjchem-2641	313	13	size	size	NOUN
eurjchem-2641	313	14	,	,	PUNCT
eurjchem-2641	313	15	shape	shape	NOUN
eurjchem-2641	313	16	,	,	PUNCT
eurjchem-2641	313	17	and	and	CCONJ
eurjchem-2641	313	18	membrane	membrane	NOUN
eurjchem-2641	313	19	irregularity	irregularity	NOUN
eurjchem-2641	313	20	,	,	PUNCT
eurjchem-2641	313	21	were	be	AUX
eurjchem-2641	313	22	observed	observe	VERB
eurjchem-2641	313	23	in	in	ADP
eurjchem-2641	313	24	bc	bc	PROPN
eurjchem-2641	313	25	patients	patient	NOUN
eurjchem-2641	313	26	.	.	PUNCT
eurjchem-2641	314	1	these	these	DET
eurjchem-2641	314	2	results	result	NOUN
eurjchem-2641	314	3	are	be	AUX
eurjchem-2641	314	4	consistent	consistent	ADJ
eurjchem-2641	314	5	with	with	ADP
eurjchem-2641	314	6	a	a	DET
eurjchem-2641	314	7	previous	previous	ADJ
eurjchem-2641	314	8	study	study	NOUN
eurjchem-2641	314	9	that	that	PRON
eurjchem-2641	314	10	demonstrated	demonstrate	VERB
eurjchem-2641	314	11	significant	significant	ADJ
eurjchem-2641	314	12	abnormalities	abnormality	NOUN
eurjchem-2641	314	13	in	in	ADP
eurjchem-2641	314	14	nuclear	nuclear	ADJ
eurjchem-2641	314	15	characteristics	characteristic	NOUN
eurjchem-2641	314	16	in	in	ADP
eurjchem-2641	314	17	bc	bc	PROPN
eurjchem-2641	314	18	patients	patient	NOUN
eurjchem-2641	314	19	[	[	X
eurjchem-2641	314	20	59	59	NUM
eurjchem-2641	314	21	]	]	PUNCT
eurjchem-2641	314	22	.	.	PUNCT
eurjchem-2641	315	1	the	the	DET
eurjchem-2641	315	2	nuclear	nuclear	ADJ
eurjchem-2641	315	3	morphological	morphological	ADJ
eurjchem-2641	315	4	changes	change	NOUN
eurjchem-2641	315	5	are	be	AUX
eurjchem-2641	315	6	vigorous	vigorous	ADJ
eurjchem-2641	315	7	for	for	ADP
eurjchem-2641	315	8	understanding	understanding	NOUN
eurjchem-2641	315	9	and	and	CCONJ
eurjchem-2641	315	10	confirming	confirm	VERB
eurjchem-2641	315	11	molecular	molecular	ADJ
eurjchem-2641	315	12	function	function	NOUN
eurjchem-2641	315	13	[	[	X
eurjchem-2641	315	14	59	59	NUM
eurjchem-2641	315	15	]	]	PUNCT
eurjchem-2641	315	16	.	.	PUNCT
eurjchem-2641	316	1	therefore	therefore	ADV
eurjchem-2641	316	2	,	,	PUNCT
eurjchem-2641	316	3	the	the	DET
eurjchem-2641	316	4	findings	finding	NOUN
eurjchem-2641	316	5	of	of	ADP
eurjchem-2641	316	6	the	the	DET
eurjchem-2641	316	7	histopathological	histopathological	ADJ
eurjchem-2641	316	8	studies	study	NOUN
eurjchem-2641	316	9	confirmed	confirm	VERB
eurjchem-2641	316	10	the	the	DET
eurjchem-2641	316	11	biochemical	biochemical	ADJ
eurjchem-2641	316	12	and	and	CCONJ
eurjchem-2641	316	13	molecular	molecular	ADJ
eurjchem-2641	316	14	biology	biology	NOUN
eurjchem-2641	316	15	findings	finding	VERB
eurjchem-2641	316	16	on	on	ADP
eurjchem-2641	316	17	bcs	bc	NOUN
eurjchem-2641	316	18	in	in	ADP
eurjchem-2641	316	19	the	the	DET
eurjchem-2641	316	20	present	present	ADJ
eurjchem-2641	316	21	study	study	NOUN
eurjchem-2641	316	22	.	.	PUNCT
eurjchem-2641	317	1	regarding	regard	VERB
eurjchem-2641	317	2	hematological	hematological	ADJ
eurjchem-2641	317	3	parameters	parameter	NOUN
eurjchem-2641	317	4	,	,	PUNCT
eurjchem-2641	317	5	the	the	DET
eurjchem-2641	317	6	control	control	NOUN
eurjchem-2641	317	7	and	and	CCONJ
eurjchem-2641	317	8	patients	patient	NOUN
eurjchem-2641	317	9	enrolled	enrol	VERB
eurjchem-2641	317	10	in	in	ADP
eurjchem-2641	317	11	the	the	DET
eurjchem-2641	317	12	present	present	ADJ
eurjchem-2641	317	13	study	study	NOUN
eurjchem-2641	317	14	were	be	AUX
eurjchem-2641	317	15	investigated	investigate	VERB
eurjchem-2641	317	16	for	for	ADP
eurjchem-2641	317	17	cbc	cbc	NOUN
eurjchem-2641	317	18	.	.	PUNCT
eurjchem-2641	318	1	the	the	DET
eurjchem-2641	318	2	current	current	ADJ
eurjchem-2641	318	3	results	result	NOUN
eurjchem-2641	318	4	indicated	indicate	VERB
eurjchem-2641	318	5	that	that	SCONJ
eurjchem-2641	318	6	hemoglobin	hemoglobin	NOUN
eurjchem-2641	318	7	levels	level	NOUN
eurjchem-2641	318	8	in	in	ADP
eurjchem-2641	318	9	the	the	DET
eurjchem-2641	318	10	chemotherapy	chemotherapy	NOUN
eurjchem-2641	318	11	and	and	CCONJ
eurjchem-2641	318	12	surgery	surgery	NOUN
eurjchem-2641	318	13	groups	group	NOUN
eurjchem-2641	318	14	were	be	AUX
eurjchem-2641	318	15	significantly	significantly	ADV
eurjchem-2641	318	16	lower	low	ADJ
eurjchem-2641	318	17	than	than	ADP
eurjchem-2641	318	18	in	in	ADP
eurjchem-2641	318	19	the	the	DET
eurjchem-2641	318	20	healthy	healthy	ADJ
eurjchem-2641	318	21	control	control	NOUN
eurjchem-2641	318	22	subjects	subject	NOUN
eurjchem-2641	318	23	.	.	PUNCT
eurjchem-2641	319	1	however	however	ADV
eurjchem-2641	319	2	,	,	PUNCT
eurjchem-2641	319	3	there	there	PRON
eurjchem-2641	319	4	was	be	VERB
eurjchem-2641	319	5	no	no	DET
eurjchem-2641	319	6	significant	significant	ADJ
eurjchem-2641	319	7	decrease	decrease	NOUN
eurjchem-2641	319	8	in	in	ADP
eurjchem-2641	319	9	hemoglobin	hemoglobin	NOUN
eurjchem-2641	319	10	levels	level	NOUN
eurjchem-2641	319	11	in	in	ADP
eurjchem-2641	319	12	the	the	DET
eurjchem-2641	319	13	early	early	ADJ
eurjchem-2641	319	14	stage	stage	NOUN
eurjchem-2641	319	15	group	group	NOUN
eurjchem-2641	319	16	compared	compare	VERB
eurjchem-2641	319	17	with	with	ADP
eurjchem-2641	319	18	the	the	DET
eurjchem-2641	319	19	control	control	NOUN
eurjchem-2641	319	20	group	group	NOUN
eurjchem-2641	319	21	.	.	PUNCT
eurjchem-2641	320	1	these	these	DET
eurjchem-2641	320	2	findings	finding	NOUN
eurjchem-2641	320	3	were	be	AUX
eurjchem-2641	320	4	consistent	consistent	ADJ
eurjchem-2641	320	5	with	with	ADP
eurjchem-2641	320	6	raza	raza	PROPN
eurjchem-2641	320	7	et	et	PROPN
eurjchem-2641	320	8	al	al	PROPN
eurjchem-2641	320	9	.	.	PROPN
eurjchem-2641	320	10	,	,	PUNCT
eurjchem-2641	320	11	who	who	PRON
eurjchem-2641	320	12	investigated	investigate	VERB
eurjchem-2641	320	13	post	post	ADJ
eurjchem-2641	320	14	-	-	ADJ
eurjchem-2641	320	15	treatment	treatment	ADJ
eurjchem-2641	320	16	hematological	hematological	ADJ
eurjchem-2641	320	17	variations	variation	NOUN
eurjchem-2641	320	18	in	in	ADP
eurjchem-2641	320	19	bc	bc	PROPN
eurjchem-2641	320	20	patients	patient	NOUN
eurjchem-2641	320	21	[	[	X
eurjchem-2641	320	22	60	60	NUM
eurjchem-2641	320	23	]	]	PUNCT
eurjchem-2641	320	24	.	.	PUNCT
eurjchem-2641	321	1	their	their	PRON
eurjchem-2641	321	2	results	result	NOUN
eurjchem-2641	321	3	showed	show	VERB
eurjchem-2641	321	4	that	that	SCONJ
eurjchem-2641	321	5	patients	patient	NOUN
eurjchem-2641	321	6	who	who	PRON
eurjchem-2641	321	7	received	receive	VERB
eurjchem-2641	321	8	surgery	surgery	NOUN
eurjchem-2641	321	9	,	,	PUNCT
eurjchem-2641	321	10	radiation	radiation	NOUN
eurjchem-2641	321	11	therapy	therapy	NOUN
eurjchem-2641	321	12	,	,	PUNCT
eurjchem-2641	321	13	or	or	CCONJ
eurjchem-2641	321	14	chemotherapy	chemotherapy	NOUN
eurjchem-2641	321	15	had	have	VERB
eurjchem-2641	321	16	a	a	DET
eurjchem-2641	321	17	statistically	statistically	ADV
eurjchem-2641	321	18	significant	significant	ADJ
eurjchem-2641	321	19	decrease	decrease	NOUN
eurjchem-2641	321	20	in	in	ADP
eurjchem-2641	321	21	hemoglobin	hemoglobin	NOUN
eurjchem-2641	321	22	and	and	CCONJ
eurjchem-2641	321	23	cbc	cbc	NOUN
eurjchem-2641	321	24	after	after	ADP
eurjchem-2641	321	25	treatment	treatment	NOUN
eurjchem-2641	321	26	[	[	X
eurjchem-2641	321	27	60	60	NUM
eurjchem-2641	321	28	]	]	PUNCT
eurjchem-2641	321	29	.	.	PUNCT
eurjchem-2641	322	1	cbc	cbc	PROPN
eurjchem-2641	322	2	is	be	AUX
eurjchem-2641	322	3	a	a	DET
eurjchem-2641	322	4	mirror	mirror	NOUN
eurjchem-2641	322	5	for	for	ADP
eurjchem-2641	322	6	the	the	DET
eurjchem-2641	322	7	cellular	cellular	ADJ
eurjchem-2641	322	8	immune	immune	ADJ
eurjchem-2641	322	9	response	response	NOUN
eurjchem-2641	322	10	in	in	ADP
eurjchem-2641	322	11	patients	patient	NOUN
eurjchem-2641	322	12	with	with	ADP
eurjchem-2641	322	13	malignancy	malignancy	NOUN
eurjchem-2641	322	14	.	.	PUNCT
eurjchem-2641	323	1	therefore	therefore	ADV
eurjchem-2641	323	2	,	,	PUNCT
eurjchem-2641	323	3	the	the	DET
eurjchem-2641	323	4	changes	change	NOUN
eurjchem-2641	323	5	in	in	ADP
eurjchem-2641	323	6	hematological	hematological	ADJ
eurjchem-2641	323	7	parameters	parameter	NOUN
eurjchem-2641	323	8	reflect	reflect	VERB
eurjchem-2641	323	9	tumor	tumor	NOUN
eurjchem-2641	323	10	development	development	NOUN
eurjchem-2641	323	11	[	[	X
eurjchem-2641	323	12	54	54	NUM
eurjchem-2641	323	13	]	]	PUNCT
eurjchem-2641	323	14	.	.	PUNCT
eurjchem-2641	324	1	specific	specific	ADJ
eurjchem-2641	324	2	cbc	cbc	PROPN
eurjchem-2641	324	3	indices	index	NOUN
eurjchem-2641	324	4	are	be	AUX
eurjchem-2641	324	5	valuable	valuable	ADJ
eurjchem-2641	324	6	in	in	ADP
eurjchem-2641	324	7	predicting	predict	VERB
eurjchem-2641	324	8	results	result	NOUN
eurjchem-2641	324	9	in	in	ADP
eurjchem-2641	324	10	patients	patient	NOUN
eurjchem-2641	324	11	with	with	ADP
eurjchem-2641	324	12	bc	bc	PROPN
eurjchem-2641	324	13	[	[	X
eurjchem-2641	324	14	54	54	NUM
eurjchem-2641	324	15	]	]	PUNCT
eurjchem-2641	324	16	.	.	PUNCT
eurjchem-2641	325	1	furthermore	furthermore	ADV
eurjchem-2641	325	2	,	,	PUNCT
eurjchem-2641	325	3	the	the	DET
eurjchem-2641	325	4	hematological	hematological	ADJ
eurjchem-2641	325	5	profile	profile	NOUN
eurjchem-2641	325	6	of	of	ADP
eurjchem-2641	325	7	patients	patient	NOUN
eurjchem-2641	325	8	not	not	PART
eurjchem-2641	325	9	only	only	ADV
eurjchem-2641	325	10	fluctuates	fluctuate	VERB
eurjchem-2641	325	11	dramatically	dramatically	ADV
eurjchem-2641	325	12	after	after	ADP
eurjchem-2641	325	13	treatment	treatment	NOUN
eurjchem-2641	325	14	,	,	PUNCT
eurjchem-2641	325	15	but	but	CCONJ
eurjchem-2641	325	16	is	be	AUX
eurjchem-2641	325	17	also	also	ADV
eurjchem-2641	325	18	influenced	influence	VERB
eurjchem-2641	325	19	by	by	ADP
eurjchem-2641	325	20	the	the	DET
eurjchem-2641	325	21	treatment	treatment	NOUN
eurjchem-2641	325	22	pattern	pattern	NOUN
eurjchem-2641	325	23	and	and	CCONJ
eurjchem-2641	325	24	stage	stage	NOUN
eurjchem-2641	325	25	of	of	ADP
eurjchem-2641	325	26	the	the	DET
eurjchem-2641	325	27	disease	disease	NOUN
eurjchem-2641	325	28	[	[	X
eurjchem-2641	325	29	60	60	NUM
eurjchem-2641	325	30	]	]	PUNCT
eurjchem-2641	325	31	.	.	PUNCT
eurjchem-2641	326	1	equally	equally	ADV
eurjchem-2641	326	2	,	,	PUNCT
eurjchem-2641	326	3	similar	similar	ADJ
eurjchem-2641	326	4	observations	observation	NOUN
eurjchem-2641	326	5	were	be	AUX
eurjchem-2641	326	6	documented	document	VERB
eurjchem-2641	326	7	by	by	ADP
eurjchem-2641	326	8	another	another	DET
eurjchem-2641	326	9	study	study	NOUN
eurjchem-2641	326	10	that	that	PRON
eurjchem-2641	326	11	evaluated	evaluate	VERB
eurjchem-2641	326	12	the	the	DET
eurjchem-2641	326	13	connection	connection	NOUN
eurjchem-2641	326	14	of	of	ADP
eurjchem-2641	326	15	cbc	cbc	PROPN
eurjchem-2641	326	16	to	to	ADP
eurjchem-2641	326	17	the	the	DET
eurjchem-2641	326	18	survival	survival	NOUN
eurjchem-2641	326	19	of	of	ADP
eurjchem-2641	326	20	bc	bc	PROPN
eurjchem-2641	326	21	patients	patient	NOUN
eurjchem-2641	326	22	[	[	X
eurjchem-2641	326	23	61	61	NUM
eurjchem-2641	326	24	]	]	PUNCT
eurjchem-2641	326	25	.	.	PUNCT
eurjchem-2641	327	1	the	the	DET
eurjchem-2641	327	2	current	current	ADJ
eurjchem-2641	327	3	study	study	NOUN
eurjchem-2641	327	4	confirmed	confirm	VERB
eurjchem-2641	327	5	the	the	DET
eurjchem-2641	327	6	cbc	cbc	NOUN
eurjchem-2641	327	7	indices	indice	VERB
eurjchem-2641	327	8	as	as	ADP
eurjchem-2641	327	9	an	an	DET
eurjchem-2641	327	10	indicator	indicator	NOUN
eurjchem-2641	327	11	for	for	ADP
eurjchem-2641	327	12	the	the	DET
eurjchem-2641	327	13	development	development	NOUN
eurjchem-2641	327	14	of	of	ADP
eurjchem-2641	327	15	bcs	bc	NOUN
eurjchem-2641	327	16	and	and	CCONJ
eurjchem-2641	327	17	the	the	DET
eurjchem-2641	327	18	influence	influence	NOUN
eurjchem-2641	327	19	of	of	ADP
eurjchem-2641	327	20	different	different	ADJ
eurjchem-2641	327	21	therapeutic	therapeutic	ADJ
eurjchem-2641	327	22	modalities	modality	NOUN
eurjchem-2641	327	23	.	.	PUNCT
eurjchem-2641	328	1	however	however	ADV
eurjchem-2641	328	2	,	,	PUNCT
eurjchem-2641	328	3	several	several	ADJ
eurjchem-2641	328	4	clinical	clinical	ADJ
eurjchem-2641	328	5	trials	trial	NOUN
eurjchem-2641	328	6	have	have	AUX
eurjchem-2641	328	7	shown	show	VERB
eurjchem-2641	328	8	that	that	SCONJ
eurjchem-2641	328	9	patients	patient	NOUN
eurjchem-2641	328	10	with	with	ADP
eurjchem-2641	328	11	bc	bc	PROPN
eurjchem-2641	328	12	had	have	VERB
eurjchem-2641	328	13	adverse	adverse	ADJ
eurjchem-2641	328	14	hematological	hematological	ADJ
eurjchem-2641	328	15	outcomes	outcome	NOUN
eurjchem-2641	329	1	[	[	X
eurjchem-2641	329	2	62,63	62,63	NOUN
eurjchem-2641	329	3	]	]	PUNCT
eurjchem-2641	329	4	.	.	PUNCT
eurjchem-2641	330	1	similarly	similarly	ADV
eurjchem-2641	330	2	,	,	PUNCT
eurjchem-2641	330	3	females	female	NOUN
eurjchem-2641	330	4	with	with	ADP
eurjchem-2641	330	5	bc	bc	PROPN
eurjchem-2641	330	6	have	have	AUX
eurjchem-2641	330	7	been	be	AUX
eurjchem-2641	330	8	reported	report	VERB
eurjchem-2641	330	9	to	to	PART
eurjchem-2641	330	10	show	show	VERB
eurjchem-2641	330	11	disturbed	disturbed	ADJ
eurjchem-2641	330	12	cbc	cbc	NOUN
eurjchem-2641	330	13	compared	compare	VERB
eurjchem-2641	330	14	to	to	ADP
eurjchem-2641	330	15	healthy	healthy	ADJ
eurjchem-2641	330	16	people	people	NOUN
eurjchem-2641	330	17	[	[	X
eurjchem-2641	330	18	54	54	NUM
eurjchem-2641	330	19	]	]	PUNCT
eurjchem-2641	330	20	.	.	PUNCT
eurjchem-2641	331	1	furthermore	furthermore	ADV
eurjchem-2641	331	2	,	,	PUNCT
eurjchem-2641	331	3	post	post	ADJ
eurjchem-2641	331	4	-	-	ADJ
eurjchem-2641	331	5	treatment	treatment	NOUN
eurjchem-2641	331	6	anemia	anemia	NOUN
eurjchem-2641	331	7	has	have	AUX
eurjchem-2641	331	8	been	be	AUX
eurjchem-2641	331	9	linked	link	VERB
eurjchem-2641	331	10	to	to	ADP
eurjchem-2641	331	11	chemotherapeutic	chemotherapeutic	ADJ
eurjchem-2641	331	12	drugs	drug	NOUN
eurjchem-2641	331	13	such	such	ADJ
eurjchem-2641	331	14	as	as	ADP
eurjchem-2641	331	15	platinum	platinum	NOUN
eurjchem-2641	331	16	salts	salt	NOUN
eurjchem-2641	331	17	,	,	PUNCT
eurjchem-2641	331	18	anthracycline	anthracycline	NOUN
eurjchem-2641	331	19	,	,	PUNCT
eurjchem-2641	331	20	and	and	CCONJ
eurjchem-2641	331	21	gemcitabine	gemcitabine	VERB
eurjchem-2641	331	22	[	[	X
eurjchem-2641	331	23	62,63	62,63	NOUN
eurjchem-2641	331	24	]	]	PUNCT
eurjchem-2641	331	25	.	.	PUNCT
eurjchem-2641	332	1	this	this	PRON
eurjchem-2641	332	2	is	be	AUX
eurjchem-2641	332	3	attributed	attribute	VERB
eurjchem-2641	332	4	to	to	ADP
eurjchem-2641	332	5	suppression	suppression	NOUN
eurjchem-2641	332	6	of	of	ADP
eurjchem-2641	332	7	hematopoiesis	hematopoiesis	NOUN
eurjchem-2641	332	8	and	and	CCONJ
eurjchem-2641	332	9	the	the	DET
eurjchem-2641	332	10	reduction	reduction	NOUN
eurjchem-2641	332	11	of	of	ADP
eurjchem-2641	332	12	erythropoietin	erythropoietin	ADJ
eurjchem-2641	332	13	levels	level	NOUN
eurjchem-2641	332	14	due	due	ADP
eurjchem-2641	332	15	to	to	ADP
eurjchem-2641	332	16	renal	renal	ADJ
eurjchem-2641	332	17	impairment	impairment	NOUN
eurjchem-2641	332	18	[	[	X
eurjchem-2641	332	19	62,63	62,63	NOUN
eurjchem-2641	332	20	]	]	PUNCT
eurjchem-2641	332	21	.	.	PUNCT
eurjchem-2641	333	1	in	in	ADP
eurjchem-2641	333	2	addition	addition	NOUN
eurjchem-2641	333	3	,	,	PUNCT
eurjchem-2641	333	4	most	most	ADJ
eurjchem-2641	333	5	chemotherapy	chemotherapy	NOUN
eurjchem-2641	333	6	drugs	drug	NOUN
eurjchem-2641	333	7	induced	induce	VERB
eurjchem-2641	333	8	myelosuppression	myelosuppression	NOUN
eurjchem-2641	333	9	and	and	CCONJ
eurjchem-2641	333	10	progression	progression	NOUN
eurjchem-2641	333	11	of	of	ADP
eurjchem-2641	333	12	anemia	anemia	NOUN
eurjchem-2641	333	13	with	with	ADP
eurjchem-2641	333	14	each	each	DET
eurjchem-2641	333	15	cycle	cycle	NOUN
eurjchem-2641	333	16	of	of	ADP
eurjchem-2641	333	17	chemotherapy	chemotherapy	NOUN
eurjchem-2641	333	18	[	[	X
eurjchem-2641	333	19	62,63	62,63	NOUN
eurjchem-2641	333	20	]	]	PUNCT
eurjchem-2641	333	21	.	.	PUNCT
eurjchem-2641	334	1	furthermore	furthermore	ADV
eurjchem-2641	334	2	,	,	PUNCT
eurjchem-2641	334	3	compared	compare	VERB
eurjchem-2641	334	4	to	to	ADP
eurjchem-2641	334	5	the	the	DET
eurjchem-2641	334	6	control	control	NOUN
eurjchem-2641	334	7	group	group	NOUN
eurjchem-2641	334	8	,	,	PUNCT
eurjchem-2641	334	9	there	there	PRON
eurjchem-2641	334	10	was	be	VERB
eurjchem-2641	334	11	a	a	DET
eurjchem-2641	334	12	significant	significant	ADJ
eurjchem-2641	334	13	increase	increase	NOUN
eurjchem-2641	334	14	in	in	ADP
eurjchem-2641	334	15	wbc	wbc	PROPN
eurjchem-2641	334	16	and	and	CCONJ
eurjchem-2641	334	17	lymphocyte	lymphocyte	ADJ
eurjchem-2641	334	18	levels	level	NOUN
eurjchem-2641	334	19	among	among	ADP
eurjchem-2641	334	20	patients	patient	NOUN
eurjchem-2641	334	21	in	in	ADP
eurjchem-2641	334	22	the	the	DET
eurjchem-2641	334	23	early	early	ADJ
eurjchem-2641	334	24	stages	stage	NOUN
eurjchem-2641	334	25	,	,	PUNCT
eurjchem-2641	334	26	chemotherapy	chemotherapy	NOUN
eurjchem-2641	334	27	,	,	PUNCT
eurjchem-2641	334	28	and	and	CCONJ
eurjchem-2641	334	29	surgery	surgery	NOUN
eurjchem-2641	334	30	groups	group	NOUN
eurjchem-2641	334	31	.	.	PUNCT
eurjchem-2641	335	1	these	these	DET
eurjchem-2641	335	2	findings	finding	NOUN
eurjchem-2641	335	3	are	be	AUX
eurjchem-2641	335	4	in	in	ADP
eurjchem-2641	335	5	conjunction	conjunction	NOUN
eurjchem-2641	335	6	with	with	ADP
eurjchem-2641	335	7	several	several	ADJ
eurjchem-2641	335	8	studies	study	NOUN
eurjchem-2641	335	9	that	that	PRON
eurjchem-2641	335	10	reported	report	VERB
eurjchem-2641	335	11	a	a	DET
eurjchem-2641	335	12	higher	high	ADJ
eurjchem-2641	335	13	elevation	elevation	NOUN
eurjchem-2641	335	14	of	of	ADP
eurjchem-2641	335	15	wbc	wbc	PROPN
eurjchem-2641	335	16	counts	count	NOUN
eurjchem-2641	335	17	in	in	ADP
eurjchem-2641	335	18	bc	bc	PROPN
eurjchem-2641	335	19	patients	patient	NOUN
eurjchem-2641	335	20	than	than	ADP
eurjchem-2641	335	21	in	in	ADP
eurjchem-2641	335	22	healthy	healthy	ADJ
eurjchem-2641	335	23	subjects	subject	NOUN
eurjchem-2641	335	24	[	[	X
eurjchem-2641	335	25	63	63	NUM
eurjchem-2641	335	26	]	]	PUNCT
eurjchem-2641	335	27	.	.	PUNCT
eurjchem-2641	336	1	in	in	ADP
eurjchem-2641	336	2	contrast	contrast	NOUN
eurjchem-2641	336	3	,	,	PUNCT
eurjchem-2641	336	4	the	the	DET
eurjchem-2641	336	5	results	result	NOUN
eurjchem-2641	336	6	obtained	obtain	VERB
eurjchem-2641	336	7	by	by	ADP
eurjchem-2641	336	8	raza	raza	PROPN
eurjchem-2641	336	9	et	et	PROPN
eurjchem-2641	336	10	al	al	PROPN
eurjchem-2641	336	11	.	.	PROPN
eurjchem-2641	336	12	were	be	AUX
eurjchem-2641	336	13	incompatible	incompatible	ADJ
eurjchem-2641	336	14	with	with	ADP
eurjchem-2641	336	15	the	the	DET
eurjchem-2641	336	16	wbc	wbc	PROPN
eurjchem-2641	336	17	results	result	NOUN
eurjchem-2641	336	18	of	of	ADP
eurjchem-2641	336	19	the	the	DET
eurjchem-2641	336	20	present	present	ADJ
eurjchem-2641	336	21	study	study	NOUN
eurjchem-2641	336	22	[	[	X
eurjchem-2641	336	23	60	60	NUM
eurjchem-2641	336	24	]	]	PUNCT
eurjchem-2641	336	25	.	.	PUNCT
eurjchem-2641	337	1	regarding	regard	VERB
eurjchem-2641	337	2	platelet	platelet	NOUN
eurjchem-2641	337	3	count	count	NOUN
eurjchem-2641	337	4	,	,	PUNCT
eurjchem-2641	337	5	it	it	PRON
eurjchem-2641	337	6	was	be	AUX
eurjchem-2641	337	7	significantly	significantly	ADV
eurjchem-2641	337	8	lower	low	ADJ
eurjchem-2641	337	9	in	in	ADP
eurjchem-2641	337	10	patients	patient	NOUN
eurjchem-2641	337	11	in	in	ADP
eurjchem-2641	337	12	the	the	DET
eurjchem-2641	337	13	early	early	ADJ
eurjchem-2641	337	14	stage	stage	NOUN
eurjchem-2641	337	15	,	,	PUNCT
eurjchem-2641	337	16	chemotherapy	chemotherapy	NOUN
eurjchem-2641	337	17	,	,	PUNCT
eurjchem-2641	337	18	and	and	CCONJ
eurjchem-2641	337	19	surgery	surgery	NOUN
eurjchem-2641	337	20	groups	group	NOUN
eurjchem-2641	337	21	compared	compare	VERB
eurjchem-2641	337	22	to	to	ADP
eurjchem-2641	337	23	healthy	healthy	ADJ
eurjchem-2641	337	24	control	control	NOUN
eurjchem-2641	337	25	subjects	subject	NOUN
eurjchem-2641	337	26	.	.	PUNCT
eurjchem-2641	338	1	similarly	similarly	ADV
eurjchem-2641	338	2	,	,	PUNCT
eurjchem-2641	338	3	another	another	DET
eurjchem-2641	338	4	study	study	NOUN
eurjchem-2641	338	5	showed	show	VERB
eurjchem-2641	338	6	that	that	SCONJ
eurjchem-2641	338	7	deaths	death	NOUN
eurjchem-2641	338	8	in	in	ADP
eurjchem-2641	338	9	bc	bc	PROPN
eurjchem-2641	338	10	patients	patient	NOUN
eurjchem-2641	338	11	from	from	ADP
eurjchem-2641	338	12	chemotherapy	chemotherapy	NOUN
eurjchem-2641	338	13	have	have	AUX
eurjchem-2641	338	14	decreased	decrease	VERB
eurjchem-2641	338	15	platelet	platelet	NOUN
eurjchem-2641	338	16	count	count	NOUN
eurjchem-2641	338	17	as	as	ADP
eurjchem-2641	338	18	one	one	NUM
eurjchem-2641	338	19	of	of	ADP
eurjchem-2641	338	20	the	the	DET
eurjchem-2641	338	21	complications	complication	NOUN
eurjchem-2641	338	22	of	of	ADP
eurjchem-2641	338	23	diseases	disease	NOUN
eurjchem-2641	338	24	and	and	CCONJ
eurjchem-2641	338	25	side	side	NOUN
eurjchem-2641	338	26	effects	effect	NOUN
eurjchem-2641	338	27	of	of	ADP
eurjchem-2641	338	28	chemotherapy	chemotherapy	NOUN
eurjchem-2641	338	29	[	[	X
eurjchem-2641	338	30	63,64	63,64	NOUN
eurjchem-2641	338	31	]	]	PUNCT
eurjchem-2641	338	32	.	.	PUNCT
eurjchem-2641	339	1	this	this	DET
eurjchem-2641	339	2	work	work	NOUN
eurjchem-2641	339	3	has	have	VERB
eurjchem-2641	339	4	limitations	limitation	NOUN
eurjchem-2641	339	5	;	;	PUNCT
eurjchem-2641	339	6	however	however	ADV
eurjchem-2641	339	7	,	,	PUNCT
eurjchem-2641	339	8	it	it	PRON
eurjchem-2641	339	9	is	be	AUX
eurjchem-2641	339	10	cross	cross	ADJ
eurjchem-2641	339	11	-	-	ADJ
eurjchem-2641	339	12	sectional	sectional	ADJ
eurjchem-2641	339	13	work	work	NOUN
eurjchem-2641	339	14	,	,	PUNCT
eurjchem-2641	339	15	which	which	PRON
eurjchem-2641	339	16	does	do	AUX
eurjchem-2641	339	17	not	not	PART
eurjchem-2641	339	18	allow	allow	VERB
eurjchem-2641	339	19	causal	causal	ADJ
eurjchem-2641	339	20	inferences	inference	NOUN
eurjchem-2641	339	21	or	or	CCONJ
eurjchem-2641	339	22	understanding	understanding	NOUN
eurjchem-2641	339	23	of	of	ADP
eurjchem-2641	339	24	temporal	temporal	ADJ
eurjchem-2641	339	25	relationships	relationship	NOUN
eurjchem-2641	339	26	between	between	ADP
eurjchem-2641	339	27	mirna-148b	mirna-148b	PROPN
eurjchem-2641	339	28	levels	level	NOUN
eurjchem-2641	339	29	,	,	PUNCT
eurjchem-2641	339	30	along	along	ADP
eurjchem-2641	339	31	with	with	ADP
eurjchem-2641	339	32	bax	bax	PROPN
eurjchem-2641	339	33	,	,	PUNCT
eurjchem-2641	339	34	caspase-3	caspase-3	NUM
eurjchem-2641	339	35	,	,	PUNCT
eurjchem-2641	339	36	bcl-2	bcl-2	VERB
eurjchem-2641	339	37	and	and	CCONJ
eurjchem-2641	339	38	tac	tac	PROPN
eurjchem-2641	339	39	levels	level	NOUN
eurjchem-2641	339	40	and	and	CCONJ
eurjchem-2641	339	41	treatment	treatment	NOUN
eurjchem-2641	339	42	outcomes	outcome	NOUN
eurjchem-2641	339	43	.	.	PUNCT
eurjchem-2641	340	1	the	the	DET
eurjchem-2641	340	2	preliminary	preliminary	ADJ
eurjchem-2641	340	3	data	datum	NOUN
eurjchem-2641	340	4	of	of	ADP
eurjchem-2641	340	5	this	this	DET
eurjchem-2641	340	6	work	work	NOUN
eurjchem-2641	340	7	,	,	PUNCT
eurjchem-2641	340	8	the	the	DET
eurjchem-2641	340	9	low	low	ADJ
eurjchem-2641	340	10	sample	sample	NOUN
eurjchem-2641	340	11	230	230	NUM
eurjchem-2641	340	12	harisa	harisa	NOUN
eurjchem-2641	340	13	et	et	PROPN
eurjchem-2641	340	14	al	al	PROPN
eurjchem-2641	340	15	.	.	PUNCT
eurjchem-2641	340	16	/	/	SYM
eurjchem-2641	340	17	european	european	PROPN
eurjchem-2641	340	18	journal	journal	PROPN
eurjchem-2641	340	19	of	of	ADP
eurjchem-2641	340	20	chemistry	chemistry	NOUN
eurjchem-2641	340	21	16	16	NUM
eurjchem-2641	340	22	(	(	PUNCT
eurjchem-2641	340	23	2	2	NUM
eurjchem-2641	340	24	)	)	PUNCT
eurjchem-2641	340	25	(	(	PUNCT
eurjchem-2641	340	26	2025	2025	NUM
eurjchem-2641	340	27	)	)	PUNCT
eurjchem-2641	340	28	222	222	NUM
eurjchem-2641	340	29	-	-	SYM
eurjchem-2641	340	30	232	232	NUM
eurjchem-2641	340	31	2025	2025	NUM
eurjchem-2641	340	32	–	–	PUNCT
eurjchem-2641	340	33	european	european	ADJ
eurjchem-2641	340	34	journal	journal	NOUN
eurjchem-2641	340	35	of	of	ADP
eurjchem-2641	340	36	chemistry	chemistry	NOUN
eurjchem-2641	340	37	–	–	PUNCT
eurjchem-2641	340	38	cc	cc	NOUN
eurjchem-2641	340	39	by	by	ADP
eurjchem-2641	340	40	nc	nc	PROPN
eurjchem-2641	340	41	–	–	PUNCT
eurjchem-2641	340	42	doi	doi	NOUN
eurjchem-2641	340	43	:	:	PUNCT
eurjchem-2641	340	44	10.5155	10.5155	NUM
eurjchem-2641	340	45	/	/	SYM
eurjchem-2641	340	46	eurjchem.16.2.222	eurjchem.16.2.222	NOUN
eurjchem-2641	340	47	-	-	SYM
eurjchem-2641	340	48	232.2641	232.2641	NUM
eurjchem-2641	340	49	size	size	NOUN
eurjchem-2641	340	50	,	,	PUNCT
eurjchem-2641	340	51	may	may	AUX
eurjchem-2641	340	52	be	be	AUX
eurjchem-2641	340	53	inadequate	inadequate	ADJ
eurjchem-2641	340	54	to	to	PART
eurjchem-2641	340	55	draw	draw	VERB
eurjchem-2641	340	56	generalizable	generalizable	ADJ
eurjchem-2641	340	57	assumptions	assumption	NOUN
eurjchem-2641	340	58	.	.	PUNCT
eurjchem-2641	341	1	studies	study	NOUN
eurjchem-2641	341	2	with	with	ADP
eurjchem-2641	341	3	larger	large	ADJ
eurjchem-2641	341	4	sample	sample	NOUN
eurjchem-2641	341	5	sizes	size	NOUN
eurjchem-2641	341	6	must	must	AUX
eurjchem-2641	341	7	approve	approve	VERB
eurjchem-2641	341	8	the	the	DET
eurjchem-2641	341	9	present	present	ADJ
eurjchem-2641	341	10	results	result	NOUN
eurjchem-2641	341	11	and	and	CCONJ
eurjchem-2641	341	12	their	their	PRON
eurjchem-2641	341	13	clinical	clinical	ADJ
eurjchem-2641	341	14	importance	importance	NOUN
eurjchem-2641	341	15	.	.	PUNCT
eurjchem-2641	342	1	the	the	DET
eurjchem-2641	342	2	study	study	NOUN
eurjchem-2641	342	3	only	only	ADV
eurjchem-2641	342	4	evaluated	evaluate	VERB
eurjchem-2641	342	5	mirna-148b	mirna-148b	PROPN
eurjchem-2641	342	6	levels	level	NOUN
eurjchem-2641	342	7	and	and	CCONJ
eurjchem-2641	342	8	bax	bax	PROPN
eurjchem-2641	342	9	,	,	PUNCT
eurjchem-2641	342	10	caspase-3	caspase-3	NUM
eurjchem-2641	342	11	,	,	PUNCT
eurjchem-2641	342	12	bcl-2	bcl-2	NOUN
eurjchem-2641	342	13	,	,	PUNCT
eurjchem-2641	342	14	and	and	CCONJ
eurjchem-2641	342	15	tac	tac	PROPN
eurjchem-2641	342	16	levels	level	NOUN
eurjchem-2641	342	17	simultaneously	simultaneously	ADV
eurjchem-2641	342	18	,	,	PUNCT
eurjchem-2641	342	19	this	this	DET
eurjchem-2641	342	20	study	study	NOUN
eurjchem-2641	342	21	touched	touch	VERB
eurjchem-2641	342	22	on	on	ADP
eurjchem-2641	342	23	their	their	PRON
eurjchem-2641	342	24	prognostic	prognostic	ADJ
eurjchem-2641	342	25	value	value	NOUN
eurjchem-2641	342	26	and	and	CCONJ
eurjchem-2641	342	27	response	response	NOUN
eurjchem-2641	342	28	to	to	ADP
eurjchem-2641	342	29	therapy	therapy	NOUN
eurjchem-2641	342	30	.	.	PUNCT
eurjchem-2641	343	1	therefore	therefore	ADV
eurjchem-2641	343	2	,	,	PUNCT
eurjchem-2641	343	3	longitudinal	longitudinal	ADJ
eurjchem-2641	343	4	studies	study	NOUN
eurjchem-2641	343	5	are	be	AUX
eurjchem-2641	343	6	vital	vital	ADJ
eurjchem-2641	343	7	to	to	ADP
eurjchem-2641	343	8	the	the	DET
eurjchem-2641	343	9	management	management	NOUN
eurjchem-2641	343	10	of	of	ADP
eurjchem-2641	343	11	bc	bc	PROPN
eurjchem-2641	343	12	patients	patient	NOUN
eurjchem-2641	343	13	.	.	PUNCT
eurjchem-2641	344	1	the	the	DET
eurjchem-2641	344	2	characteristics	characteristic	NOUN
eurjchem-2641	344	3	of	of	ADP
eurjchem-2641	344	4	the	the	DET
eurjchem-2641	344	5	control	control	NOUN
eurjchem-2641	344	6	group	group	NOUN
eurjchem-2641	344	7	should	should	AUX
eurjchem-2641	344	8	be	be	AUX
eurjchem-2641	344	9	carefully	carefully	ADV
eurjchem-2641	344	10	considered	consider	VERB
eurjchem-2641	344	11	,	,	PUNCT
eurjchem-2641	344	12	as	as	SCONJ
eurjchem-2641	344	13	differences	difference	NOUN
eurjchem-2641	344	14	in	in	ADP
eurjchem-2641	344	15	demographics	demographic	NOUN
eurjchem-2641	344	16	could	could	AUX
eurjchem-2641	344	17	influence	influence	VERB
eurjchem-2641	344	18	measured	measure	VERB
eurjchem-2641	344	19	mirna-148b	mirna-148b	PROPN
eurjchem-2641	344	20	levels	level	NOUN
eurjchem-2641	344	21	,	,	PUNCT
eurjchem-2641	344	22	along	along	ADP
eurjchem-2641	344	23	with	with	ADP
eurjchem-2641	344	24	bax	bax	PROPN
eurjchem-2641	344	25	,	,	PUNCT
eurjchem-2641	344	26	caspase-3	caspase-3	NUM
eurjchem-2641	344	27	,	,	PUNCT
eurjchem-2641	344	28	bcl-2	bcl-2	NOUN
eurjchem-2641	344	29	,	,	PUNCT
eurjchem-2641	344	30	and	and	CCONJ
eurjchem-2641	344	31	tac	tac	PROPN
eurjchem-2641	344	32	as	as	ADP
eurjchem-2641	344	33	bc	bc	PROPN
eurjchem-2641	344	34	biomarkers	biomarker	NOUN
eurjchem-2641	344	35	.	.	PUNCT
eurjchem-2641	345	1	4	4	X
eurjchem-2641	345	2	.	.	X
eurjchem-2641	345	3	conclusions	conclusion	NOUN
eurjchem-2641	345	4	this	this	DET
eurjchem-2641	345	5	study	study	NOUN
eurjchem-2641	345	6	concludes	conclude	VERB
eurjchem-2641	345	7	that	that	SCONJ
eurjchem-2641	345	8	mirna-148b	mirna-148b	PROPN
eurjchem-2641	345	9	and	and	CCONJ
eurjchem-2641	345	10	apoptosis	apoptosis	NOUN
eurjchem-2641	345	11	markers	marker	NOUN
eurjchem-2641	345	12	in	in	ADP
eurjchem-2641	345	13	the	the	DET
eurjchem-2641	345	14	blood	blood	NOUN
eurjchem-2641	345	15	are	be	AUX
eurjchem-2641	345	16	encouraged	encourage	VERB
eurjchem-2641	345	17	non	non	ADJ
eurjchem-2641	345	18	-	-	ADJ
eurjchem-2641	345	19	invasive	invasive	ADJ
eurjchem-2641	345	20	biomarkers	biomarker	NOUN
eurjchem-2641	345	21	for	for	ADP
eurjchem-2641	345	22	the	the	DET
eurjchem-2641	345	23	prediction	prediction	NOUN
eurjchem-2641	345	24	,	,	PUNCT
eurjchem-2641	345	25	diagnosis	diagnosis	NOUN
eurjchem-2641	345	26	,	,	PUNCT
eurjchem-2641	345	27	monitoring	monitoring	NOUN
eurjchem-2641	345	28	,	,	PUNCT
eurjchem-2641	345	29	assessment	assessment	NOUN
eurjchem-2641	345	30	of	of	ADP
eurjchem-2641	345	31	the	the	DET
eurjchem-2641	345	32	anticancer	anticancer	NOUN
eurjchem-2641	345	33	response	response	NOUN
eurjchem-2641	345	34	and	and	CCONJ
eurjchem-2641	345	35	general	general	ADJ
eurjchem-2641	345	36	follow	follow	NOUN
eurjchem-2641	345	37	-	-	PUNCT
eurjchem-2641	345	38	up	up	NOUN
eurjchem-2641	345	39	of	of	ADP
eurjchem-2641	345	40	bc	bc	PROPN
eurjchem-2641	345	41	patients	patient	NOUN
eurjchem-2641	345	42	.	.	PUNCT
eurjchem-2641	346	1	therefore	therefore	ADV
eurjchem-2641	346	2	,	,	PUNCT
eurjchem-2641	346	3	measuring	measure	VERB
eurjchem-2641	346	4	circulating	circulate	VERB
eurjchem-2641	346	5	blood	blood	NOUN
eurjchem-2641	346	6	mirna-148b	mirna-148b	PROPN
eurjchem-2641	346	7	and	and	CCONJ
eurjchem-2641	346	8	caspase-3	caspase-3	PRON
eurjchem-2641	346	9	could	could	AUX
eurjchem-2641	346	10	enhance	enhance	VERB
eurjchem-2641	346	11	the	the	DET
eurjchem-2641	346	12	management	management	NOUN
eurjchem-2641	346	13	of	of	ADP
eurjchem-2641	346	14	bc	bc	PROPN
eurjchem-2641	346	15	.	.	PROPN
eurjchem-2641	347	1	despite	despite	SCONJ
eurjchem-2641	347	2	the	the	DET
eurjchem-2641	347	3	promising	promising	ADJ
eurjchem-2641	347	4	findings	finding	NOUN
eurjchem-2641	347	5	of	of	ADP
eurjchem-2641	347	6	this	this	DET
eurjchem-2641	347	7	study	study	NOUN
eurjchem-2641	347	8	,	,	PUNCT
eurjchem-2641	347	9	it	it	PRON
eurjchem-2641	347	10	has	have	VERB
eurjchem-2641	347	11	several	several	ADJ
eurjchem-2641	347	12	limitations	limitation	NOUN
eurjchem-2641	347	13	,	,	PUNCT
eurjchem-2641	347	14	such	such	ADJ
eurjchem-2641	347	15	as	as	ADP
eurjchem-2641	347	16	a	a	DET
eurjchem-2641	347	17	small	small	ADJ
eurjchem-2641	347	18	sample	sample	NOUN
eurjchem-2641	347	19	size	size	NOUN
eurjchem-2641	347	20	that	that	PRON
eurjchem-2641	347	21	can	can	AUX
eurjchem-2641	347	22	affect	affect	VERB
eurjchem-2641	347	23	the	the	DET
eurjchem-2641	347	24	generalizability	generalizability	NOUN
eurjchem-2641	347	25	of	of	ADP
eurjchem-2641	347	26	the	the	DET
eurjchem-2641	347	27	results	result	NOUN
eurjchem-2641	347	28	.	.	PUNCT
eurjchem-2641	348	1	moreover	moreover	ADV
eurjchem-2641	348	2	,	,	PUNCT
eurjchem-2641	348	3	this	this	DET
eurjchem-2641	348	4	study	study	NOUN
eurjchem-2641	348	5	's	's	PART
eurjchem-2641	348	6	focus	focus	NOUN
eurjchem-2641	348	7	on	on	ADP
eurjchem-2641	348	8	the	the	DET
eurjchem-2641	348	9	homogeneous	homogeneous	ADJ
eurjchem-2641	348	10	population	population	NOUN
eurjchem-2641	348	11	(	(	PUNCT
eurjchem-2641	348	12	egyptian	egyptian	ADJ
eurjchem-2641	348	13	females	female	NOUN
eurjchem-2641	348	14	)	)	PUNCT
eurjchem-2641	348	15	limits	limit	VERB
eurjchem-2641	348	16	applicability	applicability	NOUN
eurjchem-2641	348	17	to	to	ADP
eurjchem-2641	348	18	other	other	ADJ
eurjchem-2641	348	19	demographics	demographic	NOUN
eurjchem-2641	348	20	.	.	PUNCT
eurjchem-2641	349	1	moreover	moreover	ADV
eurjchem-2641	349	2	,	,	PUNCT
eurjchem-2641	349	3	the	the	DET
eurjchem-2641	349	4	lack	lack	NOUN
eurjchem-2641	349	5	of	of	ADP
eurjchem-2641	349	6	longitudinal	longitudinal	ADJ
eurjchem-2641	349	7	and	and	CCONJ
eurjchem-2641	349	8	multicenter	multicenter	ADJ
eurjchem-2641	349	9	approach	approach	NOUN
eurjchem-2641	349	10	limits	limit	VERB
eurjchem-2641	349	11	the	the	DET
eurjchem-2641	349	12	applicability	applicability	NOUN
eurjchem-2641	349	13	of	of	ADP
eurjchem-2641	349	14	the	the	DET
eurjchem-2641	349	15	findings	finding	NOUN
eurjchem-2641	349	16	.	.	PUNCT
eurjchem-2641	350	1	disclosure	disclosure	NOUN
eurjchem-2641	350	2	statement	statement	NOUN
eurjchem-2641	350	3	conflict	conflict	NOUN
eurjchem-2641	350	4	of	of	ADP
eurjchem-2641	350	5	interest	interest	NOUN
eurjchem-2641	350	6	:	:	PUNCT
eurjchem-2641	350	7	the	the	DET
eurjchem-2641	350	8	authors	author	NOUN
eurjchem-2641	350	9	declare	declare	VERB
eurjchem-2641	350	10	that	that	SCONJ
eurjchem-2641	350	11	they	they	PRON
eurjchem-2641	350	12	have	have	VERB
eurjchem-2641	350	13	no	no	DET
eurjchem-2641	350	14	conflicts	conflict	NOUN
eurjchem-2641	350	15	of	of	ADP
eurjchem-2641	350	16	interest	interest	NOUN
eurjchem-2641	350	17	to	to	PART
eurjchem-2641	350	18	report	report	VERB
eurjchem-2641	350	19	on	on	ADP
eurjchem-2641	350	20	the	the	DET
eurjchem-2641	350	21	present	present	ADJ
eurjchem-2641	350	22	study	study	NOUN
eurjchem-2641	350	23	.	.	PUNCT
eurjchem-2641	351	1	ethical	ethical	ADJ
eurjchem-2641	351	2	approval	approval	NOUN
eurjchem-2641	351	3	:	:	PUNCT
eurjchem-2641	351	4	this	this	DET
eurjchem-2641	351	5	study	study	NOUN
eurjchem-2641	351	6	was	be	AUX
eurjchem-2641	351	7	conducted	conduct	VERB
eurjchem-2641	351	8	at	at	ADP
eurjchem-2641	351	9	the	the	DET
eurjchem-2641	351	10	outpatient	outpatient	NOUN
eurjchem-2641	351	11	clinic	clinic	NOUN
eurjchem-2641	351	12	of	of	ADP
eurjchem-2641	351	13	damanhour	damanhour	NOUN
eurjchem-2641	351	14	oncology	oncology	NOUN
eurjchem-2641	351	15	center	center	NOUN
eurjchem-2641	351	16	from	from	ADP
eurjchem-2641	351	17	december	december	PROPN
eurjchem-2641	351	18	2021	2021	NUM
eurjchem-2641	351	19	to	to	ADP
eurjchem-2641	351	20	february	february	PROPN
eurjchem-2641	351	21	2023	2023	NUM
eurjchem-2641	351	22	.	.	PUNCT
eurjchem-2641	352	1	the	the	DET
eurjchem-2641	352	2	research	research	NOUN
eurjchem-2641	352	3	ethics	ethic	NOUN
eurjchem-2641	352	4	committee	committee	PROPN
eurjchem-2641	352	5	of	of	ADP
eurjchem-2641	352	6	the	the	DET
eurjchem-2641	352	7	faculty	faculty	NOUN
eurjchem-2641	352	8	of	of	ADP
eurjchem-2641	352	9	pharmacy	pharmacy	NOUN
eurjchem-2641	352	10	,	,	PUNCT
eurjchem-2641	352	11	damanhour	damanhour	NOUN
eurjchem-2641	352	12	university	university	PROPN
eurjchem-2641	352	13	,	,	PUNCT
eurjchem-2641	352	14	egypt	egypt	PROPN
eurjchem-2641	352	15	,	,	PUNCT
eurjchem-2641	352	16	approved	approve	VERB
eurjchem-2641	352	17	the	the	DET
eurjchem-2641	352	18	study	study	NOUN
eurjchem-2641	352	19	(	(	PUNCT
eurjchem-2641	352	20	ref	ref	NOUN
eurjchem-2641	352	21	.	.	PUNCT
eurjchem-2641	353	1	no	no	INTJ
eurjchem-2641	353	2	.	.	PUNCT
eurjchem-2641	354	1	620pb20	620pb20	NUM
eurjchem-2641	354	2	)	)	PUNCT
eurjchem-2641	354	3	.	.	PUNCT
eurjchem-2641	355	1	the	the	DET
eurjchem-2641	355	2	study	study	NOUN
eurjchem-2641	355	3	adhered	adhere	VERB
eurjchem-2641	355	4	to	to	ADP
eurjchem-2641	355	5	the	the	DET
eurjchem-2641	355	6	helsinki	helsinki	PROPN
eurjchem-2641	355	7	declaration	declaration	PROPN
eurjchem-2641	355	8	of	of	ADP
eurjchem-2641	355	9	ethical	ethical	ADJ
eurjchem-2641	355	10	principles	principle	NOUN
eurjchem-2641	355	11	for	for	ADP
eurjchem-2641	355	12	research	research	NOUN
eurjchem-2641	355	13	involving	involve	VERB
eurjchem-2641	355	14	human	human	ADJ
eurjchem-2641	355	15	subjects	subject	NOUN
eurjchem-2641	355	16	.	.	PUNCT
eurjchem-2641	356	1	data	datum	NOUN
eurjchem-2641	356	2	availability	availability	NOUN
eurjchem-2641	356	3	:	:	PUNCT
eurjchem-2641	356	4	all	all	DET
eurjchem-2641	356	5	data	datum	NOUN
eurjchem-2641	356	6	are	be	AUX
eurjchem-2641	356	7	included	include	VERB
eurjchem-2641	356	8	in	in	ADP
eurjchem-2641	356	9	the	the	DET
eurjchem-2641	356	10	manuscript	manuscript	NOUN
eurjchem-2641	356	11	.	.	PUNCT
eurjchem-2641	357	1	consent	consent	NOUN
eurjchem-2641	357	2	to	to	PART
eurjchem-2641	357	3	participate	participate	VERB
eurjchem-2641	357	4	:	:	PUNCT
eurjchem-2641	357	5	informed	inform	VERB
eurjchem-2641	357	6	consent	consent	NOUN
eurjchem-2641	357	7	was	be	AUX
eurjchem-2641	357	8	obtained	obtain	VERB
eurjchem-2641	357	9	from	from	ADP
eurjchem-2641	357	10	all	all	DET
eurjchem-2641	357	11	participants	participant	NOUN
eurjchem-2641	357	12	.	.	PUNCT
eurjchem-2641	358	1	credit	credit	NOUN
eurjchem-2641	358	2	authorship	authorship	NOUN
eurjchem-2641	358	3	contribution	contribution	NOUN
eurjchem-2641	358	4	statement	statement	NOUN
eurjchem-2641	358	5	conceptualization	conceptualization	NOUN
eurjchem-2641	358	6	:	:	PUNCT
eurjchem-2641	358	7	tarek	tarek	PROPN
eurjchem-2641	358	8	mahmoud	mahmoud	PROPN
eurjchem-2641	358	9	okda	okda	PROPN
eurjchem-2641	358	10	,	,	PUNCT
eurjchem-2641	358	11	gamal	gamal	PROPN
eurjchem-2641	358	12	abd	abd	PROPN
eurjchem-2641	358	13	el	el	PROPN
eurjchem-2641	358	14	-	-	PROPN
eurjchem-2641	358	15	hay	hay	PROPN
eurjchem-2641	358	16	omran	omran	NOUN
eurjchem-2641	358	17	;	;	PUNCT
eurjchem-2641	358	18	methodology	methodology	NOUN
eurjchem-2641	358	19	:	:	PUNCT
eurjchem-2641	358	20	gamaleldin	gamaleldin	VERB
eurjchem-2641	358	21	ibrahim	ibrahim	PROPN
eurjchem-2641	358	22	harisa	harisa	PROPN
eurjchem-2641	358	23	,	,	PUNCT
eurjchem-2641	358	24	tarek	tarek	PROPN
eurjchem-2641	358	25	mahmoud	mahmoud	PROPN
eurjchem-2641	358	26	okda	okda	PROPN
eurjchem-2641	358	27	,	,	PUNCT
eurjchem-2641	358	28	gamal	gamal	PROPN
eurjchem-2641	358	29	abd	abd	PROPN
eurjchem-2641	358	30	el	el	PROPN
eurjchem-2641	358	31	-	-	PROPN
eurjchem-2641	358	32	hay	hay	PROPN
eurjchem-2641	358	33	omran	omran	NOUN
eurjchem-2641	358	34	,	,	PUNCT
eurjchem-2641	358	35	mohamed	mohamed	PROPN
eurjchem-2641	358	36	noureldin	noureldin	PROPN
eurjchem-2641	358	37	;	;	PUNCT
eurjchem-2641	358	38	software	software	NOUN
eurjchem-2641	358	39	:	:	PUNCT
eurjchem-2641	358	40	gamaleldin	gamaleldin	VERB
eurjchem-2641	358	41	ibrahim	ibrahim	PROPN
eurjchem-2641	358	42	harisa	harisa	PROPN
eurjchem-2641	358	43	,	,	PUNCT
eurjchem-2641	358	44	tarek	tarek	PROPN
eurjchem-2641	358	45	mahmoud	mahmoud	PROPN
eurjchem-2641	358	46	okda	okda	PROPN
eurjchem-2641	358	47	,	,	PUNCT
eurjchem-2641	358	48	gamal	gamal	PROPN
eurjchem-2641	358	49	abd	abd	PROPN
eurjchem-2641	358	50	el	el	PROPN
eurjchem-2641	358	51	-	-	PROPN
eurjchem-2641	358	52	hay	hay	PROPN
eurjchem-2641	358	53	omran	omran	NOUN
eurjchem-2641	358	54	;	;	PUNCT
eurjchem-2641	358	55	validation	validation	NOUN
eurjchem-2641	358	56	:	:	PUNCT
eurjchem-2641	358	57	gamaleldin	gamaleldin	VERB
eurjchem-2641	358	58	ibrahim	ibrahim	PROPN
eurjchem-2641	358	59	harisa	harisa	PROPN
eurjchem-2641	358	60	,	,	PUNCT
eurjchem-2641	358	61	tarek	tarek	PROPN
eurjchem-2641	358	62	mahmoud	mahmoud	PROPN
eurjchem-2641	358	63	okda	okda	PROPN
eurjchem-2641	358	64	,	,	PUNCT
eurjchem-2641	358	65	gamal	gamal	PROPN
eurjchem-2641	358	66	abd	abd	PROPN
eurjchem-2641	358	67	el	el	PROPN
eurjchem-2641	358	68	-	-	PROPN
eurjchem-2641	358	69	hay	hay	PROPN
eurjchem-2641	358	70	omran	omran	NOUN
eurjchem-2641	358	71	;	;	PUNCT
eurjchem-2641	358	72	formal	formal	ADJ
eurjchem-2641	358	73	analysis	analysis	NOUN
eurjchem-2641	358	74	:	:	PUNCT
eurjchem-2641	358	75	tarek	tarek	PROPN
eurjchem-2641	358	76	mahmoud	mahmoud	PROPN
eurjchem-2641	358	77	okda	okda	PROPN
eurjchem-2641	358	78	,	,	PUNCT
eurjchem-2641	358	79	gamal	gamal	PROPN
eurjchem-2641	358	80	abd	abd	PROPN
eurjchem-2641	358	81	el	el	PROPN
eurjchem-2641	358	82	-	-	PROPN
eurjchem-2641	358	83	hay	hay	PROPN
eurjchem-2641	358	84	omran	omran	NOUN
eurjchem-2641	358	85	;	;	PUNCT
eurjchem-2641	358	86	investigation	investigation	NOUN
eurjchem-2641	358	87	:	:	PUNCT
eurjchem-2641	358	88	tarek	tarek	PROPN
eurjchem-2641	358	89	mahmoud	mahmoud	PROPN
eurjchem-2641	358	90	okda	okda	PROPN
eurjchem-2641	358	91	,	,	PUNCT
eurjchem-2641	358	92	gamal	gamal	PROPN
eurjchem-2641	358	93	abd	abd	PROPN
eurjchem-2641	358	94	el	el	PROPN
eurjchem-2641	358	95	-	-	PROPN
eurjchem-2641	358	96	hay	hay	PROPN
eurjchem-2641	358	97	omran	omran	NOUN
eurjchem-2641	358	98	,	,	PUNCT
eurjchem-2641	358	99	ahmed	ahmed	PROPN
eurjchem-2641	358	100	noreldin	noreldin	PROPN
eurjchem-2641	358	101	;	;	PUNCT
eurjchem-2641	358	102	resources	resource	NOUN
eurjchem-2641	358	103	:	:	PUNCT
eurjchem-2641	358	104	gamaleldin	gamaleldin	VERB
eurjchem-2641	358	105	ibrahim	ibrahim	PROPN
eurjchem-2641	358	106	harisa	harisa	PROPN
eurjchem-2641	358	107	,	,	PUNCT
eurjchem-2641	358	108	tarek	tarek	PROPN
eurjchem-2641	358	109	mahmoud	mahmoud	PROPN
eurjchem-2641	358	110	okda	okda	PROPN
eurjchem-2641	358	111	,	,	PUNCT
eurjchem-2641	358	112	gamal	gamal	PROPN
eurjchem-2641	358	113	abd	abd	PROPN
eurjchem-2641	358	114	elhay	elhay	PROPN
eurjchem-2641	358	115	omran	omran	PROPN
eurjchem-2641	358	116	;	;	PUNCT
eurjchem-2641	358	117	data	datum	NOUN
eurjchem-2641	358	118	curation	curation	NOUN
eurjchem-2641	358	119	:	:	PUNCT
eurjchem-2641	358	120	gamaleldin	gamaleldin	VERB
eurjchem-2641	358	121	ibrahim	ibrahim	PROPN
eurjchem-2641	358	122	harisa	harisa	PROPN
eurjchem-2641	358	123	,	,	PUNCT
eurjchem-2641	358	124	tarek	tarek	PROPN
eurjchem-2641	358	125	mahmoud	mahmoud	PROPN
eurjchem-2641	358	126	okda	okda	PROPN
eurjchem-2641	358	127	,	,	PUNCT
eurjchem-2641	358	128	gamal	gamal	PROPN
eurjchem-2641	358	129	abd	abd	PROPN
eurjchem-2641	358	130	el	el	PROPN
eurjchem-2641	358	131	-	-	PROPN
eurjchem-2641	358	132	hay	hay	PROPN
eurjchem-2641	358	133	omran	omran	NOUN
eurjchem-2641	358	134	;	;	PUNCT
eurjchem-2641	358	135	writing	write	VERB
eurjchem-2641	358	136	original	original	ADJ
eurjchem-2641	358	137	draft	draft	NOUN
eurjchem-2641	358	138	:	:	PUNCT
eurjchem-2641	358	139	tarek	tarek	PROPN
eurjchem-2641	358	140	mahmoud	mahmoud	PROPN
eurjchem-2641	358	141	okda	okda	PROPN
eurjchem-2641	358	142	,	,	PUNCT
eurjchem-2641	358	143	gamal	gamal	PROPN
eurjchem-2641	358	144	abd	abd	PROPN
eurjchem-2641	358	145	el	el	PROPN
eurjchem-2641	358	146	-	-	PROPN
eurjchem-2641	358	147	hay	hay	PROPN
eurjchem-2641	358	148	omran	omran	NOUN
eurjchem-2641	358	149	;	;	PUNCT
eurjchem-2641	358	150	writing	write	VERB
eurjchem-2641	358	151	review	review	NOUN
eurjchem-2641	358	152	and	and	CCONJ
eurjchem-2641	358	153	editing	editing	NOUN
eurjchem-2641	358	154	:	:	PUNCT
eurjchem-2641	358	155	gamaleldin	gamaleldin	VERB
eurjchem-2641	358	156	ibrahim	ibrahim	PROPN
eurjchem-2641	358	157	harisa	harisa	PROPN
eurjchem-2641	358	158	,	,	PUNCT
eurjchem-2641	358	159	samiyah	samiyah	NOUN
eurjchem-2641	358	160	alshehri	alshehri	PROPN
eurjchem-2641	358	161	,	,	PUNCT
eurjchem-2641	358	162	sulthan	sulthan	PROPN
eurjchem-2641	358	163	al	al	PROPN
eurjchem-2641	358	164	rashid	rashid	PROPN
eurjchem-2641	358	165	;	;	PUNCT
eurjchem-2641	358	166	visualization	visualization	NOUN
eurjchem-2641	358	167	:	:	PUNCT
eurjchem-2641	358	168	gamaleldin	gamaleldin	VERB
eurjchem-2641	358	169	ibrahim	ibrahim	PROPN
eurjchem-2641	358	170	harisa	harisa	PROPN
eurjchem-2641	358	171	,	,	PUNCT
eurjchem-2641	358	172	tarek	tarek	PROPN
eurjchem-2641	358	173	mahmoud	mahmoud	PROPN
eurjchem-2641	358	174	okda	okda	PROPN
eurjchem-2641	358	175	,	,	PUNCT
eurjchem-2641	358	176	gamal	gamal	PROPN
eurjchem-2641	358	177	abd	abd	PROPN
eurjchem-2641	358	178	el	el	PROPN
eurjchem-2641	358	179	-	-	PROPN
eurjchem-2641	358	180	hay	hay	PROPN
eurjchem-2641	358	181	omran	omran	NOUN
eurjchem-2641	358	182	;	;	PUNCT
eurjchem-2641	358	183	funding	funding	NOUN
eurjchem-2641	358	184	acquisition	acquisition	NOUN
eurjchem-2641	358	185	:	:	PUNCT
eurjchem-2641	358	186	gamaleldin	gamaleldin	VERB
eurjchem-2641	358	187	ibrahim	ibrahim	PROPN
eurjchem-2641	358	188	harisa	harisa	NOUN
eurjchem-2641	358	189	;	;	PUNCT
eurjchem-2641	358	190	supervision	supervision	NOUN
eurjchem-2641	358	191	:	:	PUNCT
eurjchem-2641	358	192	gamaleldin	gamaleldin	VERB
eurjchem-2641	358	193	ibrahim	ibrahim	PROPN
eurjchem-2641	358	194	harisa	harisa	PROPN
eurjchem-2641	358	195	,	,	PUNCT
eurjchem-2641	358	196	tarek	tarek	PROPN
eurjchem-2641	358	197	mahmoud	mahmoud	PROPN
eurjchem-2641	358	198	okda	okda	PROPN
eurjchem-2641	358	199	,	,	PUNCT
eurjchem-2641	358	200	gamal	gamal	PROPN
eurjchem-2641	358	201	abd	abd	PROPN
eurjchem-2641	358	202	el	el	PROPN
eurjchem-2641	358	203	-	-	PROPN
eurjchem-2641	358	204	hay	hay	PROPN
eurjchem-2641	358	205	omran	omran	NOUN
eurjchem-2641	358	206	;	;	PUNCT
eurjchem-2641	358	207	project	project	NOUN
eurjchem-2641	358	208	administration	administration	NOUN
eurjchem-2641	358	209	:	:	PUNCT
eurjchem-2641	358	210	gamaleldin	gamaleldin	VERB
eurjchem-2641	358	211	ibrahim	ibrahim	PROPN
eurjchem-2641	358	212	harisa	harisa	PROPN
eurjchem-2641	358	213	,	,	PUNCT
eurjchem-2641	358	214	tarek	tarek	PROPN
eurjchem-2641	358	215	mahmoud	mahmoud	PROPN
eurjchem-2641	358	216	okda	okda	PROPN
eurjchem-2641	358	217	,	,	PUNCT
eurjchem-2641	358	218	gamal	gamal	PROPN
eurjchem-2641	358	219	abd	abd	PROPN
eurjchem-2641	358	220	el	el	PROPN
eurjchem-2641	358	221	-	-	PROPN
eurjchem-2641	358	222	hay	hay	PROPN
eurjchem-2641	358	223	omran	omran	NOUN
eurjchem-2641	358	224	.	.	PUNCT
eurjchem-2641	359	1	orcid	orcid	NOUN
eurjchem-2641	359	2	and	and	CCONJ
eurjchem-2641	359	3	email	email	NOUN
eurjchem-2641	359	4	gamaleldin	gamaleldin	VERB
eurjchem-2641	359	5	ibrahim	ibrahim	PROPN
eurjchem-2641	359	6	harisa	harisa	PROPN
eurjchem-2641	359	7	harisa@ksu.edu.sa	harisa@ksu.edu.sa	PROPN
eurjchem-2641	359	8	https://orcid.org/0000-0002-7988-4421	https://orcid.org/0000-0002-7988-4421	VERB
eurjchem-2641	359	9	gamal	gamal	PROPN
eurjchem-2641	359	10	abd	abd	PROPN
eurjchem-2641	359	11	el	el	PROPN
eurjchem-2641	359	12	-	-	PROPN
eurjchem-2641	359	13	hay	hay	PROPN
eurjchem-2641	359	14	omran	omran	NOUN
eurjchem-2641	359	15	gmalomran@pharm.dmu.edu.eg	gmalomran@pharm.dmu.edu.eg	PROPN
eurjchem-2641	359	16	https://orcid.org/0000-0002-1609-8802	https://orcid.org/0000-0002-1609-8802	PROPN
eurjchem-2641	359	17	mohamed	mohame	VERB
eurjchem-2641	359	18	noureldin	noureldin	VERB
eurjchem-2641	359	19	mohamed.noureldin@aast.edu	mohamed.noureldin@aast.edu	PROPN
eurjchem-2641	359	20	https://orcid.org/0000-0001-7733-2124	https://orcid.org/0000-0001-7733-2124	PROPN
eurjchem-2641	359	21	ahmed	ahme	VERB
eurjchem-2641	359	22	noreldin	noreldin	VERB
eurjchem-2641	359	23	ahmed.noureldeen@vetmed.dmu.edu.eg	ahmed.noureldeen@vetmed.dmu.edu.eg	NOUN
eurjchem-2641	359	24	https://orcid.org/0000-0002-8344-0807	https://orcid.org/0000-0002-8344-0807	ADJ
eurjchem-2641	359	25	samiyah	samiyah	NOUN
eurjchem-2641	359	26	alshehri	alshehri	PROPN
eurjchem-2641	359	27	saalshehri@ksu.edu.sa	saalshehri@ksu.edu.sa	PROPN
eurjchem-2641	359	28	https://orcid.org/0000-0002-8452-4789	https://orcid.org/0000-0002-8452-4789	PROPN
eurjchem-2641	359	29	sulthan	sulthan	PROPN
eurjchem-2641	359	30	al	al	PROPN
eurjchem-2641	359	31	rashid	rashid	PROPN
eurjchem-2641	359	32	sulthanalrashid@gmail.com	sulthanalrashid@gmail.com	PROPN
eurjchem-2641	360	1	https://orcid.org/0000-0001-7506-3039	https://orcid.org/0000-0001-7506-3039	PROPN
eurjchem-2641	360	2	tarek	tarek	PROPN
eurjchem-2641	360	3	mahmoud	mahmoud	PROPN
eurjchem-2641	360	4	okda	okda	PROPN
eurjchem-2641	360	5	tarekokda@pharm.dmu.edu.eg	tarekokda@pharm.dmu.edu.eg	PROPN
eurjchem-2641	360	6	https://orcid.org/0000-0001-7030-6169	https://orcid.org/0000-0001-7030-6169	PROPN
eurjchem-2641	360	7	references	reference	NOUN
eurjchem-2641	360	8	[	[	X
eurjchem-2641	360	9	1	1	NUM
eurjchem-2641	360	10	]	]	PUNCT
eurjchem-2641	360	11	.	.	PUNCT
eurjchem-2641	361	1	jørgensen	jørgensen	PROPN
eurjchem-2641	361	2	,	,	PUNCT
eurjchem-2641	361	3	k.	k.	PROPN
eurjchem-2641	361	4	j.	j.	PROPN
eurjchem-2641	361	5	;	;	PUNCT
eurjchem-2641	361	6	kalager	kalager	NOUN
eurjchem-2641	361	7	,	,	PUNCT
eurjchem-2641	361	8	m.	m.	NOUN
eurjchem-2641	361	9	;	;	PUNCT
eurjchem-2641	361	10	barratt	barratt	PROPN
eurjchem-2641	361	11	,	,	PUNCT
eurjchem-2641	361	12	a.	a.	NOUN
eurjchem-2641	361	13	;	;	PUNCT
eurjchem-2641	361	14	baines	baine	NOUN
eurjchem-2641	361	15	,	,	PUNCT
eurjchem-2641	361	16	c.	c.	PROPN
eurjchem-2641	361	17	;	;	PUNCT
eurjchem-2641	361	18	zahl	zahl	PROPN
eurjchem-2641	361	19	,	,	PUNCT
eurjchem-2641	361	20	p.	p.	NOUN
eurjchem-2641	361	21	;	;	PUNCT
eurjchem-2641	361	22	brodersen	brodersen	PROPN
eurjchem-2641	361	23	,	,	PUNCT
eurjchem-2641	361	24	j.	j.	PROPN
eurjchem-2641	361	25	;	;	PUNCT
eurjchem-2641	361	26	harris	harris	PROPN
eurjchem-2641	361	27	,	,	PUNCT
eurjchem-2641	361	28	r.	r.	PROPN
eurjchem-2641	361	29	p.	p.	PROPN
eurjchem-2641	361	30	overview	overview	NOUN
eurjchem-2641	361	31	of	of	ADP
eurjchem-2641	361	32	guidelines	guideline	NOUN
eurjchem-2641	361	33	on	on	ADP
eurjchem-2641	361	34	breast	breast	NOUN
eurjchem-2641	361	35	screening	screening	NOUN
eurjchem-2641	361	36	:	:	PUNCT
eurjchem-2641	361	37	why	why	SCONJ
eurjchem-2641	361	38	recommendations	recommendation	NOUN
eurjchem-2641	361	39	differ	differ	VERB
eurjchem-2641	361	40	and	and	CCONJ
eurjchem-2641	361	41	what	what	PRON
eurjchem-2641	361	42	to	to	PART
eurjchem-2641	361	43	do	do	VERB
eurjchem-2641	361	44	about	about	ADP
eurjchem-2641	361	45	it	it	PRON
eurjchem-2641	361	46	.	.	PUNCT
eurjchem-2641	362	1	breast	breast	NOUN
eurjchem-2641	362	2	2017	2017	NUM
eurjchem-2641	362	3	,	,	PUNCT
eurjchem-2641	362	4	31	31	NUM
eurjchem-2641	362	5	,	,	PUNCT
eurjchem-2641	362	6	261–269	261–269	NUM
eurjchem-2641	362	7	.	.	PUNCT
eurjchem-2641	363	1	[	[	X
eurjchem-2641	363	2	2	2	NUM
eurjchem-2641	363	3	]	]	PUNCT
eurjchem-2641	363	4	.	.	PUNCT
eurjchem-2641	364	1	sherif	sherif	PROPN
eurjchem-2641	364	2	,	,	PUNCT
eurjchem-2641	364	3	a.	a.	NOUN
eurjchem-2641	364	4	y.	y.	PROPN
eurjchem-2641	364	5	;	;	PUNCT
eurjchem-2641	364	6	harisa	harisa	NOUN
eurjchem-2641	364	7	,	,	PUNCT
eurjchem-2641	364	8	g.	g.	PROPN
eurjchem-2641	364	9	i.	i.	PROPN
eurjchem-2641	364	10	;	;	PUNCT
eurjchem-2641	364	11	shahba	shahba	NOUN
eurjchem-2641	364	12	,	,	PUNCT
eurjchem-2641	364	13	a.	a.	NOUN
eurjchem-2641	364	14	a.	a.	PROPN
eurjchem-2641	364	15	;	;	PUNCT
eurjchem-2641	364	16	nasr	nasr	PROPN
eurjchem-2641	364	17	,	,	PUNCT
eurjchem-2641	364	18	f.	f.	PROPN
eurjchem-2641	364	19	a.	a.	PROPN
eurjchem-2641	364	20	;	;	PUNCT
eurjchem-2641	364	21	taha	taha	PROPN
eurjchem-2641	364	22	,	,	PUNCT
eurjchem-2641	364	23	e.	e.	PROPN
eurjchem-2641	364	24	i.	i.	PROPN
eurjchem-2641	364	25	;	;	PUNCT
eurjchem-2641	364	26	alqahtani	alqahtani	PROPN
eurjchem-2641	364	27	,	,	PUNCT
eurjchem-2641	364	28	a.	a.	PROPN
eurjchem-2641	364	29	s.	s.	PROPN
eurjchem-2641	364	30	assembly	assembly	PROPN
eurjchem-2641	364	31	of	of	ADP
eurjchem-2641	364	32	nanostructured	nanostructure	VERB
eurjchem-2641	364	33	lipid	lipid	NOUN
eurjchem-2641	364	34	carriers	carrier	NOUN
eurjchem-2641	364	35	loaded	load	VERB
eurjchem-2641	364	36	gefitinib	gefitinib	NOUN
eurjchem-2641	364	37	and	and	CCONJ
eurjchem-2641	364	38	simvastatin	simvastatin	NOUN
eurjchem-2641	364	39	as	as	ADP
eurjchem-2641	364	40	hybrid	hybrid	NOUN
eurjchem-2641	364	41	therapy	therapy	NOUN
eurjchem-2641	364	42	for	for	ADP
eurjchem-2641	364	43	metastatic	metastatic	ADJ
eurjchem-2641	364	44	breast	breast	NOUN
eurjchem-2641	364	45	cancer	cancer	NOUN
eurjchem-2641	364	46	:	:	PUNCT
eurjchem-2641	364	47	codelivery	codelivery	NOUN
eurjchem-2641	364	48	and	and	CCONJ
eurjchem-2641	364	49	repurposing	repurpose	VERB
eurjchem-2641	364	50	approach	approach	NOUN
eurjchem-2641	364	51	.	.	PUNCT
eurjchem-2641	365	1	drug	drug	PROPN
eurjchem-2641	365	2	dev	dev	PROPN
eurjchem-2641	365	3	.	.	PUNCT
eurjchem-2641	366	1	res	re	NOUN
eurjchem-2641	366	2	.	.	PROPN
eurjchem-2641	367	1	2023	2023	NUM
eurjchem-2641	367	2	,	,	PUNCT
eurjchem-2641	367	3	84	84	NUM
eurjchem-2641	367	4	,	,	PUNCT
eurjchem-2641	367	5	1453–1467	1453–1467	NUM
eurjchem-2641	367	6	.	.	PUNCT
eurjchem-2641	368	1	[	[	X
eurjchem-2641	368	2	3	3	NUM
eurjchem-2641	368	3	]	]	PUNCT
eurjchem-2641	368	4	.	.	PUNCT
eurjchem-2641	369	1	siegel	siegel	PROPN
eurjchem-2641	369	2	,	,	PUNCT
eurjchem-2641	369	3	r.	r.	PROPN
eurjchem-2641	369	4	l.	l.	PROPN
eurjchem-2641	369	5	;	;	PUNCT
eurjchem-2641	369	6	miller	miller	PROPN
eurjchem-2641	369	7	,	,	PUNCT
eurjchem-2641	369	8	k.	k.	PROPN
eurjchem-2641	369	9	d.	d.	PROPN
eurjchem-2641	369	10	;	;	PUNCT
eurjchem-2641	369	11	fuchs	fuchs	PROPN
eurjchem-2641	369	12	,	,	PUNCT
eurjchem-2641	369	13	h.	h.	PROPN
eurjchem-2641	369	14	e.	e.	PROPN
eurjchem-2641	369	15	;	;	PUNCT
eurjchem-2641	369	16	jemal	jemal	ADJ
eurjchem-2641	369	17	,	,	PUNCT
eurjchem-2641	369	18	a.	a.	NOUN
eurjchem-2641	369	19	cancer	cancer	NOUN
eurjchem-2641	369	20	statistics	statistic	NOUN
eurjchem-2641	369	21	,	,	PUNCT
eurjchem-2641	369	22	2021	2021	NUM
eurjchem-2641	369	23	.	.	PUNCT
eurjchem-2641	370	1	ca	can	AUX
eurjchem-2641	370	2	.	.	PUNCT
eurjchem-2641	370	3	a.	a.	PROPN
eurjchem-2641	370	4	cancer	cancer	PROPN
eurjchem-2641	370	5	j.	j.	PROPN
eurjchem-2641	370	6	clinicians	clinician	NOUN
eurjchem-2641	370	7	2021	2021	NUM
eurjchem-2641	370	8	,	,	PUNCT
eurjchem-2641	370	9	71	71	NUM
eurjchem-2641	370	10	(	(	PUNCT
eurjchem-2641	370	11	1	1	NUM
eurjchem-2641	370	12	)	)	PUNCT
eurjchem-2641	370	13	,	,	PUNCT
eurjchem-2641	370	14	7–33	7–33	PROPN
eurjchem-2641	370	15	.	.	PUNCT
eurjchem-2641	371	1	[	[	X
eurjchem-2641	371	2	4	4	NUM
eurjchem-2641	371	3	]	]	PUNCT
eurjchem-2641	371	4	.	.	PUNCT
eurjchem-2641	372	1	coughlin	coughlin	PROPN
eurjchem-2641	372	2	,	,	PUNCT
eurjchem-2641	372	3	s.	s.	PROPN
eurjchem-2641	372	4	s.	s.	PROPN
eurjchem-2641	372	5	epidemiology	epidemiology	PROPN
eurjchem-2641	372	6	of	of	ADP
eurjchem-2641	372	7	breast	breast	NOUN
eurjchem-2641	372	8	cancer	cancer	NOUN
eurjchem-2641	372	9	in	in	ADP
eurjchem-2641	372	10	women	woman	NOUN
eurjchem-2641	372	11	.	.	PUNCT
eurjchem-2641	373	1	adv	adv	PROPN
eurjchem-2641	373	2	.	.	PUNCT
eurjchem-2641	374	1	exp	exp	PROPN
eurjchem-2641	374	2	.	.	PROPN
eurjchem-2641	374	3	med	med	PROPN
eurjchem-2641	374	4	.	.	PUNCT
eurjchem-2641	375	1	biol	biol	PROPN
eurjchem-2641	375	2	.	.	PUNCT
eurjchem-2641	376	1	2019	2019	NUM
eurjchem-2641	376	2	,	,	PUNCT
eurjchem-2641	376	3	9–29	9–29	NOUN
eurjchem-2641	376	4	.	.	PUNCT
eurjchem-2641	377	1	[	[	X
eurjchem-2641	377	2	5	5	NUM
eurjchem-2641	377	3	]	]	PUNCT
eurjchem-2641	377	4	.	.	PUNCT
eurjchem-2641	378	1	britt	britt	PROPN
eurjchem-2641	378	2	,	,	PUNCT
eurjchem-2641	378	3	k.	k.	PROPN
eurjchem-2641	378	4	l.	l.	PROPN
eurjchem-2641	378	5	;	;	PUNCT
eurjchem-2641	378	6	cuzick	cuzick	PROPN
eurjchem-2641	378	7	,	,	PUNCT
eurjchem-2641	378	8	j.	j.	PROPN
eurjchem-2641	378	9	;	;	PUNCT
eurjchem-2641	378	10	phillips	phillips	PROPN
eurjchem-2641	378	11	,	,	PUNCT
eurjchem-2641	378	12	k.	k.	PROPN
eurjchem-2641	378	13	key	key	ADJ
eurjchem-2641	378	14	steps	step	NOUN
eurjchem-2641	378	15	for	for	ADP
eurjchem-2641	378	16	effective	effective	ADJ
eurjchem-2641	378	17	breast	breast	NOUN
eurjchem-2641	378	18	cancer	cancer	NOUN
eurjchem-2641	378	19	prevention	prevention	NOUN
eurjchem-2641	378	20	.	.	PUNCT
eurjchem-2641	379	1	nat	nat	PROPN
eurjchem-2641	379	2	.	.	PUNCT
eurjchem-2641	380	1	rev	rev	PROPN
eurjchem-2641	380	2	.	.	PROPN
eurjchem-2641	381	1	cancer	cancer	NOUN
eurjchem-2641	381	2	2020	2020	NUM
eurjchem-2641	381	3	,	,	PUNCT
eurjchem-2641	381	4	20	20	NUM
eurjchem-2641	381	5	(	(	PUNCT
eurjchem-2641	381	6	8)	8)	NUM
eurjchem-2641	381	7	,	,	PUNCT
eurjchem-2641	381	8	417–436	417–436	NUM
eurjchem-2641	381	9	.	.	PUNCT
eurjchem-2641	382	1	[	[	X
eurjchem-2641	382	2	6	6	NUM
eurjchem-2641	382	3	]	]	PUNCT
eurjchem-2641	382	4	.	.	PUNCT
eurjchem-2641	383	1	yeo	yeo	PROPN
eurjchem-2641	383	2	,	,	PUNCT
eurjchem-2641	383	3	s.	s.	PROPN
eurjchem-2641	383	4	k.	k.	PROPN
eurjchem-2641	383	5	;	;	PUNCT
eurjchem-2641	383	6	guan	guan	PROPN
eurjchem-2641	383	7	,	,	PUNCT
eurjchem-2641	383	8	j.	j.	PROPN
eurjchem-2641	383	9	breast	breast	PROPN
eurjchem-2641	383	10	cancer	cancer	NOUN
eurjchem-2641	383	11	:	:	PUNCT
eurjchem-2641	383	12	multiple	multiple	ADJ
eurjchem-2641	383	13	subtypes	subtype	NOUN
eurjchem-2641	383	14	within	within	ADP
eurjchem-2641	383	15	a	a	DET
eurjchem-2641	383	16	tumor	tumor	NOUN
eurjchem-2641	383	17	?	?	PUNCT
eurjchem-2641	383	18	.	.	PUNCT
eurjchem-2641	384	1	trends	trend	NOUN
eurjchem-2641	384	2	cancer	cancer	NOUN
eurjchem-2641	384	3	2017	2017	NUM
eurjchem-2641	384	4	,	,	PUNCT
eurjchem-2641	384	5	3	3	NUM
eurjchem-2641	384	6	(	(	PUNCT
eurjchem-2641	384	7	11	11	NUM
eurjchem-2641	384	8	)	)	PUNCT
eurjchem-2641	384	9	,	,	PUNCT
eurjchem-2641	384	10	753–760	753–760	NUM
eurjchem-2641	384	11	.	.	PUNCT
eurjchem-2641	385	1	[	[	X
eurjchem-2641	385	2	7	7	NUM
eurjchem-2641	385	3	]	]	PUNCT
eurjchem-2641	385	4	.	.	PUNCT
eurjchem-2641	385	5	zubair	zubair	PROPN
eurjchem-2641	385	6	,	,	PUNCT
eurjchem-2641	385	7	m.	m.	NOUN
eurjchem-2641	385	8	;	;	PUNCT
eurjchem-2641	385	9	wang	wang	PROPN
eurjchem-2641	385	10	,	,	PUNCT
eurjchem-2641	385	11	s.	s.	PROPN
eurjchem-2641	385	12	;	;	PUNCT
eurjchem-2641	385	13	ali	ali	PROPN
eurjchem-2641	385	14	,	,	PUNCT
eurjchem-2641	385	15	n.	n.	PROPN
eurjchem-2641	385	16	advanced	advanced	ADJ
eurjchem-2641	385	17	approaches	approach	NOUN
eurjchem-2641	385	18	to	to	ADP
eurjchem-2641	385	19	breast	breast	NOUN
eurjchem-2641	385	20	cancer	cancer	NOUN
eurjchem-2641	385	21	classification	classification	NOUN
eurjchem-2641	385	22	and	and	CCONJ
eurjchem-2641	385	23	diagnosis	diagnosis	NOUN
eurjchem-2641	385	24	.	.	PUNCT
eurjchem-2641	386	1	front	front	NOUN
eurjchem-2641	386	2	.	.	PUNCT
eurjchem-2641	387	1	pharmacol	pharmacol	PROPN
eurjchem-2641	387	2	.	.	PROPN
eurjchem-2641	387	3	2021	2021	NUM
eurjchem-2641	387	4	,	,	PUNCT
eurjchem-2641	387	5	11	11	NUM
eurjchem-2641	387	6	,	,	PUNCT
eurjchem-2641	387	7	632079	632079	NUM
eurjchem-2641	387	8	https://doi.org/10.3389/fphar.2020.632079	https://doi.org/10.3389/fphar.2020.632079	PROPN
eurjchem-2641	387	9	.	.	PUNCT
eurjchem-2641	388	1	[	[	X
eurjchem-2641	388	2	8	8	NUM
eurjchem-2641	388	3	]	]	PUNCT
eurjchem-2641	388	4	.	.	PUNCT
eurjchem-2641	388	5	shefer	shefer	PROPN
eurjchem-2641	388	6	,	,	PUNCT
eurjchem-2641	388	7	a.	a.	NOUN
eurjchem-2641	388	8	;	;	PUNCT
eurjchem-2641	388	9	yalovaya	yalovaya	PROPN
eurjchem-2641	388	10	,	,	PUNCT
eurjchem-2641	388	11	a.	a.	NOUN
eurjchem-2641	388	12	;	;	PUNCT
eurjchem-2641	388	13	tamkovich	tamkovich	PROPN
eurjchem-2641	388	14	,	,	PUNCT
eurjchem-2641	388	15	s.	s.	PROPN
eurjchem-2641	388	16	exosomes	exosome	VERB
eurjchem-2641	388	17	in	in	ADP
eurjchem-2641	388	18	breast	breast	NOUN
eurjchem-2641	388	19	cancer	cancer	NOUN
eurjchem-2641	388	20	:	:	PUNCT
eurjchem-2641	388	21	involvement	involvement	NOUN
eurjchem-2641	388	22	in	in	ADP
eurjchem-2641	388	23	tumor	tumor	NOUN
eurjchem-2641	388	24	dissemination	dissemination	NOUN
eurjchem-2641	388	25	and	and	CCONJ
eurjchem-2641	388	26	prospects	prospect	NOUN
eurjchem-2641	388	27	for	for	ADP
eurjchem-2641	388	28	liquid	liquid	ADJ
eurjchem-2641	388	29	biopsy	biopsy	NOUN
eurjchem-2641	388	30	.	.	PUNCT
eurjchem-2641	389	1	ijms	ijms	PROPN
eurjchem-2641	389	2	.	.	PUNCT
eurjchem-2641	390	1	2022	2022	NUM
eurjchem-2641	390	2	,	,	PUNCT
eurjchem-2641	390	3	23	23	NUM
eurjchem-2641	390	4	(	(	PUNCT
eurjchem-2641	390	5	16	16	NUM
eurjchem-2641	390	6	)	)	PUNCT
eurjchem-2641	390	7	,	,	PUNCT
eurjchem-2641	390	8	8845	8845	NUM
eurjchem-2641	390	9	.	.	PUNCT
eurjchem-2641	391	1	[	[	X
eurjchem-2641	391	2	9	9	NUM
eurjchem-2641	391	3	]	]	PUNCT
eurjchem-2641	391	4	.	.	PUNCT
eurjchem-2641	391	5	skouras	skouras	PROPN
eurjchem-2641	391	6	,	,	PUNCT
eurjchem-2641	391	7	p.	p.	NOUN
eurjchem-2641	391	8	;	;	PUNCT
eurjchem-2641	391	9	markouli	markouli	PROPN
eurjchem-2641	391	10	,	,	PUNCT
eurjchem-2641	391	11	m.	m.	NOUN
eurjchem-2641	391	12	;	;	PUNCT
eurjchem-2641	391	13	kalamatianos	kalamatiano	NOUN
eurjchem-2641	391	14	,	,	PUNCT
eurjchem-2641	391	15	t.	t.	PROPN
eurjchem-2641	391	16	;	;	PUNCT
eurjchem-2641	391	17	stranjalis	stranjalis	PROPN
eurjchem-2641	391	18	,	,	PUNCT
eurjchem-2641	391	19	g.	g.	PROPN
eurjchem-2641	391	20	;	;	PUNCT
eurjchem-2641	391	21	korkolopoulou	korkolopoulou	PROPN
eurjchem-2641	391	22	,	,	PUNCT
eurjchem-2641	391	23	p.	p.	NOUN
eurjchem-2641	391	24	;	;	PUNCT
eurjchem-2641	391	25	piperi	piperi	PROPN
eurjchem-2641	391	26	,	,	PUNCT
eurjchem-2641	391	27	c.	c.	NOUN
eurjchem-2641	391	28	advances	advance	VERB
eurjchem-2641	391	29	on	on	ADP
eurjchem-2641	391	30	liquid	liquid	ADJ
eurjchem-2641	391	31	biopsy	biopsy	NOUN
eurjchem-2641	391	32	analysis	analysis	NOUN
eurjchem-2641	391	33	for	for	ADP
eurjchem-2641	391	34	glioma	glioma	ADJ
eurjchem-2641	391	35	diagnosis	diagnosis	NOUN
eurjchem-2641	391	36	.	.	PUNCT
eurjchem-2641	392	1	biomedicines	biomedicine	VERB
eurjchem-2641	392	2	2023	2023	NUM
eurjchem-2641	392	3	,	,	PUNCT
eurjchem-2641	392	4	11	11	NUM
eurjchem-2641	392	5	(	(	PUNCT
eurjchem-2641	392	6	9	9	NUM
eurjchem-2641	392	7	)	)	PUNCT
eurjchem-2641	392	8	,	,	PUNCT
eurjchem-2641	392	9	2371	2371	NUM
eurjchem-2641	392	10	.	.	PUNCT
eurjchem-2641	393	1	[	[	X
eurjchem-2641	393	2	10	10	NUM
eurjchem-2641	393	3	]	]	PUNCT
eurjchem-2641	393	4	.	.	PUNCT
eurjchem-2641	393	5	irmer	irmer	PROPN
eurjchem-2641	393	6	,	,	PUNCT
eurjchem-2641	393	7	b.	b.	PROPN
eurjchem-2641	393	8	;	;	PUNCT
eurjchem-2641	393	9	chandrabalan	chandrabalan	PROPN
eurjchem-2641	393	10	,	,	PUNCT
eurjchem-2641	393	11	s.	s.	PROPN
eurjchem-2641	393	12	;	;	PUNCT
eurjchem-2641	393	13	maas	maas	PROPN
eurjchem-2641	393	14	,	,	PUNCT
eurjchem-2641	393	15	l.	l.	PROPN
eurjchem-2641	393	16	;	;	PUNCT
eurjchem-2641	393	17	bleckmann	bleckmann	PROPN
eurjchem-2641	393	18	,	,	PUNCT
eurjchem-2641	393	19	a.	a.	NOUN
eurjchem-2641	393	20	;	;	PUNCT
eurjchem-2641	393	21	menck	menck	NUM
eurjchem-2641	393	22	,	,	PUNCT
eurjchem-2641	393	23	k.	k.	PROPN
eurjchem-2641	393	24	extracellular	extracellular	ADJ
eurjchem-2641	393	25	vesicles	vesicle	NOUN
eurjchem-2641	393	26	in	in	ADP
eurjchem-2641	393	27	liquid	liquid	ADJ
eurjchem-2641	393	28	biopsies	biopsy	NOUN
eurjchem-2641	393	29	as	as	ADP
eurjchem-2641	393	30	biomarkers	biomarker	NOUN
eurjchem-2641	393	31	for	for	ADP
eurjchem-2641	393	32	solid	solid	ADJ
eurjchem-2641	393	33	tumors	tumor	NOUN
eurjchem-2641	393	34	.	.	PUNCT
eurjchem-2641	394	1	cancers	cancer	NOUN
eurjchem-2641	394	2	2023	2023	NUM
eurjchem-2641	394	3	,	,	PUNCT
eurjchem-2641	394	4	15	15	NUM
eurjchem-2641	394	5	(	(	PUNCT
eurjchem-2641	394	6	4	4	NUM
eurjchem-2641	394	7	)	)	PUNCT
eurjchem-2641	394	8	,	,	PUNCT
eurjchem-2641	394	9	1307	1307	NUM
eurjchem-2641	394	10	.	.	PUNCT
eurjchem-2641	395	1	[	[	X
eurjchem-2641	395	2	11	11	NUM
eurjchem-2641	395	3	]	]	PUNCT
eurjchem-2641	395	4	.	.	PUNCT
eurjchem-2641	395	5	freitas	freitas	PROPN
eurjchem-2641	395	6	,	,	PUNCT
eurjchem-2641	395	7	a.	a.	PROPN
eurjchem-2641	395	8	j.	j.	PROPN
eurjchem-2641	395	9	;	;	PUNCT
eurjchem-2641	395	10	causin	causin	PROPN
eurjchem-2641	395	11	,	,	PUNCT
eurjchem-2641	395	12	r.	r.	PROPN
eurjchem-2641	395	13	l.	l.	PROPN
eurjchem-2641	395	14	;	;	PUNCT
eurjchem-2641	395	15	varuzza	varuzza	PROPN
eurjchem-2641	395	16	,	,	PUNCT
eurjchem-2641	395	17	m.	m.	PROPN
eurjchem-2641	395	18	b.	b.	PROPN
eurjchem-2641	395	19	;	;	PUNCT
eurjchem-2641	395	20	calfa	calfa	PROPN
eurjchem-2641	395	21	,	,	PUNCT
eurjchem-2641	395	22	s.	s.	PROPN
eurjchem-2641	395	23	;	;	PUNCT
eurjchem-2641	395	24	hidalgo	hidalgo	PROPN
eurjchem-2641	395	25	filho	filho	PROPN
eurjchem-2641	395	26	,	,	PUNCT
eurjchem-2641	395	27	c.	c.	PROPN
eurjchem-2641	395	28	m.	m.	NOUN
eurjchem-2641	395	29	;	;	PUNCT
eurjchem-2641	395	30	komoto	komoto	PROPN
eurjchem-2641	395	31	,	,	PUNCT
eurjchem-2641	395	32	t.	t.	PROPN
eurjchem-2641	395	33	t.	t.	PROPN
eurjchem-2641	395	34	;	;	PUNCT
eurjchem-2641	395	35	souza	souza	PROPN
eurjchem-2641	395	36	,	,	PUNCT
eurjchem-2641	395	37	c.	c.	PROPN
eurjchem-2641	395	38	d.	d.	PROPN
eurjchem-2641	395	39	;	;	PUNCT
eurjchem-2641	395	40	marques	marques	PROPN
eurjchem-2641	395	41	,	,	PUNCT
eurjchem-2641	395	42	m.	m.	NOUN
eurjchem-2641	395	43	m.	m.	NOUN
eurjchem-2641	395	44	liquid	liquid	NOUN
eurjchem-2641	395	45	biopsy	biopsy	NOUN
eurjchem-2641	395	46	as	as	ADP
eurjchem-2641	395	47	a	a	DET
eurjchem-2641	395	48	tool	tool	NOUN
eurjchem-2641	395	49	for	for	ADP
eurjchem-2641	395	50	the	the	DET
eurjchem-2641	395	51	diagnosis	diagnosis	NOUN
eurjchem-2641	395	52	,	,	PUNCT
eurjchem-2641	395	53	treatment	treatment	NOUN
eurjchem-2641	395	54	,	,	PUNCT
eurjchem-2641	395	55	and	and	CCONJ
eurjchem-2641	395	56	monitoring	monitoring	NOUN
eurjchem-2641	395	57	of	of	ADP
eurjchem-2641	395	58	breast	breast	NOUN
eurjchem-2641	395	59	cancer	cancer	NOUN
eurjchem-2641	395	60	.	.	PUNCT
eurjchem-2641	396	1	ijms	ijms	PROPN
eurjchem-2641	396	2	.	.	PUNCT
eurjchem-2641	397	1	2022	2022	NUM
eurjchem-2641	397	2	,	,	PUNCT
eurjchem-2641	397	3	23	23	NUM
eurjchem-2641	397	4	(	(	PUNCT
eurjchem-2641	397	5	17	17	NUM
eurjchem-2641	397	6	)	)	PUNCT
eurjchem-2641	397	7	,	,	PUNCT
eurjchem-2641	397	8	9952	9952	NUM
eurjchem-2641	397	9	.	.	PUNCT
eurjchem-2641	398	1	[	[	X
eurjchem-2641	398	2	12	12	NUM
eurjchem-2641	398	3	]	]	PUNCT
eurjchem-2641	398	4	.	.	PUNCT
eurjchem-2641	399	1	jafari	jafari	PROPN
eurjchem-2641	399	2	,	,	PUNCT
eurjchem-2641	399	3	s.	s.	PROPN
eurjchem-2641	399	4	h.	h.	PROPN
eurjchem-2641	399	5	;	;	PUNCT
eurjchem-2641	399	6	saadatpour	saadatpour	PROPN
eurjchem-2641	399	7	,	,	PUNCT
eurjchem-2641	399	8	z.	z.	PROPN
eurjchem-2641	399	9	;	;	PUNCT
eurjchem-2641	399	10	salmaninejad	salmaninejad	PROPN
eurjchem-2641	399	11	,	,	PUNCT
eurjchem-2641	399	12	a.	a.	NOUN
eurjchem-2641	399	13	;	;	PUNCT
eurjchem-2641	399	14	momeni	momeni	PROPN
eurjchem-2641	399	15	,	,	PUNCT
eurjchem-2641	399	16	f.	f.	PROPN
eurjchem-2641	399	17	;	;	PUNCT
eurjchem-2641	399	18	mokhtari	mokhtari	PROPN
eurjchem-2641	399	19	,	,	PUNCT
eurjchem-2641	399	20	m.	m.	NOUN
eurjchem-2641	399	21	;	;	PUNCT
eurjchem-2641	399	22	nahand	nahand	NOUN
eurjchem-2641	399	23	,	,	PUNCT
eurjchem-2641	399	24	j.	j.	PROPN
eurjchem-2641	399	25	s.	s.	PROPN
eurjchem-2641	399	26	;	;	PUNCT
eurjchem-2641	399	27	rahmati	rahmati	NOUN
eurjchem-2641	399	28	,	,	PUNCT
eurjchem-2641	399	29	m.	m.	NOUN
eurjchem-2641	399	30	;	;	PUNCT
eurjchem-2641	399	31	mirzaei	mirzaei	ADJ
eurjchem-2641	399	32	,	,	PUNCT
eurjchem-2641	399	33	h.	h.	PROPN
eurjchem-2641	399	34	;	;	PUNCT
eurjchem-2641	399	35	kianmehr	kianmehr	NOUN
eurjchem-2641	399	36	,	,	PUNCT
eurjchem-2641	399	37	m.	m.	NOUN
eurjchem-2641	399	38	breast	breast	NOUN
eurjchem-2641	399	39	cancer	cancer	NOUN
eurjchem-2641	399	40	diagnosis	diagnosis	NOUN
eurjchem-2641	399	41	:	:	PUNCT
eurjchem-2641	399	42	imaging	imaging	NOUN
eurjchem-2641	399	43	techniques	technique	NOUN
eurjchem-2641	399	44	and	and	CCONJ
eurjchem-2641	399	45	biochemical	biochemical	ADJ
eurjchem-2641	399	46	markers	marker	NOUN
eurjchem-2641	399	47	.	.	PUNCT
eurjchem-2641	400	1	journal	journal	PROPN
eurjchem-2641	400	2	cellular	cellular	ADJ
eurjchem-2641	400	3	physiology	physiology	NOUN
eurjchem-2641	400	4	2018	2018	NUM
eurjchem-2641	400	5	,	,	PUNCT
eurjchem-2641	400	6	233	233	NUM
eurjchem-2641	400	7	(	(	PUNCT
eurjchem-2641	400	8	7	7	NUM
eurjchem-2641	400	9	)	)	PUNCT
eurjchem-2641	400	10	,	,	PUNCT
eurjchem-2641	400	11	5200–5213	5200–5213	NUM
eurjchem-2641	400	12	.	.	PUNCT
eurjchem-2641	401	1	[	[	X
eurjchem-2641	401	2	13	13	NUM
eurjchem-2641	401	3	]	]	PUNCT
eurjchem-2641	401	4	.	.	PUNCT
eurjchem-2641	401	5	alimirzaie	alimirzaie	PROPN
eurjchem-2641	401	6	,	,	PUNCT
eurjchem-2641	401	7	s.	s.	PROPN
eurjchem-2641	401	8	;	;	PUNCT
eurjchem-2641	401	9	bagherzadeh	bagherzadeh	NOUN
eurjchem-2641	401	10	,	,	PUNCT
eurjchem-2641	401	11	m.	m.	NOUN
eurjchem-2641	401	12	;	;	PUNCT
eurjchem-2641	401	13	akbari	akbari	PROPN
eurjchem-2641	401	14	,	,	PUNCT
eurjchem-2641	401	15	m.	m.	NOUN
eurjchem-2641	401	16	r.	r.	PROPN
eurjchem-2641	401	17	liquid	liquid	PROPN
eurjchem-2641	401	18	biopsy	biopsy	NOUN
eurjchem-2641	401	19	in	in	ADP
eurjchem-2641	401	20	breast	breast	NOUN
eurjchem-2641	401	21	cancer	cancer	NOUN
eurjchem-2641	401	22	:	:	PUNCT
eurjchem-2641	401	23	a	a	DET
eurjchem-2641	401	24	comprehensive	comprehensive	ADJ
eurjchem-2641	401	25	review	review	NOUN
eurjchem-2641	401	26	.	.	PUNCT
eurjchem-2641	402	1	clin	clin	PROPN
eurjchem-2641	402	2	.	.	PUNCT
eurjchem-2641	403	1	genet	genet	PROPN
eurjchem-2641	403	2	.	.	PUNCT
eurjchem-2641	404	1	2019	2019	NUM
eurjchem-2641	404	2	,	,	PUNCT
eurjchem-2641	404	3	95	95	NUM
eurjchem-2641	404	4	(	(	PUNCT
eurjchem-2641	404	5	6	6	NUM
eurjchem-2641	404	6	)	)	PUNCT
eurjchem-2641	404	7	,	,	PUNCT
eurjchem-2641	404	8	643–660	643–660	NUM
eurjchem-2641	404	9	.	.	PUNCT
eurjchem-2641	405	1	[	[	X
eurjchem-2641	405	2	14	14	NUM
eurjchem-2641	405	3	]	]	SYM
eurjchem-2641	405	4	.	.	PUNCT
eurjchem-2641	406	1	wu	wu	PROPN
eurjchem-2641	406	2	,	,	PUNCT
eurjchem-2641	406	3	h.	h.	PROPN
eurjchem-2641	406	4	;	;	PUNCT
eurjchem-2641	406	5	chu	chu	PROPN
eurjchem-2641	406	6	,	,	PUNCT
eurjchem-2641	406	7	p.	p.	NOUN
eurjchem-2641	406	8	current	current	ADJ
eurjchem-2641	406	9	and	and	CCONJ
eurjchem-2641	406	10	developing	develop	VERB
eurjchem-2641	406	11	liquid	liquid	ADJ
eurjchem-2641	406	12	biopsy	biopsy	NOUN
eurjchem-2641	406	13	techniques	technique	NOUN
eurjchem-2641	406	14	for	for	ADP
eurjchem-2641	406	15	breast	breast	NOUN
eurjchem-2641	406	16	cancer	cancer	NOUN
eurjchem-2641	406	17	.	.	PUNCT
eurjchem-2641	407	1	cancers	cancer	NOUN
eurjchem-2641	407	2	2022	2022	NUM
eurjchem-2641	407	3	,	,	PUNCT
eurjchem-2641	407	4	14	14	NUM
eurjchem-2641	407	5	(	(	PUNCT
eurjchem-2641	407	6	9	9	NUM
eurjchem-2641	407	7	)	)	PUNCT
eurjchem-2641	407	8	,	,	PUNCT
eurjchem-2641	407	9	2052	2052	NUM
eurjchem-2641	407	10	.	.	PUNCT
eurjchem-2641	408	1	[	[	X
eurjchem-2641	408	2	15	15	NUM
eurjchem-2641	408	3	]	]	PUNCT
eurjchem-2641	408	4	.	.	PUNCT
eurjchem-2641	409	1	friedrich	friedrich	PROPN
eurjchem-2641	409	2	,	,	PUNCT
eurjchem-2641	409	3	m.	m.	NOUN
eurjchem-2641	409	4	;	;	PUNCT
eurjchem-2641	409	5	pracht	pracht	NOUN
eurjchem-2641	409	6	,	,	PUNCT
eurjchem-2641	409	7	k.	k.	PROPN
eurjchem-2641	409	8	;	;	PUNCT
eurjchem-2641	409	9	mashreghi	mashreghi	PROPN
eurjchem-2641	409	10	,	,	PUNCT
eurjchem-2641	409	11	m.	m.	NOUN
eurjchem-2641	409	12	;	;	PUNCT
eurjchem-2641	409	13	jäck	jäck	PROPN
eurjchem-2641	409	14	,	,	PUNCT
eurjchem-2641	409	15	h.	h.	PROPN
eurjchem-2641	409	16	;	;	PUNCT
eurjchem-2641	409	17	radbruch	radbruch	PROPN
eurjchem-2641	409	18	,	,	PUNCT
eurjchem-2641	409	19	a.	a.	NOUN
eurjchem-2641	409	20	;	;	PUNCT
eurjchem-2641	409	21	seliger	seliger	PROPN
eurjchem-2641	409	22	,	,	PUNCT
eurjchem-2641	409	23	b.	b.	PROPN
eurjchem-2641	410	1	the	the	DET
eurjchem-2641	410	2	role	role	NOUN
eurjchem-2641	410	3	of	of	ADP
eurjchem-2641	410	4	the	the	DET
eurjchem-2641	410	5	mir-148/-152	mir-148/-152	PROPN
eurjchem-2641	410	6	family	family	NOUN
eurjchem-2641	410	7	in	in	ADP
eurjchem-2641	410	8	physiology	physiology	NOUN
eurjchem-2641	410	9	and	and	CCONJ
eurjchem-2641	410	10	disease	disease	NOUN
eurjchem-2641	410	11	.	.	PUNCT
eurjchem-2641	411	1	eur	eur	PROPN
eurjchem-2641	411	2	j.	j.	PROPN
eurjchem-2641	411	3	immunol	immunol	PROPN
eurjchem-2641	411	4	2017	2017	NUM
eurjchem-2641	411	5	,	,	PUNCT
eurjchem-2641	411	6	47	47	NUM
eurjchem-2641	411	7	(	(	PUNCT
eurjchem-2641	411	8	12	12	NUM
eurjchem-2641	411	9	)	)	PUNCT
eurjchem-2641	411	10	,	,	PUNCT
eurjchem-2641	411	11	2026–2038	2026–2038	NUM
eurjchem-2641	411	12	.	.	PUNCT
eurjchem-2641	412	1	[	[	X
eurjchem-2641	412	2	16	16	NUM
eurjchem-2641	412	3	]	]	PUNCT
eurjchem-2641	412	4	.	.	PUNCT
eurjchem-2641	413	1	harisa	harisa	NOUN
eurjchem-2641	413	2	,	,	PUNCT
eurjchem-2641	413	3	g.	g.	PROPN
eurjchem-2641	413	4	i.	i.	PROPN
eurjchem-2641	413	5	;	;	PUNCT
eurjchem-2641	413	6	faris	faris	PROPN
eurjchem-2641	413	7	,	,	PUNCT
eurjchem-2641	413	8	t.	t.	NOUN
eurjchem-2641	413	9	m.	m.	NOUN
eurjchem-2641	413	10	;	;	PUNCT
eurjchem-2641	413	11	sherif	sherif	PROPN
eurjchem-2641	413	12	,	,	PUNCT
eurjchem-2641	413	13	a.	a.	NOUN
eurjchem-2641	413	14	y.	y.	PROPN
eurjchem-2641	413	15	;	;	PUNCT
eurjchem-2641	413	16	alzhrani	alzhrani	PROPN
eurjchem-2641	413	17	,	,	PUNCT
eurjchem-2641	413	18	r.	r.	PROPN
eurjchem-2641	413	19	f.	f.	PROPN
eurjchem-2641	413	20	;	;	PUNCT
eurjchem-2641	413	21	alanazi	alanazi	PROPN
eurjchem-2641	413	22	,	,	PUNCT
eurjchem-2641	413	23	s.	s.	PROPN
eurjchem-2641	413	24	a.	a.	PROPN
eurjchem-2641	413	25	;	;	PUNCT
eurjchem-2641	413	26	kohaf	kohaf	PROPN
eurjchem-2641	413	27	,	,	PUNCT
eurjchem-2641	413	28	n.	n.	PROPN
eurjchem-2641	413	29	a.	a.	PROPN
eurjchem-2641	413	30	;	;	PUNCT
eurjchem-2641	413	31	alanazi	alanazi	NOUN
eurjchem-2641	413	32	,	,	PUNCT
eurjchem-2641	413	33	f.	f.	PROPN
eurjchem-2641	413	34	k.	k.	PROPN
eurjchem-2641	413	35	gene	gene	NOUN
eurjchem-2641	413	36	-	-	PUNCT
eurjchem-2641	413	37	editing	edit	VERB
eurjchem-2641	413	38	technology	technology	NOUN
eurjchem-2641	413	39	,	,	PUNCT
eurjchem-2641	413	40	from	from	ADP
eurjchem-2641	413	41	macromolecule	macromolecule	ADJ
eurjchem-2641	413	42	therapeutics	therapeutic	NOUN
eurjchem-2641	413	43	to	to	PART
eurjchem-2641	413	44	organ	organ	NOUN
eurjchem-2641	413	45	transplantation	transplantation	NOUN
eurjchem-2641	413	46	:	:	PUNCT
eurjchem-2641	413	47	applications	application	NOUN
eurjchem-2641	413	48	,	,	PUNCT
eurjchem-2641	413	49	limitations	limitation	NOUN
eurjchem-2641	413	50	,	,	PUNCT
eurjchem-2641	413	51	and	and	CCONJ
eurjchem-2641	413	52	prospective	prospective	ADJ
eurjchem-2641	413	53	uses	use	NOUN
eurjchem-2641	413	54	.	.	PUNCT
eurjchem-2641	414	1	int	int	NOUN
eurjchem-2641	414	2	.	.	PUNCT
eurjchem-2641	415	1	j.	j.	PROPN
eurjchem-2641	415	2	biol	biol	PROPN
eurjchem-2641	415	3	.	.	PUNCT
eurjchem-2641	416	1	macromol	macromol	PROPN
eurjchem-2641	416	2	.	.	PUNCT
eurjchem-2641	417	1	2023	2023	NUM
eurjchem-2641	417	2	,	,	PUNCT
eurjchem-2641	417	3	253	253	NUM
eurjchem-2641	417	4	,	,	PUNCT
eurjchem-2641	417	5	127055	127055	NUM
eurjchem-2641	417	6	.	.	PUNCT
eurjchem-2641	418	1	[	[	X
eurjchem-2641	418	2	17	17	NUM
eurjchem-2641	418	3	]	]	PUNCT
eurjchem-2641	418	4	.	.	PUNCT
eurjchem-2641	419	1	li	li	PROPN
eurjchem-2641	419	2	,	,	PUNCT
eurjchem-2641	419	3	y.	y.	PROPN
eurjchem-2641	419	4	;	;	PUNCT
eurjchem-2641	419	5	deng	deng	PROPN
eurjchem-2641	419	6	,	,	PUNCT
eurjchem-2641	419	7	x.	x.	PROPN
eurjchem-2641	419	8	;	;	PUNCT
eurjchem-2641	419	9	zeng	zeng	PROPN
eurjchem-2641	419	10	,	,	PUNCT
eurjchem-2641	419	11	x.	x.	PROPN
eurjchem-2641	419	12	;	;	PUNCT
eurjchem-2641	419	13	peng	peng	PROPN
eurjchem-2641	419	14	,	,	PUNCT
eurjchem-2641	419	15	x.	x.	NOUN
eurjchem-2641	419	16	the	the	DET
eurjchem-2641	419	17	role	role	NOUN
eurjchem-2641	419	18	of	of	ADP
eurjchem-2641	419	19	mir-148a	mir-148a	PROPN
eurjchem-2641	419	20	in	in	ADP
eurjchem-2641	419	21	cancer	cancer	NOUN
eurjchem-2641	419	22	.	.	PUNCT
eurjchem-2641	420	1	j.	j.	PROPN
eurjchem-2641	420	2	cancer	cancer	PROPN
eurjchem-2641	420	3	2016	2016	NUM
eurjchem-2641	420	4	,	,	PUNCT
eurjchem-2641	420	5	7	7	NUM
eurjchem-2641	420	6	(	(	PUNCT
eurjchem-2641	420	7	10	10	NUM
eurjchem-2641	420	8	)	)	PUNCT
eurjchem-2641	420	9	,	,	PUNCT
eurjchem-2641	420	10	1233–1241	1233–1241	NUM
eurjchem-2641	420	11	.	.	PUNCT
eurjchem-2641	421	1	[	[	X
eurjchem-2641	421	2	18	18	NUM
eurjchem-2641	421	3	]	]	PUNCT
eurjchem-2641	421	4	.	.	PUNCT
eurjchem-2641	422	1	muñoz	muñoz	PROPN
eurjchem-2641	422	2	,	,	PUNCT
eurjchem-2641	422	3	j.	j.	PROPN
eurjchem-2641	422	4	p.	p.	PROPN
eurjchem-2641	422	5	;	;	PUNCT
eurjchem-2641	422	6	pérez	pérez	NOUN
eurjchem-2641	422	7	-	-	PUNCT
eurjchem-2641	422	8	moreno	moreno	PROPN
eurjchem-2641	422	9	,	,	PUNCT
eurjchem-2641	422	10	p.	p.	NOUN
eurjchem-2641	422	11	;	;	PUNCT
eurjchem-2641	422	12	pérez	pérez	NOUN
eurjchem-2641	422	13	,	,	PUNCT
eurjchem-2641	422	14	y.	y.	PROPN
eurjchem-2641	422	15	;	;	PUNCT
eurjchem-2641	422	16	calaf	calaf	PROPN
eurjchem-2641	422	17	,	,	PUNCT
eurjchem-2641	422	18	g.	g.	PROPN
eurjchem-2641	422	19	m.	m.	NOUN
eurjchem-2641	422	20	the	the	DET
eurjchem-2641	422	21	role	role	NOUN
eurjchem-2641	422	22	of	of	ADP
eurjchem-2641	422	23	micrornas	microrna	NOUN
eurjchem-2641	422	24	in	in	ADP
eurjchem-2641	422	25	breast	breast	NOUN
eurjchem-2641	422	26	cancer	cancer	NOUN
eurjchem-2641	422	27	and	and	CCONJ
eurjchem-2641	422	28	the	the	DET
eurjchem-2641	422	29	challenges	challenge	NOUN
eurjchem-2641	422	30	of	of	ADP
eurjchem-2641	422	31	their	their	PRON
eurjchem-2641	422	32	clinical	clinical	ADJ
eurjchem-2641	422	33	application	application	NOUN
eurjchem-2641	422	34	.	.	PUNCT
eurjchem-2641	423	1	diagnostics	diagnostic	NOUN
eurjchem-2641	423	2	2023	2023	NUM
eurjchem-2641	423	3	,	,	PUNCT
eurjchem-2641	423	4	13	13	NUM
eurjchem-2641	423	5	(	(	PUNCT
eurjchem-2641	423	6	19	19	NUM
eurjchem-2641	423	7	)	)	PUNCT
eurjchem-2641	423	8	,	,	PUNCT
eurjchem-2641	423	9	3072	3072	NUM
eurjchem-2641	423	10	.	.	PUNCT
eurjchem-2641	424	1	[	[	X
eurjchem-2641	424	2	19	19	NUM
eurjchem-2641	424	3	]	]	PUNCT
eurjchem-2641	424	4	.	.	PUNCT
eurjchem-2641	425	1	ghafouri	ghafouri	NOUN
eurjchem-2641	425	2	-	-	NOUN
eurjchem-2641	425	3	fard	fard	NOUN
eurjchem-2641	425	4	,	,	PUNCT
eurjchem-2641	425	5	s.	s.	PROPN
eurjchem-2641	425	6	;	;	PUNCT
eurjchem-2641	425	7	khanbabapour	khanbabapour	PROPN
eurjchem-2641	425	8	sasi	sasi	PROPN
eurjchem-2641	425	9	,	,	PUNCT
eurjchem-2641	425	10	a.	a.	NOUN
eurjchem-2641	425	11	;	;	PUNCT
eurjchem-2641	425	12	abak	abak	NOUN
eurjchem-2641	425	13	,	,	PUNCT
eurjchem-2641	425	14	a.	a.	NOUN
eurjchem-2641	425	15	;	;	PUNCT
eurjchem-2641	425	16	shoorei	shoorei	PROPN
eurjchem-2641	425	17	,	,	PUNCT
eurjchem-2641	425	18	h.	h.	PROPN
eurjchem-2641	425	19	;	;	PUNCT
eurjchem-2641	425	20	khoshkar	khoshkar	PROPN
eurjchem-2641	425	21	,	,	PUNCT
eurjchem-2641	425	22	a.	a.	NOUN
eurjchem-2641	425	23	;	;	PUNCT
eurjchem-2641	425	24	taheri	taheri	NOUN
eurjchem-2641	425	25	,	,	PUNCT
eurjchem-2641	425	26	m.	m.	NOUN
eurjchem-2641	425	27	contribution	contribution	NOUN
eurjchem-2641	425	28	of	of	ADP
eurjchem-2641	425	29	mirnas	mirna	NOUN
eurjchem-2641	425	30	in	in	ADP
eurjchem-2641	425	31	the	the	DET
eurjchem-2641	425	32	pathogenesis	pathogenesis	NOUN
eurjchem-2641	425	33	of	of	ADP
eurjchem-2641	425	34	breast	breast	NOUN
eurjchem-2641	425	35	cancer	cancer	NOUN
eurjchem-2641	425	36	.	.	PUNCT
eurjchem-2641	426	1	front	front	ADJ
eurjchem-2641	426	2	.	.	PUNCT
eurjchem-2641	427	1	oncol	oncol	ADJ
eurjchem-2641	427	2	.	.	PUNCT
eurjchem-2641	428	1	2021	2021	NUM
eurjchem-2641	428	2	,	,	PUNCT
eurjchem-2641	428	3	11	11	NUM
eurjchem-2641	428	4	,	,	PUNCT
eurjchem-2641	428	5	768949	768949	NUM
eurjchem-2641	428	6	https://doi.org/10.3389/fonc.2021.768949	https://doi.org/10.3389/fonc.2021.768949	X
eurjchem-2641	428	7	.	.	PUNCT
eurjchem-2641	429	1	[	[	X
eurjchem-2641	429	2	20	20	NUM
eurjchem-2641	429	3	]	]	PUNCT
eurjchem-2641	429	4	.	.	PUNCT
eurjchem-2641	430	1	ding	ding	PROPN
eurjchem-2641	430	2	,	,	PUNCT
eurjchem-2641	430	3	f.	f.	PROPN
eurjchem-2641	430	4	;	;	PUNCT
eurjchem-2641	430	5	wu	wu	PROPN
eurjchem-2641	430	6	,	,	PUNCT
eurjchem-2641	430	7	h.	h.	PROPN
eurjchem-2641	430	8	;	;	PUNCT
eurjchem-2641	430	9	han	han	PROPN
eurjchem-2641	430	10	,	,	PUNCT
eurjchem-2641	430	11	x.	x.	PROPN
eurjchem-2641	430	12	;	;	PUNCT
eurjchem-2641	430	13	jiang	jiang	PROPN
eurjchem-2641	430	14	,	,	PUNCT
eurjchem-2641	430	15	x.	x.	PROPN
eurjchem-2641	430	16	;	;	PUNCT
eurjchem-2641	430	17	xiao	xiao	PROPN
eurjchem-2641	430	18	,	,	PUNCT
eurjchem-2641	430	19	y.	y.	PROPN
eurjchem-2641	430	20	;	;	PUNCT
eurjchem-2641	430	21	tu	tu	PROPN
eurjchem-2641	430	22	,	,	PUNCT
eurjchem-2641	430	23	y.	y.	PROPN
eurjchem-2641	430	24	;	;	PUNCT
eurjchem-2641	430	25	yu	yu	PROPN
eurjchem-2641	430	26	,	,	PUNCT
eurjchem-2641	430	27	m.	m.	NOUN
eurjchem-2641	430	28	;	;	PUNCT
eurjchem-2641	430	29	lei	lei	PROPN
eurjchem-2641	430	30	,	,	PUNCT
eurjchem-2641	430	31	w.	w.	PROPN
eurjchem-2641	430	32	;	;	PUNCT
eurjchem-2641	430	33	hu	hu	PROPN
eurjchem-2641	430	34	,	,	PUNCT
eurjchem-2641	430	35	s.	s.	PROPN
eurjchem-2641	430	36	the	the	DET
eurjchem-2641	430	37	mir-148/152	mir-148/152	PROPN
eurjchem-2641	430	38	family	family	NOUN
eurjchem-2641	430	39	contributes	contribute	VERB
eurjchem-2641	430	40	to	to	ADP
eurjchem-2641	430	41	angiogenesis	angiogenesis	NOUN
eurjchem-2641	430	42	of	of	ADP
eurjchem-2641	430	43	human	human	ADJ
eurjchem-2641	430	44	pluripotent	pluripotent	ADJ
eurjchem-2641	430	45	stem	stem	NOUN
eurjchem-2641	430	46	cellderived	cellderive	VERB
eurjchem-2641	430	47	endothelial	endothelial	NOUN
eurjchem-2641	430	48	cells	cell	NOUN
eurjchem-2641	430	49	by	by	ADP
eurjchem-2641	430	50	inhibiting	inhibit	VERB
eurjchem-2641	430	51	meox2	meox2	PROPN
eurjchem-2641	430	52	.	.	PUNCT
eurjchem-2641	431	1	mol	mol	PROPN
eurjchem-2641	431	2	.	.	PROPN
eurjchem-2641	432	1	ther	ther	PROPN
eurjchem-2641	432	2	.	.	PUNCT
eurjchem-2641	433	1	nucleic	nucleic	ADJ
eurjchem-2641	433	2	acids	acid	NOUN
eurjchem-2641	433	3	2023	2023	NUM
eurjchem-2641	433	4	,	,	PUNCT
eurjchem-2641	433	5	32	32	NUM
eurjchem-2641	433	6	,	,	PUNCT
eurjchem-2641	433	7	582–593	582–593	NUM
eurjchem-2641	433	8	.	.	PUNCT
eurjchem-2641	434	1	[	[	X
eurjchem-2641	434	2	21	21	NUM
eurjchem-2641	434	3	]	]	PUNCT
eurjchem-2641	434	4	.	.	PUNCT
eurjchem-2641	435	1	alba	alba	PROPN
eurjchem-2641	435	2	-	-	PUNCT
eurjchem-2641	435	3	bernal	bernal	PROPN
eurjchem-2641	435	4	,	,	PUNCT
eurjchem-2641	435	5	a.	a.	NOUN
eurjchem-2641	435	6	;	;	PUNCT
eurjchem-2641	435	7	lavado	lavado	PROPN
eurjchem-2641	435	8	-	-	PUNCT
eurjchem-2641	435	9	valenzuela	valenzuela	PROPN
eurjchem-2641	435	10	,	,	PUNCT
eurjchem-2641	435	11	r.	r.	PROPN
eurjchem-2641	435	12	;	;	PUNCT
eurjchem-2641	435	13	domínguez	domínguez	NOUN
eurjchem-2641	435	14	-	-	PUNCT
eurjchem-2641	435	15	recio	recio	PROPN
eurjchem-2641	435	16	,	,	PUNCT
eurjchem-2641	435	17	m.	m.	PROPN
eurjchem-2641	435	18	e.	e.	PROPN
eurjchem-2641	435	19	;	;	PUNCT
eurjchem-2641	435	20	jiménez	jiménez	PROPN
eurjchem-2641	435	21	-	-	PUNCT
eurjchem-2641	435	22	rodriguez	rodriguez	PROPN
eurjchem-2641	435	23	,	,	PUNCT
eurjchem-2641	435	24	b.	b.	PROPN
eurjchem-2641	435	25	;	;	PUNCT
eurjchem-2641	435	26	queipo	queipo	PROPN
eurjchem-2641	435	27	-	-	PUNCT
eurjchem-2641	435	28	ortuño	ortuño	PROPN
eurjchem-2641	435	29	,	,	PUNCT
eurjchem-2641	435	30	m.	m.	NOUN
eurjchem-2641	435	31	i.	i.	PROPN
eurjchem-2641	435	32	;	;	PUNCT
eurjchem-2641	435	33	alba	alba	PROPN
eurjchem-2641	435	34	,	,	PUNCT
eurjchem-2641	435	35	e.	e.	PROPN
eurjchem-2641	435	36	;	;	PUNCT
eurjchem-2641	435	37	comino	comino	PROPN
eurjchem-2641	435	38	-	-	PUNCT
eurjchem-2641	435	39	méndez	méndez	PROPN
eurjchem-2641	435	40	,	,	PUNCT
eurjchem-2641	435	41	i.	i.	NOUN
eurjchem-2641	435	42	challenges	challenge	NOUN
eurjchem-2641	435	43	and	and	CCONJ
eurjchem-2641	435	44	achievements	achievement	NOUN
eurjchem-2641	435	45	of	of	ADP
eurjchem-2641	435	46	liquid	liquid	ADJ
eurjchem-2641	435	47	biopsy	biopsy	NOUN
eurjchem-2641	435	48	technologies	technology	NOUN
eurjchem-2641	435	49	employed	employ	VERB
eurjchem-2641	435	50	in	in	ADP
eurjchem-2641	435	51	early	early	ADJ
eurjchem-2641	435	52	breast	breast	NOUN
eurjchem-2641	435	53	cancer	cancer	NOUN
eurjchem-2641	435	54	.	.	PUNCT
eurjchem-2641	436	1	ebiomedicine	ebiomedicine	PROPN
eurjchem-2641	436	2	2020	2020	NUM
eurjchem-2641	436	3	,	,	PUNCT
eurjchem-2641	436	4	62	62	NUM
eurjchem-2641	436	5	,	,	PUNCT
eurjchem-2641	436	6	103100	103100	NUM
eurjchem-2641	436	7	.	.	PUNCT
eurjchem-2641	437	1	[	[	X
eurjchem-2641	437	2	22	22	NUM
eurjchem-2641	437	3	]	]	PUNCT
eurjchem-2641	437	4	.	.	PUNCT
eurjchem-2641	438	1	ryu	ryu	PROPN
eurjchem-2641	438	2	,	,	PUNCT
eurjchem-2641	438	3	i.	i.	PROPN
eurjchem-2641	438	4	s.	s.	PROPN
eurjchem-2641	438	5	;	;	PUNCT
eurjchem-2641	438	6	kim	kim	PROPN
eurjchem-2641	438	7	,	,	PUNCT
eurjchem-2641	438	8	d.	d.	PROPN
eurjchem-2641	438	9	h.	h.	PROPN
eurjchem-2641	438	10	;	;	PUNCT
eurjchem-2641	438	11	ro	ro	X
eurjchem-2641	438	12	,	,	PUNCT
eurjchem-2641	438	13	j.-y	j.-y	NOUN
eurjchem-2641	438	14	.	.	PUNCT
eurjchem-2641	438	15	;	;	PUNCT
eurjchem-2641	438	16	park	park	NOUN
eurjchem-2641	438	17	,	,	PUNCT
eurjchem-2641	438	18	b.-g	b.-g	PROPN
eurjchem-2641	438	19	.	.	PUNCT
eurjchem-2641	438	20	;	;	PUNCT
eurjchem-2641	438	21	kim	kim	PROPN
eurjchem-2641	438	22	,	,	PUNCT
eurjchem-2641	438	23	s.	s.	PROPN
eurjchem-2641	438	24	h.	h.	PROPN
eurjchem-2641	438	25	;	;	PUNCT
eurjchem-2641	438	26	i	i	PROPN
eurjchem-2641	438	27	m	m	PROPN
eurjchem-2641	438	28	,	,	PUNCT
eurjchem-2641	438	29	j.-y	j.-y	PROPN
eurjchem-2641	438	30	.	.	PUNCT
eurjchem-2641	438	31	;	;	PUNCT
eurjchem-2641	438	32	lee	lee	PROPN
eurjchem-2641	438	33	,	,	PUNCT
eurjchem-2641	438	34	j.-y	j.-y	PROPN
eurjchem-2641	438	35	.	.	PUNCT
eurjchem-2641	438	36	;	;	PUNCT
eurjchem-2641	439	1	yoon	yoon	PROPN
eurjchem-2641	439	2	,	,	PUNCT
eurjchem-2641	439	3	s.	s.	PROPN
eurjchem-2641	439	4	j.	j.	PROPN
eurjchem-2641	439	5	;	;	PUNCT
eurjchem-2641	439	6	kang	kang	PROPN
eurjchem-2641	439	7	,	,	PUNCT
eurjchem-2641	439	8	h.	h.	PROPN
eurjchem-2641	439	9	;	;	PUNCT
eurjchem-2641	439	10	iwatsubo	iwatsubo	ADJ
eurjchem-2641	439	11	,	,	PUNCT
eurjchem-2641	439	12	t.	t.	PROPN
eurjchem-2641	439	13	;	;	PUNCT
eurjchem-2641	439	14	teunissen	teunissen	NOUN
eurjchem-2641	439	15	,	,	PUNCT
eurjchem-2641	439	16	c.	c.	PROPN
eurjchem-2641	439	17	e.	e.	PROPN
eurjchem-2641	439	18	;	;	PUNCT
eurjchem-2641	439	19	cho	cho	PROPN
eurjchem-2641	439	20	,	,	PUNCT
eurjchem-2641	439	21	h.-j	h.-j	PROPN
eurjchem-2641	439	22	.	.	PUNCT
eurjchem-2641	439	23	;	;	PUNCT
eurjchem-2641	439	24	ryu	ryu	ADJ
eurjchem-2641	439	25	,	,	PUNCT
eurjchem-2641	439	26	j.-h	j.-h	PROPN
eurjchem-2641	439	27	.	.	PUNCT
eurjchem-2641	440	1	the	the	DET
eurjchem-2641	440	2	microrna-485	microrna-485	NOUN
eurjchem-2641	440	3	-	-	PUNCT
eurjchem-2641	440	4	3p	3p	NUM
eurjchem-2641	440	5	concentration	concentration	NOUN
eurjchem-2641	440	6	in	in	ADP
eurjchem-2641	440	7	salivary	salivary	ADJ
eurjchem-2641	440	8	exosome	exosome	ADV
eurjchem-2641	440	9	-	-	PUNCT
eurjchem-2641	440	10	enriched	enrich	VERB
eurjchem-2641	440	11	extracellular	extracellular	ADJ
eurjchem-2641	440	12	vesicles	vesicle	NOUN
eurjchem-2641	440	13	is	be	AUX
eurjchem-2641	440	14	related	relate	VERB
eurjchem-2641	440	15	to	to	PART
eurjchem-2641	440	16	amyloid	amyloid	VERB
eurjchem-2641	440	17	β	β	NOUN
eurjchem-2641	440	18	deposition	deposition	NOUN
eurjchem-2641	440	19	in	in	ADP
eurjchem-2641	440	20	the	the	DET
eurjchem-2641	440	21	brain	brain	NOUN
eurjchem-2641	440	22	of	of	ADP
eurjchem-2641	440	23	patients	patient	NOUN
eurjchem-2641	440	24	with	with	ADP
eurjchem-2641	440	25	alzheimer	alzheimer	PROPN
eurjchem-2641	440	26	’s	’s	PART
eurjchem-2641	440	27	disease	disease	NOUN
eurjchem-2641	440	28	.	.	PUNCT
eurjchem-2641	441	1	clin	clin	PROPN
eurjchem-2641	441	2	.	.	PUNCT
eurjchem-2641	442	1	biochem	biochem	PROPN
eurjchem-2641	442	2	.	.	PUNCT
eurjchem-2641	443	1	2023	2023	NUM
eurjchem-2641	443	2	,	,	PUNCT
eurjchem-2641	443	3	118	118	NUM
eurjchem-2641	443	4	,	,	PUNCT
eurjchem-2641	443	5	110603	110603	NUM
eurjchem-2641	443	6	.	.	PUNCT
eurjchem-2641	444	1	mailto:harisa@ksu.edu.sa	mailto:harisa@ksu.edu.sa	PROPN
eurjchem-2641	444	2	https://orcid.org/0000-0002-7988-4421	https://orcid.org/0000-0002-7988-4421	VERB
eurjchem-2641	444	3	mailto:gmalomran@pharm.dmu.edu.eg	mailto:gmalomran@pharm.dmu.edu.eg	PROPN
eurjchem-2641	444	4	https://orcid.org/0000-0002-1609-8802	https://orcid.org/0000-0002-1609-8802	NOUN
eurjchem-2641	444	5	mailto:mohamed.noureldin@aast.edu	mailto:mohamed.noureldin@aast.edu	NOUN
eurjchem-2641	444	6	https://orcid.org/0000-0001-7733-2124	https://orcid.org/0000-0001-7733-2124	PROPN
eurjchem-2641	444	7	mailto:ahmed.noureldeen@vetmed.dmu.edu.eg	mailto:ahmed.noureldeen@vetmed.dmu.edu.eg	PROPN
eurjchem-2641	444	8	https://orcid.org/0000-0002-8344-0807	https://orcid.org/0000-0002-8344-0807	ADJ
eurjchem-2641	444	9	mailto:saalshehri@ksu.edu.sa	mailto:saalshehri@ksu.edu.sa	NOUN
eurjchem-2641	444	10	https://orcid.org/0000-0002-8452-4789	https://orcid.org/0000-0002-8452-4789	ADV
eurjchem-2641	444	11	mailto:sulthanalrashid@gmail.com	mailto:sulthanalrashid@gmail.com	PROPN
eurjchem-2641	445	1	https://orcid.org/0000-0001-7506-3039	https://orcid.org/0000-0001-7506-3039	PROPN
eurjchem-2641	445	2	mailto:tarekokda@pharm.dmu.edu.eg	mailto:tarekokda@pharm.dmu.edu.eg	PROPN
eurjchem-2641	445	3	https://orcid.org/0000-0001-7030-6169	https://orcid.org/0000-0001-7030-6169	PROPN
eurjchem-2641	445	4	https://doi.org/10.3389/fphar.2020.632079	https://doi.org/10.3389/fphar.2020.632079	PROPN
eurjchem-2641	445	5	https://doi.org/10.3389/fonc.2021.768949	https://doi.org/10.3389/fonc.2021.768949	PROPN
eurjchem-2641	445	6	harisa	harisa	NOUN
eurjchem-2641	445	7	et	et	PROPN
eurjchem-2641	445	8	al	al	PROPN
eurjchem-2641	445	9	.	.	PUNCT
eurjchem-2641	445	10	/	/	SYM
eurjchem-2641	445	11	european	european	PROPN
eurjchem-2641	445	12	journal	journal	PROPN
eurjchem-2641	445	13	of	of	ADP
eurjchem-2641	445	14	chemistry	chemistry	NOUN
eurjchem-2641	445	15	16	16	NUM
eurjchem-2641	445	16	(	(	PUNCT
eurjchem-2641	445	17	2	2	NUM
eurjchem-2641	445	18	)	)	PUNCT
eurjchem-2641	445	19	(	(	PUNCT
eurjchem-2641	445	20	2025	2025	NUM
eurjchem-2641	445	21	)	)	PUNCT
eurjchem-2641	445	22	222	222	NUM
eurjchem-2641	445	23	-	-	SYM
eurjchem-2641	445	24	232	232	NUM
eurjchem-2641	445	25	231	231	NUM
eurjchem-2641	445	26	2025	2025	NUM
eurjchem-2641	445	27	–	–	PUNCT
eurjchem-2641	445	28	european	european	ADJ
eurjchem-2641	445	29	journal	journal	NOUN
eurjchem-2641	445	30	of	of	ADP
eurjchem-2641	445	31	chemistry	chemistry	NOUN
eurjchem-2641	445	32	–	–	PUNCT
eurjchem-2641	445	33	cc	cc	NOUN
eurjchem-2641	445	34	by	by	ADP
eurjchem-2641	445	35	nc	nc	PROPN
eurjchem-2641	445	36	–	–	PUNCT
eurjchem-2641	445	37	doi	doi	NOUN
eurjchem-2641	445	38	:	:	PUNCT
eurjchem-2641	445	39	10.5155	10.5155	NUM
eurjchem-2641	445	40	/	/	SYM
eurjchem-2641	445	41	eurjchem.16.2.222	eurjchem.16.2.222	NOUN
eurjchem-2641	445	42	-	-	SYM
eurjchem-2641	445	43	232.2641	232.2641	NUM
eurjchem-2641	445	44	[	[	X
eurjchem-2641	445	45	23	23	NUM
eurjchem-2641	445	46	]	]	PUNCT
eurjchem-2641	445	47	.	.	PUNCT
eurjchem-2641	446	1	bidarra	bidarra	PROPN
eurjchem-2641	446	2	,	,	PUNCT
eurjchem-2641	446	3	d.	d.	PROPN
eurjchem-2641	446	4	;	;	PUNCT
eurjchem-2641	446	5	constâncio	constâncio	PROPN
eurjchem-2641	446	6	,	,	PUNCT
eurjchem-2641	446	7	v.	v.	PROPN
eurjchem-2641	446	8	;	;	PUNCT
eurjchem-2641	446	9	barros	barros	PROPN
eurjchem-2641	446	10	-	-	PUNCT
eurjchem-2641	446	11	silva	silva	PROPN
eurjchem-2641	446	12	,	,	PUNCT
eurjchem-2641	446	13	d.	d.	PROPN
eurjchem-2641	446	14	;	;	PUNCT
eurjchem-2641	446	15	ramalho	ramalho	PROPN
eurjchem-2641	446	16	-	-	PUNCT
eurjchem-2641	446	17	carvalho	carvalho	PROPN
eurjchem-2641	446	18	,	,	PUNCT
eurjchem-2641	446	19	j.	j.	PROPN
eurjchem-2641	446	20	;	;	PUNCT
eurjchem-2641	446	21	moreira	moreira	PROPN
eurjchem-2641	446	22	-	-	PUNCT
eurjchem-2641	446	23	barbosa	barbosa	PROPN
eurjchem-2641	446	24	,	,	PUNCT
eurjchem-2641	446	25	c.	c.	PROPN
eurjchem-2641	446	26	;	;	PUNCT
eurjchem-2641	446	27	antunes	antunes	PROPN
eurjchem-2641	446	28	,	,	PUNCT
eurjchem-2641	446	29	l.	l.	PROPN
eurjchem-2641	446	30	;	;	PUNCT
eurjchem-2641	446	31	maurício	maurício	PROPN
eurjchem-2641	446	32	,	,	PUNCT
eurjchem-2641	446	33	j.	j.	PROPN
eurjchem-2641	446	34	;	;	PUNCT
eurjchem-2641	446	35	oliveira	oliveira	PROPN
eurjchem-2641	446	36	,	,	PUNCT
eurjchem-2641	446	37	j.	j.	PROPN
eurjchem-2641	446	38	;	;	PUNCT
eurjchem-2641	446	39	henrique	henrique	PROPN
eurjchem-2641	446	40	,	,	PUNCT
eurjchem-2641	446	41	r.	r.	PROPN
eurjchem-2641	446	42	;	;	PUNCT
eurjchem-2641	446	43	jerónimo	jerónimo	PROPN
eurjchem-2641	446	44	,	,	PUNCT
eurjchem-2641	446	45	c.	c.	NOUN
eurjchem-2641	446	46	circulating	circulate	VERB
eurjchem-2641	446	47	micrornas	microrna	NOUN
eurjchem-2641	446	48	as	as	ADP
eurjchem-2641	446	49	biomarkers	biomarker	NOUN
eurjchem-2641	446	50	for	for	ADP
eurjchem-2641	446	51	prostate	prostate	NOUN
eurjchem-2641	446	52	cancer	cancer	NOUN
eurjchem-2641	446	53	detection	detection	NOUN
eurjchem-2641	446	54	and	and	CCONJ
eurjchem-2641	446	55	metastasis	metastasis	NOUN
eurjchem-2641	446	56	development	development	NOUN
eurjchem-2641	446	57	prediction	prediction	NOUN
eurjchem-2641	446	58	.	.	PUNCT
eurjchem-2641	447	1	front	front	ADJ
eurjchem-2641	447	2	.	.	PUNCT
eurjchem-2641	448	1	oncol	oncol	ADJ
eurjchem-2641	448	2	.	.	PUNCT
eurjchem-2641	449	1	2019	2019	NUM
eurjchem-2641	449	2	,	,	PUNCT
eurjchem-2641	449	3	9	9	NUM
eurjchem-2641	449	4	,	,	PUNCT
eurjchem-2641	449	5	900	900	NUM
eurjchem-2641	449	6	https://doi.org/10.3389/fonc.2019.00900	https://doi.org/10.3389/fonc.2019.00900	NOUN
eurjchem-2641	449	7	.	.	PUNCT
eurjchem-2641	450	1	[	[	X
eurjchem-2641	450	2	24	24	NUM
eurjchem-2641	450	3	]	]	PUNCT
eurjchem-2641	450	4	.	.	PUNCT
eurjchem-2641	450	5	kaloni	kaloni	PROPN
eurjchem-2641	450	6	,	,	PUNCT
eurjchem-2641	450	7	d.	d.	PROPN
eurjchem-2641	450	8	;	;	PUNCT
eurjchem-2641	450	9	diepstraten	diepstraten	VERB
eurjchem-2641	450	10	,	,	PUNCT
eurjchem-2641	450	11	s.	s.	PROPN
eurjchem-2641	450	12	t.	t.	PROPN
eurjchem-2641	450	13	;	;	PUNCT
eurjchem-2641	450	14	strasser	strasser	PROPN
eurjchem-2641	450	15	,	,	PUNCT
eurjchem-2641	450	16	a.	a.	NOUN
eurjchem-2641	450	17	;	;	PUNCT
eurjchem-2641	450	18	kelly	kelly	PROPN
eurjchem-2641	450	19	,	,	PUNCT
eurjchem-2641	450	20	g.	g.	PROPN
eurjchem-2641	450	21	l.	l.	PROPN
eurjchem-2641	450	22	bcl-2	bcl-2	PUNCT
eurjchem-2641	450	23	protein	protein	NOUN
eurjchem-2641	450	24	family	family	NOUN
eurjchem-2641	450	25	:	:	PUNCT
eurjchem-2641	450	26	attractive	attractive	ADJ
eurjchem-2641	450	27	targets	target	NOUN
eurjchem-2641	450	28	for	for	ADP
eurjchem-2641	450	29	cancer	cancer	NOUN
eurjchem-2641	450	30	therapy	therapy	NOUN
eurjchem-2641	450	31	.	.	PUNCT
eurjchem-2641	451	1	apoptosis	apoptosis	NOUN
eurjchem-2641	451	2	2022	2022	NUM
eurjchem-2641	451	3	,	,	PUNCT
eurjchem-2641	451	4	28	28	NUM
eurjchem-2641	451	5	(	(	PUNCT
eurjchem-2641	451	6	1	1	NUM
eurjchem-2641	451	7	-	-	SYM
eurjchem-2641	451	8	2	2	NUM
eurjchem-2641	451	9	)	)	PUNCT
eurjchem-2641	451	10	,	,	PUNCT
eurjchem-2641	451	11	20–38	20–38	NUM
eurjchem-2641	451	12	.	.	PUNCT
eurjchem-2641	452	1	[	[	X
eurjchem-2641	452	2	25	25	NUM
eurjchem-2641	452	3	]	]	PUNCT
eurjchem-2641	452	4	.	.	PUNCT
eurjchem-2641	453	1	bagherian	bagherian	PROPN
eurjchem-2641	453	2	,	,	PUNCT
eurjchem-2641	453	3	t.	t.	PROPN
eurjchem-2641	453	4	;	;	PUNCT
eurjchem-2641	453	5	tackallou	tackallou	NUM
eurjchem-2641	453	6	,	,	PUNCT
eurjchem-2641	453	7	s.	s.	PROPN
eurjchem-2641	453	8	h.	h.	PROPN
eurjchem-2641	453	9	;	;	PUNCT
eurjchem-2641	453	10	mohammadgholi	mohammadgholi	PROPN
eurjchem-2641	453	11	,	,	PUNCT
eurjchem-2641	453	12	a.	a.	PROPN
eurjchem-2641	453	13	quantitative	quantitative	PROPN
eurjchem-2641	453	14	measurement	measurement	NOUN
eurjchem-2641	453	15	of	of	ADP
eurjchem-2641	453	16	bax	bax	PROPN
eurjchem-2641	453	17	and	and	CCONJ
eurjchem-2641	453	18	bcl2	bcl2	NOUN
eurjchem-2641	453	19	genes	gene	NOUN
eurjchem-2641	453	20	and	and	CCONJ
eurjchem-2641	453	21	protein	protein	NOUN
eurjchem-2641	453	22	expression	expression	NOUN
eurjchem-2641	453	23	in	in	ADP
eurjchem-2641	453	24	mcf7	mcf7	NOUN
eurjchem-2641	453	25	cell	cell	NOUN
eurjchem-2641	453	26	-	-	PUNCT
eurjchem-2641	453	27	line	line	NOUN
eurjchem-2641	453	28	when	when	SCONJ
eurjchem-2641	453	29	treated	treat	VERB
eurjchem-2641	453	30	by	by	ADP
eurjchem-2641	453	31	aloe	aloe	PROPN
eurjchem-2641	453	32	vera	vera	NOUN
eurjchem-2641	453	33	extract	extract	NOUN
eurjchem-2641	453	34	.	.	PUNCT
eurjchem-2641	454	1	gene	gene	NOUN
eurjchem-2641	454	2	rep	rep	PROPN
eurjchem-2641	454	3	.	.	PROPN
eurjchem-2641	454	4	2021	2021	NUM
eurjchem-2641	454	5	,	,	PUNCT
eurjchem-2641	454	6	23	23	NUM
eurjchem-2641	454	7	,	,	PUNCT
eurjchem-2641	454	8	101123	101123	NUM
eurjchem-2641	454	9	.	.	PUNCT
eurjchem-2641	455	1	[	[	X
eurjchem-2641	455	2	26	26	NUM
eurjchem-2641	455	3	]	]	PUNCT
eurjchem-2641	455	4	.	.	PUNCT
eurjchem-2641	456	1	avrutsky	avrutsky	PROPN
eurjchem-2641	456	2	,	,	PUNCT
eurjchem-2641	456	3	m.	m.	NOUN
eurjchem-2641	456	4	i.	i.	PROPN
eurjchem-2641	456	5	;	;	PUNCT
eurjchem-2641	456	6	troy	troy	PROPN
eurjchem-2641	456	7	,	,	PUNCT
eurjchem-2641	456	8	c.	c.	PROPN
eurjchem-2641	456	9	m.	m.	PROPN
eurjchem-2641	456	10	caspase-9	caspase-9	PROPN
eurjchem-2641	456	11	:	:	PUNCT
eurjchem-2641	456	12	a	a	DET
eurjchem-2641	456	13	multimodal	multimodal	ADJ
eurjchem-2641	456	14	therapeutic	therapeutic	ADJ
eurjchem-2641	456	15	target	target	NOUN
eurjchem-2641	456	16	with	with	ADP
eurjchem-2641	456	17	diverse	diverse	ADJ
eurjchem-2641	456	18	cellular	cellular	ADJ
eurjchem-2641	456	19	expression	expression	NOUN
eurjchem-2641	456	20	in	in	ADP
eurjchem-2641	456	21	human	human	ADJ
eurjchem-2641	456	22	disease	disease	NOUN
eurjchem-2641	456	23	.	.	PUNCT
eurjchem-2641	457	1	front	front	NOUN
eurjchem-2641	457	2	.	.	PUNCT
eurjchem-2641	458	1	pharmacol	pharmacol	PROPN
eurjchem-2641	458	2	.	.	PROPN
eurjchem-2641	458	3	2021	2021	NUM
eurjchem-2641	458	4	,	,	PUNCT
eurjchem-2641	458	5	12	12	NUM
eurjchem-2641	458	6	,	,	PUNCT
eurjchem-2641	458	7	701301	701301	NUM
eurjchem-2641	458	8	https://doi.org/10.3389/fphar.2021.701301	https://doi.org/10.3389/fphar.2021.701301	PROPN
eurjchem-2641	458	9	.	.	PUNCT
eurjchem-2641	459	1	[	[	X
eurjchem-2641	459	2	27	27	NUM
eurjchem-2641	459	3	]	]	PUNCT
eurjchem-2641	459	4	.	.	PUNCT
eurjchem-2641	460	1	ozawa	ozawa	PROPN
eurjchem-2641	460	2	,	,	PUNCT
eurjchem-2641	460	3	p.	p.	NOUN
eurjchem-2641	460	4	m.	m.	NOUN
eurjchem-2641	460	5	;	;	PUNCT
eurjchem-2641	460	6	jucoski	jucoski	NOUN
eurjchem-2641	460	7	,	,	PUNCT
eurjchem-2641	460	8	t.	t.	PROPN
eurjchem-2641	460	9	s.	s.	PROPN
eurjchem-2641	460	10	;	;	PUNCT
eurjchem-2641	460	11	vieira	vieira	PROPN
eurjchem-2641	460	12	,	,	PUNCT
eurjchem-2641	460	13	e.	e.	PROPN
eurjchem-2641	460	14	;	;	PUNCT
eurjchem-2641	460	15	carvalho	carvalho	PROPN
eurjchem-2641	460	16	,	,	PUNCT
eurjchem-2641	460	17	t.	t.	NOUN
eurjchem-2641	460	18	m.	m.	NOUN
eurjchem-2641	460	19	;	;	PUNCT
eurjchem-2641	460	20	malheiros	malheiros	PROPN
eurjchem-2641	460	21	,	,	PUNCT
eurjchem-2641	460	22	d.	d.	PROPN
eurjchem-2641	460	23	;	;	PUNCT
eurjchem-2641	460	24	ribeiro	ribeiro	PROPN
eurjchem-2641	460	25	,	,	PUNCT
eurjchem-2641	460	26	e.	e.	PROPN
eurjchem-2641	460	27	m.	m.	PROPN
eurjchem-2641	460	28	liquid	liquid	PROPN
eurjchem-2641	460	29	biopsy	biopsy	NOUN
eurjchem-2641	460	30	for	for	ADP
eurjchem-2641	460	31	breast	breast	NOUN
eurjchem-2641	460	32	cancer	cancer	NOUN
eurjchem-2641	460	33	using	use	VERB
eurjchem-2641	460	34	extracellular	extracellular	ADJ
eurjchem-2641	460	35	vesicles	vesicle	NOUN
eurjchem-2641	460	36	and	and	CCONJ
eurjchem-2641	460	37	cell	cell	NOUN
eurjchem-2641	460	38	-	-	PUNCT
eurjchem-2641	460	39	free	free	ADJ
eurjchem-2641	460	40	micrornas	microrna	NOUN
eurjchem-2641	460	41	as	as	ADP
eurjchem-2641	460	42	biomarkers	biomarker	NOUN
eurjchem-2641	460	43	.	.	PUNCT
eurjchem-2641	461	1	transl	transl	PROPN
eurjchem-2641	461	2	.	.	PUNCT
eurjchem-2641	462	1	res	re	NOUN
eurjchem-2641	462	2	.	.	PUNCT
eurjchem-2641	463	1	2020	2020	NUM
eurjchem-2641	463	2	,	,	PUNCT
eurjchem-2641	463	3	223	223	NUM
eurjchem-2641	463	4	,	,	PUNCT
eurjchem-2641	463	5	40–60	40–60	NOUN
eurjchem-2641	463	6	.	.	PUNCT
eurjchem-2641	464	1	[	[	X
eurjchem-2641	464	2	28	28	NUM
eurjchem-2641	464	3	]	]	PUNCT
eurjchem-2641	464	4	.	.	PUNCT
eurjchem-2641	465	1	andre	andre	PROPN
eurjchem-2641	465	2	,	,	PUNCT
eurjchem-2641	465	3	f.	f.	PROPN
eurjchem-2641	465	4	;	;	PUNCT
eurjchem-2641	465	5	ismaila	ismaila	PROPN
eurjchem-2641	465	6	,	,	PUNCT
eurjchem-2641	465	7	n.	n.	PROPN
eurjchem-2641	465	8	;	;	PUNCT
eurjchem-2641	465	9	allison	allison	PROPN
eurjchem-2641	465	10	,	,	PUNCT
eurjchem-2641	465	11	k.	k.	PROPN
eurjchem-2641	465	12	h.	h.	PROPN
eurjchem-2641	465	13	;	;	PUNCT
eurjchem-2641	465	14	barlow	barlow	PROPN
eurjchem-2641	465	15	,	,	PUNCT
eurjchem-2641	465	16	w.	w.	PROPN
eurjchem-2641	465	17	e.	e.	PROPN
eurjchem-2641	465	18	;	;	PUNCT
eurjchem-2641	465	19	collyar	collyar	PROPN
eurjchem-2641	465	20	,	,	PUNCT
eurjchem-2641	465	21	d.	d.	PROPN
eurjchem-2641	465	22	e.	e.	PROPN
eurjchem-2641	465	23	;	;	PUNCT
eurjchem-2641	465	24	damodaran	damodaran	VERB
eurjchem-2641	465	25	,	,	PUNCT
eurjchem-2641	465	26	s.	s.	PROPN
eurjchem-2641	465	27	;	;	PUNCT
eurjchem-2641	465	28	henry	henry	PROPN
eurjchem-2641	465	29	,	,	PUNCT
eurjchem-2641	465	30	n.	n.	PROPN
eurjchem-2641	465	31	l.	l.	PROPN
eurjchem-2641	465	32	;	;	PUNCT
eurjchem-2641	465	33	jhaveri	jhaveri	PROPN
eurjchem-2641	465	34	,	,	PUNCT
eurjchem-2641	465	35	k.	k.	PROPN
eurjchem-2641	465	36	;	;	PUNCT
eurjchem-2641	465	37	kalinsky	kalinsky	PROPN
eurjchem-2641	465	38	,	,	PUNCT
eurjchem-2641	465	39	k.	k.	PROPN
eurjchem-2641	465	40	;	;	PUNCT
eurjchem-2641	465	41	kuderer	kuderer	PROPN
eurjchem-2641	465	42	,	,	PUNCT
eurjchem-2641	465	43	n.	n.	NOUN
eurjchem-2641	465	44	m.	m.	NOUN
eurjchem-2641	465	45	;	;	PUNCT
eurjchem-2641	465	46	litvak	litvak	PROPN
eurjchem-2641	465	47	,	,	PUNCT
eurjchem-2641	465	48	a.	a.	NOUN
eurjchem-2641	465	49	;	;	PUNCT
eurjchem-2641	465	50	mayer	mayer	PROPN
eurjchem-2641	465	51	,	,	PUNCT
eurjchem-2641	465	52	e.	e.	PROPN
eurjchem-2641	465	53	l.	l.	PROPN
eurjchem-2641	465	54	;	;	PUNCT
eurjchem-2641	465	55	pusztai	pusztai	NOUN
eurjchem-2641	465	56	,	,	PUNCT
eurjchem-2641	465	57	l.	l.	PROPN
eurjchem-2641	465	58	;	;	PUNCT
eurjchem-2641	465	59	raab	raab	PROPN
eurjchem-2641	465	60	,	,	PUNCT
eurjchem-2641	465	61	r.	r.	PROPN
eurjchem-2641	465	62	;	;	PUNCT
eurjchem-2641	465	63	wolff	wolff	NOUN
eurjchem-2641	465	64	,	,	PUNCT
eurjchem-2641	465	65	a.	a.	PROPN
eurjchem-2641	465	66	c.	c.	PROPN
eurjchem-2641	465	67	;	;	PUNCT
eurjchem-2641	465	68	stearns	stearns	PROPN
eurjchem-2641	465	69	,	,	PUNCT
eurjchem-2641	465	70	v.	v.	ADP
eurjchem-2641	465	71	biomarkers	biomarker	NOUN
eurjchem-2641	465	72	for	for	ADP
eurjchem-2641	465	73	adjuvant	adjuvant	ADJ
eurjchem-2641	465	74	endocrine	endocrine	NOUN
eurjchem-2641	465	75	and	and	CCONJ
eurjchem-2641	465	76	chemotherapy	chemotherapy	NOUN
eurjchem-2641	465	77	in	in	ADP
eurjchem-2641	465	78	early	early	ADJ
eurjchem-2641	465	79	-	-	PUNCT
eurjchem-2641	465	80	stage	stage	NOUN
eurjchem-2641	465	81	breast	breast	NOUN
eurjchem-2641	465	82	cancer	cancer	NOUN
eurjchem-2641	465	83	:	:	PUNCT
eurjchem-2641	465	84	asco	asco	PROPN
eurjchem-2641	465	85	guideline	guideline	NOUN
eurjchem-2641	465	86	update	update	NOUN
eurjchem-2641	465	87	.	.	PUNCT
eurjchem-2641	466	1	jco	jco	PROPN
eurjchem-2641	466	2	.	.	PROPN
eurjchem-2641	466	3	2022	2022	NUM
eurjchem-2641	466	4	,	,	PUNCT
eurjchem-2641	466	5	40	40	NUM
eurjchem-2641	466	6	(	(	PUNCT
eurjchem-2641	466	7	16	16	NUM
eurjchem-2641	466	8	)	)	PUNCT
eurjchem-2641	466	9	,	,	PUNCT
eurjchem-2641	466	10	1816	1816	NUM
eurjchem-2641	466	11	–	–	PUNCT
eurjchem-2641	466	12	1837	1837	NUM
eurjchem-2641	466	13	.	.	PUNCT
eurjchem-2641	467	1	[	[	X
eurjchem-2641	467	2	29	29	NUM
eurjchem-2641	467	3	]	]	PUNCT
eurjchem-2641	467	4	.	.	PUNCT
eurjchem-2641	467	5	sriram	sriram	PROPN
eurjchem-2641	467	6	,	,	PUNCT
eurjchem-2641	467	7	h.	h.	PROPN
eurjchem-2641	467	8	;	;	PUNCT
eurjchem-2641	467	9	deshpande	deshpande	PROPN
eurjchem-2641	467	10	,	,	PUNCT
eurjchem-2641	467	11	n.	n.	NOUN
eurjchem-2641	467	12	;	;	PUNCT
eurjchem-2641	467	13	tembhare	tembhare	PROPN
eurjchem-2641	467	14	,	,	PUNCT
eurjchem-2641	467	15	p.	p.	PROPN
eurjchem-2641	467	16	r.	r.	PROPN
eurjchem-2641	467	17	;	;	PUNCT
eurjchem-2641	467	18	hasan	hasan	PROPN
eurjchem-2641	467	19	,	,	PUNCT
eurjchem-2641	467	20	s.	s.	PROPN
eurjchem-2641	467	21	;	;	PUNCT
eurjchem-2641	467	22	gujral	gujral	PROPN
eurjchem-2641	467	23	,	,	PUNCT
eurjchem-2641	467	24	s.	s.	PROPN
eurjchem-2641	467	25	;	;	PUNCT
eurjchem-2641	467	26	subramanian	subramanian	PROPN
eurjchem-2641	467	27	,	,	PUNCT
eurjchem-2641	467	28	p.	p.	NOUN
eurjchem-2641	467	29	g.	g.	PROPN
eurjchem-2641	467	30	;	;	PUNCT
eurjchem-2641	467	31	patkar	patkar	NOUN
eurjchem-2641	467	32	,	,	PUNCT
eurjchem-2641	467	33	n.	n.	PROPN
eurjchem-2641	467	34	v.	v.	PROPN
eurjchem-2641	467	35	;	;	PUNCT
eurjchem-2641	467	36	rajpal	rajpal	PROPN
eurjchem-2641	467	37	,	,	PUNCT
eurjchem-2641	467	38	s.	s.	PROPN
eurjchem-2641	467	39	;	;	PUNCT
eurjchem-2641	467	40	chatterjee	chatterjee	PROPN
eurjchem-2641	467	41	,	,	PUNCT
eurjchem-2641	467	42	g.	g.	PROPN
eurjchem-2641	467	43	;	;	PUNCT
eurjchem-2641	467	44	ghogale	ghogale	PROPN
eurjchem-2641	467	45	,	,	PUNCT
eurjchem-2641	467	46	s.	s.	PROPN
eurjchem-2641	467	47	;	;	PUNCT
eurjchem-2641	467	48	tyagi	tyagi	PROPN
eurjchem-2641	467	49	,	,	PUNCT
eurjchem-2641	467	50	p.	p.	PROPN
eurjchem-2641	467	51	;	;	PUNCT
eurjchem-2641	467	52	kedia	kedia	PROPN
eurjchem-2641	467	53	,	,	PUNCT
eurjchem-2641	467	54	s.	s.	PROPN
eurjchem-2641	467	55	;	;	PUNCT
eurjchem-2641	467	56	khanka	khanka	ADJ
eurjchem-2641	467	57	,	,	PUNCT
eurjchem-2641	467	58	t.	t.	PROPN
eurjchem-2641	467	59	improved	improve	VERB
eurjchem-2641	467	60	protocol	protocol	NOUN
eurjchem-2641	467	61	for	for	ADP
eurjchem-2641	467	62	plasma	plasma	NOUN
eurjchem-2641	467	63	microrna	microrna	PROPN
eurjchem-2641	467	64	extraction	extraction	NOUN
eurjchem-2641	467	65	and	and	CCONJ
eurjchem-2641	467	66	comparison	comparison	NOUN
eurjchem-2641	467	67	of	of	ADP
eurjchem-2641	467	68	commercial	commercial	ADJ
eurjchem-2641	467	69	kits	kit	NOUN
eurjchem-2641	467	70	.	.	PUNCT
eurjchem-2641	468	1	biochem	biochem	PROPN
eurjchem-2641	468	2	.	.	PUNCT
eurjchem-2641	469	1	med	med	PROPN
eurjchem-2641	469	2	.	.	PUNCT
eurjchem-2641	470	1	(	(	PUNCT
eurjchem-2641	470	2	online	online	ADJ
eurjchem-2641	470	3	)	)	PUNCT
eurjchem-2641	470	4	2021	2021	NUM
eurjchem-2641	470	5	,	,	PUNCT
eurjchem-2641	470	6	31	31	NUM
eurjchem-2641	470	7	(	(	PUNCT
eurjchem-2641	470	8	3	3	NUM
eurjchem-2641	470	9	)	)	PUNCT
eurjchem-2641	470	10	,	,	PUNCT
eurjchem-2641	470	11	467–475	467–475	NUM
eurjchem-2641	470	12	.	.	PUNCT
eurjchem-2641	471	1	[	[	X
eurjchem-2641	471	2	30	30	NUM
eurjchem-2641	471	3	]	]	PUNCT
eurjchem-2641	471	4	.	.	PUNCT
eurjchem-2641	472	1	schmittgen	schmittgen	PROPN
eurjchem-2641	472	2	,	,	PUNCT
eurjchem-2641	472	3	t.	t.	PROPN
eurjchem-2641	472	4	d.	d.	PROPN
eurjchem-2641	472	5	real	real	ADJ
eurjchem-2641	472	6	-	-	PUNCT
eurjchem-2641	472	7	time	time	NOUN
eurjchem-2641	472	8	quantitative	quantitative	ADJ
eurjchem-2641	472	9	pcr	pcr	NOUN
eurjchem-2641	472	10	.	.	PUNCT
eurjchem-2641	473	1	methods	method	NOUN
eurjchem-2641	473	2	2001	2001	NUM
eurjchem-2641	473	3	,	,	PUNCT
eurjchem-2641	473	4	25	25	NUM
eurjchem-2641	473	5	(	(	PUNCT
eurjchem-2641	473	6	4	4	NUM
eurjchem-2641	473	7	)	)	PUNCT
eurjchem-2641	473	8	,	,	PUNCT
eurjchem-2641	473	9	383–385	383–385	NUM
eurjchem-2641	473	10	.	.	PUNCT
eurjchem-2641	474	1	[	[	X
eurjchem-2641	474	2	31	31	NUM
eurjchem-2641	474	3	]	]	PUNCT
eurjchem-2641	474	4	.	.	PUNCT
eurjchem-2641	475	1	xia	xia	PROPN
eurjchem-2641	475	2	,	,	PUNCT
eurjchem-2641	475	3	j.	j.	PROPN
eurjchem-2641	475	4	;	;	PUNCT
eurjchem-2641	475	5	jiang	jiang	PROPN
eurjchem-2641	475	6	,	,	PUNCT
eurjchem-2641	475	7	n.	n.	PROPN
eurjchem-2641	475	8	;	;	PUNCT
eurjchem-2641	475	9	li	li	PROPN
eurjchem-2641	475	10	,	,	PUNCT
eurjchem-2641	475	11	y.	y.	PROPN
eurjchem-2641	475	12	;	;	PUNCT
eurjchem-2641	475	13	wei	wei	PROPN
eurjchem-2641	475	14	,	,	PUNCT
eurjchem-2641	475	15	y.	y.	PROPN
eurjchem-2641	475	16	;	;	PUNCT
eurjchem-2641	475	17	zhang	zhang	PROPN
eurjchem-2641	475	18	,	,	PUNCT
eurjchem-2641	475	19	x.	x.	VERB
eurjchem-2641	475	20	the	the	DET
eurjchem-2641	475	21	long	long	ADJ
eurjchem-2641	475	22	noncoding	noncoding	ADJ
eurjchem-2641	475	23	rna	rna	NOUN
eurjchem-2641	475	24	thril	thril	NOUN
eurjchem-2641	475	25	knockdown	knockdown	NOUN
eurjchem-2641	475	26	protects	protect	VERB
eurjchem-2641	475	27	hypoxia	hypoxia	NOUN
eurjchem-2641	475	28	-	-	PUNCT
eurjchem-2641	475	29	induced	induce	VERB
eurjchem-2641	475	30	injuries	injury	NOUN
eurjchem-2641	475	31	of	of	ADP
eurjchem-2641	475	32	h9c2	h9c2	NOUN
eurjchem-2641	475	33	cells	cell	NOUN
eurjchem-2641	475	34	through	through	ADP
eurjchem-2641	475	35	regulating	regulate	VERB
eurjchem-2641	475	36	mir-99a	mir-99a	NUM
eurjchem-2641	475	37	.	.	PUNCT
eurjchem-2641	476	1	cardiol	cardiol	PROPN
eurjchem-2641	476	2	j.	j.	PROPN
eurjchem-2641	476	3	2019	2019	NUM
eurjchem-2641	476	4	,	,	PUNCT
eurjchem-2641	476	5	26	26	NUM
eurjchem-2641	476	6	(	(	PUNCT
eurjchem-2641	476	7	5	5	NUM
eurjchem-2641	476	8	)	)	PUNCT
eurjchem-2641	476	9	,	,	PUNCT
eurjchem-2641	476	10	564–574	564–574	NUM
eurjchem-2641	476	11	.	.	PUNCT
eurjchem-2641	477	1	[	[	X
eurjchem-2641	477	2	32	32	NUM
eurjchem-2641	477	3	]	]	PUNCT
eurjchem-2641	477	4	.	.	PUNCT
eurjchem-2641	478	1	hahn	hahn	PROPN
eurjchem-2641	478	2	,	,	PUNCT
eurjchem-2641	478	3	h.	h.	PROPN
eurjchem-2641	478	4	p.	p.	PROPN
eurjchem-2641	478	5	;	;	PUNCT
eurjchem-2641	478	6	bundock	bundock	PROPN
eurjchem-2641	478	7	,	,	PUNCT
eurjchem-2641	478	8	e.	e.	PROPN
eurjchem-2641	478	9	a.	a.	PROPN
eurjchem-2641	478	10	;	;	PUNCT
eurjchem-2641	478	11	hornick	hornick	PROPN
eurjchem-2641	478	12	,	,	PUNCT
eurjchem-2641	478	13	j.	j.	PROPN
eurjchem-2641	478	14	l.	l.	PROPN
eurjchem-2641	478	15	immunohistochemical	immunohistochemical	PROPN
eurjchem-2641	478	16	staining	stain	VERB
eurjchem-2641	478	17	for	for	ADP
eurjchem-2641	478	18	claudin-1	claudin-1	PROPN
eurjchem-2641	478	19	can	can	AUX
eurjchem-2641	478	20	help	help	VERB
eurjchem-2641	478	21	distinguish	distinguish	VERB
eurjchem-2641	478	22	meningiomas	meningioma	NOUN
eurjchem-2641	478	23	from	from	ADP
eurjchem-2641	478	24	histologic	histologic	ADJ
eurjchem-2641	478	25	mimics	mimic	NOUN
eurjchem-2641	478	26	.	.	PUNCT
eurjchem-2641	479	1	am	be	AUX
eurjchem-2641	479	2	.	.	PUNCT
eurjchem-2641	480	1	j.	j.	PROPN
eurjchem-2641	480	2	clin	clin	PROPN
eurjchem-2641	480	3	.	.	PUNCT
eurjchem-2641	481	1	pathol	pathol	PROPN
eurjchem-2641	481	2	.	.	PUNCT
eurjchem-2641	482	1	2006	2006	NUM
eurjchem-2641	482	2	,	,	PUNCT
eurjchem-2641	482	3	125	125	NUM
eurjchem-2641	482	4	(	(	PUNCT
eurjchem-2641	482	5	2	2	NUM
eurjchem-2641	482	6	)	)	PUNCT
eurjchem-2641	482	7	,	,	PUNCT
eurjchem-2641	482	8	203–208	203–208	NUM
eurjchem-2641	482	9	.	.	PUNCT
eurjchem-2641	483	1	[	[	X
eurjchem-2641	483	2	33	33	NUM
eurjchem-2641	483	3	]	]	PUNCT
eurjchem-2641	483	4	.	.	PUNCT
eurjchem-2641	483	5	kinnel	kinnel	PROPN
eurjchem-2641	483	6	,	,	PUNCT
eurjchem-2641	483	7	b.	b.	PROPN
eurjchem-2641	483	8	;	;	PUNCT
eurjchem-2641	483	9	singh	singh	PROPN
eurjchem-2641	483	10	,	,	PUNCT
eurjchem-2641	483	11	s.	s.	PROPN
eurjchem-2641	483	12	k.	k.	PROPN
eurjchem-2641	483	13	;	;	PUNCT
eurjchem-2641	483	14	oprea	oprea	PROPN
eurjchem-2641	483	15	-	-	PUNCT
eurjchem-2641	483	16	ilies	ilie	NOUN
eurjchem-2641	483	17	,	,	PUNCT
eurjchem-2641	483	18	g.	g.	PROPN
eurjchem-2641	483	19	;	;	PUNCT
eurjchem-2641	483	20	singh	singh	PROPN
eurjchem-2641	483	21	,	,	PUNCT
eurjchem-2641	483	22	r.	r.	PROPN
eurjchem-2641	483	23	targeted	target	VERB
eurjchem-2641	483	24	therapy	therapy	NOUN
eurjchem-2641	483	25	and	and	CCONJ
eurjchem-2641	483	26	mechanisms	mechanism	NOUN
eurjchem-2641	483	27	of	of	ADP
eurjchem-2641	483	28	drug	drug	NOUN
eurjchem-2641	483	29	resistance	resistance	NOUN
eurjchem-2641	483	30	in	in	ADP
eurjchem-2641	483	31	breast	breast	NOUN
eurjchem-2641	483	32	cancer	cancer	NOUN
eurjchem-2641	483	33	.	.	PUNCT
eurjchem-2641	484	1	cancers	cancer	NOUN
eurjchem-2641	484	2	2023	2023	NUM
eurjchem-2641	484	3	,	,	PUNCT
eurjchem-2641	484	4	15	15	NUM
eurjchem-2641	484	5	(	(	PUNCT
eurjchem-2641	484	6	4	4	NUM
eurjchem-2641	484	7	)	)	PUNCT
eurjchem-2641	484	8	,	,	PUNCT
eurjchem-2641	484	9	1320	1320	NUM
eurjchem-2641	484	10	.	.	PUNCT
eurjchem-2641	485	1	[	[	X
eurjchem-2641	485	2	34	34	NUM
eurjchem-2641	485	3	]	]	PUNCT
eurjchem-2641	485	4	.	.	PUNCT
eurjchem-2641	486	1	si	si	PROPN
eurjchem-2641	486	2	,	,	PUNCT
eurjchem-2641	486	3	w.	w.	PROPN
eurjchem-2641	486	4	;	;	PUNCT
eurjchem-2641	486	5	shen	shen	PROPN
eurjchem-2641	486	6	,	,	PUNCT
eurjchem-2641	486	7	j.	j.	PROPN
eurjchem-2641	486	8	;	;	PUNCT
eurjchem-2641	486	9	zheng	zheng	PROPN
eurjchem-2641	486	10	,	,	PUNCT
eurjchem-2641	486	11	h.	h.	PROPN
eurjchem-2641	486	12	;	;	PUNCT
eurjchem-2641	486	13	fan	fan	PROPN
eurjchem-2641	486	14	,	,	PUNCT
eurjchem-2641	486	15	w.	w.	NOUN
eurjchem-2641	486	16	the	the	DET
eurjchem-2641	486	17	role	role	NOUN
eurjchem-2641	486	18	and	and	CCONJ
eurjchem-2641	486	19	mechanisms	mechanism	NOUN
eurjchem-2641	486	20	of	of	ADP
eurjchem-2641	486	21	action	action	NOUN
eurjchem-2641	486	22	of	of	ADP
eurjchem-2641	486	23	micrornas	microrna	NOUN
eurjchem-2641	486	24	in	in	ADP
eurjchem-2641	486	25	cancer	cancer	NOUN
eurjchem-2641	486	26	drug	drug	NOUN
eurjchem-2641	486	27	resistance	resistance	NOUN
eurjchem-2641	486	28	.	.	PUNCT
eurjchem-2641	487	1	clin	clin	PROPN
eurjchem-2641	487	2	epigenet	epigenet	PROPN
eurjchem-2641	487	3	2019	2019	NUM
eurjchem-2641	487	4	,	,	PUNCT
eurjchem-2641	487	5	11	11	NUM
eurjchem-2641	487	6	(	(	PUNCT
eurjchem-2641	487	7	1	1	NUM
eurjchem-2641	487	8	)	)	PUNCT
eurjchem-2641	487	9	,	,	PUNCT
eurjchem-2641	487	10	https://doi.org/10.1186/s13148–018–0587–8	https://doi.org/10.1186/s13148–018–0587–8	NOUN
eurjchem-2641	487	11	.	.	PUNCT
eurjchem-2641	488	1	[	[	X
eurjchem-2641	488	2	35	35	NUM
eurjchem-2641	488	3	]	]	SYM
eurjchem-2641	488	4	.	.	PUNCT
eurjchem-2641	489	1	sharma	sharma	PROPN
eurjchem-2641	489	2	,	,	PUNCT
eurjchem-2641	489	3	s.	s.	PROPN
eurjchem-2641	489	4	;	;	PUNCT
eurjchem-2641	489	5	patnaik	patnaik	PROPN
eurjchem-2641	489	6	,	,	PUNCT
eurjchem-2641	489	7	p.	p.	PROPN
eurjchem-2641	489	8	k.	k.	PROPN
eurjchem-2641	489	9	;	;	PUNCT
eurjchem-2641	489	10	aronov	aronov	PROPN
eurjchem-2641	489	11	,	,	PUNCT
eurjchem-2641	489	12	s.	s.	PROPN
eurjchem-2641	489	13	;	;	PUNCT
eurjchem-2641	489	14	kulshreshtha	kulshreshtha	PROPN
eurjchem-2641	489	15	,	,	PUNCT
eurjchem-2641	489	16	r.	r.	PROPN
eurjchem-2641	489	17	apoptomirs	apoptomirs	PROPN
eurjchem-2641	489	18	of	of	ADP
eurjchem-2641	489	19	breast	breast	NOUN
eurjchem-2641	489	20	cancer	cancer	NOUN
eurjchem-2641	489	21	:	:	PUNCT
eurjchem-2641	489	22	basics	basic	NOUN
eurjchem-2641	489	23	to	to	ADP
eurjchem-2641	489	24	clinics	clinic	NOUN
eurjchem-2641	489	25	.	.	PUNCT
eurjchem-2641	490	1	front	front	ADJ
eurjchem-2641	490	2	.	.	PUNCT
eurjchem-2641	491	1	genet	genet	NOUN
eurjchem-2641	491	2	.	.	PUNCT
eurjchem-2641	492	1	2016	2016	NUM
eurjchem-2641	492	2	,	,	PUNCT
eurjchem-2641	492	3	7	7	NUM
eurjchem-2641	492	4	,	,	PUNCT
eurjchem-2641	492	5	219910	219910	NUM
eurjchem-2641	492	6	https://doi.org/10.3389/fgene.2016.00175	https://doi.org/10.3389/fgene.2016.00175	PROPN
eurjchem-2641	492	7	.	.	PUNCT
eurjchem-2641	493	1	[	[	X
eurjchem-2641	493	2	36	36	NUM
eurjchem-2641	493	3	]	]	PUNCT
eurjchem-2641	493	4	.	.	PUNCT
eurjchem-2641	494	1	dai	dai	PROPN
eurjchem-2641	494	2	,	,	PUNCT
eurjchem-2641	494	3	w.	w.	PROPN
eurjchem-2641	494	4	;	;	PUNCT
eurjchem-2641	494	5	he	he	PRON
eurjchem-2641	494	6	,	,	PUNCT
eurjchem-2641	494	7	j.	j.	PROPN
eurjchem-2641	494	8	;	;	PUNCT
eurjchem-2641	494	9	zheng	zheng	PROPN
eurjchem-2641	494	10	,	,	PUNCT
eurjchem-2641	494	11	l.	l.	PROPN
eurjchem-2641	494	12	;	;	PUNCT
eurjchem-2641	494	13	bi	bi	NOUN
eurjchem-2641	494	14	,	,	PUNCT
eurjchem-2641	494	15	m.	m.	NOUN
eurjchem-2641	494	16	;	;	PUNCT
eurjchem-2641	494	17	hu	hu	PROPN
eurjchem-2641	494	18	,	,	PUNCT
eurjchem-2641	494	19	f.	f.	PROPN
eurjchem-2641	494	20	;	;	PUNCT
eurjchem-2641	494	21	chen	chen	PROPN
eurjchem-2641	494	22	,	,	PUNCT
eurjchem-2641	494	23	m.	m.	NOUN
eurjchem-2641	494	24	;	;	PUNCT
eurjchem-2641	494	25	niu	niu	PROPN
eurjchem-2641	494	26	,	,	PUNCT
eurjchem-2641	494	27	h.	h.	PROPN
eurjchem-2641	494	28	;	;	PUNCT
eurjchem-2641	494	29	yang	yang	PROPN
eurjchem-2641	494	30	,	,	PUNCT
eurjchem-2641	494	31	j.	j.	PROPN
eurjchem-2641	494	32	;	;	PUNCT
eurjchem-2641	494	33	luo	luo	PROPN
eurjchem-2641	494	34	,	,	PUNCT
eurjchem-2641	494	35	y.	y.	PROPN
eurjchem-2641	494	36	;	;	PUNCT
eurjchem-2641	494	37	tang	tang	PROPN
eurjchem-2641	494	38	,	,	PUNCT
eurjchem-2641	494	39	w.	w.	PROPN
eurjchem-2641	494	40	;	;	PUNCT
eurjchem-2641	494	41	sheng	sheng	PROPN
eurjchem-2641	494	42	,	,	PUNCT
eurjchem-2641	494	43	m.	m.	NOUN
eurjchem-2641	494	44	mir-148b-3p	mir-148b-3p	PROPN
eurjchem-2641	494	45	,	,	PUNCT
eurjchem-2641	494	46	mir-190b	mir-190b	ADJ
eurjchem-2641	494	47	,	,	PUNCT
eurjchem-2641	494	48	and	and	CCONJ
eurjchem-2641	494	49	mir-429	mir-429	ADJ
eurjchem-2641	494	50	regulate	regulate	NOUN
eurjchem-2641	494	51	cell	cell	NOUN
eurjchem-2641	494	52	progression	progression	NOUN
eurjchem-2641	494	53	and	and	CCONJ
eurjchem-2641	494	54	act	act	NOUN
eurjchem-2641	494	55	as	as	ADP
eurjchem-2641	494	56	potential	potential	ADJ
eurjchem-2641	494	57	biomarkers	biomarker	NOUN
eurjchem-2641	494	58	for	for	ADP
eurjchem-2641	494	59	breast	breast	NOUN
eurjchem-2641	494	60	cancer	cancer	NOUN
eurjchem-2641	494	61	.	.	PUNCT
eurjchem-2641	495	1	j.	j.	PROPN
eurjchem-2641	495	2	breast	breast	PROPN
eurjchem-2641	495	3	cancer	cancer	PROPN
eurjchem-2641	495	4	2019	2019	NUM
eurjchem-2641	495	5	,	,	PUNCT
eurjchem-2641	495	6	22	22	NUM
eurjchem-2641	495	7	(	(	PUNCT
eurjchem-2641	495	8	2	2	NUM
eurjchem-2641	495	9	)	)	PUNCT
eurjchem-2641	495	10	,	,	PUNCT
eurjchem-2641	495	11	219	219	NUM
eurjchem-2641	495	12	.	.	PUNCT
eurjchem-2641	496	1	[	[	X
eurjchem-2641	496	2	37	37	NUM
eurjchem-2641	496	3	]	]	PUNCT
eurjchem-2641	496	4	.	.	PUNCT
eurjchem-2641	497	1	ruiz	ruiz	NOUN
eurjchem-2641	497	2	-	-	PUNCT
eurjchem-2641	497	3	manriquez	manriquez	NOUN
eurjchem-2641	497	4	,	,	PUNCT
eurjchem-2641	497	5	l.	l.	PROPN
eurjchem-2641	497	6	m.	m.	PROPN
eurjchem-2641	497	7	;	;	PUNCT
eurjchem-2641	497	8	villarreal	villarreal	NOUN
eurjchem-2641	497	9	-	-	PUNCT
eurjchem-2641	497	10	garza	garza	NOUN
eurjchem-2641	497	11	,	,	PUNCT
eurjchem-2641	497	12	c.	c.	PROPN
eurjchem-2641	497	13	;	;	PUNCT
eurjchem-2641	497	14	benavides	benavides	PROPN
eurjchem-2641	497	15	-	-	PUNCT
eurjchem-2641	497	16	aguilar	aguilar	PROPN
eurjchem-2641	497	17	,	,	PUNCT
eurjchem-2641	497	18	j.	j.	PROPN
eurjchem-2641	497	19	a.	a.	PROPN
eurjchem-2641	497	20	;	;	PUNCT
eurjchem-2641	497	21	torres	torre	NOUN
eurjchem-2641	497	22	-	-	PUNCT
eurjchem-2641	497	23	copado	copado	NOUN
eurjchem-2641	497	24	,	,	PUNCT
eurjchem-2641	497	25	a.	a.	NOUN
eurjchem-2641	497	26	;	;	PUNCT
eurjchem-2641	497	27	isidoro	isidoro	PROPN
eurjchem-2641	497	28	-	-	PUNCT
eurjchem-2641	497	29	sánchez	sánchez	NOUN
eurjchem-2641	497	30	,	,	PUNCT
eurjchem-2641	497	31	j.	j.	PROPN
eurjchem-2641	497	32	;	;	PUNCT
eurjchem-2641	497	33	estrada	estrada	PROPN
eurjchem-2641	497	34	-	-	PUNCT
eurjchem-2641	497	35	meza	meza	PROPN
eurjchem-2641	497	36	,	,	PUNCT
eurjchem-2641	497	37	c.	c.	PROPN
eurjchem-2641	497	38	;	;	PUNCT
eurjchem-2641	497	39	arvizuespinosa	arvizuespinosa	PROPN
eurjchem-2641	497	40	,	,	PUNCT
eurjchem-2641	497	41	m.	m.	NOUN
eurjchem-2641	497	42	g.	g.	PROPN
eurjchem-2641	497	43	;	;	PUNCT
eurjchem-2641	497	44	paul	paul	PROPN
eurjchem-2641	497	45	,	,	PUNCT
eurjchem-2641	497	46	s.	s.	PROPN
eurjchem-2641	497	47	;	;	PUNCT
eurjchem-2641	497	48	cuevas	cuevas	PROPN
eurjchem-2641	497	49	-	-	PUNCT
eurjchem-2641	497	50	diaz	diaz	PROPN
eurjchem-2641	497	51	duran	duran	PROPN
eurjchem-2641	497	52	,	,	PUNCT
eurjchem-2641	497	53	r.	r.	PROPN
eurjchem-2641	497	54	exploring	explore	VERB
eurjchem-2641	497	55	the	the	DET
eurjchem-2641	497	56	potential	potential	ADJ
eurjchem-2641	497	57	role	role	NOUN
eurjchem-2641	497	58	of	of	ADP
eurjchem-2641	497	59	circulating	circulate	VERB
eurjchem-2641	497	60	micrornas	microrna	NOUN
eurjchem-2641	497	61	as	as	ADP
eurjchem-2641	497	62	biomarkers	biomarker	NOUN
eurjchem-2641	497	63	for	for	ADP
eurjchem-2641	497	64	predicting	predict	VERB
eurjchem-2641	497	65	clinical	clinical	ADJ
eurjchem-2641	497	66	response	response	NOUN
eurjchem-2641	497	67	to	to	ADP
eurjchem-2641	497	68	neoadjuvant	neoadjuvant	ADJ
eurjchem-2641	497	69	therapy	therapy	NOUN
eurjchem-2641	497	70	in	in	ADP
eurjchem-2641	497	71	breast	breast	NOUN
eurjchem-2641	497	72	cancer	cancer	NOUN
eurjchem-2641	497	73	.	.	PUNCT
eurjchem-2641	498	1	ijms	ijms	PROPN
eurjchem-2641	498	2	.	.	PUNCT
eurjchem-2641	499	1	2023	2023	NUM
eurjchem-2641	499	2	,	,	PUNCT
eurjchem-2641	499	3	24	24	NUM
eurjchem-2641	499	4	(	(	PUNCT
eurjchem-2641	499	5	12	12	NUM
eurjchem-2641	499	6	)	)	PUNCT
eurjchem-2641	499	7	,	,	PUNCT
eurjchem-2641	499	8	9984	9984	NUM
eurjchem-2641	499	9	.	.	PUNCT
eurjchem-2641	500	1	[	[	X
eurjchem-2641	500	2	38	38	NUM
eurjchem-2641	500	3	]	]	PUNCT
eurjchem-2641	500	4	.	.	PUNCT
eurjchem-2641	501	1	adam	adam	PROPN
eurjchem-2641	501	2	-	-	PUNCT
eurjchem-2641	501	3	artigues	artigue	NOUN
eurjchem-2641	501	4	,	,	PUNCT
eurjchem-2641	501	5	a.	a.	NOUN
eurjchem-2641	501	6	;	;	PUNCT
eurjchem-2641	501	7	garrido	garrido	PROPN
eurjchem-2641	501	8	-	-	PUNCT
eurjchem-2641	501	9	cano	cano	PROPN
eurjchem-2641	501	10	,	,	PUNCT
eurjchem-2641	501	11	i.	i.	PROPN
eurjchem-2641	501	12	;	;	PUNCT
eurjchem-2641	501	13	carbonell	carbonell	NOUN
eurjchem-2641	501	14	-	-	PUNCT
eurjchem-2641	501	15	asins	asin	NOUN
eurjchem-2641	501	16	,	,	PUNCT
eurjchem-2641	501	17	j.	j.	PROPN
eurjchem-2641	501	18	a.	a.	PROPN
eurjchem-2641	501	19	;	;	PUNCT
eurjchem-2641	501	20	lameirinhas	lameirinhas	PROPN
eurjchem-2641	501	21	,	,	PUNCT
eurjchem-2641	501	22	a.	a.	NOUN
eurjchem-2641	501	23	;	;	PUNCT
eurjchem-2641	501	24	simón	simón	PROPN
eurjchem-2641	501	25	,	,	PUNCT
eurjchem-2641	501	26	s.	s.	PROPN
eurjchem-2641	501	27	;	;	PUNCT
eurjchem-2641	501	28	ortega	ortega	PROPN
eurjchem-2641	501	29	-	-	PUNCT
eurjchem-2641	501	30	morillo	morillo	PROPN
eurjchem-2641	501	31	,	,	PUNCT
eurjchem-2641	501	32	b.	b.	PROPN
eurjchem-2641	501	33	;	;	PUNCT
eurjchem-2641	501	34	martínez	martínez	PROPN
eurjchem-2641	501	35	,	,	PUNCT
eurjchem-2641	501	36	m.	m.	NOUN
eurjchem-2641	501	37	t.	t.	PROPN
eurjchem-2641	501	38	;	;	PUNCT
eurjchem-2641	501	39	hernando	hernando	PROPN
eurjchem-2641	501	40	,	,	PUNCT
eurjchem-2641	501	41	c.	c.	PROPN
eurjchem-2641	501	42	;	;	PUNCT
eurjchem-2641	501	43	constâncio	constâncio	PROPN
eurjchem-2641	501	44	,	,	PUNCT
eurjchem-2641	501	45	v.	v.	PROPN
eurjchem-2641	501	46	;	;	PUNCT
eurjchem-2641	501	47	burgues	burgue	NOUN
eurjchem-2641	501	48	,	,	PUNCT
eurjchem-2641	501	49	o.	o.	PROPN
eurjchem-2641	501	50	;	;	PUNCT
eurjchem-2641	501	51	bermejo	bermejo	PROPN
eurjchem-2641	501	52	,	,	PUNCT
eurjchem-2641	501	53	b.	b.	PROPN
eurjchem-2641	501	54	;	;	PUNCT
eurjchem-2641	501	55	henrique	henrique	PROPN
eurjchem-2641	501	56	,	,	PUNCT
eurjchem-2641	501	57	r.	r.	PROPN
eurjchem-2641	501	58	;	;	PUNCT
eurjchem-2641	501	59	lluch	lluch	PROPN
eurjchem-2641	501	60	,	,	PUNCT
eurjchem-2641	501	61	a.	a.	NOUN
eurjchem-2641	501	62	;	;	PUNCT
eurjchem-2641	501	63	jerónimo	jerónimo	PROPN
eurjchem-2641	501	64	,	,	PUNCT
eurjchem-2641	501	65	c.	c.	PROPN
eurjchem-2641	501	66	;	;	PUNCT
eurjchem-2641	501	67	eroles	erole	NOUN
eurjchem-2641	501	68	,	,	PUNCT
eurjchem-2641	501	69	p.	p.	NOUN
eurjchem-2641	501	70	;	;	PUNCT
eurjchem-2641	501	71	cejalvo	cejalvo	PROPN
eurjchem-2641	501	72	,	,	PUNCT
eurjchem-2641	501	73	j.	j.	PROPN
eurjchem-2641	501	74	m.	m.	PROPN
eurjchem-2641	501	75	identification	identification	NOUN
eurjchem-2641	501	76	of	of	ADP
eurjchem-2641	501	77	a	a	DET
eurjchem-2641	501	78	twomicrorna	twomicrorna	NOUN
eurjchem-2641	501	79	signature	signature	NOUN
eurjchem-2641	501	80	in	in	ADP
eurjchem-2641	501	81	plasma	plasma	NOUN
eurjchem-2641	501	82	as	as	ADP
eurjchem-2641	501	83	a	a	DET
eurjchem-2641	501	84	novel	novel	NOUN
eurjchem-2641	501	85	biomarker	biomarker	NOUN
eurjchem-2641	501	86	for	for	ADP
eurjchem-2641	501	87	very	very	ADV
eurjchem-2641	501	88	early	early	ADJ
eurjchem-2641	501	89	diagnosis	diagnosis	NOUN
eurjchem-2641	501	90	of	of	ADP
eurjchem-2641	501	91	breast	breast	NOUN
eurjchem-2641	501	92	cancer	cancer	NOUN
eurjchem-2641	501	93	.	.	PUNCT
eurjchem-2641	502	1	cancers	cancer	NOUN
eurjchem-2641	502	2	2021	2021	NUM
eurjchem-2641	502	3	,	,	PUNCT
eurjchem-2641	502	4	13	13	NUM
eurjchem-2641	502	5	(	(	PUNCT
eurjchem-2641	502	6	11	11	NUM
eurjchem-2641	502	7	)	)	PUNCT
eurjchem-2641	502	8	,	,	PUNCT
eurjchem-2641	502	9	2848	2848	NUM
eurjchem-2641	502	10	.	.	PUNCT
eurjchem-2641	503	1	[	[	X
eurjchem-2641	503	2	39	39	NUM
eurjchem-2641	503	3	]	]	PUNCT
eurjchem-2641	503	4	.	.	PUNCT
eurjchem-2641	504	1	he	he	PRON
eurjchem-2641	504	2	,	,	PUNCT
eurjchem-2641	504	3	y.	y.	PROPN
eurjchem-2641	504	4	;	;	PUNCT
eurjchem-2641	504	5	deng	deng	PROPN
eurjchem-2641	504	6	,	,	PUNCT
eurjchem-2641	504	7	f.	f.	PROPN
eurjchem-2641	504	8	;	;	PUNCT
eurjchem-2641	504	9	yang	yang	PROPN
eurjchem-2641	504	10	,	,	PUNCT
eurjchem-2641	504	11	s.	s.	PROPN
eurjchem-2641	504	12	;	;	PUNCT
eurjchem-2641	504	13	wang	wang	PROPN
eurjchem-2641	504	14	,	,	PUNCT
eurjchem-2641	504	15	d.	d.	PROPN
eurjchem-2641	504	16	;	;	PUNCT
eurjchem-2641	504	17	chen	chen	PROPN
eurjchem-2641	504	18	,	,	PUNCT
eurjchem-2641	504	19	x.	x.	PROPN
eurjchem-2641	504	20	;	;	PUNCT
eurjchem-2641	504	21	zhong	zhong	PROPN
eurjchem-2641	504	22	,	,	PUNCT
eurjchem-2641	504	23	s.	s.	PROPN
eurjchem-2641	504	24	;	;	PUNCT
eurjchem-2641	504	25	zhao	zhao	PROPN
eurjchem-2641	504	26	,	,	PUNCT
eurjchem-2641	504	27	j.	j.	PROPN
eurjchem-2641	504	28	;	;	PUNCT
eurjchem-2641	504	29	tang	tang	PROPN
eurjchem-2641	504	30	,	,	PUNCT
eurjchem-2641	504	31	j.	j.	PROPN
eurjchem-2641	504	32	exosomal	exosomal	PROPN
eurjchem-2641	504	33	microrna	microrna	PROPN
eurjchem-2641	504	34	:	:	PUNCT
eurjchem-2641	504	35	a	a	DET
eurjchem-2641	504	36	novel	novel	NOUN
eurjchem-2641	504	37	biomarker	biomarker	NOUN
eurjchem-2641	504	38	for	for	ADP
eurjchem-2641	504	39	breast	breast	NOUN
eurjchem-2641	504	40	cancer	cancer	NOUN
eurjchem-2641	504	41	.	.	PUNCT
eurjchem-2641	505	1	biomark	biomark	PROPN
eurjchem-2641	505	2	.	.	PUNCT
eurjchem-2641	506	1	med	med	PROPN
eurjchem-2641	506	2	.	.	PROPN
eurjchem-2641	507	1	2017	2017	NUM
eurjchem-2641	507	2	,	,	PUNCT
eurjchem-2641	507	3	12	12	NUM
eurjchem-2641	507	4	(	(	PUNCT
eurjchem-2641	507	5	2	2	NUM
eurjchem-2641	507	6	)	)	PUNCT
eurjchem-2641	507	7	,	,	PUNCT
eurjchem-2641	507	8	177–188	177–188	NUM
eurjchem-2641	507	9	.	.	PUNCT
eurjchem-2641	508	1	[	[	X
eurjchem-2641	508	2	40	40	NUM
eurjchem-2641	508	3	]	]	PUNCT
eurjchem-2641	508	4	.	.	PUNCT
eurjchem-2641	509	1	zubor	zubor	PROPN
eurjchem-2641	509	2	,	,	PUNCT
eurjchem-2641	509	3	p.	p.	PROPN
eurjchem-2641	509	4	;	;	PUNCT
eurjchem-2641	509	5	kubatka	kubatka	PROPN
eurjchem-2641	509	6	,	,	PUNCT
eurjchem-2641	509	7	p.	p.	PROPN
eurjchem-2641	509	8	;	;	PUNCT
eurjchem-2641	509	9	kajo	kajo	PROPN
eurjchem-2641	509	10	,	,	PUNCT
eurjchem-2641	509	11	k.	k.	PROPN
eurjchem-2641	509	12	;	;	PUNCT
eurjchem-2641	509	13	dankova	dankova	PROPN
eurjchem-2641	509	14	,	,	PUNCT
eurjchem-2641	509	15	z.	z.	PROPN
eurjchem-2641	509	16	;	;	PUNCT
eurjchem-2641	509	17	polacek	polacek	PROPN
eurjchem-2641	509	18	,	,	PUNCT
eurjchem-2641	509	19	h.	h.	PROPN
eurjchem-2641	509	20	;	;	PUNCT
eurjchem-2641	509	21	bielik	bielik	PROPN
eurjchem-2641	509	22	,	,	PUNCT
eurjchem-2641	509	23	t.	t.	PROPN
eurjchem-2641	509	24	;	;	PUNCT
eurjchem-2641	509	25	kudela	kudela	PROPN
eurjchem-2641	509	26	,	,	PUNCT
eurjchem-2641	509	27	e.	e.	PROPN
eurjchem-2641	509	28	;	;	PUNCT
eurjchem-2641	509	29	samec	samec	PROPN
eurjchem-2641	509	30	,	,	PUNCT
eurjchem-2641	509	31	m.	m.	NOUN
eurjchem-2641	509	32	;	;	PUNCT
eurjchem-2641	509	33	liskova	liskova	PROPN
eurjchem-2641	509	34	,	,	PUNCT
eurjchem-2641	509	35	a.	a.	NOUN
eurjchem-2641	509	36	;	;	PUNCT
eurjchem-2641	509	37	vlcakova	vlcakova	NUM
eurjchem-2641	509	38	,	,	PUNCT
eurjchem-2641	509	39	d.	d.	PROPN
eurjchem-2641	509	40	;	;	PUNCT
eurjchem-2641	509	41	kulkovska	kulkovska	PROPN
eurjchem-2641	509	42	,	,	PUNCT
eurjchem-2641	509	43	t.	t.	PROPN
eurjchem-2641	509	44	;	;	PUNCT
eurjchem-2641	509	45	stastny	stastny	PROPN
eurjchem-2641	509	46	,	,	PUNCT
eurjchem-2641	509	47	i.	i.	PROPN
eurjchem-2641	509	48	;	;	PUNCT
eurjchem-2641	509	49	holubekova	holubekova	PROPN
eurjchem-2641	509	50	,	,	PUNCT
eurjchem-2641	509	51	v.	v.	ADV
eurjchem-2641	509	52	;	;	PUNCT
eurjchem-2641	509	53	bujnak	bujnak	PROPN
eurjchem-2641	509	54	,	,	PUNCT
eurjchem-2641	509	55	j.	j.	PROPN
eurjchem-2641	509	56	;	;	PUNCT
eurjchem-2641	509	57	laucekova	laucekova	PROPN
eurjchem-2641	509	58	,	,	PUNCT
eurjchem-2641	509	59	z.	z.	PROPN
eurjchem-2641	509	60	;	;	PUNCT
eurjchem-2641	509	61	büsselberg	büsselberg	PROPN
eurjchem-2641	509	62	,	,	PUNCT
eurjchem-2641	509	63	d.	d.	PROPN
eurjchem-2641	509	64	;	;	PUNCT
eurjchem-2641	509	65	adamek	adamek	PROPN
eurjchem-2641	509	66	,	,	PUNCT
eurjchem-2641	509	67	m.	m.	NOUN
eurjchem-2641	509	68	;	;	PUNCT
eurjchem-2641	509	69	kuhn	kuhn	PROPN
eurjchem-2641	509	70	,	,	PUNCT
eurjchem-2641	509	71	w.	w.	PROPN
eurjchem-2641	509	72	;	;	PUNCT
eurjchem-2641	509	73	danko	danko	PROPN
eurjchem-2641	509	74	,	,	PUNCT
eurjchem-2641	509	75	j.	j.	PROPN
eurjchem-2641	509	76	;	;	PUNCT
eurjchem-2641	509	77	golubnitschaja	golubnitschaja	PROPN
eurjchem-2641	509	78	,	,	PUNCT
eurjchem-2641	509	79	o.	o.	VERB
eurjchem-2641	509	80	why	why	SCONJ
eurjchem-2641	509	81	the	the	DET
eurjchem-2641	509	82	gold	gold	ADJ
eurjchem-2641	509	83	standard	standard	ADJ
eurjchem-2641	509	84	approach	approach	NOUN
eurjchem-2641	509	85	by	by	ADP
eurjchem-2641	509	86	mammography	mammography	NOUN
eurjchem-2641	509	87	demands	demand	NOUN
eurjchem-2641	509	88	extension	extension	NOUN
eurjchem-2641	509	89	by	by	ADP
eurjchem-2641	509	90	multiomics	multiomic	NOUN
eurjchem-2641	509	91	?	?	PUNCT
eurjchem-2641	510	1	application	application	NOUN
eurjchem-2641	510	2	of	of	ADP
eurjchem-2641	510	3	liquid	liquid	ADJ
eurjchem-2641	510	4	biopsy	biopsy	NOUN
eurjchem-2641	510	5	mirna	mirna	PROPN
eurjchem-2641	510	6	profiles	profile	NOUN
eurjchem-2641	510	7	to	to	ADP
eurjchem-2641	510	8	breast	breast	NOUN
eurjchem-2641	510	9	cancer	cancer	NOUN
eurjchem-2641	510	10	disease	disease	NOUN
eurjchem-2641	510	11	management	management	NOUN
eurjchem-2641	510	12	.	.	PUNCT
eurjchem-2641	511	1	ijms	ijms	PROPN
eurjchem-2641	511	2	.	.	PROPN
eurjchem-2641	512	1	2019	2019	NUM
eurjchem-2641	512	2	,	,	PUNCT
eurjchem-2641	512	3	20	20	NUM
eurjchem-2641	512	4	(	(	PUNCT
eurjchem-2641	512	5	12	12	NUM
eurjchem-2641	512	6	)	)	PUNCT
eurjchem-2641	512	7	,	,	PUNCT
eurjchem-2641	512	8	2878	2878	NUM
eurjchem-2641	512	9	.	.	PUNCT
eurjchem-2641	513	1	[	[	X
eurjchem-2641	513	2	41	41	NUM
eurjchem-2641	513	3	]	]	PUNCT
eurjchem-2641	513	4	.	.	PUNCT
eurjchem-2641	514	1	dorraki	dorraki	PROPN
eurjchem-2641	514	2	,	,	PUNCT
eurjchem-2641	514	3	n.	n.	NOUN
eurjchem-2641	514	4	;	;	PUNCT
eurjchem-2641	514	5	ghale	ghale	NOUN
eurjchem-2641	514	6	-	-	PUNCT
eurjchem-2641	514	7	noie	noie	ADJ
eurjchem-2641	514	8	,	,	PUNCT
eurjchem-2641	514	9	z.	z.	PROPN
eurjchem-2641	514	10	n.	n.	PROPN
eurjchem-2641	514	11	;	;	PUNCT
eurjchem-2641	514	12	ahmadi	ahmadi	PROPN
eurjchem-2641	514	13	,	,	PUNCT
eurjchem-2641	514	14	n.	n.	PROPN
eurjchem-2641	514	15	s.	s.	PROPN
eurjchem-2641	514	16	;	;	PUNCT
eurjchem-2641	514	17	keyvani	keyvani	PROPN
eurjchem-2641	514	18	,	,	PUNCT
eurjchem-2641	514	19	v.	v.	PROPN
eurjchem-2641	514	20	;	;	PUNCT
eurjchem-2641	514	21	bahadori	bahadori	PROPN
eurjchem-2641	514	22	,	,	PUNCT
eurjchem-2641	514	23	r.	r.	PROPN
eurjchem-2641	514	24	a.	a.	PROPN
eurjchem-2641	514	25	;	;	PUNCT
eurjchem-2641	514	26	nejad	nejad	PROPN
eurjchem-2641	514	27	,	,	PUNCT
eurjchem-2641	514	28	a.	a.	PROPN
eurjchem-2641	514	29	s.	s.	PROPN
eurjchem-2641	514	30	;	;	PUNCT
eurjchem-2641	514	31	aschner	aschner	NOUN
eurjchem-2641	514	32	,	,	PUNCT
eurjchem-2641	514	33	m.	m.	NOUN
eurjchem-2641	514	34	;	;	PUNCT
eurjchem-2641	514	35	pourghadamyari	pourghadamyari	INTJ
eurjchem-2641	514	36	,	,	PUNCT
eurjchem-2641	514	37	h.	h.	PROPN
eurjchem-2641	514	38	;	;	PUNCT
eurjchem-2641	514	39	mollazadeh	mollazadeh	PROPN
eurjchem-2641	514	40	,	,	PUNCT
eurjchem-2641	514	41	s.	s.	PROPN
eurjchem-2641	514	42	;	;	PUNCT
eurjchem-2641	514	43	mirzaei	mirzaei	PROPN
eurjchem-2641	514	44	,	,	PUNCT
eurjchem-2641	514	45	h.	h.	PROPN
eurjchem-2641	514	46	mirna-148b	mirna-148b	PROPN
eurjchem-2641	514	47	and	and	CCONJ
eurjchem-2641	514	48	its	its	PRON
eurjchem-2641	514	49	role	role	NOUN
eurjchem-2641	514	50	in	in	ADP
eurjchem-2641	514	51	various	various	ADJ
eurjchem-2641	514	52	cancers	cancer	NOUN
eurjchem-2641	514	53	.	.	PUNCT
eurjchem-2641	515	1	epigenomics	epigenomic	NOUN
eurjchem-2641	515	2	2021	2021	NUM
eurjchem-2641	515	3	,	,	PUNCT
eurjchem-2641	515	4	13	13	NUM
eurjchem-2641	515	5	(	(	PUNCT
eurjchem-2641	515	6	24	24	NUM
eurjchem-2641	515	7	)	)	PUNCT
eurjchem-2641	515	8	,	,	PUNCT
eurjchem-2641	515	9	1939–1960	1939–1960	NUM
eurjchem-2641	515	10	.	.	PUNCT
eurjchem-2641	516	1	[	[	X
eurjchem-2641	516	2	42	42	NUM
eurjchem-2641	516	3	]	]	PUNCT
eurjchem-2641	516	4	.	.	PUNCT
eurjchem-2641	517	1	cuk	cuk	PROPN
eurjchem-2641	517	2	,	,	PUNCT
eurjchem-2641	517	3	k.	k.	PROPN
eurjchem-2641	517	4	;	;	PUNCT
eurjchem-2641	517	5	zucknick	zucknick	NOUN
eurjchem-2641	517	6	,	,	PUNCT
eurjchem-2641	517	7	m.	m.	NOUN
eurjchem-2641	517	8	;	;	PUNCT
eurjchem-2641	517	9	heil	heil	X
eurjchem-2641	517	10	,	,	PUNCT
eurjchem-2641	517	11	j.	j.	PROPN
eurjchem-2641	517	12	;	;	PUNCT
eurjchem-2641	517	13	madhavan	madhavan	PROPN
eurjchem-2641	517	14	,	,	PUNCT
eurjchem-2641	517	15	d.	d.	PROPN
eurjchem-2641	517	16	;	;	PUNCT
eurjchem-2641	517	17	schott	schott	PROPN
eurjchem-2641	517	18	,	,	PUNCT
eurjchem-2641	517	19	s.	s.	PROPN
eurjchem-2641	517	20	;	;	PUNCT
eurjchem-2641	517	21	turchinovich	turchinovich	PROPN
eurjchem-2641	517	22	,	,	PUNCT
eurjchem-2641	517	23	a.	a.	NOUN
eurjchem-2641	517	24	;	;	PUNCT
eurjchem-2641	517	25	arlt	arlt	NOUN
eurjchem-2641	517	26	,	,	PUNCT
eurjchem-2641	517	27	d.	d.	PROPN
eurjchem-2641	517	28	;	;	PUNCT
eurjchem-2641	517	29	rath	rath	PROPN
eurjchem-2641	517	30	,	,	PUNCT
eurjchem-2641	517	31	m.	m.	NOUN
eurjchem-2641	517	32	;	;	PUNCT
eurjchem-2641	517	33	sohn	sohn	PROPN
eurjchem-2641	517	34	,	,	PUNCT
eurjchem-2641	517	35	c.	c.	PROPN
eurjchem-2641	517	36	;	;	PUNCT
eurjchem-2641	517	37	benner	benner	PROPN
eurjchem-2641	517	38	,	,	PUNCT
eurjchem-2641	517	39	a.	a.	NOUN
eurjchem-2641	517	40	;	;	PUNCT
eurjchem-2641	517	41	junkermann	junkermann	PROPN
eurjchem-2641	517	42	,	,	PUNCT
eurjchem-2641	517	43	h.	h.	PROPN
eurjchem-2641	517	44	;	;	PUNCT
eurjchem-2641	517	45	schneeweiss	schneeweiss	PROPN
eurjchem-2641	517	46	,	,	PUNCT
eurjchem-2641	517	47	a.	a.	NOUN
eurjchem-2641	517	48	;	;	PUNCT
eurjchem-2641	517	49	burwinkel	burwinkel	NOUN
eurjchem-2641	517	50	,	,	PUNCT
eurjchem-2641	517	51	b.	b.	PROPN
eurjchem-2641	517	52	circulating	circulate	VERB
eurjchem-2641	517	53	micrornas	microrna	NOUN
eurjchem-2641	517	54	in	in	ADP
eurjchem-2641	517	55	plasma	plasma	NOUN
eurjchem-2641	517	56	as	as	ADP
eurjchem-2641	517	57	early	early	ADJ
eurjchem-2641	517	58	detection	detection	NOUN
eurjchem-2641	517	59	markers	marker	NOUN
eurjchem-2641	517	60	for	for	ADP
eurjchem-2641	517	61	breast	breast	NOUN
eurjchem-2641	517	62	cancer	cancer	NOUN
eurjchem-2641	517	63	.	.	PUNCT
eurjchem-2641	518	1	intl	intl	PROPN
eurjchem-2641	518	2	.	.	PUNCT
eurjchem-2641	519	1	journal	journal	PROPN
eurjchem-2641	519	2	of	of	ADP
eurjchem-2641	519	3	cancer	cancer	NOUN
eurjchem-2641	519	4	2012	2012	NUM
eurjchem-2641	519	5	,	,	PUNCT
eurjchem-2641	519	6	132	132	NUM
eurjchem-2641	519	7	(	(	PUNCT
eurjchem-2641	519	8	7	7	NUM
eurjchem-2641	519	9	)	)	PUNCT
eurjchem-2641	519	10	,	,	PUNCT
eurjchem-2641	519	11	1602	1602	NUM
eurjchem-2641	519	12	–	–	PUNCT
eurjchem-2641	519	13	1612	1612	NUM
eurjchem-2641	519	14	.	.	PUNCT
eurjchem-2641	520	1	[	[	X
eurjchem-2641	520	2	43	43	NUM
eurjchem-2641	520	3	]	]	PUNCT
eurjchem-2641	520	4	.	.	PUNCT
eurjchem-2641	521	1	nassar	nassar	PROPN
eurjchem-2641	521	2	,	,	PUNCT
eurjchem-2641	521	3	f.	f.	PROPN
eurjchem-2641	521	4	j.	j.	PROPN
eurjchem-2641	521	5	;	;	PUNCT
eurjchem-2641	521	6	el	el	PROPN
eurjchem-2641	521	7	sabban	sabban	PROPN
eurjchem-2641	521	8	,	,	PUNCT
eurjchem-2641	521	9	m.	m.	NOUN
eurjchem-2641	521	10	;	;	PUNCT
eurjchem-2641	521	11	zgheib	zgheib	NOUN
eurjchem-2641	521	12	,	,	PUNCT
eurjchem-2641	521	13	n.	n.	PROPN
eurjchem-2641	521	14	k.	k.	PROPN
eurjchem-2641	521	15	;	;	PUNCT
eurjchem-2641	521	16	tfayli	tfayli	NOUN
eurjchem-2641	521	17	,	,	PUNCT
eurjchem-2641	521	18	a.	a.	NOUN
eurjchem-2641	521	19	;	;	PUNCT
eurjchem-2641	521	20	boulos	boulo	NOUN
eurjchem-2641	521	21	,	,	PUNCT
eurjchem-2641	521	22	f.	f.	PROPN
eurjchem-2641	521	23	;	;	PUNCT
eurjchem-2641	521	24	jabbour	jabbour	NOUN
eurjchem-2641	521	25	,	,	PUNCT
eurjchem-2641	521	26	m.	m.	NOUN
eurjchem-2641	521	27	;	;	PUNCT
eurjchem-2641	521	28	saghir	saghir	PROPN
eurjchem-2641	521	29	,	,	PUNCT
eurjchem-2641	521	30	n.	n.	PROPN
eurjchem-2641	521	31	s.	s.	PROPN
eurjchem-2641	521	32	;	;	PUNCT
eurjchem-2641	521	33	talhouk	talhouk	PROPN
eurjchem-2641	521	34	,	,	PUNCT
eurjchem-2641	521	35	r.	r.	PROPN
eurjchem-2641	521	36	;	;	PUNCT
eurjchem-2641	521	37	bazarbachi	bazarbachi	PROPN
eurjchem-2641	521	38	,	,	PUNCT
eurjchem-2641	521	39	a.	a.	NOUN
eurjchem-2641	521	40	;	;	PUNCT
eurjchem-2641	521	41	calin	calin	PROPN
eurjchem-2641	521	42	,	,	PUNCT
eurjchem-2641	521	43	g.	g.	PROPN
eurjchem-2641	521	44	a.	a.	PROPN
eurjchem-2641	521	45	;	;	PUNCT
eurjchem-2641	521	46	nasr	nasr	PROPN
eurjchem-2641	521	47	,	,	PUNCT
eurjchem-2641	521	48	r.	r.	PROPN
eurjchem-2641	521	49	mirna	mirna	PROPN
eurjchem-2641	521	50	as	as	ADP
eurjchem-2641	521	51	potential	potential	ADJ
eurjchem-2641	521	52	biomarkers	biomarker	NOUN
eurjchem-2641	521	53	of	of	ADP
eurjchem-2641	521	54	breast	breast	NOUN
eurjchem-2641	521	55	cancer	cancer	NOUN
eurjchem-2641	521	56	in	in	ADP
eurjchem-2641	521	57	the	the	DET
eurjchem-2641	521	58	lebanese	lebanese	ADJ
eurjchem-2641	521	59	population	population	NOUN
eurjchem-2641	521	60	and	and	CCONJ
eurjchem-2641	521	61	in	in	ADP
eurjchem-2641	521	62	young	young	ADJ
eurjchem-2641	521	63	women	woman	NOUN
eurjchem-2641	521	64	:	:	PUNCT
eurjchem-2641	521	65	a	a	DET
eurjchem-2641	521	66	pilot	pilot	NOUN
eurjchem-2641	521	67	study	study	NOUN
eurjchem-2641	521	68	.	.	PUNCT
eurjchem-2641	522	1	plos	plos	PROPN
eurjchem-2641	522	2	one	one	NUM
eurjchem-2641	522	3	2014	2014	NUM
eurjchem-2641	522	4	,	,	PUNCT
eurjchem-2641	522	5	9	9	NUM
eurjchem-2641	522	6	(	(	PUNCT
eurjchem-2641	522	7	9	9	NUM
eurjchem-2641	522	8	)	)	PUNCT
eurjchem-2641	522	9	,	,	PUNCT
eurjchem-2641	522	10	e107566	e107566	PROPN
eurjchem-2641	522	11	.	.	PUNCT
eurjchem-2641	523	1	[	[	X
eurjchem-2641	523	2	44	44	NUM
eurjchem-2641	523	3	]	]	PUNCT
eurjchem-2641	523	4	.	.	PUNCT
eurjchem-2641	524	1	sun	sun	PROPN
eurjchem-2641	524	2	,	,	PUNCT
eurjchem-2641	524	3	r.	r.	PROPN
eurjchem-2641	524	4	;	;	PUNCT
eurjchem-2641	524	5	guo	guo	PROPN
eurjchem-2641	524	6	,	,	PUNCT
eurjchem-2641	524	7	m.	m.	NOUN
eurjchem-2641	524	8	;	;	PUNCT
eurjchem-2641	524	9	fan	fan	PROPN
eurjchem-2641	524	10	,	,	PUNCT
eurjchem-2641	524	11	x.	x.	PROPN
eurjchem-2641	524	12	;	;	PUNCT
eurjchem-2641	524	13	meng	meng	PROPN
eurjchem-2641	524	14	,	,	PUNCT
eurjchem-2641	524	15	q.	q.	PROPN
eurjchem-2641	524	16	;	;	PUNCT
eurjchem-2641	524	17	yuan	yuan	PROPN
eurjchem-2641	524	18	,	,	PUNCT
eurjchem-2641	524	19	d.	d.	PROPN
eurjchem-2641	524	20	;	;	PUNCT
eurjchem-2641	524	21	yang	yang	PROPN
eurjchem-2641	524	22	,	,	PUNCT
eurjchem-2641	524	23	x.	x.	PROPN
eurjchem-2641	524	24	;	;	PUNCT
eurjchem-2641	524	25	yan	yan	PROPN
eurjchem-2641	524	26	,	,	PUNCT
eurjchem-2641	524	27	k.	k.	PROPN
eurjchem-2641	524	28	;	;	PUNCT
eurjchem-2641	524	29	deng	deng	PROPN
eurjchem-2641	524	30	,	,	PUNCT
eurjchem-2641	524	31	h.	h.	PROPN
eurjchem-2641	524	32	microrna-148b	microrna-148b	PROPN
eurjchem-2641	524	33	inhibits	inhibit	VERB
eurjchem-2641	524	34	the	the	DET
eurjchem-2641	524	35	malignant	malignant	ADJ
eurjchem-2641	524	36	biological	biological	ADJ
eurjchem-2641	524	37	behavior	behavior	NOUN
eurjchem-2641	524	38	of	of	ADP
eurjchem-2641	524	39	melanoma	melanoma	NOUN
eurjchem-2641	524	40	by	by	ADP
eurjchem-2641	524	41	reducing	reduce	VERB
eurjchem-2641	524	42	sirtuin	sirtuin	NOUN
eurjchem-2641	524	43	7	7	NUM
eurjchem-2641	524	44	expression	expression	NOUN
eurjchem-2641	524	45	levels	level	NOUN
eurjchem-2641	524	46	.	.	PUNCT
eurjchem-2641	525	1	biomed	biome	VERB
eurjchem-2641	525	2	res	re	NOUN
eurjchem-2641	525	3	.	.	PUNCT
eurjchem-2641	526	1	int	int	NOUN
eurjchem-2641	526	2	.	.	PUNCT
eurjchem-2641	527	1	2020	2020	NUM
eurjchem-2641	527	2	,	,	PUNCT
eurjchem-2641	527	3	2020	2020	NUM
eurjchem-2641	527	4	(	(	PUNCT
eurjchem-2641	527	5	1	1	NUM
eurjchem-2641	527	6	)	)	PUNCT
eurjchem-2641	527	7	,	,	PUNCT
eurjchem-2641	527	8	https://doi.org/10.1155/2020/9568976	https://doi.org/10.1155/2020/9568976	NOUN
eurjchem-2641	527	9	.	.	PUNCT
eurjchem-2641	528	1	[	[	X
eurjchem-2641	528	2	45	45	NUM
eurjchem-2641	528	3	]	]	PUNCT
eurjchem-2641	528	4	.	.	PUNCT
eurjchem-2641	529	1	pluta	pluta	ADJ
eurjchem-2641	529	2	,	,	PUNCT
eurjchem-2641	529	3	p.	p.	NOUN
eurjchem-2641	529	4	;	;	PUNCT
eurjchem-2641	529	5	smolewski	smolewski	NOUN
eurjchem-2641	529	6	,	,	PUNCT
eurjchem-2641	529	7	p.	p.	NOUN
eurjchem-2641	529	8	;	;	PUNCT
eurjchem-2641	529	9	pluta	pluta	ADV
eurjchem-2641	529	10	,	,	PUNCT
eurjchem-2641	529	11	a.	a.	NOUN
eurjchem-2641	529	12	;	;	PUNCT
eurjchem-2641	529	13	cebula	cebula	NOUN
eurjchem-2641	529	14	-	-	PUNCT
eurjchem-2641	529	15	obrzut	obrzut	NOUN
eurjchem-2641	529	16	,	,	PUNCT
eurjchem-2641	529	17	b.	b.	PROPN
eurjchem-2641	529	18	;	;	PUNCT
eurjchem-2641	529	19	wierzbowska	wierzbowska	PROPN
eurjchem-2641	529	20	,	,	PUNCT
eurjchem-2641	529	21	a.	a.	NOUN
eurjchem-2641	529	22	;	;	PUNCT
eurjchem-2641	529	23	nejc	nejc	PROPN
eurjchem-2641	529	24	,	,	PUNCT
eurjchem-2641	529	25	d.	d.	PROPN
eurjchem-2641	529	26	;	;	PUNCT
eurjchem-2641	529	27	robak	robak	NOUN
eurjchem-2641	529	28	,	,	PUNCT
eurjchem-2641	529	29	t.	t.	PROPN
eurjchem-2641	529	30	;	;	PUNCT
eurjchem-2641	529	31	kordek	kordek	PROPN
eurjchem-2641	529	32	,	,	PUNCT
eurjchem-2641	529	33	r.	r.	PROPN
eurjchem-2641	529	34	;	;	PUNCT
eurjchem-2641	529	35	gottwald	gottwald	PROPN
eurjchem-2641	529	36	,	,	PUNCT
eurjchem-2641	529	37	l.	l.	PROPN
eurjchem-2641	529	38	;	;	PUNCT
eurjchem-2641	529	39	piekarski	piekarski	PROPN
eurjchem-2641	529	40	,	,	PUNCT
eurjchem-2641	529	41	j.	j.	PROPN
eurjchem-2641	529	42	;	;	PUNCT
eurjchem-2641	529	43	jeziorski	jeziorski	PROPN
eurjchem-2641	529	44	,	,	PUNCT
eurjchem-2641	529	45	a.	a.	NOUN
eurjchem-2641	529	46	significance	significance	NOUN
eurjchem-2641	529	47	of	of	ADP
eurjchem-2641	529	48	bax	bax	NOUN
eurjchem-2641	529	49	expression	expression	NOUN
eurjchem-2641	529	50	in	in	ADP
eurjchem-2641	529	51	breast	breast	NOUN
eurjchem-2641	529	52	cancer	cancer	NOUN
eurjchem-2641	529	53	patients	patient	NOUN
eurjchem-2641	529	54	.	.	PUNCT
eurjchem-2641	530	1	pol	pol	PROPN
eurjchem-2641	530	2	.	.	PUNCT
eurjchem-2641	531	1	j.	j.	PROPN
eurjchem-2641	531	2	surg	surg	PROPN
eurjchem-2641	531	3	.	.	PUNCT
eurjchem-2641	532	1	2011	2011	NUM
eurjchem-2641	532	2	,	,	PUNCT
eurjchem-2641	532	3	83	83	NUM
eurjchem-2641	532	4	(	(	PUNCT
eurjchem-2641	532	5	10	10	NUM
eurjchem-2641	532	6	)	)	PUNCT
eurjchem-2641	532	7	,	,	PUNCT
eurjchem-2641	532	8	549–553	549–553	NUM
eurjchem-2641	532	9	https://doi.org/10.2478/v10035–011	https://doi.org/10.2478/v10035–011	NOUN
eurjchem-2641	532	10	–	–	PUNCT
eurjchem-2641	532	11	0087–4	0087–4	X
eurjchem-2641	532	12	.	.	PUNCT
eurjchem-2641	533	1	[	[	X
eurjchem-2641	533	2	46	46	NUM
eurjchem-2641	533	3	]	]	PUNCT
eurjchem-2641	533	4	.	.	PUNCT
eurjchem-2641	534	1	kallel	kallel	ADJ
eurjchem-2641	534	2	-	-	PUNCT
eurjchem-2641	534	3	bayoudh	bayoudh	NOUN
eurjchem-2641	534	4	,	,	PUNCT
eurjchem-2641	534	5	i.	i.	NOUN
eurjchem-2641	534	6	;	;	PUNCT
eurjchem-2641	534	7	hassen	hassen	PROPN
eurjchem-2641	534	8	,	,	PUNCT
eurjchem-2641	534	9	h.	h.	PROPN
eurjchem-2641	534	10	b.	b.	PROPN
eurjchem-2641	534	11	;	;	PUNCT
eurjchem-2641	534	12	khabir	khabir	PROPN
eurjchem-2641	534	13	,	,	PUNCT
eurjchem-2641	534	14	a.	a.	NOUN
eurjchem-2641	534	15	;	;	PUNCT
eurjchem-2641	534	16	boujelbene	boujelbene	NOUN
eurjchem-2641	534	17	,	,	PUNCT
eurjchem-2641	534	18	n.	n.	PROPN
eurjchem-2641	534	19	;	;	PUNCT
eurjchem-2641	534	20	daoud	daoud	PROPN
eurjchem-2641	534	21	,	,	PUNCT
eurjchem-2641	534	22	j.	j.	PROPN
eurjchem-2641	534	23	;	;	PUNCT
eurjchem-2641	534	24	frikha	frikha	ADJ
eurjchem-2641	534	25	,	,	PUNCT
eurjchem-2641	534	26	m.	m.	NOUN
eurjchem-2641	534	27	;	;	PUNCT
eurjchem-2641	534	28	sallemi	sallemi	NOUN
eurjchem-2641	534	29	-	-	PUNCT
eurjchem-2641	534	30	boudawara	boudawara	NOUN
eurjchem-2641	534	31	,	,	PUNCT
eurjchem-2641	534	32	t.	t.	PROPN
eurjchem-2641	534	33	;	;	PUNCT
eurjchem-2641	534	34	aifa	aifa	PROPN
eurjchem-2641	534	35	,	,	PUNCT
eurjchem-2641	534	36	s.	s.	PROPN
eurjchem-2641	534	37	;	;	PUNCT
eurjchem-2641	534	38	rebaï	rebaï	PROPN
eurjchem-2641	534	39	,	,	PUNCT
eurjchem-2641	534	40	a.	a.	NOUN
eurjchem-2641	534	41	bcl-2	bcl-2	PUNCT
eurjchem-2641	534	42	expression	expression	NOUN
eurjchem-2641	534	43	and	and	CCONJ
eurjchem-2641	534	44	triple	triple	ADJ
eurjchem-2641	534	45	negative	negative	ADJ
eurjchem-2641	534	46	profile	profile	NOUN
eurjchem-2641	534	47	in	in	ADP
eurjchem-2641	534	48	breast	breast	NOUN
eurjchem-2641	534	49	carcinoma	carcinoma	NOUN
eurjchem-2641	534	50	.	.	PUNCT
eurjchem-2641	535	1	med	med	ADJ
eurjchem-2641	535	2	.	.	PUNCT
eurjchem-2641	535	3	oncol	oncol	PROPN
eurjchem-2641	535	4	.	.	PUNCT
eurjchem-2641	536	1	2010	2010	NUM
eurjchem-2641	536	2	,	,	PUNCT
eurjchem-2641	536	3	28	28	NUM
eurjchem-2641	536	4	(	(	PUNCT
eurjchem-2641	536	5	s1	s1	NOUN
eurjchem-2641	536	6	)	)	PUNCT
eurjchem-2641	536	7	,	,	PUNCT
eurjchem-2641	536	8	55–61	55–61	NUM
eurjchem-2641	536	9	.	.	PUNCT
eurjchem-2641	537	1	[	[	X
eurjchem-2641	537	2	47	47	NUM
eurjchem-2641	537	3	]	]	PUNCT
eurjchem-2641	537	4	.	.	PUNCT
eurjchem-2641	538	1	lee	lee	PROPN
eurjchem-2641	538	2	,	,	PUNCT
eurjchem-2641	538	3	k.	k.	PROPN
eurjchem-2641	538	4	;	;	PUNCT
eurjchem-2641	538	5	i	i	PROPN
eurjchem-2641	538	6	m	m	PROPN
eurjchem-2641	538	7	,	,	PUNCT
eurjchem-2641	538	8	s.	s.	PROPN
eurjchem-2641	538	9	;	;	PUNCT
eurjchem-2641	538	10	oh	oh	INTJ
eurjchem-2641	538	11	,	,	PUNCT
eurjchem-2641	538	12	d.	d.	PROPN
eurjchem-2641	538	13	;	;	PUNCT
eurjchem-2641	538	14	lee	lee	PROPN
eurjchem-2641	538	15	,	,	PUNCT
eurjchem-2641	538	16	s.	s.	PROPN
eurjchem-2641	538	17	;	;	PUNCT
eurjchem-2641	538	18	chie	chie	PROPN
eurjchem-2641	538	19	,	,	PUNCT
eurjchem-2641	538	20	e.	e.	PROPN
eurjchem-2641	538	21	k.	k.	PROPN
eurjchem-2641	538	22	;	;	PUNCT
eurjchem-2641	538	23	han	han	PROPN
eurjchem-2641	538	24	,	,	PUNCT
eurjchem-2641	538	25	w.	w.	PROPN
eurjchem-2641	538	26	;	;	PUNCT
eurjchem-2641	538	27	kim	kim	PROPN
eurjchem-2641	538	28	,	,	PUNCT
eurjchem-2641	538	29	d.	d.	PROPN
eurjchem-2641	538	30	;	;	PUNCT
eurjchem-2641	538	31	kim	kim	PROPN
eurjchem-2641	538	32	,	,	PUNCT
eurjchem-2641	538	33	t.	t.	PROPN
eurjchem-2641	538	34	;	;	PUNCT
eurjchem-2641	538	35	park	park	PROPN
eurjchem-2641	538	36	,	,	PUNCT
eurjchem-2641	538	37	i.	i.	PROPN
eurjchem-2641	538	38	a.	a.	PROPN
eurjchem-2641	538	39	;	;	PUNCT
eurjchem-2641	538	40	noh	noh	PROPN
eurjchem-2641	538	41	,	,	PUNCT
eurjchem-2641	538	42	d.	d.	PROPN
eurjchem-2641	538	43	;	;	PUNCT
eurjchem-2641	538	44	heo	heo	PROPN
eurjchem-2641	538	45	,	,	PUNCT
eurjchem-2641	538	46	d.	d.	PROPN
eurjchem-2641	538	47	s.	s.	PROPN
eurjchem-2641	538	48	;	;	PUNCT
eurjchem-2641	538	49	ha	ha	INTJ
eurjchem-2641	538	50	,	,	PUNCT
eurjchem-2641	538	51	s.	s.	PROPN
eurjchem-2641	538	52	w.	w.	PROPN
eurjchem-2641	538	53	;	;	PUNCT
eurjchem-2641	538	54	bang	bang	PROPN
eurjchem-2641	538	55	,	,	PUNCT
eurjchem-2641	538	56	y.	y.	PROPN
eurjchem-2641	538	57	prognostic	prognostic	ADJ
eurjchem-2641	538	58	significance	significance	NOUN
eurjchem-2641	538	59	of	of	ADP
eurjchem-2641	538	60	bcl-2	bcl-2	NOUN
eurjchem-2641	538	61	expression	expression	NOUN
eurjchem-2641	538	62	in	in	ADP
eurjchem-2641	538	63	stage	stage	NOUN
eurjchem-2641	538	64	iii	iii	NUM
eurjchem-2641	538	65	breast	breast	NOUN
eurjchem-2641	538	66	cancer	cancer	NOUN
eurjchem-2641	538	67	patients	patient	NOUN
eurjchem-2641	538	68	who	who	PRON
eurjchem-2641	538	69	had	have	AUX
eurjchem-2641	538	70	received	receive	VERB
eurjchem-2641	538	71	doxorubicin	doxorubicin	PROPN
eurjchem-2641	538	72	and	and	CCONJ
eurjchem-2641	538	73	cyclophosphamide	cyclophosphamide	PROPN
eurjchem-2641	538	74	followed	follow	VERB
eurjchem-2641	538	75	by	by	ADP
eurjchem-2641	538	76	paclitaxel	paclitaxel	PROPN
eurjchem-2641	538	77	as	as	ADP
eurjchem-2641	538	78	adjuvant	adjuvant	ADJ
eurjchem-2641	538	79	chemotherapy	chemotherapy	NOUN
eurjchem-2641	538	80	.	.	PUNCT
eurjchem-2641	539	1	bmc	bmc	ADJ
eurjchem-2641	539	2	cancer	cancer	NOUN
eurjchem-2641	539	3	2007	2007	NUM
eurjchem-2641	539	4	,	,	PUNCT
eurjchem-2641	539	5	7	7	NUM
eurjchem-2641	539	6	(	(	PUNCT
eurjchem-2641	539	7	1	1	NUM
eurjchem-2641	539	8	)	)	PUNCT
eurjchem-2641	539	9	,	,	PUNCT
eurjchem-2641	539	10	https://doi.org/10.1186/1471–2407–7–63	https://doi.org/10.1186/1471–2407–7–63	PROPN
eurjchem-2641	539	11	.	.	PUNCT
eurjchem-2641	540	1	[	[	X
eurjchem-2641	540	2	48	48	NUM
eurjchem-2641	540	3	]	]	PUNCT
eurjchem-2641	540	4	.	.	PUNCT
eurjchem-2641	541	1	hata	hata	PROPN
eurjchem-2641	541	2	,	,	PUNCT
eurjchem-2641	541	3	a.	a.	NOUN
eurjchem-2641	541	4	n.	n.	NOUN
eurjchem-2641	541	5	;	;	PUNCT
eurjchem-2641	541	6	engelman	engelman	PROPN
eurjchem-2641	541	7	,	,	PUNCT
eurjchem-2641	541	8	j.	j.	PROPN
eurjchem-2641	541	9	a.	a.	PROPN
eurjchem-2641	541	10	;	;	PUNCT
eurjchem-2641	541	11	faber	faber	PROPN
eurjchem-2641	541	12	,	,	PUNCT
eurjchem-2641	541	13	a.	a.	PROPN
eurjchem-2641	541	14	c.	c.	PROPN
eurjchem-2641	541	15	the	the	DET
eurjchem-2641	541	16	bcl2	bcl2	PROPN
eurjchem-2641	541	17	family	family	NOUN
eurjchem-2641	541	18	:	:	PUNCT
eurjchem-2641	541	19	key	key	ADJ
eurjchem-2641	541	20	mediators	mediator	NOUN
eurjchem-2641	541	21	of	of	ADP
eurjchem-2641	541	22	the	the	DET
eurjchem-2641	541	23	apoptotic	apoptotic	ADJ
eurjchem-2641	541	24	response	response	NOUN
eurjchem-2641	541	25	to	to	ADP
eurjchem-2641	541	26	targeted	target	VERB
eurjchem-2641	541	27	anticancer	anticancer	NOUN
eurjchem-2641	541	28	therapeutics	therapeutic	NOUN
eurjchem-2641	541	29	.	.	PUNCT
eurjchem-2641	542	1	cancer	cancer	NOUN
eurjchem-2641	542	2	discov	discov	NOUN
eurjchem-2641	542	3	.	.	PUNCT
eurjchem-2641	543	1	2015	2015	NUM
eurjchem-2641	543	2	,	,	PUNCT
eurjchem-2641	543	3	5	5	NUM
eurjchem-2641	543	4	(	(	PUNCT
eurjchem-2641	543	5	5	5	NUM
eurjchem-2641	543	6	)	)	PUNCT
eurjchem-2641	543	7	,	,	PUNCT
eurjchem-2641	543	8	475–487	475–487	NUM
eurjchem-2641	543	9	.	.	PUNCT
eurjchem-2641	544	1	[	[	X
eurjchem-2641	544	2	49	49	NUM
eurjchem-2641	544	3	]	]	PUNCT
eurjchem-2641	544	4	.	.	PUNCT
eurjchem-2641	544	5	merino	merino	PROPN
eurjchem-2641	544	6	,	,	PUNCT
eurjchem-2641	544	7	d.	d.	PROPN
eurjchem-2641	544	8	;	;	PUNCT
eurjchem-2641	544	9	lok	lok	PROPN
eurjchem-2641	544	10	,	,	PUNCT
eurjchem-2641	544	11	s.	s.	PROPN
eurjchem-2641	544	12	w.	w.	PROPN
eurjchem-2641	544	13	;	;	PUNCT
eurjchem-2641	544	14	visvader	visvader	PROPN
eurjchem-2641	544	15	,	,	PUNCT
eurjchem-2641	544	16	j.	j.	PROPN
eurjchem-2641	544	17	e.	e.	PROPN
eurjchem-2641	544	18	;	;	PUNCT
eurjchem-2641	544	19	lindeman	lindeman	NOUN
eurjchem-2641	544	20	,	,	PUNCT
eurjchem-2641	544	21	g.	g.	PROPN
eurjchem-2641	544	22	j.	j.	PROPN
eurjchem-2641	544	23	targeting	target	VERB
eurjchem-2641	544	24	bcl-2	bcl-2	PROPN
eurjchem-2641	544	25	to	to	PART
eurjchem-2641	544	26	enhance	enhance	VERB
eurjchem-2641	544	27	vulnerability	vulnerability	NOUN
eurjchem-2641	544	28	to	to	ADP
eurjchem-2641	544	29	therapy	therapy	NOUN
eurjchem-2641	544	30	in	in	ADP
eurjchem-2641	544	31	estrogen	estrogen	NOUN
eurjchem-2641	544	32	receptor	receptor	NOUN
eurjchem-2641	544	33	-	-	PUNCT
eurjchem-2641	544	34	positive	positive	ADJ
eurjchem-2641	544	35	breast	breast	NOUN
eurjchem-2641	544	36	cancer	cancer	NOUN
eurjchem-2641	544	37	.	.	PUNCT
eurjchem-2641	545	1	oncogene	oncogene	NOUN
eurjchem-2641	545	2	2015	2015	NUM
eurjchem-2641	545	3	,	,	PUNCT
eurjchem-2641	545	4	35	35	NUM
eurjchem-2641	545	5	(	(	PUNCT
eurjchem-2641	545	6	15	15	NUM
eurjchem-2641	545	7	)	)	PUNCT
eurjchem-2641	545	8	,	,	PUNCT
eurjchem-2641	545	9	1877–1887	1877–1887	NUM
eurjchem-2641	545	10	.	.	PUNCT
eurjchem-2641	546	1	[	[	X
eurjchem-2641	546	2	50	50	NUM
eurjchem-2641	546	3	]	]	PUNCT
eurjchem-2641	546	4	.	.	PUNCT
eurjchem-2641	547	1	okda	okda	NOUN
eurjchem-2641	547	2	,	,	PUNCT
eurjchem-2641	547	3	t.	t.	NOUN
eurjchem-2641	547	4	m.	m.	NOUN
eurjchem-2641	547	5	;	;	PUNCT
eurjchem-2641	547	6	atwa	atwa	PROPN
eurjchem-2641	547	7	,	,	PUNCT
eurjchem-2641	547	8	g.	g.	PROPN
eurjchem-2641	547	9	m.	m.	PROPN
eurjchem-2641	547	10	;	;	PUNCT
eurjchem-2641	547	11	eldehn	eldehn	NOUN
eurjchem-2641	547	12	,	,	PUNCT
eurjchem-2641	547	13	a.	a.	PROPN
eurjchem-2641	547	14	f.	f.	PROPN
eurjchem-2641	547	15	;	;	PUNCT
eurjchem-2641	547	16	dahran	dahran	NOUN
eurjchem-2641	547	17	,	,	PUNCT
eurjchem-2641	547	18	n.	n.	NOUN
eurjchem-2641	547	19	;	;	PUNCT
eurjchem-2641	547	20	alsharif	alsharif	NOUN
eurjchem-2641	547	21	,	,	PUNCT
eurjchem-2641	547	22	k.	k.	PROPN
eurjchem-2641	547	23	f.	f.	PROPN
eurjchem-2641	547	24	;	;	PUNCT
eurjchem-2641	547	25	elmahallawy	elmahallawy	PROPN
eurjchem-2641	547	26	,	,	PUNCT
eurjchem-2641	547	27	e.	e.	PROPN
eurjchem-2641	547	28	k.	k.	PROPN
eurjchem-2641	548	1	a	a	DET
eurjchem-2641	548	2	novel	novel	ADJ
eurjchem-2641	548	3	role	role	NOUN
eurjchem-2641	548	4	of	of	ADP
eurjchem-2641	548	5	galectin-3	galectin-3	PROPN
eurjchem-2641	548	6	and	and	CCONJ
eurjchem-2641	548	7	thyroglobulin	thyroglobulin	PROPN
eurjchem-2641	548	8	in	in	ADP
eurjchem-2641	548	9	prognosis	prognosis	NOUN
eurjchem-2641	548	10	and	and	CCONJ
eurjchem-2641	548	11	differentiation	differentiation	NOUN
eurjchem-2641	548	12	of	of	ADP
eurjchem-2641	548	13	different	different	ADJ
eurjchem-2641	548	14	stages	stage	NOUN
eurjchem-2641	548	15	of	of	ADP
eurjchem-2641	548	16	thyroid	thyroid	NOUN
eurjchem-2641	548	17	cancer	cancer	NOUN
eurjchem-2641	548	18	and	and	CCONJ
eurjchem-2641	548	19	elucidation	elucidation	NOUN
eurjchem-2641	548	20	of	of	ADP
eurjchem-2641	548	21	the	the	DET
eurjchem-2641	548	22	potential	potential	ADJ
eurjchem-2641	548	23	contribution	contribution	NOUN
eurjchem-2641	548	24	of	of	ADP
eurjchem-2641	548	25	bcl-2	bcl-2	NOUN
eurjchem-2641	548	26	,	,	PUNCT
eurjchem-2641	548	27	il-8	il-8	PUNCT
eurjchem-2641	548	28	and	and	CCONJ
eurjchem-2641	548	29	tnf	tnf	PROPN
eurjchem-2641	548	30	-	-	PUNCT
eurjchem-2641	548	31	α	α	PROPN
eurjchem-2641	548	32	.	.	PUNCT
eurjchem-2641	548	33	biomedicines	biomedicine	VERB
eurjchem-2641	548	34	2022	2022	NUM
eurjchem-2641	548	35	,	,	PUNCT
eurjchem-2641	548	36	10	10	NUM
eurjchem-2641	548	37	(	(	PUNCT
eurjchem-2641	548	38	2	2	NUM
eurjchem-2641	548	39	)	)	PUNCT
eurjchem-2641	548	40	,	,	PUNCT
eurjchem-2641	548	41	352	352	NUM
eurjchem-2641	548	42	.	.	PUNCT
eurjchem-2641	549	1	[	[	X
eurjchem-2641	549	2	51	51	NUM
eurjchem-2641	549	3	]	]	PUNCT
eurjchem-2641	549	4	.	.	PUNCT
eurjchem-2641	550	1	ke	ke	PROPN
eurjchem-2641	550	2	,	,	PUNCT
eurjchem-2641	550	3	h.	h.	PROPN
eurjchem-2641	550	4	;	;	PUNCT
eurjchem-2641	550	5	wang	wang	PROPN
eurjchem-2641	550	6	,	,	PUNCT
eurjchem-2641	550	7	x.	x.	PROPN
eurjchem-2641	550	8	;	;	PUNCT
eurjchem-2641	550	9	zhou	zhou	PROPN
eurjchem-2641	550	10	,	,	PUNCT
eurjchem-2641	550	11	z.	z.	PROPN
eurjchem-2641	550	12	;	;	PUNCT
eurjchem-2641	550	13	ai	ai	VERB
eurjchem-2641	550	14	,	,	PUNCT
eurjchem-2641	550	15	w.	w.	PROPN
eurjchem-2641	550	16	;	;	PUNCT
eurjchem-2641	550	17	wu	wu	PROPN
eurjchem-2641	550	18	,	,	PUNCT
eurjchem-2641	550	19	z.	z.	PROPN
eurjchem-2641	550	20	;	;	PUNCT
eurjchem-2641	550	21	zhang	zhang	PROPN
eurjchem-2641	550	22	,	,	PUNCT
eurjchem-2641	550	23	y.	y.	PROPN
eurjchem-2641	550	24	effect	effect	NOUN
eurjchem-2641	550	25	of	of	ADP
eurjchem-2641	550	26	weimaining	weimaine	VERB
eurjchem-2641	550	27	on	on	ADP
eurjchem-2641	550	28	apoptosis	apoptosis	NOUN
eurjchem-2641	550	29	and	and	CCONJ
eurjchem-2641	550	30	caspase-3	caspase-3	NUM
eurjchem-2641	550	31	expression	expression	NOUN
eurjchem-2641	550	32	in	in	ADP
eurjchem-2641	550	33	a	a	DET
eurjchem-2641	550	34	breast	breast	NOUN
eurjchem-2641	550	35	cancer	cancer	NOUN
eurjchem-2641	550	36	mouse	mouse	NOUN
eurjchem-2641	550	37	model	model	NOUN
eurjchem-2641	550	38	.	.	PUNCT
eurjchem-2641	551	1	j.	j.	PROPN
eurjchem-2641	551	2	ethnopharmacol	ethnopharmacol	PROPN
eurjchem-2641	551	3	.	.	PROPN
eurjchem-2641	552	1	2021	2021	NUM
eurjchem-2641	552	2	,	,	PUNCT
eurjchem-2641	552	3	264	264	NUM
eurjchem-2641	552	4	,	,	PUNCT
eurjchem-2641	552	5	113363	113363	NUM
eurjchem-2641	552	6	.	.	PUNCT
eurjchem-2641	553	1	[	[	X
eurjchem-2641	553	2	52	52	NUM
eurjchem-2641	553	3	]	]	PUNCT
eurjchem-2641	553	4	.	.	PUNCT
eurjchem-2641	554	1	devarajan	devarajan	PROPN
eurjchem-2641	554	2	,	,	PUNCT
eurjchem-2641	554	3	e.	e.	PROPN
eurjchem-2641	554	4	;	;	PUNCT
eurjchem-2641	554	5	sahin	sahin	PROPN
eurjchem-2641	554	6	,	,	PUNCT
eurjchem-2641	554	7	a.	a.	NOUN
eurjchem-2641	554	8	a.	a.	PROPN
eurjchem-2641	554	9	;	;	PUNCT
eurjchem-2641	554	10	chen	chen	PROPN
eurjchem-2641	554	11	,	,	PUNCT
eurjchem-2641	554	12	j.	j.	PROPN
eurjchem-2641	554	13	s.	s.	PROPN
eurjchem-2641	554	14	;	;	PUNCT
eurjchem-2641	554	15	krishnamurthy	krishnamurthy	PROPN
eurjchem-2641	554	16	,	,	PUNCT
eurjchem-2641	554	17	r.	r.	PROPN
eurjchem-2641	554	18	r.	r.	PROPN
eurjchem-2641	554	19	;	;	PUNCT
eurjchem-2641	554	20	aggarwal	aggarwal	NOUN
eurjchem-2641	554	21	,	,	PUNCT
eurjchem-2641	554	22	n.	n.	NOUN
eurjchem-2641	554	23	;	;	PUNCT
eurjchem-2641	554	24	brun	brun	PROPN
eurjchem-2641	554	25	,	,	PUNCT
eurjchem-2641	554	26	a.	a.	NOUN
eurjchem-2641	554	27	;	;	PUNCT
eurjchem-2641	554	28	sapino	sapino	NOUN
eurjchem-2641	554	29	,	,	PUNCT
eurjchem-2641	554	30	a.	a.	NOUN
eurjchem-2641	554	31	;	;	PUNCT
eurjchem-2641	554	32	zhang	zhang	PROPN
eurjchem-2641	554	33	,	,	PUNCT
eurjchem-2641	554	34	f.	f.	PROPN
eurjchem-2641	554	35	;	;	PUNCT
eurjchem-2641	554	36	sharma	sharma	PROPN
eurjchem-2641	554	37	,	,	PUNCT
eurjchem-2641	554	38	d.	d.	PROPN
eurjchem-2641	554	39	;	;	PUNCT
eurjchem-2641	554	40	yang	yang	PROPN
eurjchem-2641	554	41	,	,	PUNCT
eurjchem-2641	554	42	x.	x.	PROPN
eurjchem-2641	554	43	;	;	PUNCT
eurjchem-2641	554	44	tora	tora	PROPN
eurjchem-2641	554	45	,	,	PUNCT
eurjchem-2641	554	46	a.	a.	PROPN
eurjchem-2641	554	47	d.	d.	PROPN
eurjchem-2641	554	48	;	;	PUNCT
eurjchem-2641	554	49	mehta	mehta	PROPN
eurjchem-2641	554	50	,	,	PUNCT
eurjchem-2641	554	51	k.	k.	PROPN
eurjchem-2641	554	52	down	down	ADP
eurjchem-2641	554	53	-	-	PUNCT
eurjchem-2641	554	54	regulation	regulation	NOUN
eurjchem-2641	554	55	of	of	ADP
eurjchem-2641	554	56	caspase	caspase	NOUN
eurjchem-2641	554	57	3	3	NUM
eurjchem-2641	554	58	in	in	ADP
eurjchem-2641	554	59	breast	breast	NOUN
eurjchem-2641	554	60	cancer	cancer	NOUN
eurjchem-2641	554	61	:	:	PUNCT
eurjchem-2641	554	62	a	a	DET
eurjchem-2641	554	63	possible	possible	ADJ
eurjchem-2641	554	64	mechanism	mechanism	NOUN
eurjchem-2641	554	65	for	for	ADP
eurjchem-2641	554	66	chemoresistance	chemoresistance	NOUN
eurjchem-2641	554	67	.	.	PUNCT
eurjchem-2641	555	1	oncogene	oncogene	NOUN
eurjchem-2641	555	2	2002	2002	NUM
eurjchem-2641	555	3	,	,	PUNCT
eurjchem-2641	555	4	21	21	NUM
eurjchem-2641	555	5	(	(	PUNCT
eurjchem-2641	555	6	57	57	NUM
eurjchem-2641	555	7	)	)	PUNCT
eurjchem-2641	555	8	,	,	PUNCT
eurjchem-2641	555	9	8843	8843	NUM
eurjchem-2641	555	10	–	–	PUNCT
eurjchem-2641	555	11	8851	8851	NUM
eurjchem-2641	555	12	.	.	PUNCT
eurjchem-2641	556	1	[	[	X
eurjchem-2641	556	2	53	53	NUM
eurjchem-2641	556	3	]	]	PUNCT
eurjchem-2641	556	4	.	.	PUNCT
eurjchem-2641	557	1	yang	yang	PROPN
eurjchem-2641	557	2	,	,	PUNCT
eurjchem-2641	557	3	x.	x.	PROPN
eurjchem-2641	557	4	;	;	PUNCT
eurjchem-2641	557	5	zhong	zhong	PROPN
eurjchem-2641	557	6	,	,	PUNCT
eurjchem-2641	557	7	d.	d.	PROPN
eurjchem-2641	557	8	;	;	PUNCT
eurjchem-2641	557	9	qin	qin	PROPN
eurjchem-2641	557	10	,	,	PUNCT
eurjchem-2641	557	11	h.	h.	PROPN
eurjchem-2641	557	12	;	;	PUNCT
eurjchem-2641	557	13	wu	wu	PROPN
eurjchem-2641	557	14	,	,	PUNCT
eurjchem-2641	557	15	p.	p.	PROPN
eurjchem-2641	557	16	;	;	PUNCT
eurjchem-2641	557	17	wei	wei	PROPN
eurjchem-2641	557	18	,	,	PUNCT
eurjchem-2641	557	19	k.	k.	PROPN
eurjchem-2641	557	20	;	;	PUNCT
eurjchem-2641	557	21	chen	chen	PROPN
eurjchem-2641	557	22	,	,	PUNCT
eurjchem-2641	557	23	g.	g.	PROPN
eurjchem-2641	557	24	;	;	PUNCT
eurjchem-2641	557	25	he	he	PRON
eurjchem-2641	557	26	,	,	PUNCT
eurjchem-2641	557	27	r.	r.	PROPN
eurjchem-2641	557	28	;	;	PUNCT
eurjchem-2641	557	29	zhong	zhong	PROPN
eurjchem-2641	557	30	,	,	PUNCT
eurjchem-2641	557	31	j.	j.	PROPN
eurjchem-2641	557	32	caspase-3	caspase-3	NUM
eurjchem-2641	557	33	over	over	ADP
eurjchem-2641	557	34	-	-	PUNCT
eurjchem-2641	557	35	expression	expression	NOUN
eurjchem-2641	557	36	is	be	AUX
eurjchem-2641	557	37	associated	associate	VERB
eurjchem-2641	557	38	with	with	ADP
eurjchem-2641	557	39	poor	poor	ADJ
eurjchem-2641	557	40	overall	overall	ADJ
eurjchem-2641	557	41	survival	survival	NOUN
eurjchem-2641	557	42	and	and	CCONJ
eurjchem-2641	557	43	clinicopathological	clinicopathological	ADJ
eurjchem-2641	557	44	parameters	parameter	NOUN
eurjchem-2641	557	45	in	in	ADP
eurjchem-2641	557	46	breast	breast	NOUN
eurjchem-2641	557	47	cancer	cancer	NOUN
eurjchem-2641	557	48	:	:	PUNCT
eurjchem-2641	557	49	a	a	DET
eurjchem-2641	557	50	meta	meta	ADJ
eurjchem-2641	557	51	-	-	PUNCT
eurjchem-2641	557	52	analysis	analysis	NOUN
eurjchem-2641	557	53	of	of	ADP
eurjchem-2641	557	54	3091	3091	NUM
eurjchem-2641	557	55	cases	case	NOUN
eurjchem-2641	557	56	.	.	PUNCT
eurjchem-2641	558	1	oncotarget	oncotarget	NOUN
eurjchem-2641	558	2	2017	2017	NUM
eurjchem-2641	558	3	,	,	PUNCT
eurjchem-2641	558	4	9	9	NUM
eurjchem-2641	558	5	(	(	PUNCT
eurjchem-2641	558	6	9	9	NUM
eurjchem-2641	558	7	)	)	PUNCT
eurjchem-2641	558	8	,	,	PUNCT
eurjchem-2641	558	9	8629–8641	8629–8641	NUM
eurjchem-2641	558	10	.	.	PUNCT
eurjchem-2641	559	1	[	[	X
eurjchem-2641	559	2	54	54	NUM
eurjchem-2641	559	3	]	]	PUNCT
eurjchem-2641	559	4	.	.	PUNCT
eurjchem-2641	560	1	danesh	danesh	PROPN
eurjchem-2641	560	2	,	,	PUNCT
eurjchem-2641	560	3	h.	h.	PROPN
eurjchem-2641	560	4	;	;	PUNCT
eurjchem-2641	560	5	ziamajidi	ziamajidi	PROPN
eurjchem-2641	560	6	,	,	PUNCT
eurjchem-2641	560	7	n.	n.	NOUN
eurjchem-2641	560	8	;	;	PUNCT
eurjchem-2641	560	9	mesbah	mesbah	NOUN
eurjchem-2641	560	10	-	-	PUNCT
eurjchem-2641	560	11	namin	namin	PROPN
eurjchem-2641	560	12	,	,	PUNCT
eurjchem-2641	560	13	s.	s.	PROPN
eurjchem-2641	560	14	a.	a.	PROPN
eurjchem-2641	560	15	;	;	PUNCT
eurjchem-2641	560	16	nafisi	nafisi	VERB
eurjchem-2641	560	17	,	,	PUNCT
eurjchem-2641	560	18	n.	n.	NOUN
eurjchem-2641	560	19	;	;	PUNCT
eurjchem-2641	560	20	abbasalipourkabir	abbasalipourkabir	PROPN
eurjchem-2641	560	21	,	,	PUNCT
eurjchem-2641	560	22	r.	r.	PROPN
eurjchem-2641	560	23	association	association	PROPN
eurjchem-2641	560	24	between	between	ADP
eurjchem-2641	560	25	oxidative	oxidative	ADJ
eurjchem-2641	560	26	stress	stress	NOUN
eurjchem-2641	560	27	parameters	parameter	NOUN
eurjchem-2641	560	28	and	and	CCONJ
eurjchem-2641	560	29	hematological	hematological	ADJ
eurjchem-2641	560	30	indices	index	NOUN
eurjchem-2641	560	31	in	in	ADP
eurjchem-2641	560	32	breast	breast	NOUN
eurjchem-2641	560	33	cancer	cancer	NOUN
eurjchem-2641	560	34	patients	patient	NOUN
eurjchem-2641	560	35	.	.	PUNCT
eurjchem-2641	561	1	int	int	NOUN
eurjchem-2641	561	2	.	.	PUNCT
eurjchem-2641	562	1	j.	j.	PROPN
eurjchem-2641	562	2	breast	breast	PROPN
eurjchem-2641	562	3	cancer	cancer	NOUN
eurjchem-2641	562	4	2022	2022	NUM
eurjchem-2641	562	5	,	,	PUNCT
eurjchem-2641	562	6	2022	2022	NUM
eurjchem-2641	562	7	,	,	PUNCT
eurjchem-2641	562	8	1–8	1–8	X
eurjchem-2641	562	9	.	.	PUNCT
eurjchem-2641	563	1	[	[	X
eurjchem-2641	563	2	55	55	NUM
eurjchem-2641	563	3	]	]	PUNCT
eurjchem-2641	563	4	.	.	PUNCT
eurjchem-2641	564	1	abbasalizad	abbasalizad	PROPN
eurjchem-2641	564	2	farhangi	farhangi	PROPN
eurjchem-2641	564	3	,	,	PUNCT
eurjchem-2641	564	4	m.	m.	NOUN
eurjchem-2641	564	5	;	;	PUNCT
eurjchem-2641	564	6	vajdi	vajdi	NOUN
eurjchem-2641	564	7	,	,	PUNCT
eurjchem-2641	564	8	m.	m.	NOUN
eurjchem-2641	564	9	dietary	dietary	ADJ
eurjchem-2641	564	10	total	total	ADJ
eurjchem-2641	564	11	antioxidant	antioxidant	NOUN
eurjchem-2641	564	12	capacity	capacity	NOUN
eurjchem-2641	564	13	(	(	PUNCT
eurjchem-2641	564	14	tac	tac	NOUN
eurjchem-2641	564	15	)	)	PUNCT
eurjchem-2641	564	16	significantly	significantly	ADV
eurjchem-2641	564	17	reduces	reduce	VERB
eurjchem-2641	564	18	the	the	DET
eurjchem-2641	564	19	risk	risk	NOUN
eurjchem-2641	564	20	of	of	ADP
eurjchem-2641	564	21	site	site	NOUN
eurjchem-2641	564	22	-	-	PUNCT
eurjchem-2641	564	23	specific	specific	ADJ
eurjchem-2641	564	24	cancers	cancer	NOUN
eurjchem-2641	564	25	:	:	PUNCT
eurjchem-2641	564	26	an	an	DET
eurjchem-2641	564	27	updated	update	VERB
eurjchem-2641	564	28	systematic	systematic	ADJ
eurjchem-2641	564	29	review	review	NOUN
eurjchem-2641	564	30	and	and	CCONJ
eurjchem-2641	564	31	meta	meta	ADJ
eurjchem-2641	564	32	-	-	PUNCT
eurjchem-2641	564	33	analysis	analysis	NOUN
eurjchem-2641	564	34	.	.	PUNCT
eurjchem-2641	565	1	nutr	nutr	PROPN
eurjchem-2641	565	2	.	.	PUNCT
eurjchem-2641	566	1	cancer	cancer	NOUN
eurjchem-2641	566	2	2020	2020	NUM
eurjchem-2641	566	3	,	,	PUNCT
eurjchem-2641	566	4	73	73	NUM
eurjchem-2641	566	5	(	(	PUNCT
eurjchem-2641	566	6	5	5	NUM
eurjchem-2641	566	7	)	)	PUNCT
eurjchem-2641	566	8	,	,	PUNCT
eurjchem-2641	566	9	721–739	721–739	NUM
eurjchem-2641	566	10	.	.	PUNCT
eurjchem-2641	567	1	[	[	X
eurjchem-2641	567	2	56	56	NUM
eurjchem-2641	567	3	]	]	PUNCT
eurjchem-2641	567	4	.	.	PUNCT
eurjchem-2641	568	1	rashad	rashad	PROPN
eurjchem-2641	568	2	,	,	PUNCT
eurjchem-2641	568	3	y.	y.	NOUN
eurjchem-2641	568	4	a.	a.	NOUN
eurjchem-2641	568	5	evaluation	evaluation	NOUN
eurjchem-2641	568	6	of	of	ADP
eurjchem-2641	568	7	serum	serum	NOUN
eurjchem-2641	568	8	levels	level	NOUN
eurjchem-2641	568	9	of	of	ADP
eurjchem-2641	568	10	her2	her2	PROPN
eurjchem-2641	568	11	,	,	PUNCT
eurjchem-2641	568	12	mmp-9	mmp-9	NOUN
eurjchem-2641	568	13	,	,	PUNCT
eurjchem-2641	568	14	nitric	nitric	ADJ
eurjchem-2641	568	15	oxide	oxide	NOUN
eurjchem-2641	568	16	,	,	PUNCT
eurjchem-2641	568	17	and	and	CCONJ
eurjchem-2641	568	18	total	total	ADJ
eurjchem-2641	568	19	antioxidant	antioxidant	ADJ
eurjchem-2641	568	20	capacity	capacity	NOUN
eurjchem-2641	568	21	in	in	ADP
eurjchem-2641	568	22	egyptian	egyptian	ADJ
eurjchem-2641	568	23	breast	breast	NOUN
eurjchem-2641	568	24	cancer	cancer	NOUN
eurjchem-2641	568	25	patients	patient	NOUN
eurjchem-2641	568	26	:	:	PUNCT
eurjchem-2641	568	27	correlation	correlation	NOUN
eurjchem-2641	568	28	with	with	ADP
eurjchem-2641	568	29	clinico	clinico	ADJ
eurjchem-2641	568	30	-	-	PUNCT
eurjchem-2641	568	31	pathological	pathological	ADJ
eurjchem-2641	568	32	parameters	parameter	NOUN
eurjchem-2641	568	33	.	.	PUNCT
eurjchem-2641	569	1	sci	sci	PROPN
eurjchem-2641	569	2	.	.	PUNCT
eurjchem-2641	569	3	pharm	pharm	PROPN
eurjchem-2641	569	4	.	.	PUNCT
eurjchem-2641	570	1	2014	2014	NUM
eurjchem-2641	570	2	,	,	PUNCT
eurjchem-2641	570	3	82	82	NUM
eurjchem-2641	570	4	(	(	PUNCT
eurjchem-2641	570	5	1	1	NUM
eurjchem-2641	570	6	)	)	PUNCT
eurjchem-2641	570	7	,	,	PUNCT
eurjchem-2641	570	8	129–145	129–145	NUM
eurjchem-2641	570	9	.	.	PUNCT
eurjchem-2641	571	1	[	[	X
eurjchem-2641	571	2	57	57	NUM
eurjchem-2641	571	3	]	]	PUNCT
eurjchem-2641	571	4	.	.	PUNCT
eurjchem-2641	571	5	yang	yang	PROPN
eurjchem-2641	571	6	,	,	PUNCT
eurjchem-2641	571	7	m.	m.	NOUN
eurjchem-2641	571	8	;	;	PUNCT
eurjchem-2641	571	9	kong	kong	PROPN
eurjchem-2641	571	10	,	,	PUNCT
eurjchem-2641	571	11	d.	d.	PROPN
eurjchem-2641	571	12	;	;	PUNCT
eurjchem-2641	571	13	chen	chen	PROPN
eurjchem-2641	571	14	,	,	PUNCT
eurjchem-2641	571	15	j.	j.	PROPN
eurjchem-2641	571	16	inhibition	inhibition	NOUN
eurjchem-2641	571	17	of	of	ADP
eurjchem-2641	571	18	mir-148b	mir-148b	ADJ
eurjchem-2641	571	19	ameliorates	ameliorate	VERB
eurjchem-2641	571	20	myocardial	myocardial	ADJ
eurjchem-2641	571	21	ischemia	ischemia	NOUN
eurjchem-2641	571	22	/	/	SYM
eurjchem-2641	571	23	reperfusion	reperfusion	NOUN
eurjchem-2641	571	24	injury	injury	NOUN
eurjchem-2641	571	25	via	via	ADP
eurjchem-2641	571	26	regulation	regulation	NOUN
eurjchem-2641	571	27	of	of	ADP
eurjchem-2641	571	28	wnt	wnt	PROPN
eurjchem-2641	571	29	/	/	SYM
eurjchem-2641	571	30	βcatenin	βcatenin	NOUN
eurjchem-2641	571	31	signaling	signal	VERB
eurjchem-2641	571	32	pathway	pathway	NOUN
eurjchem-2641	571	33	.	.	PUNCT
eurjchem-2641	572	1	journal	journal	NOUN
eurjchem-2641	572	2	cellular	cellular	ADJ
eurjchem-2641	572	3	physiology	physiology	NOUN
eurjchem-2641	572	4	2019	2019	NUM
eurjchem-2641	572	5	,	,	PUNCT
eurjchem-2641	572	6	234	234	NUM
eurjchem-2641	572	7	(	(	PUNCT
eurjchem-2641	572	8	10	10	NUM
eurjchem-2641	572	9	)	)	PUNCT
eurjchem-2641	572	10	,	,	PUNCT
eurjchem-2641	572	11	17757–17766	17757–17766	NUM
eurjchem-2641	572	12	.	.	PUNCT
eurjchem-2641	573	1	[	[	X
eurjchem-2641	573	2	58	58	NUM
eurjchem-2641	573	3	]	]	PUNCT
eurjchem-2641	573	4	.	.	PUNCT
eurjchem-2641	574	1	carneiro	carneiro	PROPN
eurjchem-2641	574	2	,	,	PUNCT
eurjchem-2641	574	3	g.	g.	PROPN
eurjchem-2641	574	4	;	;	PUNCT
eurjchem-2641	574	5	radcenco	radcenco	NOUN
eurjchem-2641	574	6	,	,	PUNCT
eurjchem-2641	574	7	a.	a.	PROPN
eurjchem-2641	574	8	l.	l.	PROPN
eurjchem-2641	574	9	;	;	PUNCT
eurjchem-2641	574	10	evaristo	evaristo	PROPN
eurjchem-2641	574	11	,	,	PUNCT
eurjchem-2641	574	12	j.	j.	PROPN
eurjchem-2641	574	13	;	;	PUNCT
eurjchem-2641	574	14	monnerat	monnerat	PROPN
eurjchem-2641	574	15	,	,	PUNCT
eurjchem-2641	574	16	g.	g.	NOUN
eurjchem-2641	574	17	novel	novel	ADJ
eurjchem-2641	574	18	strategies	strategy	NOUN
eurjchem-2641	574	19	for	for	ADP
eurjchem-2641	574	20	clinical	clinical	ADJ
eurjchem-2641	574	21	investigation	investigation	NOUN
eurjchem-2641	574	22	and	and	CCONJ
eurjchem-2641	574	23	biomarker	biomarker	NOUN
eurjchem-2641	574	24	discovery	discovery	NOUN
eurjchem-2641	574	25	:	:	PUNCT
eurjchem-2641	574	26	a	a	DET
eurjchem-2641	574	27	guide	guide	NOUN
eurjchem-2641	574	28	to	to	ADP
eurjchem-2641	574	29	applied	apply	VERB
eurjchem-2641	574	30	metabolomics	metabolomic	NOUN
eurjchem-2641	574	31	.	.	PUNCT
eurjchem-2641	575	1	horm	horm	PROPN
eurjchem-2641	575	2	.	.	PUNCT
eurjchem-2641	576	1	mol	mol	PROPN
eurjchem-2641	576	2	.	.	PUNCT
eurjchem-2641	577	1	biol	biol	PROPN
eurjchem-2641	577	2	.	.	PUNCT
eurjchem-2641	578	1	clin	clin	PROPN
eurjchem-2641	578	2	.	.	PUNCT
eurjchem-2641	578	3	investig	investig	PROPN
eurjchem-2641	578	4	.	.	PROPN
eurjchem-2641	578	5	2019	2019	NUM
eurjchem-2641	578	6	,	,	PUNCT
eurjchem-2641	578	7	38	38	NUM
eurjchem-2641	578	8	(	(	PUNCT
eurjchem-2641	578	9	3	3	NUM
eurjchem-2641	578	10	)	)	PUNCT
eurjchem-2641	578	11	,	,	PUNCT
eurjchem-2641	578	12	20180045	20180045	NUM
eurjchem-2641	578	13	https://doi.org/10.1515/hmbci–2018–0045	https://doi.org/10.1515/hmbci–2018–0045	NOUN
eurjchem-2641	578	14	.	.	PUNCT
eurjchem-2641	579	1	[	[	X
eurjchem-2641	579	2	59	59	NUM
eurjchem-2641	579	3	]	]	PUNCT
eurjchem-2641	579	4	.	.	PUNCT
eurjchem-2641	580	1	li	li	PROPN
eurjchem-2641	580	2	,	,	PUNCT
eurjchem-2641	580	3	j.	j.	PROPN
eurjchem-2641	580	4	;	;	PUNCT
eurjchem-2641	580	5	zhou	zhou	PROPN
eurjchem-2641	580	6	,	,	PUNCT
eurjchem-2641	580	7	y.	y.	PROPN
eurjchem-2641	580	8	;	;	PUNCT
eurjchem-2641	580	9	li	li	PROPN
eurjchem-2641	580	10	,	,	PUNCT
eurjchem-2641	580	11	y.	y.	PROPN
eurjchem-2641	580	12	;	;	PUNCT
eurjchem-2641	580	13	liu	liu	PROPN
eurjchem-2641	580	14	,	,	PUNCT
eurjchem-2641	580	15	y.	y.	PROPN
eurjchem-2641	580	16	nuclear	nuclear	ADJ
eurjchem-2641	580	17	morphological	morphological	ADJ
eurjchem-2641	580	18	characteristics	characteristic	NOUN
eurjchem-2641	580	19	in	in	ADP
eurjchem-2641	580	20	breast	breast	NOUN
eurjchem-2641	580	21	cancer	cancer	NOUN
eurjchem-2641	580	22	:	:	PUNCT
eurjchem-2641	580	23	correlation	correlation	NOUN
eurjchem-2641	580	24	with	with	ADP
eurjchem-2641	580	25	hormone	hormone	NOUN
eurjchem-2641	580	26	receptor	receptor	NOUN
eurjchem-2641	580	27	and	and	CCONJ
eurjchem-2641	580	28	human	human	ADJ
eurjchem-2641	580	29	epidermal	epidermal	ADJ
eurjchem-2641	580	30	growth	growth	NOUN
eurjchem-2641	580	31	factor	factor	NOUN
eurjchem-2641	580	32	receptor	receptor	NOUN
eurjchem-2641	580	33	2	2	NUM
eurjchem-2641	580	34	.	.	PUNCT
eurjchem-2641	580	35	anal	anal	ADJ
eurjchem-2641	580	36	.	.	PUNCT
eurjchem-2641	581	1	cell	cell	NOUN
eurjchem-2641	581	2	.	.	PUNCT
eurjchem-2641	582	1	pathol	pathol	NOUN
eurjchem-2641	582	2	.	.	PUNCT
eurjchem-2641	582	3	2021	2021	NUM
eurjchem-2641	582	4	,	,	PUNCT
eurjchem-2641	582	5	2021	2021	NUM
eurjchem-2641	582	6	,	,	PUNCT
eurjchem-2641	582	7	1	1	NUM
eurjchem-2641	582	8	–	–	PUNCT
eurjchem-2641	582	9	10	10	NUM
eurjchem-2641	582	10	.	.	PUNCT
eurjchem-2641	583	1	[	[	X
eurjchem-2641	583	2	60	60	NUM
eurjchem-2641	583	3	]	]	PUNCT
eurjchem-2641	583	4	.	.	PUNCT
eurjchem-2641	584	1	raza	raza	PROPN
eurjchem-2641	584	2	,	,	PUNCT
eurjchem-2641	584	3	u.	u.	PROPN
eurjchem-2641	584	4	;	;	PUNCT
eurjchem-2641	584	5	sheikh	sheikh	PROPN
eurjchem-2641	584	6	,	,	PUNCT
eurjchem-2641	584	7	a.	a.	PROPN
eurjchem-2641	584	8	;	;	PUNCT
eurjchem-2641	584	9	jamali	jamali	PROPN
eurjchem-2641	584	10	,	,	PUNCT
eurjchem-2641	584	11	s.	s.	PROPN
eurjchem-2641	584	12	n.	n.	PROPN
eurjchem-2641	584	13	;	;	PUNCT
eurjchem-2641	584	14	turab	turab	NOUN
eurjchem-2641	584	15	,	,	PUNCT
eurjchem-2641	584	16	m.	m.	NOUN
eurjchem-2641	584	17	;	;	PUNCT
eurjchem-2641	584	18	zaidi	zaidi	PROPN
eurjchem-2641	584	19	,	,	PUNCT
eurjchem-2641	584	20	s.	s.	PROPN
eurjchem-2641	584	21	a.	a.	PROPN
eurjchem-2641	584	22	;	;	PUNCT
eurjchem-2641	584	23	jawaid	jawaid	PROPN
eurjchem-2641	584	24	,	,	PUNCT
eurjchem-2641	584	25	h.	h.	PROPN
eurjchem-2641	584	26	posttreatment	posttreatment	NOUN
eurjchem-2641	584	27	hematological	hematological	ADJ
eurjchem-2641	584	28	variations	variation	NOUN
eurjchem-2641	584	29	and	and	CCONJ
eurjchem-2641	584	30	the	the	DET
eurjchem-2641	584	31	role	role	NOUN
eurjchem-2641	584	32	of	of	ADP
eurjchem-2641	584	33	hemoglobin	hemoglobin	NOUN
eurjchem-2641	584	34	as	as	ADP
eurjchem-2641	584	35	a	a	DET
eurjchem-2641	584	36	predictor	predictor	NOUN
eurjchem-2641	584	37	of	of	ADP
eurjchem-2641	584	38	disease	disease	NOUN
eurjchem-2641	584	39	-	-	PUNCT
eurjchem-2641	584	40	free	free	ADJ
eurjchem-2641	584	41	survival	survival	NOUN
eurjchem-2641	584	42	in	in	ADP
eurjchem-2641	584	43	stage	stage	NOUN
eurjchem-2641	584	44	2	2	NUM
eurjchem-2641	584	45	breast	breast	NOUN
eurjchem-2641	584	46	cancer	cancer	NOUN
eurjchem-2641	584	47	patients	patient	NOUN
eurjchem-2641	584	48	.	.	PUNCT
eurjchem-2641	585	1	cureus	cureus	PROPN
eurjchem-2641	585	2	2020	2020	NUM
eurjchem-2641	585	3	,	,	PUNCT
eurjchem-2641	585	4	https://doi.org/10.7759/cureus.7259	https://doi.org/10.7759/cureus.7259	NOUN
eurjchem-2641	585	5	.	.	PUNCT
eurjchem-2641	586	1	[	[	X
eurjchem-2641	586	2	61	61	NUM
eurjchem-2641	586	3	]	]	PUNCT
eurjchem-2641	586	4	.	.	PUNCT
eurjchem-2641	586	5	lee	lee	PROPN
eurjchem-2641	586	6	,	,	PUNCT
eurjchem-2641	586	7	c.	c.	PROPN
eurjchem-2641	586	8	;	;	PUNCT
eurjchem-2641	586	9	tsai	tsai	PROPN
eurjchem-2641	586	10	,	,	PUNCT
eurjchem-2641	586	11	c.	c.	PROPN
eurjchem-2641	586	12	;	;	PUNCT
eurjchem-2641	586	13	yeh	yeh	PROPN
eurjchem-2641	586	14	,	,	PUNCT
eurjchem-2641	586	15	d.	d.	PROPN
eurjchem-2641	586	16	;	;	PUNCT
eurjchem-2641	586	17	lin	lin	PROPN
eurjchem-2641	586	18	,	,	PUNCT
eurjchem-2641	586	19	c.	c.	PROPN
eurjchem-2641	586	20	;	;	PUNCT
eurjchem-2641	586	21	li	li	PROPN
eurjchem-2641	586	22	,	,	PUNCT
eurjchem-2641	586	23	y.	y.	PROPN
eurjchem-2641	586	24	;	;	PUNCT
eurjchem-2641	586	25	tzeng	tzeng	PROPN
eurjchem-2641	586	26	,	,	PUNCT
eurjchem-2641	586	27	h.	h.	PROPN
eurjchem-2641	586	28	hemoglobin	hemoglobin	PROPN
eurjchem-2641	586	29	level	level	PROPN
eurjchem-2641	586	30	trajectories	trajectory	NOUN
eurjchem-2641	586	31	in	in	ADP
eurjchem-2641	586	32	the	the	DET
eurjchem-2641	586	33	early	early	ADJ
eurjchem-2641	586	34	treatment	treatment	NOUN
eurjchem-2641	586	35	period	period	NOUN
eurjchem-2641	586	36	are	be	AUX
eurjchem-2641	586	37	related	relate	VERB
eurjchem-2641	586	38	with	with	ADP
eurjchem-2641	586	39	survival	survival	NOUN
eurjchem-2641	586	40	outcomes	outcome	NOUN
eurjchem-2641	586	41	in	in	ADP
eurjchem-2641	586	42	patients	patient	NOUN
eurjchem-2641	586	43	with	with	ADP
eurjchem-2641	586	44	breast	breast	NOUN
eurjchem-2641	586	45	cancer	cancer	NOUN
eurjchem-2641	586	46	.	.	PUNCT
eurjchem-2641	587	1	oncotarget	oncotarget	NOUN
eurjchem-2641	587	2	2016	2016	NUM
eurjchem-2641	587	3	,	,	PUNCT
eurjchem-2641	587	4	8	8	NUM
eurjchem-2641	587	5	(	(	PUNCT
eurjchem-2641	587	6	1	1	NUM
eurjchem-2641	587	7	)	)	PUNCT
eurjchem-2641	587	8	,	,	PUNCT
eurjchem-2641	587	9	1569–1579	1569–1579	NUM
eurjchem-2641	587	10	.	.	PUNCT
eurjchem-2641	588	1	[	[	X
eurjchem-2641	588	2	62	62	NUM
eurjchem-2641	588	3	]	]	PUNCT
eurjchem-2641	588	4	.	.	PUNCT
eurjchem-2641	589	1	sharma	sharma	PROPN
eurjchem-2641	589	2	,	,	PUNCT
eurjchem-2641	589	3	p.	p.	NOUN
eurjchem-2641	589	4	;	;	PUNCT
eurjchem-2641	589	5	georgy	georgy	PROPN
eurjchem-2641	589	6	,	,	PUNCT
eurjchem-2641	589	7	j.	j.	PROPN
eurjchem-2641	589	8	t.	t.	PROPN
eurjchem-2641	589	9	;	;	PUNCT
eurjchem-2641	589	10	andrews	andrews	PROPN
eurjchem-2641	589	11	,	,	PUNCT
eurjchem-2641	589	12	a.	a.	NOUN
eurjchem-2641	589	13	g.	g.	PROPN
eurjchem-2641	589	14	;	;	PUNCT
eurjchem-2641	589	15	john	john	PROPN
eurjchem-2641	589	16	,	,	PUNCT
eurjchem-2641	589	17	a.	a.	PROPN
eurjchem-2641	589	18	o.	o.	PROPN
eurjchem-2641	589	19	;	;	PUNCT
eurjchem-2641	589	20	joel	joel	PROPN
eurjchem-2641	589	21	,	,	PUNCT
eurjchem-2641	589	22	a.	a.	NOUN
eurjchem-2641	589	23	;	;	PUNCT
eurjchem-2641	589	24	chacko	chacko	NOUN
eurjchem-2641	589	25	,	,	PUNCT
eurjchem-2641	589	26	r.	r.	PROPN
eurjchem-2641	589	27	t.	t.	PROPN
eurjchem-2641	589	28	;	;	PUNCT
eurjchem-2641	589	29	premkumar	premkumar	PROPN
eurjchem-2641	589	30	,	,	PUNCT
eurjchem-2641	589	31	p.	p.	PROPN
eurjchem-2641	589	32	s.	s.	PROPN
eurjchem-2641	589	33	;	;	PUNCT
eurjchem-2641	589	34	singh	singh	PROPN
eurjchem-2641	589	35	,	,	PUNCT
eurjchem-2641	589	36	a.	a.	NOUN
eurjchem-2641	589	37	anemia	anemia	NOUN
eurjchem-2641	589	38	requiring	require	VERB
eurjchem-2641	589	39	transfusion	transfusion	NOUN
eurjchem-2641	589	40	in	in	ADP
eurjchem-2641	589	41	breast	breast	NOUN
eurjchem-2641	589	42	cancer	cancer	NOUN
eurjchem-2641	589	43	patients	patient	NOUN
eurjchem-2641	589	44	on	on	ADP
eurjchem-2641	589	45	dose	dose	NOUN
eurjchem-2641	589	46	-	-	PUNCT
eurjchem-2641	589	47	dense	dense	ADJ
eurjchem-2641	589	48	chemotherapy	chemotherapy	NOUN
eurjchem-2641	589	49	:	:	PUNCT
eurjchem-2641	589	50	prevalence	prevalence	NOUN
eurjchem-2641	589	51	,	,	PUNCT
eurjchem-2641	589	52	risk	risk	NOUN
eurjchem-2641	589	53	factors	factor	NOUN
eurjchem-2641	589	54	,	,	PUNCT
eurjchem-2641	589	55	cost	cost	NOUN
eurjchem-2641	589	56	and	and	CCONJ
eurjchem-2641	589	57	effect	effect	NOUN
eurjchem-2641	589	58	on	on	ADP
eurjchem-2641	589	59	disease	disease	NOUN
eurjchem-2641	589	60	outcome	outcome	NOUN
eurjchem-2641	589	61	.	.	PUNCT
eurjchem-2641	590	1	support	support	NOUN
eurjchem-2641	590	2	care	care	NOUN
eurjchem-2641	590	3	cancer	cancer	NOUN
eurjchem-2641	590	4	2022	2022	NUM
eurjchem-2641	590	5	,	,	PUNCT
eurjchem-2641	590	6	30	30	NUM
eurjchem-2641	590	7	(	(	PUNCT
eurjchem-2641	590	8	6	6	NUM
eurjchem-2641	590	9	)	)	PUNCT
eurjchem-2641	590	10	,	,	PUNCT
eurjchem-2641	590	11	5519–5526	5519–5526	NUM
eurjchem-2641	590	12	.	.	PUNCT
eurjchem-2641	591	1	[	[	X
eurjchem-2641	591	2	63	63	NUM
eurjchem-2641	591	3	]	]	PUNCT
eurjchem-2641	591	4	.	.	PUNCT
eurjchem-2641	592	1	akinbami	akinbami	PROPN
eurjchem-2641	592	2	,	,	PUNCT
eurjchem-2641	592	3	a.	a.	NOUN
eurjchem-2641	592	4	;	;	PUNCT
eurjchem-2641	592	5	popoola	popoola	PROPN
eurjchem-2641	592	6	,	,	PUNCT
eurjchem-2641	592	7	a.	a.	NOUN
eurjchem-2641	592	8	;	;	PUNCT
eurjchem-2641	592	9	adediran	adediran	ADJ
eurjchem-2641	592	10	,	,	PUNCT
eurjchem-2641	592	11	a.	a.	NOUN
eurjchem-2641	592	12	;	;	PUNCT
eurjchem-2641	592	13	dosunmu	dosunmu	NOUN
eurjchem-2641	592	14	,	,	PUNCT
eurjchem-2641	592	15	a.	a.	NOUN
eurjchem-2641	592	16	;	;	PUNCT
eurjchem-2641	592	17	oshinaike	oshinaike	NOUN
eurjchem-2641	592	18	,	,	PUNCT
eurjchem-2641	592	19	o.	o.	PROPN
eurjchem-2641	592	20	;	;	PUNCT
eurjchem-2641	592	21	adebola	adebola	PROPN
eurjchem-2641	592	22	,	,	PUNCT
eurjchem-2641	592	23	p.	p.	PROPN
eurjchem-2641	592	24	;	;	PUNCT
eurjchem-2641	592	25	ajibola	ajibola	PROPN
eurjchem-2641	592	26	,	,	PUNCT
eurjchem-2641	592	27	s.	s.	PROPN
eurjchem-2641	592	28	full	full	ADJ
eurjchem-2641	592	29	blood	blood	NOUN
eurjchem-2641	592	30	count	count	NOUN
eurjchem-2641	592	31	pattern	pattern	NOUN
eurjchem-2641	592	32	of	of	ADP
eurjchem-2641	592	33	pre	pre	ADJ
eurjchem-2641	592	34	-	-	ADJ
eurjchem-2641	592	35	chemotherapy	chemotherapy	ADJ
eurjchem-2641	592	36	breast	breast	NOUN
eurjchem-2641	592	37	cancer	cancer	NOUN
eurjchem-2641	592	38	patients	patient	NOUN
eurjchem-2641	592	39	in	in	ADP
eurjchem-2641	592	40	lagos	lagos	PROPN
eurjchem-2641	592	41	,	,	PUNCT
eurjchem-2641	592	42	nigeria	nigeria	PROPN
eurjchem-2641	592	43	.	.	PUNCT
eurjchem-2641	593	1	caspian	caspian	PROPN
eurjchem-2641	593	2	j.	j.	PROPN
eurjchem-2641	593	3	intern	intern	PROPN
eurjchem-2641	593	4	.	.	PUNCT
eurjchem-2641	593	5	med	med	PROPN
eurjchem-2641	593	6	.	.	PUNCT
eurjchem-2641	593	7	2013	2013	NUM
eurjchem-2641	593	8	,	,	PUNCT
eurjchem-2641	593	9	4	4	NUM
eurjchem-2641	593	10	,	,	PUNCT
eurjchem-2641	593	11	574–579	574–579	NUM
eurjchem-2641	593	12	.	.	PUNCT
eurjchem-2641	594	1	https://pubmed.ncbi.nlm.nih.gov/24009939/	https://pubmed.ncbi.nlm.nih.gov/24009939/	PROPN
eurjchem-2641	594	2	https://doi.org/10.3389/fonc.2019.00900	https://doi.org/10.3389/fonc.2019.00900	PROPN
eurjchem-2641	594	3	https://doi.org/10.3389/fphar.2021.701301	https://doi.org/10.3389/fphar.2021.701301	PROPN
eurjchem-2641	594	4	https://doi.org/10.1186/s13148%e2%80%93018%e2%80%930587%e2%80%938	https://doi.org/10.1186/s13148%e2%80%93018%e2%80%930587%e2%80%938	INTJ
eurjchem-2641	594	5	https://doi.org/10.3389/fgene.2016.00175	https://doi.org/10.3389/fgene.2016.00175	PROPN
eurjchem-2641	594	6	https://doi.org/10.1155/2020/9568976	https://doi.org/10.1155/2020/9568976	NOUN
eurjchem-2641	594	7	https://doi.org/10.2478/v10035%e2%80%93011%e2%80%930087%e2%80%934	https://doi.org/10.2478/v10035%e2%80%93011%e2%80%930087%e2%80%934	NOUN
eurjchem-2641	594	8	https://doi.org/10.2478/v10035%e2%80%93011%e2%80%930087%e2%80%934	https://doi.org/10.2478/v10035%e2%80%93011%e2%80%930087%e2%80%934	VERB
eurjchem-2641	594	9	https://doi.org/10.1186/1471%e2%80%932407%e2%80%937%e2%80%9363	https://doi.org/10.1186/1471%e2%80%932407%e2%80%937%e2%80%9363	DET
eurjchem-2641	594	10	https://doi.org/10.1515/hmbci%e2%80%932018%e2%80%930045	https://doi.org/10.1515/hmbci%e2%80%932018%e2%80%930045	NOUN
eurjchem-2641	594	11	https://doi.org/10.7759/cureus.7259	https://doi.org/10.7759/cureus.7259	NOUN
eurjchem-2641	594	12	https://pubmed.ncbi.nlm.nih.gov/24009939/	https://pubmed.ncbi.nlm.nih.gov/24009939/	PROPN
eurjchem-2641	594	13	232	232	NUM
eurjchem-2641	594	14	harisa	harisa	NOUN
eurjchem-2641	594	15	et	et	PROPN
eurjchem-2641	594	16	al	al	PROPN
eurjchem-2641	594	17	.	.	PUNCT
eurjchem-2641	594	18	/	/	SYM
eurjchem-2641	594	19	european	european	PROPN
eurjchem-2641	594	20	journal	journal	PROPN
eurjchem-2641	594	21	of	of	ADP
eurjchem-2641	594	22	chemistry	chemistry	NOUN
eurjchem-2641	594	23	16	16	NUM
eurjchem-2641	594	24	(	(	PUNCT
eurjchem-2641	594	25	2	2	NUM
eurjchem-2641	594	26	)	)	PUNCT
eurjchem-2641	594	27	(	(	PUNCT
eurjchem-2641	594	28	2025	2025	NUM
eurjchem-2641	594	29	)	)	PUNCT
eurjchem-2641	594	30	222	222	NUM
eurjchem-2641	594	31	-	-	SYM
eurjchem-2641	594	32	232	232	NUM
eurjchem-2641	594	33	2025	2025	NUM
eurjchem-2641	594	34	–	–	PUNCT
eurjchem-2641	594	35	european	european	ADJ
eurjchem-2641	594	36	journal	journal	NOUN
eurjchem-2641	594	37	of	of	ADP
eurjchem-2641	594	38	chemistry	chemistry	NOUN
eurjchem-2641	594	39	–	–	PUNCT
eurjchem-2641	594	40	cc	cc	NOUN
eurjchem-2641	594	41	by	by	ADP
eurjchem-2641	594	42	nc	nc	PROPN
eurjchem-2641	594	43	–	–	PUNCT
eurjchem-2641	594	44	doi	doi	NOUN
eurjchem-2641	594	45	:	:	PUNCT
eurjchem-2641	594	46	10.5155	10.5155	NUM
eurjchem-2641	594	47	/	/	SYM
eurjchem-2641	594	48	eurjchem.16.2.222	eurjchem.16.2.222	NOUN
eurjchem-2641	594	49	-	-	SYM
eurjchem-2641	594	50	232.2641	232.2641	NUM
eurjchem-2641	594	51	[	[	PUNCT
eurjchem-2641	594	52	64	64	NUM
eurjchem-2641	594	53	]	]	PUNCT
eurjchem-2641	594	54	.	.	PUNCT
eurjchem-2641	595	1	şahin	şahin	PROPN
eurjchem-2641	595	2	,	,	PUNCT
eurjchem-2641	595	3	a.	a.	PROPN
eurjchem-2641	595	4	b.	b.	PROPN
eurjchem-2641	595	5	;	;	PUNCT
eurjchem-2641	595	6	cubukcu	cubukcu	NOUN
eurjchem-2641	595	7	,	,	PUNCT
eurjchem-2641	595	8	e.	e.	PROPN
eurjchem-2641	595	9	;	;	PUNCT
eurjchem-2641	595	10	ocak	ocak	PROPN
eurjchem-2641	595	11	,	,	PUNCT
eurjchem-2641	595	12	b.	b.	PROPN
eurjchem-2641	595	13	;	;	PUNCT
eurjchem-2641	595	14	deligonul	deligonul	PROPN
eurjchem-2641	595	15	,	,	PUNCT
eurjchem-2641	595	16	a.	a.	NOUN
eurjchem-2641	595	17	;	;	PUNCT
eurjchem-2641	595	18	oyucu	oyucu	PROPN
eurjchem-2641	595	19	orhan	orhan	PROPN
eurjchem-2641	595	20	,	,	PUNCT
eurjchem-2641	595	21	s.	s.	PROPN
eurjchem-2641	595	22	;	;	PUNCT
eurjchem-2641	595	23	tolunay	tolunay	PROPN
eurjchem-2641	595	24	,	,	PUNCT
eurjchem-2641	595	25	s.	s.	PROPN
eurjchem-2641	595	26	;	;	PUNCT
eurjchem-2641	595	27	gokgoz	gokgoz	X
eurjchem-2641	595	28	,	,	PUNCT
eurjchem-2641	595	29	m.	m.	NOUN
eurjchem-2641	595	30	s.	s.	PROPN
eurjchem-2641	595	31	;	;	PUNCT
eurjchem-2641	595	32	cetintas	cetinta	NOUN
eurjchem-2641	595	33	,	,	PUNCT
eurjchem-2641	595	34	s.	s.	PROPN
eurjchem-2641	595	35	;	;	PUNCT
eurjchem-2641	595	36	yarbas	yarbas	PROPN
eurjchem-2641	595	37	,	,	PUNCT
eurjchem-2641	595	38	g.	g.	PROPN
eurjchem-2641	595	39	;	;	PUNCT
eurjchem-2641	595	40	senol	senol	NOUN
eurjchem-2641	595	41	,	,	PUNCT
eurjchem-2641	595	42	k.	k.	PROPN
eurjchem-2641	595	43	;	;	PUNCT
eurjchem-2641	595	44	goktug	goktug	PROPN
eurjchem-2641	595	45	,	,	PUNCT
eurjchem-2641	595	46	m.	m.	PROPN
eurjchem-2641	595	47	r.	r.	PROPN
eurjchem-2641	595	48	;	;	PUNCT
eurjchem-2641	595	49	yanasma	yanasma	PROPN
eurjchem-2641	595	50	,	,	PUNCT
eurjchem-2641	595	51	z.	z.	PROPN
eurjchem-2641	595	52	b.	b.	PROPN
eurjchem-2641	595	53	;	;	PUNCT
eurjchem-2641	595	54	hasanzade	hasanzade	PROPN
eurjchem-2641	595	55	,	,	PUNCT
eurjchem-2641	595	56	u.	u.	PROPN
eurjchem-2641	595	57	;	;	PUNCT
eurjchem-2641	595	58	evrensel	evrensel	NOUN
eurjchem-2641	595	59	,	,	PUNCT
eurjchem-2641	595	60	t.	t.	PROPN
eurjchem-2641	595	61	low	low	PROPN
eurjchem-2641	595	62	pan	pan	PROPN
eurjchem-2641	595	63	-	-	ADJ
eurjchem-2641	595	64	immuneinflammation	immuneinflammation	NOUN
eurjchem-2641	595	65	-	-	PUNCT
eurjchem-2641	595	66	value	value	NOUN
eurjchem-2641	595	67	predicts	predict	NOUN
eurjchem-2641	595	68	better	well	ADJ
eurjchem-2641	595	69	chemotherapy	chemotherapy	NOUN
eurjchem-2641	595	70	response	response	NOUN
eurjchem-2641	595	71	and	and	CCONJ
eurjchem-2641	595	72	survival	survival	NOUN
eurjchem-2641	595	73	in	in	ADP
eurjchem-2641	595	74	breast	breast	NOUN
eurjchem-2641	595	75	cancer	cancer	NOUN
eurjchem-2641	595	76	patients	patient	NOUN
eurjchem-2641	595	77	treated	treat	VERB
eurjchem-2641	595	78	with	with	ADP
eurjchem-2641	595	79	neoadjuvant	neoadjuvant	ADJ
eurjchem-2641	595	80	chemotherapy	chemotherapy	NOUN
eurjchem-2641	595	81	.	.	PUNCT
eurjchem-2641	596	1	sci	sci	PROPN
eurjchem-2641	596	2	rep	rep	PROPN
eurjchem-2641	596	3	2021	2021	NUM
eurjchem-2641	596	4	,	,	PUNCT
eurjchem-2641	596	5	11	11	NUM
eurjchem-2641	596	6	(	(	PUNCT
eurjchem-2641	596	7	1	1	NUM
eurjchem-2641	596	8	)	)	PUNCT
eurjchem-2641	596	9	,	,	PUNCT
eurjchem-2641	596	10	14662	14662	NUM
eurjchem-2641	596	11	https://doi.org/10.1038/s41598–021–94184–7	https://doi.org/10.1038/s41598–021–94184–7	PROPN
eurjchem-2641	596	12	.	.	PUNCT
eurjchem-2641	597	1	copyright	copyright	NOUN
eurjchem-2641	597	2	©	©	PROPN
eurjchem-2641	597	3	2025	2025	NUM
eurjchem-2641	597	4	by	by	ADP
eurjchem-2641	597	5	authors	author	NOUN
eurjchem-2641	597	6	.	.	PUNCT
eurjchem-2641	598	1	this	this	DET
eurjchem-2641	598	2	work	work	NOUN
eurjchem-2641	598	3	is	be	AUX
eurjchem-2641	598	4	published	publish	VERB
eurjchem-2641	598	5	and	and	CCONJ
eurjchem-2641	598	6	licensed	license	VERB
eurjchem-2641	598	7	by	by	ADP
eurjchem-2641	598	8	atlanta	atlanta	PROPN
eurjchem-2641	598	9	publishing	publishing	PROPN
eurjchem-2641	598	10	house	house	PROPN
eurjchem-2641	598	11	llc	llc	PROPN
eurjchem-2641	598	12	,	,	PUNCT
eurjchem-2641	598	13	atlanta	atlanta	PROPN
eurjchem-2641	598	14	,	,	PUNCT
eurjchem-2641	598	15	ga	ga	PROPN
eurjchem-2641	598	16	,	,	PUNCT
eurjchem-2641	598	17	usa	usa	PROPN
eurjchem-2641	598	18	.	.	PUNCT
eurjchem-2641	599	1	the	the	DET
eurjchem-2641	599	2	full	full	ADJ
eurjchem-2641	599	3	terms	term	NOUN
eurjchem-2641	599	4	of	of	ADP
eurjchem-2641	599	5	this	this	DET
eurjchem-2641	599	6	license	license	NOUN
eurjchem-2641	599	7	are	be	AUX
eurjchem-2641	599	8	available	available	ADJ
eurjchem-2641	599	9	at	at	ADP
eurjchem-2641	599	10	https://www.eurjchem.com/index.php/eurjchem/terms	https://www.eurjchem.com/index.php/eurjchem/term	NOUN
eurjchem-2641	599	11	and	and	CCONJ
eurjchem-2641	599	12	incorporate	incorporate	VERB
eurjchem-2641	599	13	the	the	DET
eurjchem-2641	599	14	creative	creative	ADJ
eurjchem-2641	599	15	commons	common	NOUN
eurjchem-2641	599	16	attribution	attribution	NOUN
eurjchem-2641	599	17	-	-	PUNCT
eurjchem-2641	599	18	non	non	ADJ
eurjchem-2641	599	19	commercial	commercial	NOUN
eurjchem-2641	599	20	(	(	PUNCT
eurjchem-2641	599	21	cc	cc	NOUN
eurjchem-2641	599	22	by	by	ADP
eurjchem-2641	599	23	nc	nc	PROPN
eurjchem-2641	599	24	)	)	PUNCT
eurjchem-2641	599	25	(	(	PUNCT
eurjchem-2641	599	26	international	international	ADJ
eurjchem-2641	599	27	,	,	PUNCT
eurjchem-2641	599	28	v4.0	v4.0	NOUN
eurjchem-2641	599	29	)	)	PUNCT
eurjchem-2641	599	30	license	license	NOUN
eurjchem-2641	599	31	(	(	PUNCT
eurjchem-2641	599	32	http://creativecommons.org/licenses/by-nc/4.0	http://creativecommons.org/licenses/by-nc/4.0	NOUN
eurjchem-2641	599	33	)	)	PUNCT
eurjchem-2641	599	34	.	.	PUNCT
eurjchem-2641	600	1	by	by	ADP
eurjchem-2641	600	2	accessing	access	VERB
eurjchem-2641	600	3	the	the	DET
eurjchem-2641	600	4	work	work	NOUN
eurjchem-2641	600	5	,	,	PUNCT
eurjchem-2641	600	6	you	you	PRON
eurjchem-2641	600	7	hereby	hereby	ADV
eurjchem-2641	600	8	accept	accept	VERB
eurjchem-2641	600	9	the	the	DET
eurjchem-2641	600	10	terms	term	NOUN
eurjchem-2641	600	11	.	.	PUNCT
eurjchem-2641	601	1	this	this	PRON
eurjchem-2641	601	2	is	be	AUX
eurjchem-2641	601	3	an	an	DET
eurjchem-2641	601	4	open	open	ADJ
eurjchem-2641	601	5	access	access	NOUN
eurjchem-2641	601	6	article	article	NOUN
eurjchem-2641	601	7	distributed	distribute	VERB
eurjchem-2641	601	8	under	under	ADP
eurjchem-2641	601	9	the	the	DET
eurjchem-2641	601	10	terms	term	NOUN
eurjchem-2641	601	11	and	and	CCONJ
eurjchem-2641	601	12	conditions	condition	NOUN
eurjchem-2641	601	13	of	of	ADP
eurjchem-2641	601	14	the	the	DET
eurjchem-2641	601	15	cc	cc	PROPN
eurjchem-2641	601	16	by	by	ADP
eurjchem-2641	601	17	nc	nc	PROPN
eurjchem-2641	601	18	license	license	PROPN
eurjchem-2641	601	19	,	,	PUNCT
eurjchem-2641	601	20	which	which	PRON
eurjchem-2641	601	21	permits	permit	VERB
eurjchem-2641	601	22	unrestricted	unrestricted	ADJ
eurjchem-2641	601	23	non	non	ADJ
eurjchem-2641	601	24	-	-	ADJ
eurjchem-2641	601	25	commercial	commercial	ADJ
eurjchem-2641	601	26	use	use	NOUN
eurjchem-2641	601	27	,	,	PUNCT
eurjchem-2641	601	28	distribution	distribution	NOUN
eurjchem-2641	601	29	,	,	PUNCT
eurjchem-2641	601	30	and	and	CCONJ
eurjchem-2641	601	31	reproduction	reproduction	NOUN
eurjchem-2641	601	32	in	in	ADP
eurjchem-2641	601	33	any	any	DET
eurjchem-2641	601	34	medium	medium	NOUN
eurjchem-2641	601	35	,	,	PUNCT
eurjchem-2641	601	36	provided	provide	VERB
eurjchem-2641	601	37	the	the	DET
eurjchem-2641	601	38	original	original	ADJ
eurjchem-2641	601	39	work	work	NOUN
eurjchem-2641	601	40	is	be	AUX
eurjchem-2641	601	41	properly	properly	ADV
eurjchem-2641	601	42	cited	cite	VERB
eurjchem-2641	601	43	without	without	ADP
eurjchem-2641	601	44	any	any	DET
eurjchem-2641	601	45	further	further	ADJ
eurjchem-2641	601	46	permission	permission	NOUN
eurjchem-2641	601	47	from	from	ADP
eurjchem-2641	601	48	atlanta	atlanta	PROPN
eurjchem-2641	601	49	publishing	publishing	PROPN
eurjchem-2641	601	50	house	house	PROPN
eurjchem-2641	601	51	llc	llc	PROPN
eurjchem-2641	601	52	(	(	PUNCT
eurjchem-2641	601	53	european	european	PROPN
eurjchem-2641	601	54	journal	journal	PROPN
eurjchem-2641	601	55	of	of	ADP
eurjchem-2641	601	56	chemistry	chemistry	NOUN
eurjchem-2641	601	57	)	)	PUNCT
eurjchem-2641	601	58	.	.	PUNCT
eurjchem-2641	602	1	no	no	DET
eurjchem-2641	602	2	use	use	NOUN
eurjchem-2641	602	3	,	,	PUNCT
eurjchem-2641	602	4	distribution	distribution	NOUN
eurjchem-2641	602	5	,	,	PUNCT
eurjchem-2641	602	6	or	or	CCONJ
eurjchem-2641	602	7	reproduction	reproduction	NOUN
eurjchem-2641	602	8	is	be	AUX
eurjchem-2641	602	9	permitted	permit	VERB
eurjchem-2641	602	10	which	which	PRON
eurjchem-2641	602	11	does	do	AUX
eurjchem-2641	602	12	not	not	PART
eurjchem-2641	602	13	comply	comply	VERB
eurjchem-2641	602	14	with	with	ADP
eurjchem-2641	602	15	these	these	DET
eurjchem-2641	602	16	terms	term	NOUN
eurjchem-2641	602	17	.	.	PUNCT
eurjchem-2641	603	1	permissions	permission	NOUN
eurjchem-2641	603	2	for	for	ADP
eurjchem-2641	603	3	commercial	commercial	ADJ
eurjchem-2641	603	4	use	use	NOUN
eurjchem-2641	603	5	of	of	ADP
eurjchem-2641	603	6	this	this	DET
eurjchem-2641	603	7	work	work	NOUN
eurjchem-2641	603	8	beyond	beyond	ADP
eurjchem-2641	603	9	the	the	DET
eurjchem-2641	603	10	scope	scope	NOUN
eurjchem-2641	603	11	of	of	ADP
eurjchem-2641	603	12	the	the	DET
eurjchem-2641	603	13	license	license	NOUN
eurjchem-2641	603	14	(	(	PUNCT
eurjchem-2641	603	15	https://www.eurjchem.com/index.php/eurjchem/terms	https://www.eurjchem.com/index.php/eurjchem/term	NOUN
eurjchem-2641	603	16	)	)	PUNCT
eurjchem-2641	603	17	are	be	AUX
eurjchem-2641	603	18	administered	administer	VERB
eurjchem-2641	603	19	by	by	ADP
eurjchem-2641	603	20	atlanta	atlanta	PROPN
eurjchem-2641	603	21	publishing	publishing	PROPN
eurjchem-2641	603	22	house	house	PROPN
eurjchem-2641	603	23	llc	llc	PROPN
eurjchem-2641	603	24	(	(	PUNCT
eurjchem-2641	603	25	european	european	PROPN
eurjchem-2641	603	26	journal	journal	PROPN
eurjchem-2641	603	27	of	of	ADP
eurjchem-2641	603	28	chemistry	chemistry	NOUN
eurjchem-2641	603	29	)	)	PUNCT
eurjchem-2641	603	30	.	.	PUNCT
eurjchem-2641	604	1	https://doi.org/10.1038/s41598%e2%80%93021%e2%80%9394184%e2%80%937	https://doi.org/10.1038/s41598%e2%80%93021%e2%80%9394184%e2%80%937	PROPN
eurjchem-2641	604	2	https://www.eurjchem.com/index.php/eurjchem/terms	https://www.eurjchem.com/index.php/eurjchem/term	NOUN
eurjchem-2641	604	3	http://creativecommons.org/licenses/by-nc/4.0	http://creativecommons.org/licenses/by-nc/4.0	PROPN
eurjchem-2641	604	4	https://www.eurjchem.com/index.php/eurjchem/terms	https://www.eurjchem.com/index.php/eurjchem/term	NOUN
eurjchem-2641	604	5	1	1	NUM
eurjchem-2641	604	6	.	.	PUNCT
eurjchem-2641	604	7	introduction	introduction	NOUN
eurjchem-2641	604	8	2	2	NUM
eurjchem-2641	604	9	.	.	PUNCT
eurjchem-2641	604	10	experimental	experimental	ADJ
eurjchem-2641	604	11	2.1	2.1	NUM
eurjchem-2641	604	12	.	.	PUNCT
eurjchem-2641	605	1	study	study	NOUN
eurjchem-2641	605	2	design	design	NOUN
eurjchem-2641	605	3	and	and	CCONJ
eurjchem-2641	605	4	ethical	ethical	ADJ
eurjchem-2641	605	5	approval	approval	NOUN
eurjchem-2641	605	6	2.2	2.2	NUM
eurjchem-2641	605	7	.	.	PUNCT
eurjchem-2641	606	1	subjects	subject	NOUN
eurjchem-2641	606	2	2.3	2.3	NUM
eurjchem-2641	606	3	.	.	PUNCT
eurjchem-2641	607	1	blood	blood	NOUN
eurjchem-2641	607	2	sample	sample	NOUN
eurjchem-2641	607	3	collection	collection	NOUN
eurjchem-2641	607	4	2.4	2.4	NUM
eurjchem-2641	607	5	.	.	PUNCT
eurjchem-2641	608	1	gene	gene	NOUN
eurjchem-2641	608	2	expression	expression	NOUN
eurjchem-2641	608	3	study	study	NOUN
eurjchem-2641	608	4	2.5	2.5	NUM
eurjchem-2641	608	5	.	.	PUNCT
eurjchem-2641	609	1	assessment	assessment	NOUN
eurjchem-2641	609	2	of	of	ADP
eurjchem-2641	609	3	caspase-3	caspase-3	NUM
eurjchem-2641	609	4	2.6	2.6	NUM
eurjchem-2641	609	5	.	.	PUNCT
eurjchem-2641	610	1	assessment	assessment	NOUN
eurjchem-2641	610	2	of	of	ADP
eurjchem-2641	610	3	bcl-2	bcl-2	NOUN
eurjchem-2641	610	4	2.7	2.7	NUM
eurjchem-2641	610	5	.	.	PUNCT
eurjchem-2641	611	1	measurement	measurement	NOUN
eurjchem-2641	611	2	of	of	ADP
eurjchem-2641	611	3	tac	tac	PROPN
eurjchem-2641	611	4	levels	level	NOUN
eurjchem-2641	611	5	2.8	2.8	NUM
eurjchem-2641	611	6	.	.	PUNCT
eurjchem-2641	612	1	histopathological	histopathological	ADJ
eurjchem-2641	612	2	investigations	investigation	NOUN
eurjchem-2641	612	3	2.9	2.9	NUM
eurjchem-2641	612	4	.	.	PUNCT
eurjchem-2641	613	1	statistical	statistical	ADJ
eurjchem-2641	613	2	analysis	analysis	NOUN
eurjchem-2641	613	3	3	3	NUM
eurjchem-2641	613	4	.	.	NOUN
eurjchem-2641	613	5	results	result	NOUN
eurjchem-2641	613	6	3.1	3.1	NUM
eurjchem-2641	613	7	.	.	PUNCT
eurjchem-2641	614	1	demographic	demographic	ADJ
eurjchem-2641	614	2	and	and	CCONJ
eurjchem-2641	614	3	clinical	clinical	ADJ
eurjchem-2641	614	4	characteristics	characteristic	NOUN
eurjchem-2641	614	5	3.2	3.2	NUM
eurjchem-2641	614	6	.	.	PUNCT
eurjchem-2641	615	1	blood	blood	NOUN
eurjchem-2641	615	2	count	count	VERB
eurjchem-2641	615	3	3.3	3.3	NUM
eurjchem-2641	615	4	.	.	PUNCT
eurjchem-2641	616	1	mirna-148b	mirna-148b	PROPN
eurjchem-2641	616	2	,	,	PUNCT
eurjchem-2641	616	3	caspase-3	caspase-3	NUM
eurjchem-2641	616	4	,	,	PUNCT
eurjchem-2641	616	5	bcl-2	bcl-2	NOUN
eurjchem-2641	616	6	and	and	CCONJ
eurjchem-2641	616	7	bax	bax	NOUN
eurjchem-2641	616	8	expression	expression	NOUN
eurjchem-2641	616	9	3.4	3.4	NUM
eurjchem-2641	616	10	.	.	PUNCT
eurjchem-2641	617	1	caspase-3	caspase-3	NUM
eurjchem-2641	617	2	and	and	CCONJ
eurjchem-2641	617	3	bcl-2	bcl-2	NUM
eurjchem-2641	617	4	3.5	3.5	NUM
eurjchem-2641	617	5	.	.	PUNCT
eurjchem-2641	618	1	tac	tac	PROPN
eurjchem-2641	618	2	3.6	3.6	NUM
eurjchem-2641	618	3	.	.	PUNCT
eurjchem-2641	619	1	histopathological	histopathological	ADJ
eurjchem-2641	619	2	findings	finding	NOUN
eurjchem-2641	619	3	3	3	NUM
eurjchem-2641	619	4	.	.	PUNCT
eurjchem-2641	619	5	discussion	discussion	NOUN
eurjchem-2641	619	6	4	4	NUM
eurjchem-2641	619	7	.	.	PUNCT
eurjchem-2641	620	1	conclusions	conclusion	NOUN
eurjchem-2641	620	2	disclosure	disclosure	NOUN
eurjchem-2641	620	3	statement	statement	NOUN
eurjchem-2641	620	4	credit	credit	NOUN
eurjchem-2641	620	5	authorship	authorship	NOUN
eurjchem-2641	620	6	contribution	contribution	NOUN
eurjchem-2641	620	7	statement	statement	NOUN
eurjchem-2641	620	8	orcid	orcid	NOUN
eurjchem-2641	620	9	and	and	CCONJ
eurjchem-2641	620	10	email	email	NOUN
eurjchem-2641	620	11	references	reference	NOUN
eurjchem-2641	620	12	printfield10	printfield10	PROPN
eurjchem-2641	620	13	:	:	PUNCT
eurjchem-2641	620	14	printfield11	printfield11	NOUN
eurjchem-2641	620	15	:	:	PUNCT
eurjchem-2641	620	16	printfield12	printfield12	PROPN
eurjchem-2641	620	17	:	:	PUNCT
eurjchem-2641	620	18	printfield13	printfield13	VERB
eurjchem-2641	620	19	:	:	PUNCT
eurjchem-2641	620	20	printfield14	printfield14	NOUN
eurjchem-2641	620	21	:	:	PUNCT
eurjchem-2641	620	22	printfield15	printfield15	NOUN
eurjchem-2641	620	23	:	:	PUNCT
eurjchem-2641	620	24	printfield16	printfield16	ADJ
eurjchem-2641	620	25	:	:	PUNCT
eurjchem-2641	620	26	printfield17	printfield17	NOUN
eurjchem-2641	620	27	:	:	PUNCT
eurjchem-2641	620	28	printfield18	printfield18	NOUN
eurjchem-2641	620	29	:	:	PUNCT
eurjchem-2641	620	30	printfield19	printfield19	NOUN
eurjchem-2641	620	31	:	:	PUNCT
eurjchem-2641	620	32	printfield110	printfield110	PROPN
eurjchem-2641	620	33	:	:	PUNCT
eurjchem-2641	620	34	printfield20	printfield20	PROPN
eurjchem-2641	620	35	:	:	PUNCT
eurjchem-2641	620	36	printfield21	printfield21	ADJ
eurjchem-2641	620	37	:	:	PUNCT
eurjchem-2641	620	38	printfield22	printfield22	NOUN
eurjchem-2641	620	39	:	:	PUNCT
eurjchem-2641	620	40	printfield23	printfield23	NOUN
eurjchem-2641	620	41	:	:	PUNCT
eurjchem-2641	620	42	printfield24	printfield24	NOUN
eurjchem-2641	620	43	:	:	PUNCT
eurjchem-2641	620	44	printfield25	printfield25	NOUN
eurjchem-2641	620	45	:	:	PUNCT
eurjchem-2641	620	46	printfield26	printfield26	ADJ
eurjchem-2641	620	47	:	:	PUNCT
eurjchem-2641	620	48	printfield27	printfield27	NOUN
eurjchem-2641	620	49	:	:	PUNCT
eurjchem-2641	620	50	printfield28	printfield28	NOUN
eurjchem-2641	620	51	:	:	PUNCT
eurjchem-2641	620	52	printfield29	printfield29	ADV
eurjchem-2641	620	53	:	:	PUNCT
eurjchem-2641	620	54	printfield210	printfield210	PROPN
eurjchem-2641	620	55	:	:	PUNCT